data_6uzj_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6uzj _Structure_validation_residue.Date_analyzed 2019-11-22 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.4 m . . . . . 0 N--CA 1.456 -0.132 0 CA-C-O 120.844 0.354 . . . . 0.0 110.484 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.51 -128.18 1.87 Allowed Glycine 0 CA--C 1.526 0.753 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 9.9 mpt_? -111.48 140.2 46.28 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.754 0.311 . . . . 0.0 110.7 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -111.1 127.1 55.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.445 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 74.2 ttt-85 -103.55 123.66 47.35 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.525 -179.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 66.1 t -77.5 123.51 34.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.621 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 35.4 p80 -105.75 -16.37 14.69 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.741 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 32.6 m -128.45 129.33 45.96 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.692 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -65.71 109.65 2.5 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.557 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 22.5 t80 -117.17 115.4 25.26 Favored 'General case' 0 C--O 1.241 0.611 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.372 179.557 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 95.5 m -131.08 128.28 22.2 Favored Pre-proline 0 N--CA 1.449 -0.502 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.754 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.5 166.41 29.9 Favored 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 123.012 2.475 . . . . 0.0 112.139 179.377 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 61.7 m -67.47 159.52 77.45 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.554 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_exo -55.62 -32.07 81.82 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.722 2.281 . . . . 0.0 112.183 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -95.51 11.45 32.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.763 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -106.69 108.73 20.38 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.339 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 5.0 t -113.51 -8.49 13.36 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.782 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 45.5 p-10 -75.59 -7.12 53.42 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.762 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 73.6 m -118.9 144.37 46.45 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-O 120.787 0.327 . . . . 0.0 110.504 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 9.5 tp -82.11 153.93 25.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.533 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -96.2 130.61 43.23 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.573 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 34.2 pt -134.93 158.53 41.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.414 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.7 tttp -137.0 145.29 43.93 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.798 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 63.4 tttm -54.45 129.2 35.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.637 -179.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.57 -16.83 59.26 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 111.174 -0.77 . . . . 0.0 111.174 -179.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -74.87 148.41 40.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.786 0.327 . . . . 0.0 110.612 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 42.9 mm -109.93 126.63 67.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.392 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 82.9 mt -119.08 129.06 75.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.606 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -77.11 122.77 25.44 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.326 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.4 mt -76.82 125.25 36.46 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.486 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 30.6 pt -114.24 -27.98 2.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.461 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 10.4 t -167.35 161.82 14.41 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.647 -179.158 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -119.14 145.26 46.12 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.231 179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 25.5 m -94.89 134.32 25.09 Favored Pre-proline 0 CA--C 1.534 0.336 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.429 -179.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -50.73 -36.19 50.42 Favored 'Trans proline' 0 N--CA 1.494 1.546 0 C-N-CA 122.806 2.338 . . . . 0.0 112.068 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 60.6 ttm -59.03 -40.23 84.37 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.324 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 144.05 -31.78 1.83 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 97.5 mtp -62.54 146.59 51.38 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.014 0.435 . . . . 0.0 110.842 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 42.6 m0 -102.0 150.79 22.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.965 -179.186 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 93.2 m -110.55 136.73 49.22 Favored 'General case' 0 C--O 1.237 0.417 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.994 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -155.87 -171.56 22.43 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 111.095 -0.802 . . . . 0.0 111.095 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -123.35 147.65 46.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.991 0.424 . . . . 0.0 110.622 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -151.09 117.37 5.64 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.69 -179.742 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 67.5 m-20 51.22 52.83 14.07 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.142 179.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 80.7 m-20 59.68 26.18 15.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.237 -179.561 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.9 tttp -130.25 113.16 14.09 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.504 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 15.6 m -99.37 140.04 19.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.761 179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -171.42 -176.67 40.65 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -179.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 -104.12 150.4 24.36 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.077 0.465 . . . . 0.0 110.459 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -146.22 156.58 43.49 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.723 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 54.6 mttp -67.01 122.18 17.18 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.005 -179.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 55.9 p90 -68.64 -29.58 68.1 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.55 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 33.6 pt -60.46 -21.21 22.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.839 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 22.4 m-85 -102.64 1.51 34.76 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.871 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 68.2 t -127.83 136.51 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 CA-C-O 121.109 0.48 . . . . 0.0 110.752 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 41.7 t0 -110.94 142.26 43.28 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.395 179.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.7 p -86.94 126.3 40.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.772 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 23.4 pt -127.19 163.32 30.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.714 179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 28.7 t -104.74 130.32 52.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.581 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 7.9 tt0 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.554 179.916 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 84.1 m . . . . . 0 N--CA 1.453 -0.325 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 172.37 -140.53 5.79 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 21.0 mmm180 -110.14 148.13 32.37 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.887 0.375 . . . . 0.0 110.311 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -121.68 143.67 49.21 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.435 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 38.6 ptt180 -120.25 135.97 54.82 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.033 0.444 . . . . 0.0 110.427 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 43.4 t -84.54 135.53 24.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.982 -178.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 97.4 m-70 -107.28 -12.79 15.28 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.732 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 11.8 t -140.87 148.83 41.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.891 0.377 . . . . 0.0 110.375 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.3 p-10 -75.13 121.43 22.06 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.026 -179.515 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -119.28 118.24 30.73 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 178.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 89.6 m -126.56 94.69 39.8 Favored Pre-proline 0 CA--C 1.534 0.361 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.434 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -56.45 147.79 66.5 Favored 'Trans proline' 0 N--CA 1.499 1.804 0 C-N-CA 122.409 2.073 . . . . 0.0 112.023 -179.635 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 93.7 p -67.92 159.21 80.62 Favored Pre-proline 0 CA--C 1.532 0.255 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.709 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -56.8 -30.77 86.17 Favored 'Trans proline' 0 N--CA 1.499 1.812 0 C-N-CA 122.832 2.355 . . . . 0.0 112.154 -179.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -61.82 -22.96 65.93 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.062 -179.444 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -107.27 103.44 12.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.041 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.9 t -87.51 -33.89 18.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.367 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -63.37 -38.03 89.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.038 179.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 53.4 m -62.38 131.65 49.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.946 0.403 . . . . 0.0 110.647 -179.31 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 1.2 tt -87.55 150.84 23.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.755 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -98.22 123.52 42.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.263 -0.426 . . . . 0.0 109.926 179.092 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 47.3 pt -130.08 159.05 42.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 120.897 0.379 . . . . 0.0 110.902 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -135.71 141.99 44.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.704 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 22.8 pttp -53.35 138.86 31.76 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.982 0.42 . . . . 0.0 110.658 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.1 -17.9 56.42 Favored Glycine 0 CA--C 1.53 0.977 0 N-CA-C 111.2 -0.76 . . . . 0.0 111.2 -179.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -84.64 156.82 21.37 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.789 0.328 . . . . 0.0 110.921 179.569 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 47.4 mm -116.46 131.51 68.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.403 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 89.7 mt -118.25 132.04 69.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.282 -179.559 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 66.9 t0 -74.52 118.48 17.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.74 179.788 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 90.6 mt -69.34 122.4 20.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 120.902 0.382 . . . . 0.0 110.664 -179.433 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 82.6 mt -108.31 -59.44 3.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.183 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 94.2 m -140.87 142.93 34.46 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.479 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 12.2 pttp -154.26 123.21 6.33 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.926 0.393 . . . . 0.0 110.821 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.8 p -75.44 161.68 75.68 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.362 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_exo -52.28 -36.18 66.9 Favored 'Trans proline' 0 N--CA 1.495 1.607 0 C-N-CA 122.506 2.138 . . . . 0.0 111.833 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 14.9 tpt -149.71 97.0 2.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.476 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 168.85 -178.65 42.09 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 111.009 -0.836 . . . . 0.0 111.009 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.1 mtp -60.69 144.51 51.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.023 0.439 . . . . 0.0 110.738 -179.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 26.2 m0 -93.82 146.35 23.94 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.293 -179.57 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.9 m -112.59 135.49 53.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.986 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -160.59 -171.69 26.87 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 67.5 ttp -121.86 135.49 54.9 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.823 0.344 . . . . 0.0 110.407 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 4.2 tt -135.35 117.03 14.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.063 179.662 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 64.8 t30 55.85 52.93 9.98 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.235 179.282 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 33.1 m120 57.94 35.08 25.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.657 0.265 . . . . 0.0 111.4 179.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -139.02 116.89 11.56 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.14 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 89.5 t -95.41 129.94 44.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.604 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -165.67 -174.08 34.85 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.337 -0.705 . . . . 0.0 111.337 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -108.95 156.72 19.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.007 0.432 . . . . 0.0 110.912 -179.555 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -157.52 160.32 38.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.096 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -71.06 117.77 12.98 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.174 0.511 . . . . 0.0 111.119 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 55.6 p90 -63.15 -30.26 71.45 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.512 179.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 18.3 pt -62.43 -18.5 20.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.77 0.319 . . . . 0.0 110.724 179.344 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 15.3 m-30 -100.63 3.63 42.68 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.909 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -132.58 159.94 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -127.59 144.47 51.07 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.526 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.7 p -93.65 128.63 44.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.579 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 44.0 pt -127.68 158.83 39.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.752 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 71.0 m -70.64 144.74 51.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.531 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.606 179.848 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 24.1 p . . . . . 0 N--CA 1.451 -0.423 0 CA-C-O 121.064 0.459 . . . . 0.0 110.195 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.97 -155.25 14.95 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 26.9 mmt85 -112.22 140.64 46.75 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.885 0.374 . . . . 0.0 110.481 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.6 117.15 30.08 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.496 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 75.5 ttt180 -91.34 124.57 35.64 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.615 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 82.5 t -82.26 129.33 37.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.6 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 88.0 m-70 -107.1 -18.18 13.97 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.851 179.76 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 95.2 m -123.94 134.53 53.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.367 179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -75.07 114.18 13.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.697 -179.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -118.22 125.18 49.65 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.345 179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 10.0 t -132.28 134.18 24.66 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.673 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -72.97 166.41 30.11 Favored 'Trans proline' 0 N--CA 1.492 1.434 0 C-N-CA 122.894 2.396 . . . . 0.0 112.388 179.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 48.8 m -64.13 156.13 76.1 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.482 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -58.51 -27.39 82.07 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.621 2.214 . . . . 0.0 112.306 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -99.29 22.74 10.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.636 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -114.31 113.22 24.28 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.437 179.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 72.8 p -110.73 -15.14 13.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.683 179.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 56.7 p-10 -88.47 10.85 18.75 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.844 179.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 67.7 m -117.26 157.96 25.15 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 120.683 0.278 . . . . 0.0 110.3 -179.668 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 63.8 tp -104.56 136.7 43.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.321 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 13.3 tmtt? -96.72 124.94 40.85 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.385 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 49.3 pt -128.21 158.49 40.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.532 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 64.6 pttt -138.47 161.23 37.54 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.633 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 23.3 pttp -63.13 137.46 58.24 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.765 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.04 -11.6 71.7 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 111.024 -0.831 . . . . 0.0 111.024 -179.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 42.0 t0 -79.43 148.66 31.85 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-O 120.829 0.347 . . . . 0.0 110.463 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 39.0 mm -110.64 127.88 67.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.399 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 93.9 mt -115.22 134.34 58.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.803 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -82.17 111.9 18.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.559 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.5 mt -63.31 130.95 28.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.746 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 97.6 mt -112.57 -63.97 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.715 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.9 t -154.0 138.94 17.21 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.588 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -92.06 153.38 19.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.275 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 81.8 p -125.08 151.91 69.82 Favored Pre-proline 0 CA--C 1.532 0.252 0 C-N-CA 120.477 -0.489 . . . . 0.0 110.695 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -63.69 -18.85 65.92 Favored 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.908 2.406 . . . . 0.0 112.315 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 39.2 mmt -61.76 -37.41 84.19 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.195 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 125.18 -44.06 1.31 Allowed Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.074 -0.811 . . . . 0.0 111.074 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 33.5 mtt -61.85 141.76 57.76 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.98 0.419 . . . . 0.0 110.436 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 26.9 m0 -96.07 147.26 23.91 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.285 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 85.6 m -112.29 137.06 50.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.977 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -158.14 -172.53 25.41 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 37.2 ttm -119.69 140.49 50.58 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 120.734 0.302 . . . . 0.0 110.383 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -144.09 115.57 8.09 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.912 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 57.0 m-20 53.27 51.13 16.12 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.334 179.445 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 52.9 t30 60.75 28.79 18.51 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.545 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 13.0 tppt? -136.83 115.32 11.9 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.45 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.9 m -97.29 142.47 14.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.868 0.366 . . . . 0.0 110.804 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -171.18 -177.65 41.14 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 110.691 -0.963 . . . . 0.0 110.691 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -103.09 157.97 16.62 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 121.083 0.468 . . . . 0.0 110.644 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 2.1 p90 -154.35 161.56 41.68 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.194 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 12.4 tptt -62.17 117.47 6.08 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-O 121.488 0.661 . . . . 0.0 110.882 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -62.3 -23.22 66.6 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.353 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 18.1 tt -73.28 -38.19 53.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.877 0.37 . . . . 0.0 110.812 179.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 22.8 m-85 -80.3 -14.92 57.99 Favored 'General case' 0 C--O 1.24 0.582 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.765 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 67.2 t -111.78 137.08 45.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.223 0 CA-C-O 121.31 0.576 . . . . 0.0 110.61 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 41.5 t0 -121.04 149.47 42.65 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.743 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.3 p -87.85 132.38 33.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.447 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 2.4 tt -104.81 146.09 12.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.654 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 72.0 m -80.17 148.26 30.97 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.473 179.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 117.911 -1.042 . . . . 0.0 110.516 179.834 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 72.9 m . . . . . 0 CA--C 1.527 0.072 0 CA-C-O 120.832 0.349 . . . . 0.0 110.455 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 176.88 -123.76 0.92 Allowed Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -179.705 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 19.2 tpp180 -121.54 133.62 55.02 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.791 0.329 . . . . 0.0 110.448 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -104.28 122.94 46.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.694 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 78.3 ttt-85 -107.12 127.16 53.25 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.722 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.0 t -81.03 125.76 39.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.272 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 32.5 p80 -117.24 -13.1 10.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.699 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 97.2 m -125.51 134.37 52.05 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.538 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -69.22 122.98 19.93 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.672 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -71.59 137.69 48.18 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.222 179.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 82.1 m -120.01 93.27 47.72 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.424 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -73.59 151.69 47.35 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.864 2.376 . . . . 0.0 112.452 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 65.5 m -76.56 159.98 78.27 Favored Pre-proline 0 N--CA 1.452 -0.355 0 CA-C-O 121.263 0.554 . . . . 0.0 110.7 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -55.44 -37.47 94.81 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 122.733 2.289 . . . . 0.0 111.638 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.2 p90 -91.1 15.59 11.39 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.624 -179.702 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -108.81 94.83 5.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.276 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 71.2 p -104.42 -22.72 13.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.638 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -87.1 6.83 30.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.696 179.3 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 82.7 p -71.59 160.06 33.34 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-O 120.882 0.372 . . . . 0.0 110.42 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 55.8 tp -91.16 136.95 32.73 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.295 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 15.9 ptpt -93.64 123.33 36.89 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.762 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.0 pt -139.26 160.22 28.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.579 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.2 tttp -143.94 141.95 30.49 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.622 179.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 23.3 pttp -48.85 134.33 16.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.661 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.25 -19.61 53.81 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -74.32 153.66 39.23 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.784 0.326 . . . . 0.0 110.741 179.436 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 43.4 mm -114.47 126.62 72.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.367 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 87.1 mt -111.49 133.9 55.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.682 -179.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -80.11 112.17 17.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.593 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 97.5 mt -63.43 124.07 17.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.494 -179.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.405 HD13 HG21 ' A' ' 58' ' ' ILE . 97.3 mt -106.73 -54.87 5.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.634 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 32.0 p -161.51 171.27 18.41 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.61 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.02 146.14 42.4 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.499 179.828 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 62.1 p -101.45 155.02 36.87 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.515 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -63.27 -22.23 72.18 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 C-N-CA 122.957 2.438 . . . . 0.0 112.183 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 39.0 mmt -76.06 -10.56 59.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.877 179.485 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 104.08 -25.1 27.35 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 91.7 mmm -63.18 147.04 52.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.902 0.382 . . . . 0.0 110.426 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 33.1 m0 -103.95 143.38 32.94 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.827 -179.493 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 86.6 m -108.18 133.68 52.11 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.664 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -150.75 -179.05 26.18 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 -179.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 61.2 ttm -117.99 143.18 46.6 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-O 120.639 0.257 . . . . 0.0 110.557 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -142.04 117.14 10.02 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.574 179.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 9.1 p30 40.99 57.64 2.71 Favored 'General case' 0 N--CA 1.463 0.18 0 O-C-N 123.391 0.432 . . . . 0.0 111.019 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 60.5 t30 60.62 38.56 18.57 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.909 -179.253 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 64.1 tttt -141.36 109.69 5.91 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.092 178.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 60.1 t -98.99 129.82 48.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.91 0.386 . . . . 0.0 110.772 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -163.63 -178.63 37.43 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -101.17 160.52 14.33 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-O 120.643 0.259 . . . . 0.0 110.449 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 19.8 p90 -158.88 159.21 34.73 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.704 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 30.1 tttt -66.41 113.78 4.92 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.491 -179.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -59.22 -23.15 62.07 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.396 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 95.7 mt -68.54 -38.73 79.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.025 0.441 . . . . 0.0 110.19 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.7 m-30 -76.07 -5.43 46.45 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.815 -179.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -126.82 165.43 25.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.629 -179.591 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -148.66 160.63 42.96 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.521 179.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 23.6 m -94.52 129.34 44.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.624 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 43.1 pt -126.11 159.87 34.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.67 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 41.4 t -105.6 123.15 47.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.589 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 25.4 pt-20 . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.538 179.991 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 31.1 p . . . . . 0 N--CA 1.456 -0.157 0 CA-C-O 120.974 0.416 . . . . 0.0 110.143 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.63 -124.25 1.59 Allowed Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 14.7 mmp_? -111.2 147.0 35.91 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.681 0.277 . . . . 0.0 110.51 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -117.79 114.41 23.25 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.718 -0.393 . . . . 0.0 110.896 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 2.8 ptm85 -87.9 128.48 35.36 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.546 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 95.7 t -84.83 131.98 32.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.2 -179.313 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 30.3 m170 -114.17 -15.32 12.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.398 179.409 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 32.9 m -127.68 132.47 49.66 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.843 0.354 . . . . 0.0 110.712 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -65.79 145.1 56.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.736 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -98.65 134.92 40.9 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.004 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.7 t -121.22 93.52 48.81 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.752 179.741 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_endo -75.01 153.1 41.47 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.397 2.064 . . . . 0.0 112.319 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 65.6 m -72.01 158.97 86.69 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.525 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -53.82 -37.16 84.73 Favored 'Trans proline' 0 N--CA 1.497 1.723 0 C-N-CA 122.633 2.222 . . . . 0.0 112.039 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 41.1 p90 -97.43 16.36 20.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.869 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -96.6 88.16 4.58 Favored 'General case' 0 C--O 1.233 0.213 0 CA-C-O 121.039 0.447 . . . . 0.0 110.544 -179.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 6.9 t -93.24 -26.16 17.48 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.437 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 56.0 p-10 -79.5 -3.36 46.4 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.023 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 34.8 t -83.55 139.63 32.76 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.661 0.267 . . . . 0.0 110.536 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 60.2 tp -85.85 145.82 27.02 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.371 -0.377 . . . . 0.0 109.997 179.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 58.2 pttt -96.27 127.03 41.91 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.45 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 35.2 pt -144.12 150.2 17.01 Favored 'Isoleucine or valine' 0 C--O 1.237 0.436 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.339 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 63.7 tttp -132.72 145.88 51.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.331 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 64.8 pttt -48.93 138.15 11.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.953 0.406 . . . . 0.0 110.682 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 93.44 -13.27 67.94 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 -179.46 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -77.37 150.95 35.07 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-O 120.817 0.342 . . . . 0.0 110.636 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 36.1 mm -114.21 126.73 71.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.208 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 92.3 mt -117.93 133.14 65.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.83 -179.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -78.58 121.97 25.32 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.276 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.7 mt -69.5 120.39 17.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.914 0.388 . . . . 0.0 110.545 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 93.3 mt -109.47 -50.65 6.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.451 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 95.3 m -140.26 151.42 45.11 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.437 179.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 37.8 mtmm -124.88 147.74 48.65 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.417 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 90.0 m -122.71 117.16 28.9 Favored Pre-proline 0 CA--C 1.537 0.466 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.202 179.569 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_exo -50.57 126.83 18.98 Favored 'Trans proline' 0 N--CA 1.497 1.715 0 C-N-CA 121.933 1.755 . . . . 0.0 111.971 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 93.7 mmm 47.15 40.62 10.27 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.613 179.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -151.77 176.37 30.17 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.152 -0.779 . . . . 0.0 111.152 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 98.9 mtp -60.0 148.33 35.81 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.006 0.432 . . . . 0.0 110.58 -179.088 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 16.1 m0 -94.89 158.25 15.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.057 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 96.2 m -118.93 138.0 53.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.238 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -160.73 -170.57 25.51 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 64.8 ttp -125.71 136.32 53.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.745 0.307 . . . . 0.0 110.337 -179.702 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 4.4 tt -137.83 120.15 15.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.392 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 67.2 t30 53.08 51.4 15.81 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.681 -0.408 . . . . 0.0 110.981 179.196 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 58.0 t30 58.87 36.26 24.57 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.653 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 4.0 tptm -139.12 113.76 9.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.37 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 91.7 t -94.54 127.36 46.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.846 0.355 . . . . 0.0 110.674 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -163.22 -178.82 37.29 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 -179.8 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -100.69 157.53 16.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.907 0.384 . . . . 0.0 110.729 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -155.88 161.21 40.62 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.841 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -73.54 121.96 21.45 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.859 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 51.2 p90 -67.69 -28.18 67.46 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.794 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 33.5 pt -63.82 -19.53 24.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.694 0.283 . . . . 0.0 111.073 179.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 21.2 m-30 -102.23 5.39 40.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.942 0.401 . . . . 0.0 110.913 179.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 1.2 p -134.23 153.17 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.315 179.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -113.41 134.11 54.82 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.375 179.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.0 p -80.09 125.94 39.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.548 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -122.76 134.42 66.0 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.418 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 69.8 m -67.49 143.39 56.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.32 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.633 179.892 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 82.6 m . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.835 0.35 . . . . 0.0 110.378 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -175.34 -152.96 9.76 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 39.5 mmt180 -112.27 143.46 43.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.78 0.324 . . . . 0.0 110.657 -179.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -117.97 132.27 56.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.225 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -110.82 133.05 53.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.232 0.539 . . . . 0.0 110.733 -179.861 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 86.5 t -85.68 133.44 29.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.511 -179.332 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -118.02 -7.31 10.88 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.171 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 72.9 p -130.65 158.82 39.0 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.892 0.377 . . . . 0.0 110.3 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -91.35 104.06 16.63 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.599 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -119.24 121.4 39.58 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.571 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 8.7 t -130.3 139.67 36.33 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.809 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -73.59 166.01 30.91 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 122.779 2.319 . . . . 0.0 112.262 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 85.7 p -68.65 161.82 67.81 Favored Pre-proline 0 C--N 1.324 -0.525 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.653 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -56.23 -34.63 94.02 Favored 'Trans proline' 0 N--CA 1.5 1.893 0 C-N-CA 122.712 2.275 . . . . 0.0 112.098 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.3 p90 -87.75 9.42 21.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.923 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -112.38 114.73 27.61 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-O 120.684 0.278 . . . . 0.0 110.397 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 58.1 p -115.34 -30.57 6.22 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.933 0.397 . . . . 0.0 110.617 179.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -63.23 -37.32 86.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.548 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 66.7 m -58.85 152.83 18.42 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.606 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -91.72 132.51 36.33 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.51 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 62.4 mttp -87.4 124.38 33.34 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 179.181 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 47.5 pt -131.06 146.52 33.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.558 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.7 mttp -135.08 159.98 39.8 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.427 -0.352 . . . . 0.0 110.274 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -55.81 121.98 10.44 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.989 0.423 . . . . 0.0 110.538 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 103.52 -21.21 39.73 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -67.01 143.09 56.98 Favored 'General case' 0 C--N 1.332 -0.194 0 C-N-CA 120.618 -0.433 . . . . 0.0 110.77 179.41 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 9.9 mm -112.69 128.71 69.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.599 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.5 mt -116.33 133.35 63.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.708 -179.417 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -79.95 117.63 20.97 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.15 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 92.0 mt -67.26 126.39 26.79 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.137 0 CA-C-O 120.919 0.39 . . . . 0.0 110.679 -179.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 93.3 mt -113.84 -59.27 3.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.47 179.721 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 94.7 m -144.77 168.8 19.34 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.938 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -115.98 141.48 48.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.187 179.573 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.9 m -98.86 137.52 20.55 Favored Pre-proline 0 CA--C 1.538 0.483 0 C-N-CA 120.149 -0.62 . . . . 0.0 110.343 -179.492 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -53.22 -36.84 79.24 Favored 'Trans proline' 0 N--CA 1.501 1.916 0 C-N-CA 122.414 2.076 . . . . 0.0 112.486 179.509 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 23.0 ptp -59.34 -18.67 40.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.885 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 119.41 -38.25 2.88 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 179.424 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 97.0 mtp -61.57 143.65 55.65 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.153 0.502 . . . . 0.0 110.59 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 45.7 m0 -98.75 155.67 17.23 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.212 -179.312 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 93.0 m -115.92 135.21 54.2 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.901 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.6 -172.13 23.57 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 16.8 tmm? -122.04 139.8 53.26 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.847 0.356 . . . . 0.0 110.751 -179.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -139.25 111.72 7.64 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.618 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 47.2 m-20 54.05 51.99 13.6 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.034 179.617 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 54.1 t30 62.41 37.3 13.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.792 0.33 . . . . 0.0 110.707 -179.387 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 46.9 tptt -137.33 113.29 9.75 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.034 179.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 88.9 t -100.46 127.28 53.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 C-N-CA 120.793 -0.363 . . . . 0.0 110.912 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -164.92 -174.09 34.26 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 -179.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -102.51 150.96 22.87 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.009 0.433 . . . . 0.0 110.483 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 44.0 p90 -150.84 158.75 44.52 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.757 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -72.29 117.36 13.85 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.94 -179.466 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -62.58 -27.51 69.23 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.683 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 13.7 tt -63.06 -33.27 59.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.999 0.428 . . . . 0.0 111.1 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -83.81 1.23 44.01 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.835 179.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -132.66 161.42 41.56 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 CA-C-O 121.038 0.447 . . . . 0.0 110.464 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 53.3 t0 -124.1 137.64 54.54 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.133 179.39 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.5 p -87.52 124.64 40.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.773 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 41.4 pt -128.27 150.71 34.24 Favored 'Isoleucine or valine' 0 C--O 1.233 0.219 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.84 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 38.4 t -84.63 138.75 32.52 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.718 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.003 -0.998 . . . . 0.0 110.611 179.714 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 29.5 p . . . . . 0 N--CA 1.455 -0.219 0 CA-C-O 120.992 0.425 . . . . 0.0 110.424 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -174.16 -154.91 11.29 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -179.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 15.6 mmp_? -108.04 142.34 38.34 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.023 0.44 . . . . 0.0 110.469 -179.397 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -106.39 117.3 33.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.184 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 61.2 ttt180 -96.09 120.83 37.08 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.055 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 86.8 t -81.28 124.78 39.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.728 -179.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 35.2 p80 -115.81 -8.97 11.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.936 179.406 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 77.4 m -129.04 136.74 50.69 Favored 'General case' 0 C--O 1.231 0.099 0 CA-C-O 120.762 0.315 . . . . 0.0 110.625 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -69.49 119.69 14.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.493 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -65.47 136.91 57.04 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 92.1 m -118.45 94.85 47.96 Favored Pre-proline 0 CA--C 1.537 0.452 0 C-N-CA 120.958 -0.297 . . . . 0.0 110.762 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_endo -74.09 157.3 46.7 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 122.352 2.035 . . . . 0.0 112.201 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.1 m -79.78 158.03 73.54 Favored Pre-proline 0 CA--C 1.532 0.263 0 C-N-CA 120.661 -0.415 . . . . 0.0 110.797 -179.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -57.23 -40.27 83.87 Favored 'Trans proline' 0 N--CA 1.5 1.912 0 C-N-CA 122.381 2.054 . . . . 0.0 112.096 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.4 p90 -89.72 16.99 7.01 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.182 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -112.69 113.39 25.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.791 0.329 . . . . 0.0 110.626 179.425 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 55.7 p -112.42 -17.55 12.66 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.458 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 57.6 p-10 -87.59 6.13 35.99 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.13 179.64 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 74.9 m -70.28 151.17 45.6 Favored 'General case' 0 C--O 1.231 0.094 0 CA-C-O 120.86 0.362 . . . . 0.0 110.662 179.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 60.6 tp -84.66 135.93 33.96 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.154 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 62.6 mtpt -93.93 119.06 32.33 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.091 179.436 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 28.9 pt -136.64 168.02 22.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.316 -179.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 23.5 pttp -148.21 156.47 42.61 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.856 0.36 . . . . 0.0 110.385 179.255 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 65.3 tttm -56.96 129.9 43.66 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.313 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.13 -16.14 60.5 Favored Glycine 0 CA--C 1.53 1.004 0 N-CA-C 111.349 -0.7 . . . . 0.0 111.349 -179.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -71.33 146.61 48.74 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 110.321 -0.251 . . . . 0.0 110.321 179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 48.2 mm -114.89 129.11 71.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.938 0.399 . . . . 0.0 110.291 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 90.9 mt -119.03 130.39 73.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.871 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -74.93 128.39 35.45 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.321 -0.552 . . . . 0.0 110.227 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.9 mt -74.11 121.52 25.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.165 0 CA-C-O 120.854 0.359 . . . . 0.0 110.514 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 12.7 tt -113.67 -35.99 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.656 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 85.7 m -147.68 152.16 37.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.589 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.3 mtpt -136.47 155.94 49.29 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.247 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 68.9 p -131.98 155.67 81.06 Favored Pre-proline 0 C--N 1.327 -0.373 0 C-N-CA 120.417 -0.513 . . . . 0.0 110.756 179.425 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -59.93 115.79 2.87 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 121.954 1.769 . . . . 0.0 111.882 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 99.3 mtp 43.75 32.92 0.63 Allowed 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.969 179.401 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -122.64 173.97 16.18 Favored Glycine 0 CA--C 1.519 0.336 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 10.6 ptm -60.07 149.61 31.89 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.83 0.348 . . . . 0.0 110.432 -179.243 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 45.4 m0 -94.55 150.55 20.13 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.968 -179.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.1 m -118.65 143.1 47.05 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.372 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -165.0 -168.5 27.25 Favored Glycine 0 CA--C 1.52 0.395 0 C-N-CA 120.167 -1.016 . . . . 0.0 111.68 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 60.9 ttm -114.86 135.94 53.64 Favored 'General case' 0 C--O 1.238 0.447 0 CA-C-O 120.969 0.414 . . . . 0.0 110.444 179.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 3.5 tt -136.71 113.68 10.49 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.596 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 66.8 t30 53.39 52.33 13.66 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.678 -0.409 . . . . 0.0 111.356 178.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 59.71 28.48 17.93 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.921 0.391 . . . . 0.0 110.921 179.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -139.87 115.74 10.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.132 -0.486 . . . . 0.0 109.82 179.027 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 19.4 m -92.28 141.88 13.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.622 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -165.9 177.68 40.92 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 -179.488 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 76.7 m-20 -107.96 144.66 34.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.919 0.39 . . . . 0.0 110.523 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.8 p90 -148.19 147.1 29.06 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.741 179.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 17.5 tptm -58.0 121.47 10.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.358 -179.094 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.7 p90 -61.28 -25.43 67.1 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.624 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 97.7 mt -64.0 -39.03 83.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-O 120.919 0.39 . . . . 0.0 110.503 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 12.7 m-30 -77.27 -1.78 31.42 Favored 'General case' 0 C--O 1.237 0.404 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.388 -179.14 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -128.5 161.6 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.68 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -130.02 143.88 51.03 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.5 p -84.72 119.74 34.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.672 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 37.9 pt -127.84 158.96 39.28 Favored 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.77 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 35.2 t -110.66 127.37 55.25 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.234 179.724 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 118.048 -0.977 . . . . 0.0 110.488 -179.615 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 26.3 p . . . . . 0 N--CA 1.455 -0.222 0 CA-C-O 120.855 0.36 . . . . 0.0 110.317 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 162.32 -130.08 2.21 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 87.7 mmt-85 -112.11 145.31 40.0 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.943 0.401 . . . . 0.0 110.741 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -108.91 121.46 45.15 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.269 179.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 46.5 ttt-85 -97.09 125.43 41.55 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.896 0.379 . . . . 0.0 110.365 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.6 t -82.48 128.62 38.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.617 -179.143 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 65.6 m170 -103.72 -10.3 18.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.192 179.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 12.2 t -144.76 145.39 31.65 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.927 0.394 . . . . 0.0 110.345 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -71.81 114.27 9.73 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.3 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 9.5 t80 -121.08 123.58 42.71 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.349 179.392 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 81.5 p -124.7 154.22 70.25 Favored Pre-proline 0 C--N 1.329 -0.29 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.824 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.14 159.22 30.21 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 C-N-CA 123.027 2.484 . . . . 0.0 112.487 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 72.4 m -82.28 158.41 66.66 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.377 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -52.86 -45.92 37.35 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 122.245 1.964 . . . . 0.0 111.981 -179.559 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -80.09 -20.78 44.29 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.91 0.386 . . . . 0.0 110.731 179.533 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -93.05 105.29 17.41 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.416 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 72.1 p -104.37 -23.55 13.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.314 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -63.2 -37.45 87.27 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.631 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.6 t -61.44 135.98 57.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.883 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 56.5 tp -80.57 146.03 31.46 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.419 -179.679 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.51 127.42 42.49 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.563 179.087 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.7 pt -139.24 160.45 28.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.565 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 19.6 ptpt -136.64 157.34 46.99 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.211 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -61.27 129.38 40.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.945 0.403 . . . . 0.0 111.071 -179.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.92 -16.31 59.64 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -76.55 146.47 38.34 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-O 120.776 0.322 . . . . 0.0 110.633 179.537 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 46.8 mm -108.89 127.55 65.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.004 0.431 . . . . 0.0 110.126 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 78.5 mt -108.58 130.62 61.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.728 -178.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -79.96 112.09 16.92 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . 0.416 HG23 HD12 ' A' ' 57' ' ' ILE . 96.6 mt -65.9 118.2 8.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.908 0.385 . . . . 0.0 110.661 -179.64 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.0 tt -101.93 -35.3 4.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.323 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 25.1 p -171.99 172.9 4.56 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.412 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 65.1 mttp -116.85 145.08 43.79 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 120.881 -0.328 . . . . 0.0 110.537 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 9.8 m -97.69 135.45 21.61 Favored Pre-proline 0 CA--C 1.536 0.417 0 C-N-CA 119.589 -0.844 . . . . 0.0 109.703 -179.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -58.7 -25.39 75.37 Favored 'Trans proline' 0 N--CA 1.501 1.915 0 C-N-CA 122.57 2.18 . . . . 0.0 112.614 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 39.2 mmt -65.19 -36.97 85.85 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.446 179.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 140.09 -39.56 1.49 Allowed Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 98.7 mtp -63.35 145.14 56.19 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.455 0.645 . . . . 0.0 111.198 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 22.4 m0 -96.35 146.95 24.3 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.828 -179.742 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 68.0 m -117.0 139.95 50.07 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 115.802 -0.636 . . . . 0.0 109.909 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.95 -172.02 23.71 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.166 -0.773 . . . . 0.0 111.166 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 67.8 ttp -116.18 143.09 45.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.152 0.501 . . . . 0.0 110.605 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -143.87 117.85 9.42 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.661 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 8.9 p30 40.64 59.73 2.08 Favored 'General case' 0 N--CA 1.469 0.525 0 O-C-N 123.442 0.464 . . . . 0.0 111.033 179.806 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 33.7 m120 59.25 35.44 23.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.025 -179.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 19.3 tptp -140.56 111.49 7.02 Favored 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.399 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 95.5 t -99.53 127.41 52.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.758 -0.377 . . . . 0.0 110.425 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -159.77 -176.8 32.25 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.886 -0.885 . . . . 0.0 110.886 -179.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.4 m120 -103.31 158.57 16.24 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.918 0.39 . . . . 0.0 110.467 -179.563 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -157.06 160.53 39.02 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.006 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 36.7 tptt -69.09 111.55 5.13 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.193 -179.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.3 p90 -59.17 -24.14 62.81 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.522 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.6 mt -67.9 -38.25 79.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.183 0.516 . . . . 0.0 110.654 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.2 m-30 -75.78 -5.94 48.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.834 -179.03 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -126.23 159.82 34.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 CA-C-O 121.042 0.449 . . . . 0.0 110.079 179.737 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 50.6 t0 -126.21 139.53 53.26 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.937 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.8 p -82.45 121.03 35.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.953 0.406 . . . . 0.0 110.961 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 41.2 pt -128.3 160.4 38.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.613 179.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 29.9 t -106.25 132.1 52.7 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.441 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 54.2 tp10 . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 117.974 -1.013 . . . . 0.0 110.332 -179.987 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 77.3 m . . . . . 0 N--CA 1.457 -0.106 0 CA-C-O 120.95 0.405 . . . . 0.0 110.369 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 169.27 -142.25 7.22 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 2.9 mpp_? -112.25 146.2 38.6 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.879 0.371 . . . . 0.0 110.454 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -116.06 125.3 52.23 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.083 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 74.2 ttt-85 -92.74 119.83 32.51 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.387 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 96.4 t -78.29 125.54 37.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.829 0.347 . . . . 0.0 110.679 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 33.2 p80 -112.51 -10.64 13.7 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.885 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 90.2 m -128.81 131.33 47.74 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.778 0.323 . . . . 0.0 110.396 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.6 t0 -68.27 131.34 45.18 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.629 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -88.28 137.22 32.52 Favored 'General case' 0 C--N 1.331 -0.2 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.167 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 43.2 p -126.82 93.79 41.36 Favored Pre-proline 0 CA--C 1.534 0.347 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.441 -179.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -73.27 155.79 51.25 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 122.172 1.915 . . . . 0.0 112.364 -179.022 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.6 m -73.47 157.96 87.16 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.801 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -55.83 -38.77 94.06 Favored 'Trans proline' 0 N--CA 1.498 1.766 0 C-N-CA 122.512 2.141 . . . . 0.0 112.046 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -88.6 6.54 37.69 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.066 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.22 101.15 12.09 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.752 0.311 . . . . 0.0 110.332 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 72.6 p -104.37 -27.52 11.91 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.883 0.373 . . . . 0.0 110.26 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -72.98 -21.27 60.88 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.775 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 41.4 t -59.62 141.36 55.15 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.404 -179.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 66.0 tp -80.27 138.84 36.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.147 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 30.2 mtpp -95.0 118.1 31.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.256 179.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 21.6 pt -138.42 146.68 26.3 Favored 'Isoleucine or valine' 0 C--O 1.237 0.419 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.186 179.676 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.04 167.23 14.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.909 0.385 . . . . 0.0 110.424 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -64.99 129.56 40.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.525 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.99 -20.83 47.41 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 111.214 -0.754 . . . . 0.0 111.214 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -69.88 148.51 48.94 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.387 179.219 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 86.5 mt -109.01 127.62 65.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.142 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 72.0 mt -109.96 130.16 63.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.447 -178.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -75.82 115.34 15.41 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.203 -0.599 . . . . 0.0 109.928 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.73 125.4 25.24 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 CA-C-O 120.823 0.344 . . . . 0.0 110.765 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 97.1 mt -108.73 -58.46 3.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.477 179.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 40.3 t -163.46 151.88 13.75 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.752 -179.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 59.0 mttm -96.85 157.78 15.74 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.073 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 74.9 p -112.29 156.95 41.31 Favored Pre-proline 0 C--N 1.329 -0.289 0 C-N-CA 120.618 -0.433 . . . . 0.0 110.784 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_exo -56.6 -33.73 93.82 Favored 'Trans proline' 0 N--CA 1.497 1.734 0 C-N-CA 122.68 2.254 . . . . 0.0 112.269 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 98.6 mtp -62.04 -38.48 88.89 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.514 -179.572 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 132.2 -32.38 2.86 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 98.5 mtp -62.4 143.8 56.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.002 0.429 . . . . 0.0 110.552 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 47.6 m0 -98.41 150.07 22.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.087 -178.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 90.0 m -110.0 135.18 51.25 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.657 179.553 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -152.66 -176.14 24.93 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 111.244 -0.742 . . . . 0.0 111.244 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.6 ttp -124.21 142.5 51.18 Favored 'General case' 0 C--O 1.237 0.432 0 CA-C-O 120.961 0.41 . . . . 0.0 110.672 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 2.1 mt -138.06 105.54 5.55 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.762 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 55.63 58.41 4.54 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.23 0.538 . . . . 0.0 109.705 178.775 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 58.5 t30 59.58 34.53 22.38 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.432 -179.515 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 8.9 tppt? -132.89 109.77 9.84 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.357 -0.383 . . . . 0.0 109.971 179.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 82.3 t -97.75 123.51 50.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 C-N-CA 120.706 -0.397 . . . . 0.0 110.499 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -156.83 179.12 32.88 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -105.69 154.54 20.31 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.958 0.409 . . . . 0.0 110.829 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.8 p90 -152.74 159.63 43.13 Favored 'General case' 0 C--O 1.237 0.443 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.823 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 30.6 tttt -68.65 116.46 9.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.209 -179.064 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -59.97 -25.71 65.45 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.571 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.6 mt -65.82 -38.46 82.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.713 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.1 m-30 -78.85 -7.32 57.79 Favored 'General case' 0 C--O 1.24 0.585 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.226 -178.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 66.5 t -121.39 138.68 50.93 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.283 0 CA-C-O 120.972 0.415 . . . . 0.0 110.991 -179.449 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -106.07 134.28 49.44 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.229 179.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.4 p -76.44 118.21 22.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.188 179.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -106.39 148.0 11.24 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.126 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.253 -179.733 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 90.0 p -112.18 147.37 36.31 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.771 -0.372 . . . . 0.0 110.093 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.388 179.908 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 16.9 p . . . . . 0 N--CA 1.454 -0.266 0 CA-C-O 120.994 0.426 . . . . 0.0 110.269 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 174.85 -139.65 4.94 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -179.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 93.5 mtt-85 -126.24 151.73 47.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.776 0.322 . . . . 0.0 110.575 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -123.01 135.75 54.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.531 -179.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 57.3 mtm180 -101.88 123.53 45.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.254 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 99.0 t -81.22 129.04 38.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.485 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -113.06 -0.22 14.79 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.961 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 12.2 t -146.47 151.49 37.48 Favored 'General case' 0 N--CA 1.455 -0.214 0 CA-C-O 120.914 0.387 . . . . 0.0 110.547 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -88.46 107.59 18.95 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.529 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 6.2 t80 -118.67 119.34 34.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.621 179.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 9.8 t -126.79 131.38 23.87 Favored Pre-proline 0 N--CA 1.451 -0.398 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.669 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -73.33 163.47 37.75 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.873 2.382 . . . . 0.0 112.38 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.3 m -66.04 156.47 84.13 Favored Pre-proline 0 C--N 1.327 -0.383 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.607 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -57.69 -31.55 92.31 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 C-N-CA 122.778 2.319 . . . . 0.0 112.332 -179.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -73.11 -10.67 60.03 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.572 179.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 48.6 t0 -110.22 114.04 27.21 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.298 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.3 t -106.12 -28.67 10.35 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.728 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -62.23 -36.56 82.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.497 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 47.2 m -63.47 139.31 58.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.704 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 59.2 tp -91.79 143.36 26.6 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.41 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 23.0 pttp -94.37 141.86 28.09 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.393 179.112 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 29.8 pt -132.0 147.5 32.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.559 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 40.7 ttmt -128.3 138.53 52.44 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.638 179.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -55.91 125.64 22.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.814 -179.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 105.51 -21.42 34.89 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.283 -0.727 . . . . 0.0 111.283 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -81.55 155.14 25.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.736 0.303 . . . . 0.0 110.806 179.29 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 46.7 mm -113.47 130.07 68.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.685 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 84.2 mt -112.49 129.06 68.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.498 -179.418 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 64.5 t0 -82.2 121.81 27.1 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.276 179.603 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 84.2 mt -70.21 128.74 33.94 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.116 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.419 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 88.8 mt -105.93 -53.49 6.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.709 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.8 t -163.84 150.66 11.89 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.78 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.7 mttp -109.29 155.34 21.27 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.251 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 81.5 p -136.05 155.09 77.85 Favored Pre-proline 0 N--CA 1.45 -0.471 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.853 179.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_exo -62.5 -21.23 72.55 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 122.863 2.375 . . . . 0.0 112.061 179.171 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 63.7 tpp -52.16 -31.6 32.11 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.417 -179.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 106.8 18.18 11.03 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 6.4 mtt -128.34 139.5 52.36 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.782 0.325 . . . . 0.0 110.474 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 33.5 m0 -93.36 139.45 30.66 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.775 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 93.0 m -98.39 131.16 44.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 109.897 179.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -154.52 -176.51 26.89 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -179.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 23.4 ptp -123.57 146.46 48.12 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.874 0.369 . . . . 0.0 110.667 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -150.03 118.78 6.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.512 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 54.8 m-20 53.59 49.71 18.83 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 54.3 t30 59.69 35.63 22.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.584 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 22.7 ttmm -138.64 117.62 12.48 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.459 179.292 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 96.9 t -99.45 131.03 47.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.733 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -158.03 177.57 34.7 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 81.7 m-20 -105.05 135.62 46.05 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.876 0.37 . . . . 0.0 110.564 -179.681 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -138.48 155.0 48.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.792 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -75.75 125.02 28.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.372 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 20.6 p90 -65.31 -20.42 66.4 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.706 -179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 6.4 pt -61.01 -23.17 28.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.505 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 41.6 m-85 -102.4 10.18 39.21 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.644 179.443 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -135.54 147.96 28.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.234 0 CA-C-O 120.863 0.363 . . . . 0.0 110.344 -179.609 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -105.62 131.95 52.37 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.302 179.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.1 p -91.31 132.98 34.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-O 120.96 0.409 . . . . 0.0 110.795 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 37.5 pt -124.0 156.63 31.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.69 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 66.0 m -113.09 148.63 34.86 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.673 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.601 179.948 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.2 m . . . . . 0 N--CA 1.458 -0.075 0 CA-C-O 120.902 0.382 . . . . 0.0 110.403 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -175.92 -149.8 7.68 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -109.03 138.21 45.74 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.94 0.4 . . . . 0.0 110.496 -179.793 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -106.11 115.15 29.73 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.198 -179.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 45.4 ttp180 -96.59 120.54 37.1 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.195 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 90.3 t -76.17 124.32 34.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.48 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 1.3 p80 -111.3 -15.87 13.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.537 179.548 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 53.0 m -131.97 135.5 46.62 Favored 'General case' 0 C--N 1.334 -0.103 0 CA-C-O 120.84 0.353 . . . . 0.0 110.833 179.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -64.44 133.91 53.47 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 120.716 -0.394 . . . . 0.0 110.49 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -120.8 135.77 55.07 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.276 179.618 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 57.0 p -135.44 90.76 19.7 Favored Pre-proline 0 CA--C 1.534 0.328 0 C-N-CA 120.92 -0.312 . . . . 0.0 110.304 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -69.83 150.6 68.01 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 122.66 2.24 . . . . 0.0 112.284 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 75.4 m -72.96 157.94 87.9 Favored Pre-proline 0 C--N 1.326 -0.439 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.653 -179.686 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -53.76 -23.09 25.34 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.835 2.357 . . . . 0.0 112.114 179.54 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -59.97 -23.05 63.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.204 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -65.8 125.87 26.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.35 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 82.8 p -70.68 -35.85 73.03 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.606 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . 0.498 ' O ' ' C ' ' A' ' 46' ' ' SER . 88.5 m-20 -100.14 5.86 44.86 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 118.337 -0.84 . . . . 0.0 111.465 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.498 ' C ' ' O ' ' A' ' 45' ' ' ASP . 6.6 t -9.88 95.3 0.01 OUTLIER 'General case' 0 C--N 1.358 0.938 0 O-C-N 125.003 1.439 . . . . 0.0 111.311 -179.291 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 66.9 tp -111.34 131.72 54.96 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.232 -178.478 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -97.29 134.31 40.75 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.563 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 48.3 pt -126.65 162.47 30.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.509 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 39.8 ttpt -134.85 135.61 41.81 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.602 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -51.43 131.16 28.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.983 0.42 . . . . 0.0 110.448 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.51 -18.14 56.69 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 111.006 -0.838 . . . . 0.0 111.006 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -72.47 155.53 40.0 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.798 0.332 . . . . 0.0 110.702 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 48.5 mm -114.38 127.68 71.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.198 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 85.6 mt -117.9 129.41 74.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.683 -179.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -74.65 120.64 20.48 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.309 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 85.0 mt -69.76 126.03 29.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.764 0.316 . . . . 0.0 110.347 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.7 mt -110.71 -43.16 5.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.768 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 46.6 t -146.52 139.13 25.2 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.572 -179.607 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.3 mtpt -119.37 153.75 34.67 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.517 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 71.5 p -133.29 153.17 80.49 Favored Pre-proline 0 C--N 1.328 -0.34 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.746 179.753 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -62.62 114.32 2.34 Favored 'Trans proline' 0 N--CA 1.493 1.484 0 C-N-CA 122.53 2.153 . . . . 0.0 112.037 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 99.4 mtp 46.55 32.74 1.74 Allowed 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.274 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -123.45 172.65 16.24 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 8.5 ptm -60.98 148.33 40.35 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.819 0.342 . . . . 0.0 110.143 -179.479 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 41.9 m0 -95.51 149.58 21.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.239 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 84.9 m -115.3 138.33 51.07 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.734 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -162.43 -166.95 22.13 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 65.3 ttp -125.72 138.36 53.87 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.826 0.346 . . . . 0.0 110.258 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 4.6 tt -134.31 115.47 14.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.426 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 65.7 t30 53.17 56.93 6.8 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.87 179.039 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 56.82 36.94 28.43 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.477 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 5.1 tptt -139.29 111.9 7.74 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.245 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 89.4 t -93.43 127.75 45.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.827 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -162.58 -177.18 35.38 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.801 -0.919 . . . . 0.0 110.801 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -107.78 156.3 19.27 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.98 0.419 . . . . 0.0 110.685 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 11.6 p90 -155.89 156.57 34.84 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.762 -0.653 . . . . 0.0 111.22 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 32.8 tttt -65.74 118.57 9.8 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.446 -179.243 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 36.5 p90 -61.18 -25.09 66.79 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.667 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 95.7 mt -63.08 -39.55 85.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 120.845 0.355 . . . . 0.0 110.634 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 18.3 m-85 -84.79 3.95 35.23 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.897 -179.54 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 86.3 t -126.22 136.09 61.86 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 CA-C-O 121.184 0.516 . . . . 0.0 110.914 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -111.17 142.48 43.3 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.422 179.461 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.5 p -89.63 122.83 41.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.767 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 36.5 pt -128.92 158.96 41.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.719 179.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 29.3 t -90.1 124.73 35.04 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.457 179.638 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 . . . . . 0 C--O 1.219 -0.517 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.674 -179.874 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 17.0 p . . . . . 0 N--CA 1.448 -0.535 0 CA-C-O 121.103 0.478 . . . . 0.0 109.997 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 169.63 -138.3 4.97 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.024 -0.831 . . . . 0.0 111.024 -179.579 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 39.1 mmt180 -111.81 142.73 43.81 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.763 0.316 . . . . 0.0 110.361 -179.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -122.41 141.08 51.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.516 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -116.08 132.22 56.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.316 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 84.0 t -82.39 125.99 39.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.819 -179.086 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 28.2 p80 -114.14 -13.75 12.39 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.91 179.609 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 87.9 m -126.28 130.45 50.89 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.418 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.4 t0 -64.22 122.15 15.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.303 -179.771 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 15.3 t80 -117.83 128.14 54.56 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.437 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.9 t -133.51 92.44 23.85 Favored Pre-proline 0 CA--C 1.539 0.53 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.485 179.561 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.85 151.45 62.86 Favored 'Trans proline' 0 N--CA 1.495 1.6 0 C-N-CA 121.955 1.77 . . . . 0.0 112.148 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 99.9 p -70.82 155.48 93.32 Favored Pre-proline 0 CA--C 1.533 0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.628 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -62.7 -21.89 73.4 Favored 'Trans proline' 0 N--CA 1.497 1.682 0 C-N-CA 122.491 2.127 . . . . 0.0 112.253 179.674 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -64.59 -25.16 67.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.442 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -64.89 143.71 57.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.356 179.442 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 61.9 p -84.39 -29.58 26.08 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.582 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . 0.437 ' O ' ' C ' ' A' ' 46' ' ' SER . 97.9 m-20 -100.23 -0.86 37.81 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.716 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 45' ' ' ASP . 16.3 t -20.81 95.86 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.675 0 O-C-N 124.033 0.833 . . . . 0.0 112.697 -178.757 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 63.5 tp -104.98 134.05 48.74 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.933 -179.427 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -97.17 129.19 44.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.558 179.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 40.2 pt -136.62 160.4 37.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.429 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -137.25 134.57 36.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.648 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 5.4 ptmm? -49.58 137.02 16.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.775 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.98 -17.76 58.71 Favored Glycine 0 CA--C 1.528 0.863 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 -179.839 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -79.15 157.57 27.88 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.831 0.348 . . . . 0.0 110.452 179.541 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 47.9 mm -114.73 129.67 70.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.298 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 85.7 mt -111.1 132.58 59.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.725 -179.494 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -78.45 113.71 16.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.841 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.4 mt -68.23 125.93 26.98 Favored 'Isoleucine or valine' 0 C--O 1.232 0.178 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.472 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 80.7 mt -105.34 -50.79 8.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.338 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 77.9 m -139.31 149.88 44.75 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.709 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.5 mtpt -132.07 159.64 38.28 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.612 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 82.4 p -132.0 158.57 75.15 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.537 179.697 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_exo -53.11 -39.23 80.72 Favored 'Trans proline' 0 N--CA 1.497 1.722 0 C-N-CA 122.488 2.125 . . . . 0.0 112.155 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 11.5 tpt -162.23 90.31 0.74 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.491 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 179.66 -178.18 48.5 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.1 mtp -62.49 147.59 48.36 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.02 0.438 . . . . 0.0 110.569 -179.406 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 43.8 m0 -95.86 147.05 24.06 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.462 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 96.8 m -107.62 132.75 52.96 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.882 179.513 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -151.3 -177.8 25.47 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.7 ttp -121.0 141.24 50.91 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 120.975 0.417 . . . . 0.0 110.631 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -140.93 110.84 6.52 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.4 179.785 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 50.9 m-20 54.99 56.38 6.66 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.876 -0.33 . . . . 0.0 110.197 179.447 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 87.0 m-20 56.13 36.52 27.56 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.724 0.297 . . . . 0.0 110.781 -179.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 18.4 tptm -138.43 113.26 9.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.11 179.337 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 98.3 t -93.48 126.89 45.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 120.811 -0.356 . . . . 0.0 110.507 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -154.77 177.62 31.96 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.653 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -106.94 155.0 20.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.057 0.456 . . . . 0.0 110.953 -179.549 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 32.1 p90 -156.29 162.75 40.09 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.02 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 7.4 ttmm -76.67 115.98 16.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.72 -179.218 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 51.9 p90 -58.34 -22.61 53.95 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.818 179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.6 mt -66.29 -39.35 83.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 121.062 0.458 . . . . 0.0 110.602 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.3 m-30 -79.65 -0.18 32.85 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.122 -179.017 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -130.0 158.09 42.52 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 CA-C-O 120.857 0.36 . . . . 0.0 110.263 179.749 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -121.08 141.31 50.9 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.46 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.3 p -92.02 126.16 44.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.816 -179.782 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 44.4 pt -128.29 154.3 38.82 Favored 'Isoleucine or valine' 0 C--O 1.236 0.375 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.764 179.691 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 36.9 t -110.5 130.73 55.49 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.608 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.6 tm-20 . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.684 -179.977 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.1 m . . . . . 0 N--CA 1.456 -0.139 0 CA-C-O 120.853 0.359 . . . . 0.0 110.285 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 166.88 -140.31 6.23 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.5 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -117.29 154.96 30.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.348 . . . . 0.0 110.7 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -122.96 137.2 55.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.391 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -99.36 118.66 36.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.347 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 69.6 t -69.41 130.05 34.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.914 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 23.9 m-70 -108.86 -22.52 12.16 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.811 179.389 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 50.7 p -125.99 158.4 35.38 Favored 'General case' 0 C--N 1.332 -0.177 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.348 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -91.27 116.55 28.92 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.823 -179.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 14.1 t80 -116.16 117.53 30.31 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.049 179.347 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 8.1 t -117.76 141.11 28.54 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.136 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -72.42 153.82 55.61 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.668 2.245 . . . . 0.0 112.456 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.5 p -72.91 166.17 45.67 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.036 -179.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -55.47 -42.14 71.02 Favored 'Trans proline' 0 N--CA 1.501 1.968 0 C-N-CA 122.906 2.404 . . . . 0.0 112.639 -179.461 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -97.37 11.43 36.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.879 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 65.2 t0 -112.19 112.07 23.42 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.768 0.318 . . . . 0.0 110.517 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 48.9 p -110.86 -24.16 10.58 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.484 179.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -63.36 -38.43 91.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.615 179.595 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.2 t -61.58 140.61 58.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.901 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 19.3 tp -89.39 143.71 26.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.748 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.8 pttt -97.03 137.55 35.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.452 179.093 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 2.4 pt -142.17 145.72 23.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.283 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.173 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 17.1 mttm -117.76 152.32 35.53 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.352 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -61.28 129.98 43.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.958 0.409 . . . . 0.0 110.285 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.19 -22.18 41.22 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -71.72 154.97 40.99 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.826 0.346 . . . . 0.0 110.609 179.186 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 76.2 mt -119.42 133.64 65.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.332 179.682 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 84.3 mt -117.66 132.04 68.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.913 -179.601 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -75.42 123.12 24.85 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 109.89 179.484 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 93.3 mt -69.11 129.34 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 O-C-N 123.881 0.738 . . . . 0.0 110.365 -179.662 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 89.9 mt -109.55 -54.53 5.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.66 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 44.1 t -163.99 147.65 9.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.189 -179.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -92.94 146.27 23.75 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.726 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.2 p -103.25 154.45 37.68 Favored Pre-proline 0 C--N 1.328 -0.346 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.514 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -62.11 -25.71 77.53 Favored 'Trans proline' 0 N--CA 1.497 1.704 0 C-N-CA 122.653 2.235 . . . . 0.0 112.159 179.332 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 96.4 mmm -70.17 -22.13 62.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.521 179.693 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 114.31 -26.26 9.87 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.4 mtp -64.95 147.04 54.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.983 0.421 . . . . 0.0 110.765 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 43.4 m0 -102.38 146.09 28.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.241 0.544 . . . . 0.0 111.321 -179.269 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 98.3 m -108.8 135.33 50.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.605 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -153.76 -176.93 26.7 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.9 ttp -118.46 140.29 50.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.933 0.397 . . . . 0.0 111.244 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -143.92 113.96 7.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.511 179.659 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 47.0 m-20 56.98 55.31 6.21 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 32.6 m120 54.53 35.91 24.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.613 0.244 . . . . 0.0 110.491 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 36.6 ttpt -139.48 114.92 9.86 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 120.624 -0.43 . . . . 0.0 110.431 179.465 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 86.9 t -93.28 128.17 44.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.442 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -156.22 179.36 32.17 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 57.2 m-80 -104.38 158.46 16.45 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.222 0.534 . . . . 0.0 110.96 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 7.2 p90 -155.97 160.23 39.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.223 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -63.94 116.27 5.68 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.109 -179.141 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -58.24 -29.0 65.4 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.514 179.753 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 16.3 tt -74.6 -33.96 33.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.896 179.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.8 m-30 -72.1 -20.79 61.59 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.519 179.596 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 6.1 p -114.97 160.07 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.112 179.06 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -128.92 149.39 50.81 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.688 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.3 p -92.85 135.19 28.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.594 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 23.2 pt -121.04 158.24 23.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.461 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 41.1 t -61.37 138.72 58.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.587 -179.74 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 20.0 tp10 . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.182 -0.913 . . . . 0.0 110.521 179.983 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.1 m . . . . . 0 N--CA 1.456 -0.139 0 CA-C-O 120.853 0.359 . . . . 0.0 110.285 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 166.88 -140.31 6.23 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.5 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -117.29 154.96 30.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.348 . . . . 0.0 110.7 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -122.96 137.2 55.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.391 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -99.36 118.66 36.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.347 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 69.6 t -69.41 130.05 34.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.914 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 23.9 m-70 -108.86 -22.52 12.16 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.811 179.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 50.7 p -125.99 158.4 35.38 Favored 'General case' 0 C--N 1.332 -0.177 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.348 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -91.27 116.55 28.92 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.823 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 14.1 t80 -116.16 117.53 30.31 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.049 179.347 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 8.1 t -117.76 141.11 28.54 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.136 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -72.42 153.82 55.61 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.668 2.245 . . . . 0.0 112.456 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.5 p -72.91 166.17 45.67 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.036 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -55.47 -42.14 71.02 Favored 'Trans proline' 0 N--CA 1.501 1.968 0 C-N-CA 122.906 2.404 . . . . 0.0 112.639 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -97.37 11.43 36.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.879 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 65.2 t0 -112.19 112.07 23.42 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.768 0.318 . . . . 0.0 110.517 -179.714 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 48.9 p -110.86 -24.16 10.58 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.484 179.241 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -63.36 -38.43 91.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.615 179.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.2 t -61.58 140.61 58.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.901 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 19.3 tp -89.39 143.71 26.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.748 -179.704 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.8 pttt -97.03 137.55 35.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.452 179.093 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 2.4 pt -142.17 145.72 23.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.283 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.173 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 17.1 mttm -117.76 152.32 35.53 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.352 179.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -61.28 129.98 43.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.958 0.409 . . . . 0.0 110.285 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.19 -22.18 41.22 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -71.72 154.97 40.99 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.826 0.346 . . . . 0.0 110.609 179.186 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 76.2 mt -119.42 133.64 65.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.332 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 84.3 mt -117.66 132.04 68.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.913 -179.601 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -75.42 123.12 24.85 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 109.89 179.484 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 93.3 mt -69.11 129.34 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 O-C-N 123.881 0.738 . . . . 0.0 110.365 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 89.9 mt -109.55 -54.53 5.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.66 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 44.1 t -163.99 147.65 9.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.189 -179.604 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -92.94 146.27 23.75 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.726 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.2 p -103.25 154.45 37.68 Favored Pre-proline 0 C--N 1.328 -0.346 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.514 -179.668 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -62.11 -25.71 77.53 Favored 'Trans proline' 0 N--CA 1.497 1.704 0 C-N-CA 122.653 2.235 . . . . 0.0 112.159 179.332 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 96.4 mmm -70.17 -22.13 62.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.521 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 114.31 -26.26 9.87 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.4 mtp -64.95 147.04 54.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.983 0.421 . . . . 0.0 110.765 179.71 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 43.4 m0 -102.38 146.09 28.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.241 0.544 . . . . 0.0 111.321 -179.269 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 98.3 m -108.8 135.33 50.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.605 179.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -153.76 -176.93 26.7 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.9 ttp -118.46 140.29 50.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.933 0.397 . . . . 0.0 111.244 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -143.92 113.96 7.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.511 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 47.0 m-20 56.98 55.31 6.21 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 32.6 m120 54.53 35.91 24.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.613 0.244 . . . . 0.0 110.491 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 36.6 ttpt -139.48 114.92 9.86 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 120.624 -0.43 . . . . 0.0 110.431 179.465 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 86.9 t -93.28 128.17 44.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.442 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -156.22 179.36 32.17 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 57.2 m-80 -104.38 158.46 16.45 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.222 0.534 . . . . 0.0 110.96 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 7.2 p90 -155.97 160.23 39.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.223 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -63.94 116.27 5.68 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.109 -179.141 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -58.24 -29.0 65.4 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.514 179.753 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 16.3 tt -74.6 -33.96 33.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.896 179.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.8 m-30 -72.1 -20.79 61.59 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.519 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 6.1 p -114.97 160.07 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.112 179.06 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -128.92 149.39 50.81 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.688 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.3 p -92.85 135.19 28.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.594 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 23.2 pt -121.04 158.24 23.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.461 179.815 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 41.1 t -61.37 138.72 58.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.587 -179.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 20.0 tp10 . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.182 -0.913 . . . . 0.0 110.521 179.983 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 31.5 p . . . . . 0 N--CA 1.455 -0.193 0 CA-C-O 120.949 0.404 . . . . 0.0 110.132 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.0 -125.45 0.98 Allowed Glycine 0 CA--C 1.523 0.537 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.237 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 28.4 mmt85 -129.56 141.72 50.91 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.053 0.454 . . . . 0.0 110.659 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -107.59 118.68 37.37 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.315 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 68.7 ttt180 -98.45 123.81 42.8 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.977 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 65.9 t -79.54 125.18 38.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.135 -178.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 33.2 p80 -105.77 -10.04 16.93 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.202 179.327 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 14.4 t -145.38 151.21 37.9 Favored 'General case' 0 C--O 1.231 0.1 0 CA-C-O 120.841 0.353 . . . . 0.0 110.174 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -80.8 110.42 16.29 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.938 -179.403 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 11.2 t80 -120.69 130.6 54.16 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.369 179.229 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 71.3 p -124.5 152.87 69.19 Favored Pre-proline 0 CA--C 1.53 0.2 0 C-N-CA 120.74 -0.384 . . . . 0.0 110.793 -179.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -76.45 159.91 35.73 Favored 'Trans proline' 0 N--CA 1.492 1.399 0 C-N-CA 122.72 2.28 . . . . 0.0 112.232 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 57.7 m -71.57 157.6 89.53 Favored Pre-proline 0 C--N 1.331 -0.213 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.663 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_exo -53.0 -43.39 57.31 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.241 1.961 . . . . 0.0 111.959 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -84.26 -13.96 51.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.963 179.647 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -91.3 104.13 16.71 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.288 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 71.7 p -102.15 -24.84 13.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.816 0.341 . . . . 0.0 110.53 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -63.08 -38.2 90.25 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.534 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.0 t -73.55 131.15 41.41 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.255 179.742 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 2.5 tp -88.5 161.58 16.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.231 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 23.6 pttm -97.35 145.72 25.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.401 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.3 pt -133.57 149.65 31.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.175 179.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 38.0 ttmt -130.71 150.64 51.8 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 57.3 mtmt -55.03 125.72 21.62 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.092 0.472 . . . . 0.0 110.819 -179.21 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.3 -17.36 57.02 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -71.77 142.8 49.71 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 116.923 0.362 . . . . 0.0 110.492 179.631 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 50.5 mm -114.89 128.18 72.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.106 179.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 85.9 mt -118.45 127.87 75.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.636 -179.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -78.44 135.22 37.34 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.479 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 97.3 mt -76.91 120.9 28.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 C-N-CA 120.822 -0.351 . . . . 0.0 110.318 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.5 mt -107.75 -51.73 7.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.771 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 49.0 t -153.71 144.36 22.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.965 -179.553 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -96.5 142.58 28.41 Favored 'General case' 0 C--N 1.325 -0.46 0 C-N-CA 120.766 -0.374 . . . . 0.0 110.018 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 28.2 m -98.93 135.6 20.86 Favored Pre-proline 0 CA--C 1.54 0.563 0 C-N-CA 120.09 -0.644 . . . . 0.0 110.117 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -50.81 -32.57 37.56 Favored 'Trans proline' 0 N--CA 1.5 1.885 0 C-N-CA 122.373 2.049 . . . . 0.0 112.456 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 24.3 mmt -60.81 -38.85 86.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.273 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 140.67 -40.16 1.4 Allowed Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 179.745 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 96.5 mtp -61.83 145.92 51.2 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.129 0.49 . . . . 0.0 110.767 -179.359 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 42.5 m0 -98.64 153.89 18.35 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.703 -179.372 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.4 m -111.12 134.56 52.62 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 109.592 -0.522 . . . . 0.0 109.592 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.25 -174.22 25.77 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.333 -0.707 . . . . 0.0 111.333 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.1 ttp -119.33 138.16 53.23 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.831 0.348 . . . . 0.0 110.593 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -145.47 126.25 14.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.342 -179.879 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 6.5 p-10 43.46 56.13 4.52 Favored 'General case' 0 N--CA 1.466 0.371 0 O-C-N 123.441 0.463 . . . . 0.0 111.363 -179.525 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 55.08 34.16 21.95 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.935 0.397 . . . . 0.0 110.544 179.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.7 mmtp -142.34 115.04 8.59 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.392 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 16.0 m -97.68 139.4 20.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 C-N-CA 120.546 -0.462 . . . . 0.0 110.509 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -168.54 -177.42 39.52 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.415 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 -103.36 149.15 25.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.959 0.409 . . . . 0.0 110.701 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -146.71 157.97 43.81 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.334 179.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 23.0 ttmt -81.67 116.89 21.61 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.779 -178.564 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 36.5 p90 -57.98 -24.58 58.69 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.989 -179.658 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 10.6 tp -58.18 -25.17 26.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.883 0.373 . . . . 0.0 110.653 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 25.1 m-85 -100.94 14.06 33.12 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.191 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -143.22 156.13 17.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.746 0.307 . . . . 0.0 110.311 -179.727 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -130.54 149.93 51.98 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.563 179.254 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.6 m -93.78 131.71 39.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.272 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 42.0 pt -126.53 149.77 31.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.832 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 83.7 p -75.85 163.37 27.29 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.732 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.018 -0.992 . . . . 0.0 110.546 179.712 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 28.1 p . . . . . 0 N--CA 1.457 -0.093 0 CA-C-O 120.887 0.375 . . . . 0.0 110.363 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.55 -146.6 6.61 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 -179.421 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 8.2 mmm180 -121.02 142.15 50.07 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.901 -0.32 . . . . 0.0 110.543 -179.516 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.11 127.68 56.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.532 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 17.9 mtp180 -105.14 128.26 53.29 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.46 179.782 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.9 t -86.28 131.26 35.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.327 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 64.4 m170 -111.89 -11.66 13.87 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.047 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 4.2 p -124.89 174.67 7.8 Favored 'General case' 0 N--CA 1.455 -0.188 0 CA-C-O 121.173 0.511 . . . . 0.0 110.419 -179.416 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -103.48 112.0 24.7 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.627 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 8.9 t80 -119.19 118.9 32.58 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-O 121.011 0.434 . . . . 0.0 110.253 179.62 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 4.8 t -133.61 95.2 18.0 Favored Pre-proline 0 CA--C 1.543 0.696 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.519 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -68.41 153.61 73.66 Favored 'Trans proline' 0 C--N 1.301 -1.924 0 C-N-CA 122.305 2.003 . . . . 0.0 112.313 -179.444 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 48.1 m -65.65 154.49 88.37 Favored Pre-proline 0 N--CA 1.453 -0.294 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.533 -179.564 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.15 -20.98 64.15 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.847 2.365 . . . . 0.0 112.0 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -66.94 -23.56 65.98 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.249 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -99.69 96.53 7.68 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.324 179.409 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.1 t -75.96 -32.8 59.69 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.614 179.617 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -66.85 -38.12 85.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.532 179.722 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 69.1 m -67.49 123.32 20.1 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.671 -179.477 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -85.08 156.31 21.12 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.586 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 60.4 mtpt -98.56 127.84 44.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.645 179.625 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 45.8 pt -138.48 148.37 24.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.509 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 28.2 mttm -127.4 163.44 24.04 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.537 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -61.37 124.61 21.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.52 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 107.42 -31.18 8.32 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.799 -0.92 . . . . 0.0 110.799 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -66.63 145.86 55.11 Favored 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 120.881 -0.328 . . . . 0.0 110.346 179.503 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 60.6 mt -116.49 132.23 66.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.51 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.7 mp -114.86 129.17 71.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.857 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -72.78 122.52 21.67 Favored 'General case' 0 CA--C 1.518 -0.286 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.122 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.96 127.02 28.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 120.986 0.422 . . . . 0.0 110.93 -179.484 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.5 mt -109.39 -54.64 5.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.247 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 20.4 p -162.64 172.6 15.1 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.614 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 31.1 mtpt -120.39 150.23 41.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.451 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 67.3 p -121.71 151.66 57.63 Favored Pre-proline 0 CA--C 1.535 0.386 0 C-N-CA 120.339 -0.545 . . . . 0.0 110.915 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -69.02 -20.73 37.92 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.682 2.255 . . . . 0.0 112.242 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 3.0 mpp? -60.0 -15.51 23.0 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.484 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 97.16 22.8 16.23 Favored Glycine 0 C--N 1.336 0.564 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 96.4 mmm -127.19 144.41 51.04 Favored 'General case' 0 C--O 1.236 0.379 0 CA-C-O 121.039 0.447 . . . . 0.0 110.671 179.726 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 6.0 m0 -98.4 142.49 29.96 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.469 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 89.0 m -105.97 132.1 52.47 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 116.01 -0.541 . . . . 0.0 109.875 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -151.66 -179.87 27.69 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 60.7 ttm -115.81 142.02 47.32 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.989 0.424 . . . . 0.0 110.878 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -143.45 107.94 4.83 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.869 -179.89 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 53.77 53.92 10.64 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.29 179.491 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 54.4 t30 61.07 30.75 19.67 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.64 -179.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 62.8 tttm -137.63 112.81 9.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.05 179.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 27.4 m -99.09 144.12 12.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.875 0.369 . . . . 0.0 110.648 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -170.09 -173.08 37.19 Favored Glycine 0 CA--C 1.528 0.901 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 -179.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 35.4 m120 -103.4 148.29 26.08 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.985 0.421 . . . . 0.0 110.851 -179.287 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.8 p90 -153.21 160.1 42.75 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.727 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.408 ' HB3' HG12 ' A' ' 80' ' ' ILE . 96.7 mttt -79.71 122.34 26.45 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-O 121.433 0.635 . . . . 0.0 110.518 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 12.0 p90 -68.99 -24.11 64.19 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.199 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.408 HG12 ' HB3' ' A' ' 78' ' ' LYS . 28.4 pt -62.2 -19.69 22.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.833 0.349 . . . . 0.0 110.825 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 30.6 m-85 -102.69 5.66 39.12 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.865 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -136.16 153.86 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 CA-C-O 121.109 0.481 . . . . 0.0 110.638 -179.697 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 -127.51 143.19 51.22 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.565 179.245 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.8 m -88.61 136.93 22.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.229 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 42.5 pt -120.23 157.79 22.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.803 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 83.3 p -72.95 160.77 31.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.656 179.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 118.015 -0.993 . . . . 0.0 110.543 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 79.9 m . . . . . 0 N--CA 1.458 -0.067 0 CA-C-O 120.887 0.375 . . . . 0.0 110.652 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -172.98 -153.29 9.36 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 -179.529 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 39.6 mmt180 -116.45 144.03 44.83 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.886 0.374 . . . . 0.0 110.58 -179.491 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -113.04 121.86 45.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.619 -179.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 94.8 mtt180 -95.77 121.4 37.46 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.51 178.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 67.2 t -76.64 119.84 25.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.352 -179.399 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 4.3 p80 -105.85 -16.05 14.76 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.438 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 1.3 m -126.34 142.56 51.49 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.579 179.653 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -77.33 104.57 7.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.978 0.418 . . . . 0.0 110.333 -179.474 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 26.0 t80 -116.52 115.25 25.43 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.63 179.674 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 10.2 t -129.76 137.42 30.88 Favored Pre-proline 0 N--CA 1.452 -0.375 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.605 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -73.49 160.79 43.77 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.855 2.37 . . . . 0.0 112.242 -179.462 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 89.1 p -70.39 161.22 77.81 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.467 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -55.35 -37.71 94.42 Favored 'Trans proline' 0 N--CA 1.496 1.652 0 C-N-CA 122.736 2.291 . . . . 0.0 112.189 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -85.59 1.49 48.9 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.72 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -107.25 108.88 20.5 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-O 120.855 0.36 . . . . 0.0 110.34 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 10.1 t -111.03 -27.26 8.84 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.77 179.809 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -62.44 -38.94 91.68 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.659 -179.684 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.5 t -69.53 141.59 53.82 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.579 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 59.8 tp -83.36 143.64 30.19 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.554 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 26.0 pttm -98.64 137.75 36.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.899 0.381 . . . . 0.0 110.74 178.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.414 HD12 HG23 ' A' ' 49' ' ' ILE . 46.3 pt -137.7 147.5 26.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.78 179.526 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -119.38 156.14 30.65 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.032 -179.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.7 ttpt -61.61 120.8 11.29 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.461 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 104.84 -22.19 34.32 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 111.092 -0.803 . . . . 0.0 111.092 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -65.81 147.54 53.21 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-O 120.884 0.373 . . . . 0.0 110.906 179.257 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 47.2 mm -108.73 126.72 65.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.661 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.4 mt -109.22 128.9 64.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.78 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -79.29 112.51 16.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.306 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.3 mt -65.35 126.5 24.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.606 -179.487 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.6 mt -112.41 -55.29 4.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.6 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.9 t -162.86 151.69 14.71 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.74 -179.439 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.4 156.08 17.83 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.46 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.4 p -110.38 154.56 42.91 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.319 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -60.03 -26.84 83.53 Favored 'Trans proline' 0 C--N 1.305 -1.735 0 C-N-CA 122.807 2.338 . . . . 0.0 112.286 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 78.9 mtm -63.99 -38.15 90.02 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.501 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 133.82 -35.55 2.24 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 8.7 mtt -63.0 147.31 51.03 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.918 0.389 . . . . 0.0 110.624 -179.601 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 21.6 m0 -101.88 151.58 21.93 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.865 -179.534 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.0 m -114.08 136.37 53.0 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.866 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -154.56 -174.54 24.7 Favored Glycine 0 CA--C 1.524 0.646 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 -179.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 65.3 ttp -117.83 141.36 48.5 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 120.624 0.249 . . . . 0.0 110.638 -179.771 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 1.3 mt -143.46 110.44 5.65 Favored 'General case' 0 C--O 1.219 -0.512 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.58 179.745 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . 0.4 ' ND2' ' N ' ' A' ' 71' ' ' ASN . 0.1 OUTLIER 54.27 54.16 9.9 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 178.926 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 59.79 28.57 18.06 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.369 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 85.1 tttt -133.99 112.99 11.67 Favored 'General case' 0 C--O 1.225 -0.214 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.107 179.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 19.1 m -99.84 144.0 12.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.855 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -174.86 -173.84 41.03 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -179.536 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 78.1 m-20 -101.57 149.45 24.09 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.849 0.357 . . . . 0.0 110.646 -179.548 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -148.96 160.78 42.98 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.857 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 24.3 tptt -82.01 114.3 20.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.434 -179.168 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -62.9 -26.18 68.67 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.588 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 10.2 tt -58.94 -30.33 42.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.814 0.34 . . . . 0.0 110.917 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 25.2 m-85 -93.32 5.34 51.89 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.04 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.42 156.44 42.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 CA-C-O 121.05 0.453 . . . . 0.0 110.68 -179.884 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 85.3 m-20 -123.6 140.07 53.36 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.436 179.352 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -93.84 142.83 12.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 120.949 0.404 . . . . 0.0 110.724 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 39.3 pt -128.6 159.02 40.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.82 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 99.1 p -106.61 160.67 15.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.598 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.569 179.966 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 81.0 m . . . . . 0 N--CA 1.454 -0.264 0 CA-C-O 121.006 0.431 . . . . 0.0 110.212 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -176.08 -144.36 5.09 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -117.83 142.87 46.82 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.694 0.283 . . . . 0.0 110.468 -179.726 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -116.44 137.1 52.43 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.853 0.359 . . . . 0.0 110.454 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 16.0 ptm180 -116.77 133.87 55.48 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 89.6 t -82.3 127.98 39.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.42 -178.669 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 88.5 m-70 -109.71 -17.13 13.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.435 179.267 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 7.4 p -120.22 173.79 6.9 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.879 0.371 . . . . 0.0 110.143 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -101.03 107.71 19.23 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.803 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -117.82 109.84 17.05 Favored 'General case' 0 N--CA 1.463 0.217 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.129 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 90.8 m -128.62 128.23 23.54 Favored Pre-proline 0 CA--C 1.537 0.45 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.852 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -74.48 163.89 35.14 Favored 'Trans proline' 0 N--CA 1.489 1.25 0 C-N-CA 122.489 2.126 . . . . 0.0 112.165 179.612 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 69.7 m -70.57 158.61 87.41 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.565 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -54.4 -35.05 83.49 Favored 'Trans proline' 0 N--CA 1.499 1.807 0 C-N-CA 122.605 2.203 . . . . 0.0 112.128 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 35.5 p90 -90.56 4.11 52.15 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.212 179.803 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -108.58 111.57 23.47 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.551 -0.295 . . . . 0.0 110.364 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 61.4 p -112.89 -19.66 11.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.729 179.504 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -61.98 -38.74 89.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.665 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 58.2 m -80.3 144.19 33.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.682 179.79 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 47.1 tp -81.98 144.03 31.18 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.721 -179.612 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 7.1 ptpp? -98.34 118.56 35.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.622 178.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 20.1 pt -140.04 158.33 26.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.163 0.506 . . . . 0.0 110.926 -179.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.5 164.45 30.31 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.016 0.436 . . . . 0.0 110.679 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -60.59 129.1 39.87 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.914 -179.674 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 109.83 -20.39 26.9 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 111.361 -0.695 . . . . 0.0 111.361 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -85.18 147.41 26.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.003 0.43 . . . . 0.0 110.495 179.273 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 21.7 mm -112.49 129.33 68.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.316 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 75.9 mt -112.55 127.93 69.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.752 -179.228 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.9 m-20 -78.62 124.94 28.7 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.232 -0.44 . . . . 0.0 109.877 179.591 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 93.4 mt -70.58 123.24 24.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 120.882 0.372 . . . . 0.0 110.478 -179.204 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.6 mt -106.34 -51.34 7.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.41 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 49.6 t -168.29 154.76 7.39 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.022 0.439 . . . . 0.0 110.975 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -90.15 136.15 33.22 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.083 179.26 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.5 t -123.45 148.02 54.34 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.87 -179.307 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -52.32 -169.67 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.454 0 C-N-CA 122.418 2.079 . . . . 0.0 112.126 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 91.6 mtp 63.64 15.85 9.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.376 -179.196 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 63.71 37.4 94.65 Favored Glycine 0 CA--C 1.522 0.471 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 179.466 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 75.0 mtp -126.46 150.68 48.54 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 120.411 -0.516 . . . . 0.0 111.387 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 10.7 m0 -110.82 147.9 33.53 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.625 179.625 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 85.1 m -104.99 131.26 52.74 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.716 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -155.94 -176.45 28.1 Favored Glycine 0 CA--C 1.522 0.487 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.487 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.4 ttp -122.46 138.31 54.59 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.757 0.313 . . . . 0.0 110.657 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -144.3 121.58 11.58 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.185 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 75.6 m-20 53.18 48.4 22.27 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 59.71 29.72 19.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.706 0.289 . . . . 0.0 110.354 -179.537 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 42.9 tptt -130.48 114.9 16.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.259 -0.428 . . . . 0.0 109.881 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 89.7 t -96.54 125.89 49.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.878 -0.329 . . . . 0.0 110.586 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -160.16 -179.71 35.12 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 -179.496 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 -98.83 149.79 22.53 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.026 0.441 . . . . 0.0 110.923 -179.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -152.17 159.16 43.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.692 179.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 1.5 mptp? -78.73 116.29 18.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.82 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 33.8 p90 -61.49 -25.11 67.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.629 179.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 40.9 pt -62.37 -20.12 23.89 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 CA-C-O 120.78 0.324 . . . . 0.0 110.8 179.634 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 49.5 m-85 -100.18 3.61 43.87 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.805 179.002 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -132.17 157.42 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 CA-C-O 120.86 0.362 . . . . 0.0 110.314 -179.544 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -120.06 133.16 55.6 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.714 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 3.2 m -88.05 137.61 20.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 C-N-CA 120.579 -0.448 . . . . 0.0 110.354 179.659 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 43.0 pt -129.71 158.79 42.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.756 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 67.2 m -112.57 143.96 42.86 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.507 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.556 179.875 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 28.4 p . . . . . 0 C--O 1.232 0.162 0 CA-C-O 120.84 0.352 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.99 -148.13 11.0 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 -179.377 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 1.7 mpt_? -113.01 141.91 46.31 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.95 0.405 . . . . 0.0 110.463 179.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -117.77 130.97 56.63 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.643 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 41.2 ttm180 -97.14 121.51 39.11 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.576 179.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 77.1 t -82.65 129.18 37.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.495 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -112.88 8.63 18.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.974 179.452 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.0 p -137.12 166.87 22.69 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.74 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -108.56 104.74 14.12 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.356 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 16.1 t80 -118.72 119.19 33.69 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.628 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 82.4 p -120.74 152.28 55.66 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.609 -179.748 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -76.14 153.44 36.49 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.763 2.309 . . . . 0.0 112.406 -179.751 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 58.3 m -73.34 156.69 88.89 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.483 179.268 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -54.28 -39.4 86.93 Favored 'Trans proline' 0 C--N 1.301 -1.948 0 C-N-CA 122.858 2.372 . . . . 0.0 112.059 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -93.15 4.14 54.5 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.427 179.385 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -113.71 117.98 33.05 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.31 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 t -112.22 -25.13 9.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.79 179.592 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 -62.04 -38.43 88.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.595 -179.741 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 62.0 m -62.13 142.54 57.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.727 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 56.8 tp -90.38 142.49 27.68 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.423 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -94.73 121.84 36.73 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-O 120.939 0.399 . . . . 0.0 110.414 179.066 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 37.8 pt -131.1 155.21 41.75 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.62 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 48.7 pttt -137.27 160.68 38.34 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.564 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -66.3 131.85 47.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.95 179.349 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 102.42 -18.75 50.31 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -82.87 152.01 25.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.823 0.344 . . . . 0.0 110.369 179.505 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 96.4 mt -116.29 133.11 63.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.62 179.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 82.5 mt -118.11 134.15 62.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.783 -179.294 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -80.49 122.94 27.62 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.189 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.3 mt -72.92 124.48 29.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.75 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 8.9 tt -107.0 -33.86 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.449 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 24.0 p -175.54 175.34 2.13 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.463 -179.324 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -126.35 151.8 47.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.536 179.464 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 31.0 p -105.18 153.42 39.56 Favored Pre-proline 0 N--CA 1.454 -0.261 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.611 -179.404 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -57.05 -35.93 99.1 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 C-N-CA 122.779 2.319 . . . . 0.0 112.227 179.717 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 98.2 mtp -61.29 -37.35 82.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.646 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 131.13 -25.46 4.1 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 96.4 mtp -62.15 139.67 58.46 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.027 0.441 . . . . 0.0 110.341 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 37.7 m0 -96.25 148.11 23.08 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.986 -179.371 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 58.3 m -119.48 140.49 50.38 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-N 116.022 -0.536 . . . . 0.0 109.885 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -164.81 -168.93 27.71 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -179.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.8 ttp -116.03 135.34 54.05 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-O 120.671 0.272 . . . . 0.0 110.739 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 3.1 tt -135.7 112.51 10.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.371 179.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 66.9 t30 55.41 53.9 9.26 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.855 178.794 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 59.02 28.61 17.92 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.743 179.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -139.33 113.31 8.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.086 179.395 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 19.4 m -95.31 143.67 11.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.859 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -172.34 -173.39 38.95 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.664 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -111.73 155.14 23.96 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.748 0.309 . . . . 0.0 110.451 -179.355 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 9.2 p90 -155.62 157.85 37.4 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.812 179.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -63.99 132.81 51.76 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.45 -179.639 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 29.6 p90 -67.08 -21.32 65.89 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.684 -179.17 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 12.5 pt -78.22 -27.0 14.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.334 -179.618 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.2 m-85 -84.3 1.16 46.21 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.71 179.724 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.1 p -139.33 157.88 28.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.31 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -132.22 147.41 52.41 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.392 179.798 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.1 p -83.36 131.21 34.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.597 179.744 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 61.1 mt -88.78 115.84 29.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.456 -178.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 70.8 p -79.4 165.34 23.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.488 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 78.2 mm-40 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.566 179.55 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 31.7 p . . . . . 0 N--CA 1.456 -0.147 0 CA-C-O 120.927 0.394 . . . . 0.0 110.342 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -166.86 -162.92 19.67 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 -179.375 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 10.9 mpt_? -119.6 147.55 44.37 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.764 0.316 . . . . 0.0 110.786 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -134.57 154.61 51.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.807 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 17.5 ptm180 -131.0 148.95 52.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.741 -179.589 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.8 t -86.26 128.71 39.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.301 -179.043 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 26.4 m170 -97.87 -16.98 19.54 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.517 178.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 13.1 t -144.53 142.8 30.48 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.885 -0.326 . . . . 0.0 110.145 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -62.59 117.45 6.26 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.777 -0.369 . . . . 0.0 110.731 -179.37 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -121.69 110.63 16.18 Favored 'General case' 0 C--O 1.233 0.201 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 88.0 m -129.14 94.73 32.91 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.057 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -54.78 152.7 27.36 Favored 'Trans proline' 0 N--CA 1.494 1.521 0 C-N-CA 122.358 2.039 . . . . 0.0 112.013 -179.596 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 39.0 m -59.14 154.73 38.59 Favored Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.474 -179.425 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -57.28 -24.65 60.86 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.554 2.17 . . . . 0.0 112.186 -179.434 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -65.87 -20.63 66.3 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.331 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 50.3 m-20 -96.11 59.68 1.96 Allowed 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 120.956 0.408 . . . . 0.0 110.521 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 12.8 t -60.46 -18.65 52.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.575 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 57.9 p-10 -90.1 7.23 38.91 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.314 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 67.8 m -106.57 144.41 33.28 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-O 120.917 0.389 . . . . 0.0 110.629 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 58.5 tp -81.6 142.03 33.16 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.536 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 1.6 mptm? -98.7 126.79 44.42 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.47 179.051 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 21.6 pt -131.49 148.5 32.65 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.631 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 39.3 ttpt -122.65 152.57 40.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.844 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 38.7 ttmt -57.11 128.35 36.56 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.058 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.38 -18.67 55.03 Favored Glycine 0 CA--C 1.524 0.635 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.451 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -72.23 144.96 48.27 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.796 0.332 . . . . 0.0 110.718 179.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.417 HG21 HD13 ' A' ' 54' ' ' ILE . 90.9 mt -111.96 129.08 68.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.35 179.243 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 81.3 mt -122.62 128.5 75.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.908 -179.172 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -76.9 134.03 39.08 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.367 179.349 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 85.9 mt -71.06 103.58 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.919 0.39 . . . . 0.0 110.16 -179.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.8 tt -89.09 -34.52 6.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.327 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 17.1 t -167.45 161.27 13.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.29 -179.46 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -120.57 144.7 47.95 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 27.6 m -101.67 135.69 19.72 Favored Pre-proline 0 CA--C 1.539 0.538 0 C-N-CA 120.232 -0.587 . . . . 0.0 109.98 -179.479 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -57.6 -25.7 68.7 Favored 'Trans proline' 0 N--CA 1.501 1.917 0 C-N-CA 122.359 2.039 . . . . 0.0 112.69 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 65.5 mtt -62.22 -38.74 90.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.959 0.409 . . . . 0.0 110.186 179.503 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 142.17 -40.12 1.32 Allowed Glycine 0 CA--C 1.524 0.634 0 N-CA-C 111.106 -0.798 . . . . 0.0 111.106 179.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 95.5 mtp -64.07 144.39 57.14 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.217 0.532 . . . . 0.0 111.108 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 38.4 m0 -97.4 156.31 16.52 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.369 -179.579 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 80.3 m -117.19 139.31 50.92 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.056 -179.719 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.23 -175.78 27.6 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 16.9 tmm? -121.31 141.55 50.81 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.723 0.297 . . . . 0.0 110.507 -179.697 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -149.31 121.62 8.41 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.992 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 69.5 m-20 50.31 49.96 19.6 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 53.0 t30 59.82 35.07 21.93 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.764 0.316 . . . . 0.0 110.708 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 24.3 tptp -134.26 115.94 14.71 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 179.43 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 97.1 t -105.78 129.03 59.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.446 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -165.86 -172.42 33.21 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.59 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.7 m-80 -101.43 153.18 19.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.024 0.44 . . . . 0.0 111.056 -179.508 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 53.4 p90 -149.93 160.43 43.61 Favored 'General case' 0 C--O 1.239 0.54 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.619 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 35.6 tptt -69.62 111.77 5.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.514 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 53.4 p90 -61.53 -24.31 66.53 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.8 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.9 mt -63.14 -39.24 84.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.022 0.439 . . . . 0.0 110.437 -179.807 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 20.6 m-85 -84.71 2.22 42.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.971 -179.581 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 85.6 t -126.02 136.9 59.43 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.147 0 CA-C-O 120.987 0.422 . . . . 0.0 110.813 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -124.41 148.42 47.59 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.373 -179.878 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 16.9 m -90.37 139.6 17.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 C-N-CA 120.662 -0.415 . . . . 0.0 110.58 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . 0.422 HG22 HD13 ' A' ' 85' ' ' ILE . 38.9 pt -120.96 149.78 23.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.796 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 83.9 p -90.84 170.49 10.05 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.674 179.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.049 -0.977 . . . . 0.0 110.482 179.756 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.43 147.74 89.96 Favored 'Trans proline' 0 C--N 1.305 -1.75 0 C-N-CA 122.911 2.407 . . . . 0.0 111.907 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -114.89 139.21 49.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.49 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.4 m -119.76 149.8 41.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.484 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.51 -128.18 1.87 Allowed Glycine 0 CA--C 1.526 0.753 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 9.9 mpt_? -111.48 140.2 46.28 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.754 0.311 . . . . 0.0 110.7 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -111.1 127.1 55.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.445 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 74.2 ttt-85 -103.55 123.66 47.35 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.525 -179.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 66.1 t -77.5 123.51 34.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.621 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 35.4 p80 -105.75 -16.37 14.69 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.741 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 32.6 m -128.45 129.33 45.96 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.692 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -65.71 109.65 2.5 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.557 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 22.5 t80 -117.17 115.4 25.26 Favored 'General case' 0 C--O 1.241 0.611 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.372 179.557 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 95.5 m -131.08 128.28 22.2 Favored Pre-proline 0 N--CA 1.449 -0.502 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.754 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.5 166.41 29.9 Favored 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 123.012 2.475 . . . . 0.0 112.139 179.377 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 61.7 m -67.47 159.52 77.45 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.554 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_exo -55.62 -32.07 81.82 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.722 2.281 . . . . 0.0 112.183 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -95.51 11.45 32.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.763 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -106.69 108.73 20.38 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.339 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 5.0 t -113.51 -8.49 13.36 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.782 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 45.5 p-10 -75.59 -7.12 53.42 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.762 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 73.6 m -118.9 144.37 46.45 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-O 120.787 0.327 . . . . 0.0 110.504 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 9.5 tp -82.11 153.93 25.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.533 -179.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -96.2 130.61 43.23 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.573 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 34.2 pt -134.93 158.53 41.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.414 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.7 tttp -137.0 145.29 43.93 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.798 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 63.4 tttm -54.45 129.2 35.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.637 -179.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.57 -16.83 59.26 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 111.174 -0.77 . . . . 0.0 111.174 -179.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -74.87 148.41 40.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.786 0.327 . . . . 0.0 110.612 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 42.9 mm -109.93 126.63 67.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.392 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 82.9 mt -119.08 129.06 75.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.606 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -77.11 122.77 25.44 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.326 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.4 mt -76.82 125.25 36.46 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.486 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 30.6 pt -114.24 -27.98 2.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.461 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 10.4 t -167.35 161.82 14.41 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.647 -179.158 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -119.14 145.26 46.12 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.231 179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 25.5 m -94.89 134.32 25.09 Favored Pre-proline 0 CA--C 1.534 0.336 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.429 -179.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -50.73 -36.19 50.42 Favored 'Trans proline' 0 N--CA 1.494 1.546 0 C-N-CA 122.806 2.338 . . . . 0.0 112.068 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 60.6 ttm -59.03 -40.23 84.37 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.324 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 144.05 -31.78 1.83 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 97.5 mtp -62.54 146.59 51.38 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.014 0.435 . . . . 0.0 110.842 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 42.6 m0 -102.0 150.79 22.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.965 -179.186 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 93.2 m -110.55 136.73 49.22 Favored 'General case' 0 C--O 1.237 0.417 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.994 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -155.87 -171.56 22.43 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 111.095 -0.802 . . . . 0.0 111.095 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -123.35 147.65 46.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.991 0.424 . . . . 0.0 110.622 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -151.09 117.37 5.64 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.69 -179.742 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 67.5 m-20 51.22 52.83 14.07 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.142 179.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 80.7 m-20 59.68 26.18 15.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.237 -179.561 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.9 tttp -130.25 113.16 14.09 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.504 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 15.6 m -99.37 140.04 19.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.761 179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -171.42 -176.67 40.65 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -179.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 -104.12 150.4 24.36 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.077 0.465 . . . . 0.0 110.459 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -146.22 156.58 43.49 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.723 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 54.6 mttp -67.01 122.18 17.18 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.005 -179.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 55.9 p90 -68.64 -29.58 68.1 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.55 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 33.6 pt -60.46 -21.21 22.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.839 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 22.4 m-85 -102.64 1.51 34.76 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.871 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 68.2 t -127.83 136.51 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 CA-C-O 121.109 0.48 . . . . 0.0 110.752 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 41.7 t0 -110.94 142.26 43.28 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.395 179.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.7 p -86.94 126.3 40.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.772 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 23.4 pt -127.19 163.32 30.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.714 179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 28.7 t -104.74 130.32 52.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.581 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 7.9 tt0 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.554 179.916 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -68.34 143.93 60.1 Favored 'Trans proline' 0 C--N 1.305 -1.716 0 C-N-CA 122.746 2.297 . . . . 0.0 111.947 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 71.7 t80 -142.19 136.65 30.15 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.52 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 84.1 m -100.14 137.53 38.46 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.43 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 172.37 -140.53 5.79 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 21.0 mmm180 -110.14 148.13 32.37 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.887 0.375 . . . . 0.0 110.311 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -121.68 143.67 49.21 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.435 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 38.6 ptt180 -120.25 135.97 54.82 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.033 0.444 . . . . 0.0 110.427 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 43.4 t -84.54 135.53 24.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.982 -178.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 97.4 m-70 -107.28 -12.79 15.28 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.732 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 11.8 t -140.87 148.83 41.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.891 0.377 . . . . 0.0 110.375 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.3 p-10 -75.13 121.43 22.06 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.026 -179.515 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -119.28 118.24 30.73 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 178.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 89.6 m -126.56 94.69 39.8 Favored Pre-proline 0 CA--C 1.534 0.361 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.434 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -56.45 147.79 66.5 Favored 'Trans proline' 0 N--CA 1.499 1.804 0 C-N-CA 122.409 2.073 . . . . 0.0 112.023 -179.635 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 93.7 p -67.92 159.21 80.62 Favored Pre-proline 0 CA--C 1.532 0.255 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.709 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -56.8 -30.77 86.17 Favored 'Trans proline' 0 N--CA 1.499 1.812 0 C-N-CA 122.832 2.355 . . . . 0.0 112.154 -179.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -61.82 -22.96 65.93 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.062 -179.444 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -107.27 103.44 12.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.041 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.9 t -87.51 -33.89 18.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.367 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -63.37 -38.03 89.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.038 179.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 53.4 m -62.38 131.65 49.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.946 0.403 . . . . 0.0 110.647 -179.31 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 1.2 tt -87.55 150.84 23.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.755 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -98.22 123.52 42.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.263 -0.426 . . . . 0.0 109.926 179.092 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 47.3 pt -130.08 159.05 42.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 120.897 0.379 . . . . 0.0 110.902 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -135.71 141.99 44.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.704 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 22.8 pttp -53.35 138.86 31.76 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.982 0.42 . . . . 0.0 110.658 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.1 -17.9 56.42 Favored Glycine 0 CA--C 1.53 0.977 0 N-CA-C 111.2 -0.76 . . . . 0.0 111.2 -179.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -84.64 156.82 21.37 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.789 0.328 . . . . 0.0 110.921 179.569 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 47.4 mm -116.46 131.51 68.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.403 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 89.7 mt -118.25 132.04 69.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.282 -179.559 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 66.9 t0 -74.52 118.48 17.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.74 179.788 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 90.6 mt -69.34 122.4 20.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 120.902 0.382 . . . . 0.0 110.664 -179.433 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 82.6 mt -108.31 -59.44 3.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.183 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 94.2 m -140.87 142.93 34.46 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.479 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 12.2 pttp -154.26 123.21 6.33 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.926 0.393 . . . . 0.0 110.821 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.8 p -75.44 161.68 75.68 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.362 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_exo -52.28 -36.18 66.9 Favored 'Trans proline' 0 N--CA 1.495 1.607 0 C-N-CA 122.506 2.138 . . . . 0.0 111.833 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 14.9 tpt -149.71 97.0 2.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.476 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 168.85 -178.65 42.09 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 111.009 -0.836 . . . . 0.0 111.009 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.1 mtp -60.69 144.51 51.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.023 0.439 . . . . 0.0 110.738 -179.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 26.2 m0 -93.82 146.35 23.94 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.293 -179.57 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.9 m -112.59 135.49 53.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.986 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -160.59 -171.69 26.87 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 67.5 ttp -121.86 135.49 54.9 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.823 0.344 . . . . 0.0 110.407 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 4.2 tt -135.35 117.03 14.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.063 179.662 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 64.8 t30 55.85 52.93 9.98 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.235 179.282 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 33.1 m120 57.94 35.08 25.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.657 0.265 . . . . 0.0 111.4 179.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -139.02 116.89 11.56 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.14 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 89.5 t -95.41 129.94 44.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.604 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -165.67 -174.08 34.85 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.337 -0.705 . . . . 0.0 111.337 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -108.95 156.72 19.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.007 0.432 . . . . 0.0 110.912 -179.555 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -157.52 160.32 38.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.096 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -71.06 117.77 12.98 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.174 0.511 . . . . 0.0 111.119 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 55.6 p90 -63.15 -30.26 71.45 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.512 179.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 18.3 pt -62.43 -18.5 20.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.77 0.319 . . . . 0.0 110.724 179.344 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 15.3 m-30 -100.63 3.63 42.68 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.909 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -132.58 159.94 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -127.59 144.47 51.07 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.526 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.7 p -93.65 128.63 44.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.579 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 44.0 pt -127.68 158.83 39.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.752 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 71.0 m -70.64 144.74 51.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.531 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.606 179.848 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.255 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -69.8 153.34 68.84 Favored 'Trans proline' 0 C--N 1.306 -1.706 0 C-N-CA 122.888 2.392 . . . . 0.0 112.201 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -114.12 133.5 55.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.607 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 24.1 p -66.45 151.66 46.72 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.064 0.459 . . . . 0.0 110.195 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.97 -155.25 14.95 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 26.9 mmt85 -112.22 140.64 46.75 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.885 0.374 . . . . 0.0 110.481 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.6 117.15 30.08 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.496 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 75.5 ttt180 -91.34 124.57 35.64 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.615 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 82.5 t -82.26 129.33 37.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.6 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 88.0 m-70 -107.1 -18.18 13.97 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.851 179.76 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 95.2 m -123.94 134.53 53.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.367 179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -75.07 114.18 13.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.697 -179.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -118.22 125.18 49.65 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.345 179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 10.0 t -132.28 134.18 24.66 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.673 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -72.97 166.41 30.11 Favored 'Trans proline' 0 N--CA 1.492 1.434 0 C-N-CA 122.894 2.396 . . . . 0.0 112.388 179.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 48.8 m -64.13 156.13 76.1 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.482 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -58.51 -27.39 82.07 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.621 2.214 . . . . 0.0 112.306 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -99.29 22.74 10.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.636 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -114.31 113.22 24.28 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.437 179.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 72.8 p -110.73 -15.14 13.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.683 179.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 56.7 p-10 -88.47 10.85 18.75 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.844 179.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 67.7 m -117.26 157.96 25.15 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 120.683 0.278 . . . . 0.0 110.3 -179.668 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 63.8 tp -104.56 136.7 43.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.321 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 13.3 tmtt? -96.72 124.94 40.85 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.385 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 49.3 pt -128.21 158.49 40.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.532 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 64.6 pttt -138.47 161.23 37.54 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.633 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 23.3 pttp -63.13 137.46 58.24 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.765 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.04 -11.6 71.7 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 111.024 -0.831 . . . . 0.0 111.024 -179.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 42.0 t0 -79.43 148.66 31.85 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-O 120.829 0.347 . . . . 0.0 110.463 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 39.0 mm -110.64 127.88 67.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.399 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 93.9 mt -115.22 134.34 58.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.803 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -82.17 111.9 18.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.559 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.5 mt -63.31 130.95 28.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.746 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 97.6 mt -112.57 -63.97 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.715 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.9 t -154.0 138.94 17.21 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.588 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -92.06 153.38 19.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.275 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 81.8 p -125.08 151.91 69.82 Favored Pre-proline 0 CA--C 1.532 0.252 0 C-N-CA 120.477 -0.489 . . . . 0.0 110.695 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -63.69 -18.85 65.92 Favored 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.908 2.406 . . . . 0.0 112.315 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 39.2 mmt -61.76 -37.41 84.19 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.195 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 125.18 -44.06 1.31 Allowed Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.074 -0.811 . . . . 0.0 111.074 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 33.5 mtt -61.85 141.76 57.76 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.98 0.419 . . . . 0.0 110.436 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 26.9 m0 -96.07 147.26 23.91 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.285 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 85.6 m -112.29 137.06 50.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.977 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -158.14 -172.53 25.41 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 37.2 ttm -119.69 140.49 50.58 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 120.734 0.302 . . . . 0.0 110.383 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -144.09 115.57 8.09 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.912 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 57.0 m-20 53.27 51.13 16.12 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.334 179.445 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 52.9 t30 60.75 28.79 18.51 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.545 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 13.0 tppt? -136.83 115.32 11.9 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.45 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.9 m -97.29 142.47 14.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.868 0.366 . . . . 0.0 110.804 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -171.18 -177.65 41.14 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 110.691 -0.963 . . . . 0.0 110.691 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -103.09 157.97 16.62 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 121.083 0.468 . . . . 0.0 110.644 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 2.1 p90 -154.35 161.56 41.68 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.194 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 12.4 tptt -62.17 117.47 6.08 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-O 121.488 0.661 . . . . 0.0 110.882 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -62.3 -23.22 66.6 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.353 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 18.1 tt -73.28 -38.19 53.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.877 0.37 . . . . 0.0 110.812 179.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 22.8 m-85 -80.3 -14.92 57.99 Favored 'General case' 0 C--O 1.24 0.582 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.765 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 67.2 t -111.78 137.08 45.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.223 0 CA-C-O 121.31 0.576 . . . . 0.0 110.61 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 41.5 t0 -121.04 149.47 42.65 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.743 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.3 p -87.85 132.38 33.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.447 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 2.4 tt -104.81 146.09 12.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.654 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 72.0 m -80.17 148.26 30.97 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.473 179.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 117.911 -1.042 . . . . 0.0 110.516 179.834 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.308 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -69.88 149.78 66.6 Favored 'Trans proline' 0 C--N 1.306 -1.71 0 C-N-CA 122.789 2.326 . . . . 0.0 112.099 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -133.22 151.18 51.94 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.513 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 72.9 m -106.14 143.26 34.52 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.455 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 176.88 -123.76 0.92 Allowed Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -179.705 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 19.2 tpp180 -121.54 133.62 55.02 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.791 0.329 . . . . 0.0 110.448 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -104.28 122.94 46.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.694 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 78.3 ttt-85 -107.12 127.16 53.25 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.722 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.0 t -81.03 125.76 39.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.272 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 32.5 p80 -117.24 -13.1 10.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.699 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 97.2 m -125.51 134.37 52.05 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.538 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -69.22 122.98 19.93 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.672 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -71.59 137.69 48.18 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.222 179.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 82.1 m -120.01 93.27 47.72 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.424 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -73.59 151.69 47.35 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.864 2.376 . . . . 0.0 112.452 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 65.5 m -76.56 159.98 78.27 Favored Pre-proline 0 N--CA 1.452 -0.355 0 CA-C-O 121.263 0.554 . . . . 0.0 110.7 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -55.44 -37.47 94.81 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 122.733 2.289 . . . . 0.0 111.638 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.2 p90 -91.1 15.59 11.39 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.624 -179.702 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -108.81 94.83 5.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.276 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 71.2 p -104.42 -22.72 13.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.638 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -87.1 6.83 30.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.696 179.3 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 82.7 p -71.59 160.06 33.34 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-O 120.882 0.372 . . . . 0.0 110.42 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 55.8 tp -91.16 136.95 32.73 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.295 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 15.9 ptpt -93.64 123.33 36.89 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.762 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.0 pt -139.26 160.22 28.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.579 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.2 tttp -143.94 141.95 30.49 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.622 179.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 23.3 pttp -48.85 134.33 16.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.661 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.25 -19.61 53.81 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -74.32 153.66 39.23 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.784 0.326 . . . . 0.0 110.741 179.436 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 43.4 mm -114.47 126.62 72.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.367 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 87.1 mt -111.49 133.9 55.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.682 -179.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -80.11 112.17 17.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.593 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 97.5 mt -63.43 124.07 17.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.494 -179.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.405 HD13 HG21 ' A' ' 58' ' ' ILE . 97.3 mt -106.73 -54.87 5.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.634 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 32.0 p -161.51 171.27 18.41 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.61 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.02 146.14 42.4 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.499 179.828 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 62.1 p -101.45 155.02 36.87 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.515 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -63.27 -22.23 72.18 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 C-N-CA 122.957 2.438 . . . . 0.0 112.183 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 39.0 mmt -76.06 -10.56 59.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.877 179.485 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 104.08 -25.1 27.35 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 91.7 mmm -63.18 147.04 52.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.902 0.382 . . . . 0.0 110.426 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 33.1 m0 -103.95 143.38 32.94 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.827 -179.493 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 86.6 m -108.18 133.68 52.11 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.664 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -150.75 -179.05 26.18 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 -179.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 61.2 ttm -117.99 143.18 46.6 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-O 120.639 0.257 . . . . 0.0 110.557 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -142.04 117.14 10.02 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.574 179.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 9.1 p30 40.99 57.64 2.71 Favored 'General case' 0 N--CA 1.463 0.18 0 O-C-N 123.391 0.432 . . . . 0.0 111.019 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 60.5 t30 60.62 38.56 18.57 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.909 -179.253 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 64.1 tttt -141.36 109.69 5.91 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.092 178.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 60.1 t -98.99 129.82 48.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.91 0.386 . . . . 0.0 110.772 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -163.63 -178.63 37.43 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -101.17 160.52 14.33 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-O 120.643 0.259 . . . . 0.0 110.449 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 19.8 p90 -158.88 159.21 34.73 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.704 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 30.1 tttt -66.41 113.78 4.92 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.491 -179.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -59.22 -23.15 62.07 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.396 179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 95.7 mt -68.54 -38.73 79.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.025 0.441 . . . . 0.0 110.19 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.7 m-30 -76.07 -5.43 46.45 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.815 -179.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -126.82 165.43 25.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.629 -179.591 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -148.66 160.63 42.96 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.521 179.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 23.6 m -94.52 129.34 44.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.624 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 43.1 pt -126.11 159.87 34.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.67 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 41.4 t -105.6 123.15 47.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.589 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 25.4 pt-20 . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.538 179.991 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.229 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_exo -58.18 142.28 97.09 Favored 'Trans proline' 0 C--N 1.307 -1.658 0 C-N-CA 122.805 2.336 . . . . 0.0 111.986 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -112.96 140.38 47.81 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.461 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 31.1 p -119.68 153.37 35.68 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.974 0.416 . . . . 0.0 110.143 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.63 -124.25 1.59 Allowed Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 14.7 mmp_? -111.2 147.0 35.91 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.681 0.277 . . . . 0.0 110.51 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -117.79 114.41 23.25 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.718 -0.393 . . . . 0.0 110.896 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 2.8 ptm85 -87.9 128.48 35.36 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.546 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 95.7 t -84.83 131.98 32.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.2 -179.313 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 30.3 m170 -114.17 -15.32 12.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.398 179.409 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 32.9 m -127.68 132.47 49.66 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.843 0.354 . . . . 0.0 110.712 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -65.79 145.1 56.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.736 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -98.65 134.92 40.9 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.004 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.7 t -121.22 93.52 48.81 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.752 179.741 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_endo -75.01 153.1 41.47 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.397 2.064 . . . . 0.0 112.319 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 65.6 m -72.01 158.97 86.69 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.525 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -53.82 -37.16 84.73 Favored 'Trans proline' 0 N--CA 1.497 1.723 0 C-N-CA 122.633 2.222 . . . . 0.0 112.039 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 41.1 p90 -97.43 16.36 20.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.869 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -96.6 88.16 4.58 Favored 'General case' 0 C--O 1.233 0.213 0 CA-C-O 121.039 0.447 . . . . 0.0 110.544 -179.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 6.9 t -93.24 -26.16 17.48 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.437 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 56.0 p-10 -79.5 -3.36 46.4 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.023 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 34.8 t -83.55 139.63 32.76 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.661 0.267 . . . . 0.0 110.536 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 60.2 tp -85.85 145.82 27.02 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.371 -0.377 . . . . 0.0 109.997 179.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 58.2 pttt -96.27 127.03 41.91 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.45 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 35.2 pt -144.12 150.2 17.01 Favored 'Isoleucine or valine' 0 C--O 1.237 0.436 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.339 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 63.7 tttp -132.72 145.88 51.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.331 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 64.8 pttt -48.93 138.15 11.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.953 0.406 . . . . 0.0 110.682 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 93.44 -13.27 67.94 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 -179.46 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -77.37 150.95 35.07 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-O 120.817 0.342 . . . . 0.0 110.636 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 36.1 mm -114.21 126.73 71.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.208 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 92.3 mt -117.93 133.14 65.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.83 -179.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -78.58 121.97 25.32 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.276 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.7 mt -69.5 120.39 17.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.914 0.388 . . . . 0.0 110.545 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 93.3 mt -109.47 -50.65 6.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.451 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 95.3 m -140.26 151.42 45.11 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.437 179.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 37.8 mtmm -124.88 147.74 48.65 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.417 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 90.0 m -122.71 117.16 28.9 Favored Pre-proline 0 CA--C 1.537 0.466 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.202 179.569 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_exo -50.57 126.83 18.98 Favored 'Trans proline' 0 N--CA 1.497 1.715 0 C-N-CA 121.933 1.755 . . . . 0.0 111.971 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 93.7 mmm 47.15 40.62 10.27 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.613 179.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -151.77 176.37 30.17 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.152 -0.779 . . . . 0.0 111.152 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 98.9 mtp -60.0 148.33 35.81 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.006 0.432 . . . . 0.0 110.58 -179.088 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 16.1 m0 -94.89 158.25 15.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.057 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 96.2 m -118.93 138.0 53.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.238 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -160.73 -170.57 25.51 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 64.8 ttp -125.71 136.32 53.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.745 0.307 . . . . 0.0 110.337 -179.702 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 4.4 tt -137.83 120.15 15.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.392 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 67.2 t30 53.08 51.4 15.81 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.681 -0.408 . . . . 0.0 110.981 179.196 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 58.0 t30 58.87 36.26 24.57 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.653 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 4.0 tptm -139.12 113.76 9.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.37 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 91.7 t -94.54 127.36 46.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.846 0.355 . . . . 0.0 110.674 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -163.22 -178.82 37.29 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 -179.8 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -100.69 157.53 16.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.907 0.384 . . . . 0.0 110.729 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -155.88 161.21 40.62 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.841 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -73.54 121.96 21.45 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.859 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 51.2 p90 -67.69 -28.18 67.46 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.794 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 33.5 pt -63.82 -19.53 24.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.694 0.283 . . . . 0.0 111.073 179.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 21.2 m-30 -102.23 5.39 40.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.942 0.401 . . . . 0.0 110.913 179.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 1.2 p -134.23 153.17 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.315 179.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -113.41 134.11 54.82 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.375 179.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.0 p -80.09 125.94 39.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.548 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -122.76 134.42 66.0 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.418 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 69.8 m -67.49 143.39 56.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.32 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.633 179.892 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.275 0 N-CA-C 109.601 -1.4 . . . . 0.0 109.601 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.49 144.28 97.05 Favored 'Trans proline' 0 N--CA 1.497 1.735 0 C-N-CA 122.852 2.368 . . . . 0.0 111.964 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -113.34 146.39 39.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.587 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 82.6 m -110.6 135.05 51.83 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.378 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -175.34 -152.96 9.76 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 39.5 mmt180 -112.27 143.46 43.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.78 0.324 . . . . 0.0 110.657 -179.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -117.97 132.27 56.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.225 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 17.6 ptm180 -110.82 133.05 53.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.232 0.539 . . . . 0.0 110.733 -179.861 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 86.5 t -85.68 133.44 29.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.511 -179.332 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -118.02 -7.31 10.88 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.171 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 72.9 p -130.65 158.82 39.0 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.892 0.377 . . . . 0.0 110.3 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -91.35 104.06 16.63 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.599 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -119.24 121.4 39.58 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.571 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 8.7 t -130.3 139.67 36.33 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.809 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -73.59 166.01 30.91 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 122.779 2.319 . . . . 0.0 112.262 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 85.7 p -68.65 161.82 67.81 Favored Pre-proline 0 C--N 1.324 -0.525 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.653 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -56.23 -34.63 94.02 Favored 'Trans proline' 0 N--CA 1.5 1.893 0 C-N-CA 122.712 2.275 . . . . 0.0 112.098 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.3 p90 -87.75 9.42 21.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.923 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -112.38 114.73 27.61 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-O 120.684 0.278 . . . . 0.0 110.397 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 58.1 p -115.34 -30.57 6.22 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.933 0.397 . . . . 0.0 110.617 179.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -63.23 -37.32 86.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.548 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 66.7 m -58.85 152.83 18.42 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.606 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -91.72 132.51 36.33 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.51 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 62.4 mttp -87.4 124.38 33.34 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 179.181 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 47.5 pt -131.06 146.52 33.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.558 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.7 mttp -135.08 159.98 39.8 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.427 -0.352 . . . . 0.0 110.274 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -55.81 121.98 10.44 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.989 0.423 . . . . 0.0 110.538 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 103.52 -21.21 39.73 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -67.01 143.09 56.98 Favored 'General case' 0 C--N 1.332 -0.194 0 C-N-CA 120.618 -0.433 . . . . 0.0 110.77 179.41 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 9.9 mm -112.69 128.71 69.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.599 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.5 mt -116.33 133.35 63.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.708 -179.417 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -79.95 117.63 20.97 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.15 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 92.0 mt -67.26 126.39 26.79 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.137 0 CA-C-O 120.919 0.39 . . . . 0.0 110.679 -179.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 93.3 mt -113.84 -59.27 3.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.47 179.721 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 94.7 m -144.77 168.8 19.34 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.938 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -115.98 141.48 48.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.187 179.573 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.9 m -98.86 137.52 20.55 Favored Pre-proline 0 CA--C 1.538 0.483 0 C-N-CA 120.149 -0.62 . . . . 0.0 110.343 -179.492 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -53.22 -36.84 79.24 Favored 'Trans proline' 0 N--CA 1.501 1.916 0 C-N-CA 122.414 2.076 . . . . 0.0 112.486 179.509 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 23.0 ptp -59.34 -18.67 40.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.885 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 119.41 -38.25 2.88 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 179.424 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 97.0 mtp -61.57 143.65 55.65 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.153 0.502 . . . . 0.0 110.59 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 45.7 m0 -98.75 155.67 17.23 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.212 -179.312 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 93.0 m -115.92 135.21 54.2 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.901 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.6 -172.13 23.57 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 16.8 tmm? -122.04 139.8 53.26 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.847 0.356 . . . . 0.0 110.751 -179.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -139.25 111.72 7.64 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.618 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 47.2 m-20 54.05 51.99 13.6 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.034 179.617 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 54.1 t30 62.41 37.3 13.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.792 0.33 . . . . 0.0 110.707 -179.387 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 46.9 tptt -137.33 113.29 9.75 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.034 179.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 88.9 t -100.46 127.28 53.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 C-N-CA 120.793 -0.363 . . . . 0.0 110.912 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -164.92 -174.09 34.26 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 -179.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -102.51 150.96 22.87 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.009 0.433 . . . . 0.0 110.483 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 44.0 p90 -150.84 158.75 44.52 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.757 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -72.29 117.36 13.85 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.94 -179.466 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -62.58 -27.51 69.23 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.683 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 13.7 tt -63.06 -33.27 59.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.999 0.428 . . . . 0.0 111.1 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -83.81 1.23 44.01 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.835 179.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -132.66 161.42 41.56 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 CA-C-O 121.038 0.447 . . . . 0.0 110.464 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 53.3 t0 -124.1 137.64 54.54 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.133 179.39 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.5 p -87.52 124.64 40.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.773 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 41.4 pt -128.27 150.71 34.24 Favored 'Isoleucine or valine' 0 C--O 1.233 0.219 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.84 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 38.4 t -84.63 138.75 32.52 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.718 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.003 -0.998 . . . . 0.0 110.611 179.714 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -69.78 151.62 68.98 Favored 'Trans proline' 0 C--N 1.305 -1.741 0 C-N-CA 122.849 2.366 . . . . 0.0 112.075 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 90.8 t80 -91.54 127.46 37.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.594 -179.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 29.5 p -100.09 129.91 46.18 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.992 0.425 . . . . 0.0 110.424 179.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -174.16 -154.91 11.29 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -179.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 15.6 mmp_? -108.04 142.34 38.34 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.023 0.44 . . . . 0.0 110.469 -179.397 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -106.39 117.3 33.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.184 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 61.2 ttt180 -96.09 120.83 37.08 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.055 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 86.8 t -81.28 124.78 39.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.728 -179.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 35.2 p80 -115.81 -8.97 11.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.936 179.406 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 77.4 m -129.04 136.74 50.69 Favored 'General case' 0 C--O 1.231 0.099 0 CA-C-O 120.762 0.315 . . . . 0.0 110.625 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -69.49 119.69 14.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.493 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -65.47 136.91 57.04 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 92.1 m -118.45 94.85 47.96 Favored Pre-proline 0 CA--C 1.537 0.452 0 C-N-CA 120.958 -0.297 . . . . 0.0 110.762 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_endo -74.09 157.3 46.7 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 122.352 2.035 . . . . 0.0 112.201 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.1 m -79.78 158.03 73.54 Favored Pre-proline 0 CA--C 1.532 0.263 0 C-N-CA 120.661 -0.415 . . . . 0.0 110.797 -179.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -57.23 -40.27 83.87 Favored 'Trans proline' 0 N--CA 1.5 1.912 0 C-N-CA 122.381 2.054 . . . . 0.0 112.096 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.4 p90 -89.72 16.99 7.01 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.182 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -112.69 113.39 25.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.791 0.329 . . . . 0.0 110.626 179.425 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 55.7 p -112.42 -17.55 12.66 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.458 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 57.6 p-10 -87.59 6.13 35.99 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.13 179.64 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 74.9 m -70.28 151.17 45.6 Favored 'General case' 0 C--O 1.231 0.094 0 CA-C-O 120.86 0.362 . . . . 0.0 110.662 179.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 60.6 tp -84.66 135.93 33.96 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.154 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 62.6 mtpt -93.93 119.06 32.33 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.091 179.436 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 28.9 pt -136.64 168.02 22.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.316 -179.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 23.5 pttp -148.21 156.47 42.61 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.856 0.36 . . . . 0.0 110.385 179.255 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 65.3 tttm -56.96 129.9 43.66 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.313 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.13 -16.14 60.5 Favored Glycine 0 CA--C 1.53 1.004 0 N-CA-C 111.349 -0.7 . . . . 0.0 111.349 -179.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 17.5 t0 -71.33 146.61 48.74 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 110.321 -0.251 . . . . 0.0 110.321 179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 48.2 mm -114.89 129.11 71.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.938 0.399 . . . . 0.0 110.291 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 90.9 mt -119.03 130.39 73.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.871 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -74.93 128.39 35.45 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.321 -0.552 . . . . 0.0 110.227 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.9 mt -74.11 121.52 25.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.165 0 CA-C-O 120.854 0.359 . . . . 0.0 110.514 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 12.7 tt -113.67 -35.99 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.656 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 85.7 m -147.68 152.16 37.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.589 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.3 mtpt -136.47 155.94 49.29 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.247 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 68.9 p -131.98 155.67 81.06 Favored Pre-proline 0 C--N 1.327 -0.373 0 C-N-CA 120.417 -0.513 . . . . 0.0 110.756 179.425 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -59.93 115.79 2.87 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 121.954 1.769 . . . . 0.0 111.882 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 99.3 mtp 43.75 32.92 0.63 Allowed 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.969 179.401 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -122.64 173.97 16.18 Favored Glycine 0 CA--C 1.519 0.336 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 10.6 ptm -60.07 149.61 31.89 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.83 0.348 . . . . 0.0 110.432 -179.243 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 45.4 m0 -94.55 150.55 20.13 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.968 -179.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.1 m -118.65 143.1 47.05 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.372 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -165.0 -168.5 27.25 Favored Glycine 0 CA--C 1.52 0.395 0 C-N-CA 120.167 -1.016 . . . . 0.0 111.68 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 60.9 ttm -114.86 135.94 53.64 Favored 'General case' 0 C--O 1.238 0.447 0 CA-C-O 120.969 0.414 . . . . 0.0 110.444 179.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 3.5 tt -136.71 113.68 10.49 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.596 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 66.8 t30 53.39 52.33 13.66 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.678 -0.409 . . . . 0.0 111.356 178.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 59.71 28.48 17.93 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.921 0.391 . . . . 0.0 110.921 179.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -139.87 115.74 10.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.132 -0.486 . . . . 0.0 109.82 179.027 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 19.4 m -92.28 141.88 13.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.622 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -165.9 177.68 40.92 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 -179.488 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 76.7 m-20 -107.96 144.66 34.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.919 0.39 . . . . 0.0 110.523 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.8 p90 -148.19 147.1 29.06 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.741 179.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 17.5 tptm -58.0 121.47 10.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.358 -179.094 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.7 p90 -61.28 -25.43 67.1 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.624 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 97.7 mt -64.0 -39.03 83.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-O 120.919 0.39 . . . . 0.0 110.503 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 12.7 m-30 -77.27 -1.78 31.42 Favored 'General case' 0 C--O 1.237 0.404 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.388 -179.14 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -128.5 161.6 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.68 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -130.02 143.88 51.03 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.5 p -84.72 119.74 34.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.672 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 37.9 pt -127.84 158.96 39.28 Favored 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.77 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 35.2 t -110.66 127.37 55.25 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.234 179.724 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 118.048 -0.977 . . . . 0.0 110.488 -179.615 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.304 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -69.79 154.47 67.57 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 C-N-CA 122.841 2.361 . . . . 0.0 112.278 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -126.96 151.98 47.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.577 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 26.3 p -116.51 152.9 33.14 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.317 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 162.32 -130.08 2.21 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 87.7 mmt-85 -112.11 145.31 40.0 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.943 0.401 . . . . 0.0 110.741 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -108.91 121.46 45.15 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.269 179.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 46.5 ttt-85 -97.09 125.43 41.55 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.896 0.379 . . . . 0.0 110.365 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.6 t -82.48 128.62 38.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.617 -179.143 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 65.6 m170 -103.72 -10.3 18.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.192 179.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 12.2 t -144.76 145.39 31.65 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.927 0.394 . . . . 0.0 110.345 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -71.81 114.27 9.73 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.3 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 9.5 t80 -121.08 123.58 42.71 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.349 179.392 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 81.5 p -124.7 154.22 70.25 Favored Pre-proline 0 C--N 1.329 -0.29 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.824 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.14 159.22 30.21 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 C-N-CA 123.027 2.484 . . . . 0.0 112.487 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 72.4 m -82.28 158.41 66.66 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.377 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -52.86 -45.92 37.35 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 122.245 1.964 . . . . 0.0 111.981 -179.559 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -80.09 -20.78 44.29 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.91 0.386 . . . . 0.0 110.731 179.533 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -93.05 105.29 17.41 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.416 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 72.1 p -104.37 -23.55 13.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.314 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -63.2 -37.45 87.27 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.631 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.6 t -61.44 135.98 57.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.883 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 56.5 tp -80.57 146.03 31.46 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.419 -179.679 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.51 127.42 42.49 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.563 179.087 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.7 pt -139.24 160.45 28.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.565 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 19.6 ptpt -136.64 157.34 46.99 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.211 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -61.27 129.38 40.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.945 0.403 . . . . 0.0 111.071 -179.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.92 -16.31 59.64 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -76.55 146.47 38.34 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-O 120.776 0.322 . . . . 0.0 110.633 179.537 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 46.8 mm -108.89 127.55 65.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.004 0.431 . . . . 0.0 110.126 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 78.5 mt -108.58 130.62 61.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.728 -178.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -79.96 112.09 16.92 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.416 HG23 HD12 ' A' ' 57' ' ' ILE . 96.6 mt -65.9 118.2 8.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.908 0.385 . . . . 0.0 110.661 -179.64 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.0 tt -101.93 -35.3 4.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.323 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 25.1 p -171.99 172.9 4.56 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.412 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 65.1 mttp -116.85 145.08 43.79 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 120.881 -0.328 . . . . 0.0 110.537 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 9.8 m -97.69 135.45 21.61 Favored Pre-proline 0 CA--C 1.536 0.417 0 C-N-CA 119.589 -0.844 . . . . 0.0 109.703 -179.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -58.7 -25.39 75.37 Favored 'Trans proline' 0 N--CA 1.501 1.915 0 C-N-CA 122.57 2.18 . . . . 0.0 112.614 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 39.2 mmt -65.19 -36.97 85.85 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.446 179.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 140.09 -39.56 1.49 Allowed Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 98.7 mtp -63.35 145.14 56.19 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.455 0.645 . . . . 0.0 111.198 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 22.4 m0 -96.35 146.95 24.3 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.828 -179.742 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 68.0 m -117.0 139.95 50.07 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 115.802 -0.636 . . . . 0.0 109.909 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.95 -172.02 23.71 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.166 -0.773 . . . . 0.0 111.166 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 67.8 ttp -116.18 143.09 45.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.152 0.501 . . . . 0.0 110.605 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -143.87 117.85 9.42 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.661 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 8.9 p30 40.64 59.73 2.08 Favored 'General case' 0 N--CA 1.469 0.525 0 O-C-N 123.442 0.464 . . . . 0.0 111.033 179.806 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 33.7 m120 59.25 35.44 23.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.025 -179.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 19.3 tptp -140.56 111.49 7.02 Favored 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.399 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 95.5 t -99.53 127.41 52.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.758 -0.377 . . . . 0.0 110.425 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -159.77 -176.8 32.25 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.886 -0.885 . . . . 0.0 110.886 -179.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.4 m120 -103.31 158.57 16.24 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.918 0.39 . . . . 0.0 110.467 -179.563 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -157.06 160.53 39.02 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.006 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 36.7 tptt -69.09 111.55 5.13 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.193 -179.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.3 p90 -59.17 -24.14 62.81 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.522 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.6 mt -67.9 -38.25 79.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.183 0.516 . . . . 0.0 110.654 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.2 m-30 -75.78 -5.94 48.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.834 -179.03 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -126.23 159.82 34.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 CA-C-O 121.042 0.449 . . . . 0.0 110.079 179.737 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 50.6 t0 -126.21 139.53 53.26 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.937 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.8 p -82.45 121.03 35.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.953 0.406 . . . . 0.0 110.961 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 41.2 pt -128.3 160.4 38.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.613 179.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 29.9 t -106.25 132.1 52.7 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.441 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 54.2 tp10 . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 117.974 -1.013 . . . . 0.0 110.332 -179.987 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -58.11 142.7 97.17 Favored 'Trans proline' 0 C--N 1.305 -1.745 0 C-N-CA 122.859 2.373 . . . . 0.0 111.876 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 81.0 m-85 -112.68 143.06 44.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.413 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 77.3 m -116.91 144.7 44.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.95 0.405 . . . . 0.0 110.369 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 169.27 -142.25 7.22 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 2.9 mpp_? -112.25 146.2 38.6 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.879 0.371 . . . . 0.0 110.454 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -116.06 125.3 52.23 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.083 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 74.2 ttt-85 -92.74 119.83 32.51 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.387 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 96.4 t -78.29 125.54 37.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.829 0.347 . . . . 0.0 110.679 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 33.2 p80 -112.51 -10.64 13.7 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.885 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 90.2 m -128.81 131.33 47.74 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.778 0.323 . . . . 0.0 110.396 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.6 t0 -68.27 131.34 45.18 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.629 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -88.28 137.22 32.52 Favored 'General case' 0 C--N 1.331 -0.2 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.167 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 43.2 p -126.82 93.79 41.36 Favored Pre-proline 0 CA--C 1.534 0.347 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.441 -179.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -73.27 155.79 51.25 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 122.172 1.915 . . . . 0.0 112.364 -179.022 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.6 m -73.47 157.96 87.16 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.801 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -55.83 -38.77 94.06 Favored 'Trans proline' 0 N--CA 1.498 1.766 0 C-N-CA 122.512 2.141 . . . . 0.0 112.046 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -88.6 6.54 37.69 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.066 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.22 101.15 12.09 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.752 0.311 . . . . 0.0 110.332 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 72.6 p -104.37 -27.52 11.91 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.883 0.373 . . . . 0.0 110.26 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -72.98 -21.27 60.88 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.775 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 41.4 t -59.62 141.36 55.15 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.404 -179.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 66.0 tp -80.27 138.84 36.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.147 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 30.2 mtpp -95.0 118.1 31.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.256 179.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 21.6 pt -138.42 146.68 26.3 Favored 'Isoleucine or valine' 0 C--O 1.237 0.419 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.186 179.676 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.04 167.23 14.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.909 0.385 . . . . 0.0 110.424 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -64.99 129.56 40.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.525 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.99 -20.83 47.41 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 111.214 -0.754 . . . . 0.0 111.214 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -69.88 148.51 48.94 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.387 179.219 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 86.5 mt -109.01 127.62 65.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.142 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 72.0 mt -109.96 130.16 63.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.447 -178.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -75.82 115.34 15.41 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.203 -0.599 . . . . 0.0 109.928 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.73 125.4 25.24 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 CA-C-O 120.823 0.344 . . . . 0.0 110.765 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 97.1 mt -108.73 -58.46 3.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.477 179.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 40.3 t -163.46 151.88 13.75 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.752 -179.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 59.0 mttm -96.85 157.78 15.74 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.073 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 74.9 p -112.29 156.95 41.31 Favored Pre-proline 0 C--N 1.329 -0.289 0 C-N-CA 120.618 -0.433 . . . . 0.0 110.784 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_exo -56.6 -33.73 93.82 Favored 'Trans proline' 0 N--CA 1.497 1.734 0 C-N-CA 122.68 2.254 . . . . 0.0 112.269 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 98.6 mtp -62.04 -38.48 88.89 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.514 -179.572 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 132.2 -32.38 2.86 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 98.5 mtp -62.4 143.8 56.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.002 0.429 . . . . 0.0 110.552 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 47.6 m0 -98.41 150.07 22.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.087 -178.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 90.0 m -110.0 135.18 51.25 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.657 179.553 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -152.66 -176.14 24.93 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 111.244 -0.742 . . . . 0.0 111.244 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.6 ttp -124.21 142.5 51.18 Favored 'General case' 0 C--O 1.237 0.432 0 CA-C-O 120.961 0.41 . . . . 0.0 110.672 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 2.1 mt -138.06 105.54 5.55 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.762 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 55.63 58.41 4.54 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.23 0.538 . . . . 0.0 109.705 178.775 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 58.5 t30 59.58 34.53 22.38 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.432 -179.515 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 8.9 tppt? -132.89 109.77 9.84 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.357 -0.383 . . . . 0.0 109.971 179.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 82.3 t -97.75 123.51 50.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 C-N-CA 120.706 -0.397 . . . . 0.0 110.499 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -156.83 179.12 32.88 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -105.69 154.54 20.31 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.958 0.409 . . . . 0.0 110.829 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.8 p90 -152.74 159.63 43.13 Favored 'General case' 0 C--O 1.237 0.443 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.823 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 30.6 tttt -68.65 116.46 9.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.209 -179.064 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -59.97 -25.71 65.45 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.571 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.6 mt -65.82 -38.46 82.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.713 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.1 m-30 -78.85 -7.32 57.79 Favored 'General case' 0 C--O 1.24 0.585 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.226 -178.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 66.5 t -121.39 138.68 50.93 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.283 0 CA-C-O 120.972 0.415 . . . . 0.0 110.991 -179.449 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -106.07 134.28 49.44 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.229 179.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.4 p -76.44 118.21 22.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.188 179.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -106.39 148.0 11.24 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.126 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.253 -179.733 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 90.0 p -112.18 147.37 36.31 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.771 -0.372 . . . . 0.0 110.093 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.388 179.908 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -69.74 152.31 69.39 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 C-N-CA 122.819 2.346 . . . . 0.0 112.146 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -126.67 153.9 44.79 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.737 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 16.9 p -60.27 151.67 26.87 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-O 120.994 0.426 . . . . 0.0 110.269 -179.642 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 174.85 -139.65 4.94 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -179.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 93.5 mtt-85 -126.24 151.73 47.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.776 0.322 . . . . 0.0 110.575 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -123.01 135.75 54.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.531 -179.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 57.3 mtm180 -101.88 123.53 45.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.254 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 99.0 t -81.22 129.04 38.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.485 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -113.06 -0.22 14.79 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.961 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 12.2 t -146.47 151.49 37.48 Favored 'General case' 0 N--CA 1.455 -0.214 0 CA-C-O 120.914 0.387 . . . . 0.0 110.547 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -88.46 107.59 18.95 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.529 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 6.2 t80 -118.67 119.34 34.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.621 179.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 9.8 t -126.79 131.38 23.87 Favored Pre-proline 0 N--CA 1.451 -0.398 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.669 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -73.33 163.47 37.75 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.873 2.382 . . . . 0.0 112.38 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.3 m -66.04 156.47 84.13 Favored Pre-proline 0 C--N 1.327 -0.383 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.607 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -57.69 -31.55 92.31 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 C-N-CA 122.778 2.319 . . . . 0.0 112.332 -179.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -73.11 -10.67 60.03 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.572 179.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 48.6 t0 -110.22 114.04 27.21 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.298 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.3 t -106.12 -28.67 10.35 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.728 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -62.23 -36.56 82.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.497 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 47.2 m -63.47 139.31 58.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.704 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 59.2 tp -91.79 143.36 26.6 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.41 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 23.0 pttp -94.37 141.86 28.09 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.393 179.112 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 29.8 pt -132.0 147.5 32.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.559 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 40.7 ttmt -128.3 138.53 52.44 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.638 179.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -55.91 125.64 22.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.814 -179.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 105.51 -21.42 34.89 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.283 -0.727 . . . . 0.0 111.283 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -81.55 155.14 25.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.736 0.303 . . . . 0.0 110.806 179.29 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 46.7 mm -113.47 130.07 68.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.685 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 84.2 mt -112.49 129.06 68.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.498 -179.418 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 64.5 t0 -82.2 121.81 27.1 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.276 179.603 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 84.2 mt -70.21 128.74 33.94 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.116 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.419 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 88.8 mt -105.93 -53.49 6.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.709 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.8 t -163.84 150.66 11.89 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.78 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.7 mttp -109.29 155.34 21.27 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.251 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 81.5 p -136.05 155.09 77.85 Favored Pre-proline 0 N--CA 1.45 -0.471 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.853 179.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_exo -62.5 -21.23 72.55 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 122.863 2.375 . . . . 0.0 112.061 179.171 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 63.7 tpp -52.16 -31.6 32.11 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.417 -179.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 106.8 18.18 11.03 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 6.4 mtt -128.34 139.5 52.36 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.782 0.325 . . . . 0.0 110.474 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 33.5 m0 -93.36 139.45 30.66 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.775 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 93.0 m -98.39 131.16 44.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 109.897 179.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -154.52 -176.51 26.89 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -179.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 23.4 ptp -123.57 146.46 48.12 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.874 0.369 . . . . 0.0 110.667 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -150.03 118.78 6.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.512 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 54.8 m-20 53.59 49.71 18.83 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 54.3 t30 59.69 35.63 22.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.584 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 22.7 ttmm -138.64 117.62 12.48 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.459 179.292 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 96.9 t -99.45 131.03 47.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.733 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -158.03 177.57 34.7 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 81.7 m-20 -105.05 135.62 46.05 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.876 0.37 . . . . 0.0 110.564 -179.681 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -138.48 155.0 48.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.792 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -75.75 125.02 28.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.372 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 20.6 p90 -65.31 -20.42 66.4 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.706 -179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 6.4 pt -61.01 -23.17 28.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.505 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 41.6 m-85 -102.4 10.18 39.21 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.644 179.443 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -135.54 147.96 28.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.234 0 CA-C-O 120.863 0.363 . . . . 0.0 110.344 -179.609 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -105.62 131.95 52.37 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.302 179.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.1 p -91.31 132.98 34.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-O 120.96 0.409 . . . . 0.0 110.795 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 37.5 pt -124.0 156.63 31.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.69 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 66.0 m -113.09 148.63 34.86 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.673 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.601 179.948 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.318 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -69.55 151.25 70.25 Favored 'Trans proline' 0 C--N 1.305 -1.745 0 C-N-CA 122.815 2.344 . . . . 0.0 112.164 179.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -141.81 145.6 34.92 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.36 -179.733 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.2 m -101.81 136.77 41.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.403 179.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -175.92 -149.8 7.68 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -109.03 138.21 45.74 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.94 0.4 . . . . 0.0 110.496 -179.793 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -106.11 115.15 29.73 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.198 -179.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 45.4 ttp180 -96.59 120.54 37.1 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.195 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 90.3 t -76.17 124.32 34.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.48 -179.492 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 1.3 p80 -111.3 -15.87 13.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.537 179.548 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 53.0 m -131.97 135.5 46.62 Favored 'General case' 0 C--N 1.334 -0.103 0 CA-C-O 120.84 0.353 . . . . 0.0 110.833 179.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -64.44 133.91 53.47 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 120.716 -0.394 . . . . 0.0 110.49 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -120.8 135.77 55.07 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.276 179.618 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 57.0 p -135.44 90.76 19.7 Favored Pre-proline 0 CA--C 1.534 0.328 0 C-N-CA 120.92 -0.312 . . . . 0.0 110.304 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -69.83 150.6 68.01 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 122.66 2.24 . . . . 0.0 112.284 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 75.4 m -72.96 157.94 87.9 Favored Pre-proline 0 C--N 1.326 -0.439 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.653 -179.686 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -53.76 -23.09 25.34 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.835 2.357 . . . . 0.0 112.114 179.54 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -59.97 -23.05 63.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.204 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -65.8 125.87 26.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.35 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 82.8 p -70.68 -35.85 73.03 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.606 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.498 ' O ' ' C ' ' A' ' 46' ' ' SER . 88.5 m-20 -100.14 5.86 44.86 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 118.337 -0.84 . . . . 0.0 111.465 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.498 ' C ' ' O ' ' A' ' 45' ' ' ASP . 6.6 t -9.88 95.3 0.01 OUTLIER 'General case' 0 C--N 1.358 0.938 0 O-C-N 125.003 1.439 . . . . 0.0 111.311 -179.291 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 66.9 tp -111.34 131.72 54.96 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.232 -178.478 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -97.29 134.31 40.75 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.563 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 48.3 pt -126.65 162.47 30.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.509 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 39.8 ttpt -134.85 135.61 41.81 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.602 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -51.43 131.16 28.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.983 0.42 . . . . 0.0 110.448 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.51 -18.14 56.69 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 111.006 -0.838 . . . . 0.0 111.006 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -72.47 155.53 40.0 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.798 0.332 . . . . 0.0 110.702 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 48.5 mm -114.38 127.68 71.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.198 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 85.6 mt -117.9 129.41 74.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.683 -179.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -74.65 120.64 20.48 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.309 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 85.0 mt -69.76 126.03 29.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.764 0.316 . . . . 0.0 110.347 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.7 mt -110.71 -43.16 5.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.768 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 46.6 t -146.52 139.13 25.2 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.572 -179.607 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.3 mtpt -119.37 153.75 34.67 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.517 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 71.5 p -133.29 153.17 80.49 Favored Pre-proline 0 C--N 1.328 -0.34 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.746 179.753 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -62.62 114.32 2.34 Favored 'Trans proline' 0 N--CA 1.493 1.484 0 C-N-CA 122.53 2.153 . . . . 0.0 112.037 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 99.4 mtp 46.55 32.74 1.74 Allowed 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.274 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -123.45 172.65 16.24 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 8.5 ptm -60.98 148.33 40.35 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.819 0.342 . . . . 0.0 110.143 -179.479 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 41.9 m0 -95.51 149.58 21.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.239 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 84.9 m -115.3 138.33 51.07 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.734 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -162.43 -166.95 22.13 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 65.3 ttp -125.72 138.36 53.87 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.826 0.346 . . . . 0.0 110.258 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 4.6 tt -134.31 115.47 14.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.426 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 65.7 t30 53.17 56.93 6.8 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.87 179.039 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 56.82 36.94 28.43 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.477 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 5.1 tptt -139.29 111.9 7.74 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.245 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 89.4 t -93.43 127.75 45.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.827 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -162.58 -177.18 35.38 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.801 -0.919 . . . . 0.0 110.801 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -107.78 156.3 19.27 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.98 0.419 . . . . 0.0 110.685 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 11.6 p90 -155.89 156.57 34.84 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.762 -0.653 . . . . 0.0 111.22 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 32.8 tttt -65.74 118.57 9.8 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.446 -179.243 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 36.5 p90 -61.18 -25.09 66.79 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.667 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 95.7 mt -63.08 -39.55 85.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 120.845 0.355 . . . . 0.0 110.634 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 18.3 m-85 -84.79 3.95 35.23 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.897 -179.54 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 86.3 t -126.22 136.09 61.86 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 CA-C-O 121.184 0.516 . . . . 0.0 110.914 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -111.17 142.48 43.3 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.422 179.461 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.5 p -89.63 122.83 41.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.767 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 36.5 pt -128.92 158.96 41.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.719 179.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 29.3 t -90.1 124.73 35.04 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.457 179.638 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 . . . . . 0 C--O 1.219 -0.517 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.674 -179.874 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.329 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -72.9 142.82 35.69 Favored 'Trans proline' 0 C--N 1.305 -1.711 0 C-N-CA 122.738 2.292 . . . . 0.0 112.183 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -138.38 151.17 47.25 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.793 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 17.0 p -69.52 162.81 26.75 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-O 121.103 0.478 . . . . 0.0 109.997 179.608 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 169.63 -138.3 4.97 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.024 -0.831 . . . . 0.0 111.024 -179.579 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 39.1 mmt180 -111.81 142.73 43.81 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.763 0.316 . . . . 0.0 110.361 -179.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -122.41 141.08 51.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.516 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -116.08 132.22 56.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.316 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 84.0 t -82.39 125.99 39.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.819 -179.086 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 28.2 p80 -114.14 -13.75 12.39 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.91 179.609 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 87.9 m -126.28 130.45 50.89 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.418 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.4 t0 -64.22 122.15 15.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.303 -179.771 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 15.3 t80 -117.83 128.14 54.56 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.437 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.9 t -133.51 92.44 23.85 Favored Pre-proline 0 CA--C 1.539 0.53 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.485 179.561 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.85 151.45 62.86 Favored 'Trans proline' 0 N--CA 1.495 1.6 0 C-N-CA 121.955 1.77 . . . . 0.0 112.148 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 99.9 p -70.82 155.48 93.32 Favored Pre-proline 0 CA--C 1.533 0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.628 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -62.7 -21.89 73.4 Favored 'Trans proline' 0 N--CA 1.497 1.682 0 C-N-CA 122.491 2.127 . . . . 0.0 112.253 179.674 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -64.59 -25.16 67.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.442 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -64.89 143.71 57.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.356 179.442 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 61.9 p -84.39 -29.58 26.08 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.582 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.437 ' O ' ' C ' ' A' ' 46' ' ' SER . 97.9 m-20 -100.23 -0.86 37.81 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.716 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 45' ' ' ASP . 16.3 t -20.81 95.86 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.675 0 O-C-N 124.033 0.833 . . . . 0.0 112.697 -178.757 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 63.5 tp -104.98 134.05 48.74 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.933 -179.427 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -97.17 129.19 44.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.558 179.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 40.2 pt -136.62 160.4 37.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.429 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -137.25 134.57 36.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.648 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 5.4 ptmm? -49.58 137.02 16.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.775 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.98 -17.76 58.71 Favored Glycine 0 CA--C 1.528 0.863 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 -179.839 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -79.15 157.57 27.88 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.831 0.348 . . . . 0.0 110.452 179.541 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 47.9 mm -114.73 129.67 70.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.298 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 85.7 mt -111.1 132.58 59.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.725 -179.494 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -78.45 113.71 16.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.841 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.4 mt -68.23 125.93 26.98 Favored 'Isoleucine or valine' 0 C--O 1.232 0.178 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.472 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 80.7 mt -105.34 -50.79 8.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.338 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 77.9 m -139.31 149.88 44.75 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.709 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.5 mtpt -132.07 159.64 38.28 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.612 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 82.4 p -132.0 158.57 75.15 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.537 179.697 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_exo -53.11 -39.23 80.72 Favored 'Trans proline' 0 N--CA 1.497 1.722 0 C-N-CA 122.488 2.125 . . . . 0.0 112.155 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 11.5 tpt -162.23 90.31 0.74 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.491 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 179.66 -178.18 48.5 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.1 mtp -62.49 147.59 48.36 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.02 0.438 . . . . 0.0 110.569 -179.406 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 43.8 m0 -95.86 147.05 24.06 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.462 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 96.8 m -107.62 132.75 52.96 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.882 179.513 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -151.3 -177.8 25.47 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.7 ttp -121.0 141.24 50.91 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 120.975 0.417 . . . . 0.0 110.631 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -140.93 110.84 6.52 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.4 179.785 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 50.9 m-20 54.99 56.38 6.66 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.876 -0.33 . . . . 0.0 110.197 179.447 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 87.0 m-20 56.13 36.52 27.56 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.724 0.297 . . . . 0.0 110.781 -179.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 18.4 tptm -138.43 113.26 9.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.11 179.337 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 98.3 t -93.48 126.89 45.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 120.811 -0.356 . . . . 0.0 110.507 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -154.77 177.62 31.96 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.653 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -106.94 155.0 20.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.057 0.456 . . . . 0.0 110.953 -179.549 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 32.1 p90 -156.29 162.75 40.09 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.02 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 7.4 ttmm -76.67 115.98 16.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.72 -179.218 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 51.9 p90 -58.34 -22.61 53.95 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.818 179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.6 mt -66.29 -39.35 83.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 121.062 0.458 . . . . 0.0 110.602 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.3 m-30 -79.65 -0.18 32.85 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.122 -179.017 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -130.0 158.09 42.52 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 CA-C-O 120.857 0.36 . . . . 0.0 110.263 179.749 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -121.08 141.31 50.9 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.46 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.3 p -92.02 126.16 44.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.816 -179.782 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 44.4 pt -128.29 154.3 38.82 Favored 'Isoleucine or valine' 0 C--O 1.236 0.375 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.764 179.691 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 36.9 t -110.5 130.73 55.49 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.608 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.6 tm-20 . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.684 -179.977 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -58.73 145.03 97.47 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 123.037 2.491 . . . . 0.0 111.952 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -112.55 138.67 48.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.421 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.1 m -115.02 145.46 42.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.285 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 166.88 -140.31 6.23 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.5 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -117.29 154.96 30.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.348 . . . . 0.0 110.7 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -122.96 137.2 55.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.391 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -99.36 118.66 36.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.347 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 69.6 t -69.41 130.05 34.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.914 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 23.9 m-70 -108.86 -22.52 12.16 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.811 179.389 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 50.7 p -125.99 158.4 35.38 Favored 'General case' 0 C--N 1.332 -0.177 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.348 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -91.27 116.55 28.92 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.823 -179.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 14.1 t80 -116.16 117.53 30.31 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.049 179.347 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 8.1 t -117.76 141.11 28.54 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.136 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -72.42 153.82 55.61 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.668 2.245 . . . . 0.0 112.456 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.5 p -72.91 166.17 45.67 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.036 -179.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -55.47 -42.14 71.02 Favored 'Trans proline' 0 N--CA 1.501 1.968 0 C-N-CA 122.906 2.404 . . . . 0.0 112.639 -179.461 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -97.37 11.43 36.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.879 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 65.2 t0 -112.19 112.07 23.42 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.768 0.318 . . . . 0.0 110.517 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 48.9 p -110.86 -24.16 10.58 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.484 179.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -63.36 -38.43 91.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.615 179.595 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.2 t -61.58 140.61 58.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.901 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 19.3 tp -89.39 143.71 26.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.748 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.8 pttt -97.03 137.55 35.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.452 179.093 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 2.4 pt -142.17 145.72 23.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.283 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.173 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 17.1 mttm -117.76 152.32 35.53 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.352 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -61.28 129.98 43.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.958 0.409 . . . . 0.0 110.285 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.19 -22.18 41.22 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -71.72 154.97 40.99 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.826 0.346 . . . . 0.0 110.609 179.186 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 76.2 mt -119.42 133.64 65.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.332 179.682 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 84.3 mt -117.66 132.04 68.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.913 -179.601 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -75.42 123.12 24.85 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 109.89 179.484 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 93.3 mt -69.11 129.34 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 O-C-N 123.881 0.738 . . . . 0.0 110.365 -179.662 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 89.9 mt -109.55 -54.53 5.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.66 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 44.1 t -163.99 147.65 9.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.189 -179.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -92.94 146.27 23.75 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.726 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.2 p -103.25 154.45 37.68 Favored Pre-proline 0 C--N 1.328 -0.346 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.514 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -62.11 -25.71 77.53 Favored 'Trans proline' 0 N--CA 1.497 1.704 0 C-N-CA 122.653 2.235 . . . . 0.0 112.159 179.332 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 96.4 mmm -70.17 -22.13 62.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.521 179.693 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 114.31 -26.26 9.87 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.4 mtp -64.95 147.04 54.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.983 0.421 . . . . 0.0 110.765 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 43.4 m0 -102.38 146.09 28.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.241 0.544 . . . . 0.0 111.321 -179.269 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 98.3 m -108.8 135.33 50.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.605 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -153.76 -176.93 26.7 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.9 ttp -118.46 140.29 50.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.933 0.397 . . . . 0.0 111.244 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -143.92 113.96 7.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.511 179.659 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 47.0 m-20 56.98 55.31 6.21 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 32.6 m120 54.53 35.91 24.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.613 0.244 . . . . 0.0 110.491 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 36.6 ttpt -139.48 114.92 9.86 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 120.624 -0.43 . . . . 0.0 110.431 179.465 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 86.9 t -93.28 128.17 44.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.442 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -156.22 179.36 32.17 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 57.2 m-80 -104.38 158.46 16.45 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.222 0.534 . . . . 0.0 110.96 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 7.2 p90 -155.97 160.23 39.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.223 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -63.94 116.27 5.68 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.109 -179.141 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -58.24 -29.0 65.4 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.514 179.753 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 16.3 tt -74.6 -33.96 33.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.896 179.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.8 m-30 -72.1 -20.79 61.59 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.519 179.596 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 6.1 p -114.97 160.07 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.112 179.06 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -128.92 149.39 50.81 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.688 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.3 p -92.85 135.19 28.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.594 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 23.2 pt -121.04 158.24 23.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.461 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 41.1 t -61.37 138.72 58.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.587 -179.74 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 20.0 tp10 . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.182 -0.913 . . . . 0.0 110.521 179.983 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -58.73 145.03 97.47 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 123.037 2.491 . . . . 0.0 111.952 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -112.55 138.67 48.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.421 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.1 m -115.02 145.46 42.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.285 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 166.88 -140.31 6.23 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.5 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -117.29 154.96 30.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.348 . . . . 0.0 110.7 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -122.96 137.2 55.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.391 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -99.36 118.66 36.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.347 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 69.6 t -69.41 130.05 34.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.914 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 23.9 m-70 -108.86 -22.52 12.16 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.811 179.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 50.7 p -125.99 158.4 35.38 Favored 'General case' 0 C--N 1.332 -0.177 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.348 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -91.27 116.55 28.92 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.823 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 14.1 t80 -116.16 117.53 30.31 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.049 179.347 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 8.1 t -117.76 141.11 28.54 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.136 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -72.42 153.82 55.61 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.668 2.245 . . . . 0.0 112.456 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.5 p -72.91 166.17 45.67 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.036 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -55.47 -42.14 71.02 Favored 'Trans proline' 0 N--CA 1.501 1.968 0 C-N-CA 122.906 2.404 . . . . 0.0 112.639 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -97.37 11.43 36.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.879 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 65.2 t0 -112.19 112.07 23.42 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.768 0.318 . . . . 0.0 110.517 -179.714 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 48.9 p -110.86 -24.16 10.58 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.484 179.241 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -63.36 -38.43 91.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.615 179.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.2 t -61.58 140.61 58.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.901 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 19.3 tp -89.39 143.71 26.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.748 -179.704 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.8 pttt -97.03 137.55 35.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.452 179.093 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 2.4 pt -142.17 145.72 23.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.283 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.173 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 17.1 mttm -117.76 152.32 35.53 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.352 179.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -61.28 129.98 43.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.958 0.409 . . . . 0.0 110.285 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.19 -22.18 41.22 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -71.72 154.97 40.99 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.826 0.346 . . . . 0.0 110.609 179.186 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 76.2 mt -119.42 133.64 65.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.332 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 84.3 mt -117.66 132.04 68.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.913 -179.601 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -75.42 123.12 24.85 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 109.89 179.484 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 93.3 mt -69.11 129.34 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 O-C-N 123.881 0.738 . . . . 0.0 110.365 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 89.9 mt -109.55 -54.53 5.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.66 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 44.1 t -163.99 147.65 9.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.189 -179.604 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -92.94 146.27 23.75 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.726 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.2 p -103.25 154.45 37.68 Favored Pre-proline 0 C--N 1.328 -0.346 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.514 -179.668 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -62.11 -25.71 77.53 Favored 'Trans proline' 0 N--CA 1.497 1.704 0 C-N-CA 122.653 2.235 . . . . 0.0 112.159 179.332 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 96.4 mmm -70.17 -22.13 62.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.521 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 114.31 -26.26 9.87 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.4 mtp -64.95 147.04 54.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.983 0.421 . . . . 0.0 110.765 179.71 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 43.4 m0 -102.38 146.09 28.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.241 0.544 . . . . 0.0 111.321 -179.269 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 98.3 m -108.8 135.33 50.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.605 179.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -153.76 -176.93 26.7 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.9 ttp -118.46 140.29 50.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.933 0.397 . . . . 0.0 111.244 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -143.92 113.96 7.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.511 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 47.0 m-20 56.98 55.31 6.21 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 32.6 m120 54.53 35.91 24.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.613 0.244 . . . . 0.0 110.491 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 36.6 ttpt -139.48 114.92 9.86 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 120.624 -0.43 . . . . 0.0 110.431 179.465 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 86.9 t -93.28 128.17 44.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.442 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -156.22 179.36 32.17 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 57.2 m-80 -104.38 158.46 16.45 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.222 0.534 . . . . 0.0 110.96 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 7.2 p90 -155.97 160.23 39.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.223 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -63.94 116.27 5.68 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.109 -179.141 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -58.24 -29.0 65.4 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.514 179.753 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 16.3 tt -74.6 -33.96 33.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.896 179.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.8 m-30 -72.1 -20.79 61.59 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.519 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 6.1 p -114.97 160.07 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.112 179.06 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -128.92 149.39 50.81 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.688 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.3 p -92.85 135.19 28.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.594 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 23.2 pt -121.04 158.24 23.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.461 179.815 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 41.1 t -61.37 138.72 58.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.587 -179.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 20.0 tp10 . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.182 -0.913 . . . . 0.0 110.521 179.983 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.208 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -59.03 146.81 92.97 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 122.992 2.461 . . . . 0.0 112.022 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -117.35 150.31 39.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.41 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 31.5 p -126.69 154.0 44.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.132 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.0 -125.45 0.98 Allowed Glycine 0 CA--C 1.523 0.537 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.237 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 28.4 mmt85 -129.56 141.72 50.91 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.053 0.454 . . . . 0.0 110.659 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -107.59 118.68 37.37 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.315 179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 68.7 ttt180 -98.45 123.81 42.8 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.977 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 65.9 t -79.54 125.18 38.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.135 -178.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 33.2 p80 -105.77 -10.04 16.93 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.202 179.327 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 14.4 t -145.38 151.21 37.9 Favored 'General case' 0 C--O 1.231 0.1 0 CA-C-O 120.841 0.353 . . . . 0.0 110.174 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -80.8 110.42 16.29 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.938 -179.403 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 11.2 t80 -120.69 130.6 54.16 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.369 179.229 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 71.3 p -124.5 152.87 69.19 Favored Pre-proline 0 CA--C 1.53 0.2 0 C-N-CA 120.74 -0.384 . . . . 0.0 110.793 -179.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -76.45 159.91 35.73 Favored 'Trans proline' 0 N--CA 1.492 1.399 0 C-N-CA 122.72 2.28 . . . . 0.0 112.232 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 57.7 m -71.57 157.6 89.53 Favored Pre-proline 0 C--N 1.331 -0.213 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.663 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_exo -53.0 -43.39 57.31 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.241 1.961 . . . . 0.0 111.959 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -84.26 -13.96 51.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.963 179.647 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -91.3 104.13 16.71 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.288 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 71.7 p -102.15 -24.84 13.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.816 0.341 . . . . 0.0 110.53 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -63.08 -38.2 90.25 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.534 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.0 t -73.55 131.15 41.41 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.255 179.742 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 2.5 tp -88.5 161.58 16.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.231 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 23.6 pttm -97.35 145.72 25.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.401 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.3 pt -133.57 149.65 31.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.175 179.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 38.0 ttmt -130.71 150.64 51.8 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 57.3 mtmt -55.03 125.72 21.62 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.092 0.472 . . . . 0.0 110.819 -179.21 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.3 -17.36 57.02 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -71.77 142.8 49.71 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 116.923 0.362 . . . . 0.0 110.492 179.631 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 50.5 mm -114.89 128.18 72.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.106 179.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 85.9 mt -118.45 127.87 75.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.636 -179.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -78.44 135.22 37.34 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.479 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 97.3 mt -76.91 120.9 28.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 C-N-CA 120.822 -0.351 . . . . 0.0 110.318 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.5 mt -107.75 -51.73 7.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.771 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 49.0 t -153.71 144.36 22.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.965 -179.553 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -96.5 142.58 28.41 Favored 'General case' 0 C--N 1.325 -0.46 0 C-N-CA 120.766 -0.374 . . . . 0.0 110.018 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 28.2 m -98.93 135.6 20.86 Favored Pre-proline 0 CA--C 1.54 0.563 0 C-N-CA 120.09 -0.644 . . . . 0.0 110.117 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -50.81 -32.57 37.56 Favored 'Trans proline' 0 N--CA 1.5 1.885 0 C-N-CA 122.373 2.049 . . . . 0.0 112.456 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 24.3 mmt -60.81 -38.85 86.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.273 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 140.67 -40.16 1.4 Allowed Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 179.745 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 96.5 mtp -61.83 145.92 51.2 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.129 0.49 . . . . 0.0 110.767 -179.359 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 42.5 m0 -98.64 153.89 18.35 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.703 -179.372 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.4 m -111.12 134.56 52.62 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 109.592 -0.522 . . . . 0.0 109.592 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.25 -174.22 25.77 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.333 -0.707 . . . . 0.0 111.333 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.1 ttp -119.33 138.16 53.23 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.831 0.348 . . . . 0.0 110.593 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -145.47 126.25 14.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.342 -179.879 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 6.5 p-10 43.46 56.13 4.52 Favored 'General case' 0 N--CA 1.466 0.371 0 O-C-N 123.441 0.463 . . . . 0.0 111.363 -179.525 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 55.08 34.16 21.95 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.935 0.397 . . . . 0.0 110.544 179.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.7 mmtp -142.34 115.04 8.59 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.392 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 16.0 m -97.68 139.4 20.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 C-N-CA 120.546 -0.462 . . . . 0.0 110.509 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -168.54 -177.42 39.52 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.415 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 -103.36 149.15 25.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.959 0.409 . . . . 0.0 110.701 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -146.71 157.97 43.81 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.334 179.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 23.0 ttmt -81.67 116.89 21.61 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.779 -178.564 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 36.5 p90 -57.98 -24.58 58.69 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.989 -179.658 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 10.6 tp -58.18 -25.17 26.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.883 0.373 . . . . 0.0 110.653 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 25.1 m-85 -100.94 14.06 33.12 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.191 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -143.22 156.13 17.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.746 0.307 . . . . 0.0 110.311 -179.727 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -130.54 149.93 51.98 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.563 179.254 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.6 m -93.78 131.71 39.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.272 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 42.0 pt -126.53 149.77 31.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.832 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 83.7 p -75.85 163.37 27.29 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.732 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.018 -0.992 . . . . 0.0 110.546 179.712 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -70.72 156.7 60.34 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 C-N-CA 122.943 2.429 . . . . 0.0 112.138 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 -125.88 150.52 47.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.502 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 28.1 p -116.45 142.4 46.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.363 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.55 -146.6 6.61 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 -179.421 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 8.2 mmm180 -121.02 142.15 50.07 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.901 -0.32 . . . . 0.0 110.543 -179.516 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.11 127.68 56.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.532 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 17.9 mtp180 -105.14 128.26 53.29 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.46 179.782 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.9 t -86.28 131.26 35.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.327 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 64.4 m170 -111.89 -11.66 13.87 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.047 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 4.2 p -124.89 174.67 7.8 Favored 'General case' 0 N--CA 1.455 -0.188 0 CA-C-O 121.173 0.511 . . . . 0.0 110.419 -179.416 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -103.48 112.0 24.7 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.627 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 8.9 t80 -119.19 118.9 32.58 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-O 121.011 0.434 . . . . 0.0 110.253 179.62 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 4.8 t -133.61 95.2 18.0 Favored Pre-proline 0 CA--C 1.543 0.696 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.519 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -68.41 153.61 73.66 Favored 'Trans proline' 0 C--N 1.301 -1.924 0 C-N-CA 122.305 2.003 . . . . 0.0 112.313 -179.444 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 48.1 m -65.65 154.49 88.37 Favored Pre-proline 0 N--CA 1.453 -0.294 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.533 -179.564 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.15 -20.98 64.15 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.847 2.365 . . . . 0.0 112.0 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -66.94 -23.56 65.98 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.249 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -99.69 96.53 7.68 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.324 179.409 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.1 t -75.96 -32.8 59.69 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.614 179.617 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -66.85 -38.12 85.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.532 179.722 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 69.1 m -67.49 123.32 20.1 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.671 -179.477 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -85.08 156.31 21.12 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.586 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 60.4 mtpt -98.56 127.84 44.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.645 179.625 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 45.8 pt -138.48 148.37 24.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.509 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 28.2 mttm -127.4 163.44 24.04 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.537 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -61.37 124.61 21.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.52 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 107.42 -31.18 8.32 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.799 -0.92 . . . . 0.0 110.799 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -66.63 145.86 55.11 Favored 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 120.881 -0.328 . . . . 0.0 110.346 179.503 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 60.6 mt -116.49 132.23 66.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.51 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.7 mp -114.86 129.17 71.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.857 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -72.78 122.52 21.67 Favored 'General case' 0 CA--C 1.518 -0.286 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.122 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.96 127.02 28.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 120.986 0.422 . . . . 0.0 110.93 -179.484 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.5 mt -109.39 -54.64 5.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.247 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 20.4 p -162.64 172.6 15.1 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.614 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 31.1 mtpt -120.39 150.23 41.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.451 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 67.3 p -121.71 151.66 57.63 Favored Pre-proline 0 CA--C 1.535 0.386 0 C-N-CA 120.339 -0.545 . . . . 0.0 110.915 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -69.02 -20.73 37.92 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.682 2.255 . . . . 0.0 112.242 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 3.0 mpp? -60.0 -15.51 23.0 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.484 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 97.16 22.8 16.23 Favored Glycine 0 C--N 1.336 0.564 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 96.4 mmm -127.19 144.41 51.04 Favored 'General case' 0 C--O 1.236 0.379 0 CA-C-O 121.039 0.447 . . . . 0.0 110.671 179.726 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 6.0 m0 -98.4 142.49 29.96 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.469 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 89.0 m -105.97 132.1 52.47 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 116.01 -0.541 . . . . 0.0 109.875 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -151.66 -179.87 27.69 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 60.7 ttm -115.81 142.02 47.32 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.989 0.424 . . . . 0.0 110.878 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -143.45 107.94 4.83 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.869 -179.89 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 53.77 53.92 10.64 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.29 179.491 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 54.4 t30 61.07 30.75 19.67 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.64 -179.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 62.8 tttm -137.63 112.81 9.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.05 179.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 27.4 m -99.09 144.12 12.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.875 0.369 . . . . 0.0 110.648 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -170.09 -173.08 37.19 Favored Glycine 0 CA--C 1.528 0.901 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 -179.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 35.4 m120 -103.4 148.29 26.08 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.985 0.421 . . . . 0.0 110.851 -179.287 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.8 p90 -153.21 160.1 42.75 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.727 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.408 ' HB3' HG12 ' A' ' 80' ' ' ILE . 96.7 mttt -79.71 122.34 26.45 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-O 121.433 0.635 . . . . 0.0 110.518 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 12.0 p90 -68.99 -24.11 64.19 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.199 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.408 HG12 ' HB3' ' A' ' 78' ' ' LYS . 28.4 pt -62.2 -19.69 22.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.833 0.349 . . . . 0.0 110.825 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 30.6 m-85 -102.69 5.66 39.12 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.865 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -136.16 153.86 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 CA-C-O 121.109 0.481 . . . . 0.0 110.638 -179.697 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 -127.51 143.19 51.22 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.565 179.245 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.8 m -88.61 136.93 22.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.229 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 42.5 pt -120.23 157.79 22.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.803 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 83.3 p -72.95 160.77 31.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.656 179.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 118.015 -0.993 . . . . 0.0 110.543 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -69.39 154.56 69.03 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 C-N-CA 122.855 2.37 . . . . 0.0 112.203 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 32.9 t80 -121.09 139.56 53.16 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.277 -179.487 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 79.9 m -107.38 135.03 49.56 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.652 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -172.98 -153.29 9.36 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 -179.529 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 39.6 mmt180 -116.45 144.03 44.83 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.886 0.374 . . . . 0.0 110.58 -179.491 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -113.04 121.86 45.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.619 -179.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 94.8 mtt180 -95.77 121.4 37.46 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.51 178.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 67.2 t -76.64 119.84 25.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.352 -179.399 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 4.3 p80 -105.85 -16.05 14.76 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.438 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 1.3 m -126.34 142.56 51.49 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.579 179.653 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -77.33 104.57 7.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.978 0.418 . . . . 0.0 110.333 -179.474 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 26.0 t80 -116.52 115.25 25.43 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.63 179.674 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 10.2 t -129.76 137.42 30.88 Favored Pre-proline 0 N--CA 1.452 -0.375 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.605 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -73.49 160.79 43.77 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.855 2.37 . . . . 0.0 112.242 -179.462 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 89.1 p -70.39 161.22 77.81 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.467 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -55.35 -37.71 94.42 Favored 'Trans proline' 0 N--CA 1.496 1.652 0 C-N-CA 122.736 2.291 . . . . 0.0 112.189 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -85.59 1.49 48.9 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.72 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -107.25 108.88 20.5 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-O 120.855 0.36 . . . . 0.0 110.34 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 10.1 t -111.03 -27.26 8.84 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.77 179.809 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -62.44 -38.94 91.68 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.659 -179.684 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.5 t -69.53 141.59 53.82 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.579 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 59.8 tp -83.36 143.64 30.19 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.554 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 26.0 pttm -98.64 137.75 36.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.899 0.381 . . . . 0.0 110.74 178.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.414 HD12 HG23 ' A' ' 49' ' ' ILE . 46.3 pt -137.7 147.5 26.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.78 179.526 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -119.38 156.14 30.65 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.032 -179.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.7 ttpt -61.61 120.8 11.29 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.461 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 104.84 -22.19 34.32 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 111.092 -0.803 . . . . 0.0 111.092 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -65.81 147.54 53.21 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-O 120.884 0.373 . . . . 0.0 110.906 179.257 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 47.2 mm -108.73 126.72 65.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.661 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.4 mt -109.22 128.9 64.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.78 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -79.29 112.51 16.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.306 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.3 mt -65.35 126.5 24.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.606 -179.487 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.6 mt -112.41 -55.29 4.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.6 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.9 t -162.86 151.69 14.71 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.74 -179.439 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.4 156.08 17.83 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.46 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.4 p -110.38 154.56 42.91 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.319 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -60.03 -26.84 83.53 Favored 'Trans proline' 0 C--N 1.305 -1.735 0 C-N-CA 122.807 2.338 . . . . 0.0 112.286 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 78.9 mtm -63.99 -38.15 90.02 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.501 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 133.82 -35.55 2.24 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 8.7 mtt -63.0 147.31 51.03 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.918 0.389 . . . . 0.0 110.624 -179.601 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 21.6 m0 -101.88 151.58 21.93 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.865 -179.534 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.0 m -114.08 136.37 53.0 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.866 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -154.56 -174.54 24.7 Favored Glycine 0 CA--C 1.524 0.646 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 -179.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 65.3 ttp -117.83 141.36 48.5 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 120.624 0.249 . . . . 0.0 110.638 -179.771 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 1.3 mt -143.46 110.44 5.65 Favored 'General case' 0 C--O 1.219 -0.512 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.58 179.745 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . 0.4 ' ND2' ' N ' ' A' ' 71' ' ' ASN . 0.1 OUTLIER 54.27 54.16 9.9 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 178.926 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 59.79 28.57 18.06 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.369 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 85.1 tttt -133.99 112.99 11.67 Favored 'General case' 0 C--O 1.225 -0.214 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.107 179.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 19.1 m -99.84 144.0 12.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.855 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -174.86 -173.84 41.03 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -179.536 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 78.1 m-20 -101.57 149.45 24.09 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.849 0.357 . . . . 0.0 110.646 -179.548 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -148.96 160.78 42.98 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.857 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 24.3 tptt -82.01 114.3 20.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.434 -179.168 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -62.9 -26.18 68.67 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.588 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 10.2 tt -58.94 -30.33 42.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.814 0.34 . . . . 0.0 110.917 -179.408 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 25.2 m-85 -93.32 5.34 51.89 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.04 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -131.42 156.44 42.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 CA-C-O 121.05 0.453 . . . . 0.0 110.68 -179.884 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 85.3 m-20 -123.6 140.07 53.36 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.436 179.352 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -93.84 142.83 12.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 120.949 0.404 . . . . 0.0 110.724 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 39.3 pt -128.6 159.02 40.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.82 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 99.1 p -106.61 160.67 15.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.598 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.569 179.966 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -69.57 148.09 65.52 Favored 'Trans proline' 0 C--N 1.305 -1.741 0 C-N-CA 122.768 2.312 . . . . 0.0 112.084 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 83.4 t80 -137.22 130.39 30.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.478 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 81.0 m -105.9 133.73 50.15 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.006 0.431 . . . . 0.0 110.212 179.736 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -176.08 -144.36 5.09 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -117.83 142.87 46.82 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.694 0.283 . . . . 0.0 110.468 -179.726 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -116.44 137.1 52.43 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.853 0.359 . . . . 0.0 110.454 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 16.0 ptm180 -116.77 133.87 55.48 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 89.6 t -82.3 127.98 39.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.42 -178.669 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 88.5 m-70 -109.71 -17.13 13.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.435 179.267 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 7.4 p -120.22 173.79 6.9 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.879 0.371 . . . . 0.0 110.143 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -101.03 107.71 19.23 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.803 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -117.82 109.84 17.05 Favored 'General case' 0 N--CA 1.463 0.217 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.129 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 90.8 m -128.62 128.23 23.54 Favored Pre-proline 0 CA--C 1.537 0.45 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.852 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -74.48 163.89 35.14 Favored 'Trans proline' 0 N--CA 1.489 1.25 0 C-N-CA 122.489 2.126 . . . . 0.0 112.165 179.612 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 69.7 m -70.57 158.61 87.41 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.565 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -54.4 -35.05 83.49 Favored 'Trans proline' 0 N--CA 1.499 1.807 0 C-N-CA 122.605 2.203 . . . . 0.0 112.128 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 35.5 p90 -90.56 4.11 52.15 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.212 179.803 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -108.58 111.57 23.47 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.551 -0.295 . . . . 0.0 110.364 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 61.4 p -112.89 -19.66 11.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.729 179.504 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -61.98 -38.74 89.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.665 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 58.2 m -80.3 144.19 33.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.682 179.79 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 47.1 tp -81.98 144.03 31.18 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.721 -179.612 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 7.1 ptpp? -98.34 118.56 35.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.622 178.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 20.1 pt -140.04 158.33 26.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.163 0.506 . . . . 0.0 110.926 -179.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.5 164.45 30.31 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.016 0.436 . . . . 0.0 110.679 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -60.59 129.1 39.87 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.914 -179.674 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 109.83 -20.39 26.9 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 111.361 -0.695 . . . . 0.0 111.361 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -85.18 147.41 26.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.003 0.43 . . . . 0.0 110.495 179.273 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 21.7 mm -112.49 129.33 68.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.316 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 75.9 mt -112.55 127.93 69.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.752 -179.228 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.9 m-20 -78.62 124.94 28.7 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.232 -0.44 . . . . 0.0 109.877 179.591 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 93.4 mt -70.58 123.24 24.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 120.882 0.372 . . . . 0.0 110.478 -179.204 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.6 mt -106.34 -51.34 7.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.41 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 49.6 t -168.29 154.76 7.39 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.022 0.439 . . . . 0.0 110.975 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -90.15 136.15 33.22 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.083 179.26 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.5 t -123.45 148.02 54.34 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.87 -179.307 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -52.32 -169.67 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.454 0 C-N-CA 122.418 2.079 . . . . 0.0 112.126 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 91.6 mtp 63.64 15.85 9.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.376 -179.196 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 63.71 37.4 94.65 Favored Glycine 0 CA--C 1.522 0.471 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 179.466 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 75.0 mtp -126.46 150.68 48.54 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 120.411 -0.516 . . . . 0.0 111.387 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 10.7 m0 -110.82 147.9 33.53 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.625 179.625 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 85.1 m -104.99 131.26 52.74 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.716 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -155.94 -176.45 28.1 Favored Glycine 0 CA--C 1.522 0.487 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.487 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.4 ttp -122.46 138.31 54.59 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.757 0.313 . . . . 0.0 110.657 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -144.3 121.58 11.58 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.185 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 75.6 m-20 53.18 48.4 22.27 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 59.71 29.72 19.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.706 0.289 . . . . 0.0 110.354 -179.537 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 42.9 tptt -130.48 114.9 16.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.259 -0.428 . . . . 0.0 109.881 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 89.7 t -96.54 125.89 49.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.878 -0.329 . . . . 0.0 110.586 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -160.16 -179.71 35.12 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 -179.496 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 -98.83 149.79 22.53 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.026 0.441 . . . . 0.0 110.923 -179.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -152.17 159.16 43.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.692 179.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 1.5 mptp? -78.73 116.29 18.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.82 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 33.8 p90 -61.49 -25.11 67.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.629 179.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 40.9 pt -62.37 -20.12 23.89 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 CA-C-O 120.78 0.324 . . . . 0.0 110.8 179.634 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 49.5 m-85 -100.18 3.61 43.87 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.805 179.002 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -132.17 157.42 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 CA-C-O 120.86 0.362 . . . . 0.0 110.314 -179.544 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -120.06 133.16 55.6 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.714 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 3.2 m -88.05 137.61 20.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 C-N-CA 120.579 -0.448 . . . . 0.0 110.354 179.659 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 43.0 pt -129.71 158.79 42.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.756 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 67.2 m -112.57 143.96 42.86 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.507 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.556 179.875 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -58.9 145.56 96.6 Favored 'Trans proline' 0 C--N 1.304 -1.783 0 C-N-CA 122.901 2.401 . . . . 0.0 112.057 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -119.7 148.26 43.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.601 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 28.4 p -124.88 149.16 47.82 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.575 -179.612 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.99 -148.13 11.0 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 -179.377 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 1.7 mpt_? -113.01 141.91 46.31 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.95 0.405 . . . . 0.0 110.463 179.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -117.77 130.97 56.63 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.643 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 41.2 ttm180 -97.14 121.51 39.11 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.576 179.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 77.1 t -82.65 129.18 37.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.495 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -112.88 8.63 18.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.974 179.452 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.0 p -137.12 166.87 22.69 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.74 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -108.56 104.74 14.12 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.356 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 16.1 t80 -118.72 119.19 33.69 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.628 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 82.4 p -120.74 152.28 55.66 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.609 -179.748 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -76.14 153.44 36.49 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.763 2.309 . . . . 0.0 112.406 -179.751 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 58.3 m -73.34 156.69 88.89 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.483 179.268 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -54.28 -39.4 86.93 Favored 'Trans proline' 0 C--N 1.301 -1.948 0 C-N-CA 122.858 2.372 . . . . 0.0 112.059 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -93.15 4.14 54.5 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.427 179.385 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -113.71 117.98 33.05 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.31 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 t -112.22 -25.13 9.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.79 179.592 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 -62.04 -38.43 88.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.595 -179.741 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 62.0 m -62.13 142.54 57.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.727 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 56.8 tp -90.38 142.49 27.68 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.423 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -94.73 121.84 36.73 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-O 120.939 0.399 . . . . 0.0 110.414 179.066 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 37.8 pt -131.1 155.21 41.75 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.62 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 48.7 pttt -137.27 160.68 38.34 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.564 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -66.3 131.85 47.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.95 179.349 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 102.42 -18.75 50.31 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -82.87 152.01 25.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.823 0.344 . . . . 0.0 110.369 179.505 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 96.4 mt -116.29 133.11 63.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.62 179.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 82.5 mt -118.11 134.15 62.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.783 -179.294 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -80.49 122.94 27.62 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.189 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.3 mt -72.92 124.48 29.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.75 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 8.9 tt -107.0 -33.86 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.449 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 24.0 p -175.54 175.34 2.13 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.463 -179.324 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -126.35 151.8 47.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.536 179.464 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 31.0 p -105.18 153.42 39.56 Favored Pre-proline 0 N--CA 1.454 -0.261 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.611 -179.404 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -57.05 -35.93 99.1 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 C-N-CA 122.779 2.319 . . . . 0.0 112.227 179.717 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 98.2 mtp -61.29 -37.35 82.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.646 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 131.13 -25.46 4.1 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 96.4 mtp -62.15 139.67 58.46 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.027 0.441 . . . . 0.0 110.341 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 37.7 m0 -96.25 148.11 23.08 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.986 -179.371 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 58.3 m -119.48 140.49 50.38 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-N 116.022 -0.536 . . . . 0.0 109.885 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -164.81 -168.93 27.71 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -179.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.8 ttp -116.03 135.34 54.05 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-O 120.671 0.272 . . . . 0.0 110.739 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 3.1 tt -135.7 112.51 10.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.371 179.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 66.9 t30 55.41 53.9 9.26 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.855 178.794 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 59.02 28.61 17.92 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.743 179.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -139.33 113.31 8.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.086 179.395 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 19.4 m -95.31 143.67 11.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.859 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -172.34 -173.39 38.95 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.664 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -111.73 155.14 23.96 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.748 0.309 . . . . 0.0 110.451 -179.355 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 9.2 p90 -155.62 157.85 37.4 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.812 179.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -63.99 132.81 51.76 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.45 -179.639 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 29.6 p90 -67.08 -21.32 65.89 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.684 -179.17 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 12.5 pt -78.22 -27.0 14.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.334 -179.618 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.2 m-85 -84.3 1.16 46.21 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.71 179.724 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 7.1 p -139.33 157.88 28.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.31 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -132.22 147.41 52.41 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.392 179.798 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.1 p -83.36 131.21 34.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.597 179.744 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 61.1 mt -88.78 115.84 29.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.456 -178.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 70.8 p -79.4 165.34 23.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.488 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 78.2 mm-40 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.566 179.55 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.231 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.71 147.43 87.91 Favored 'Trans proline' 0 C--N 1.303 -1.844 0 C-N-CA 123.063 2.509 . . . . 0.0 112.069 179.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -118.57 152.7 35.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.27 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 31.7 p -116.94 140.32 49.61 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.927 0.394 . . . . 0.0 110.342 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -166.86 -162.92 19.67 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 -179.375 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 10.9 mpt_? -119.6 147.55 44.37 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.764 0.316 . . . . 0.0 110.786 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -134.57 154.61 51.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.807 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 17.5 ptm180 -131.0 148.95 52.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.741 -179.589 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.8 t -86.26 128.71 39.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.301 -179.043 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 26.4 m170 -97.87 -16.98 19.54 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.517 178.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 13.1 t -144.53 142.8 30.48 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.885 -0.326 . . . . 0.0 110.145 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -62.59 117.45 6.26 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.777 -0.369 . . . . 0.0 110.731 -179.37 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -121.69 110.63 16.18 Favored 'General case' 0 C--O 1.233 0.201 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 88.0 m -129.14 94.73 32.91 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.057 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -54.78 152.7 27.36 Favored 'Trans proline' 0 N--CA 1.494 1.521 0 C-N-CA 122.358 2.039 . . . . 0.0 112.013 -179.596 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 39.0 m -59.14 154.73 38.59 Favored Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.474 -179.425 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -57.28 -24.65 60.86 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.554 2.17 . . . . 0.0 112.186 -179.434 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -65.87 -20.63 66.3 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.331 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 50.3 m-20 -96.11 59.68 1.96 Allowed 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 120.956 0.408 . . . . 0.0 110.521 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 12.8 t -60.46 -18.65 52.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.575 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 57.9 p-10 -90.1 7.23 38.91 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.314 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 67.8 m -106.57 144.41 33.28 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-O 120.917 0.389 . . . . 0.0 110.629 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 58.5 tp -81.6 142.03 33.16 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.536 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 1.6 mptm? -98.7 126.79 44.42 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.47 179.051 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 21.6 pt -131.49 148.5 32.65 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.631 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 39.3 ttpt -122.65 152.57 40.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.844 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 38.7 ttmt -57.11 128.35 36.56 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.058 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.38 -18.67 55.03 Favored Glycine 0 CA--C 1.524 0.635 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.451 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -72.23 144.96 48.27 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.796 0.332 . . . . 0.0 110.718 179.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.417 HG21 HD13 ' A' ' 54' ' ' ILE . 90.9 mt -111.96 129.08 68.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.35 179.243 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 81.3 mt -122.62 128.5 75.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.908 -179.172 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -76.9 134.03 39.08 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.367 179.349 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 85.9 mt -71.06 103.58 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.919 0.39 . . . . 0.0 110.16 -179.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.8 tt -89.09 -34.52 6.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.327 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 17.1 t -167.45 161.27 13.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.29 -179.46 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -120.57 144.7 47.95 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 27.6 m -101.67 135.69 19.72 Favored Pre-proline 0 CA--C 1.539 0.538 0 C-N-CA 120.232 -0.587 . . . . 0.0 109.98 -179.479 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -57.6 -25.7 68.7 Favored 'Trans proline' 0 N--CA 1.501 1.917 0 C-N-CA 122.359 2.039 . . . . 0.0 112.69 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 65.5 mtt -62.22 -38.74 90.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.959 0.409 . . . . 0.0 110.186 179.503 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 142.17 -40.12 1.32 Allowed Glycine 0 CA--C 1.524 0.634 0 N-CA-C 111.106 -0.798 . . . . 0.0 111.106 179.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 95.5 mtp -64.07 144.39 57.14 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.217 0.532 . . . . 0.0 111.108 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 38.4 m0 -97.4 156.31 16.52 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.369 -179.579 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 80.3 m -117.19 139.31 50.92 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.056 -179.719 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.23 -175.78 27.6 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 16.9 tmm? -121.31 141.55 50.81 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.723 0.297 . . . . 0.0 110.507 -179.697 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -149.31 121.62 8.41 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.992 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 69.5 m-20 50.31 49.96 19.6 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 53.0 t30 59.82 35.07 21.93 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.764 0.316 . . . . 0.0 110.708 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 24.3 tptp -134.26 115.94 14.71 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 179.43 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 97.1 t -105.78 129.03 59.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.446 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -165.86 -172.42 33.21 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.59 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.7 m-80 -101.43 153.18 19.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.024 0.44 . . . . 0.0 111.056 -179.508 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 53.4 p90 -149.93 160.43 43.61 Favored 'General case' 0 C--O 1.239 0.54 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.619 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 35.6 tptt -69.62 111.77 5.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.514 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 53.4 p90 -61.53 -24.31 66.53 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.8 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.9 mt -63.14 -39.24 84.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.022 0.439 . . . . 0.0 110.437 -179.807 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 20.6 m-85 -84.71 2.22 42.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.971 -179.581 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 85.6 t -126.02 136.9 59.43 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.147 0 CA-C-O 120.987 0.422 . . . . 0.0 110.813 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -124.41 148.42 47.59 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.373 -179.878 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 16.9 m -90.37 139.6 17.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 C-N-CA 120.662 -0.415 . . . . 0.0 110.58 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . 0.422 HG22 HD13 ' A' ' 85' ' ' ILE . 38.9 pt -120.96 149.78 23.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.796 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 83.9 p -90.84 170.49 10.05 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.674 179.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.049 -0.977 . . . . 0.0 110.482 179.756 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.4 m . . . . . 0 N--CA 1.456 -0.132 0 CA-C-O 120.844 0.354 . . . . 0.0 110.484 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.51 -128.18 1.87 Allowed Glycine 0 CA--C 1.526 0.753 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 9.9 mpt_? -111.48 140.2 46.28 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.754 0.311 . . . . 0.0 110.7 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.464 ' HB1' ' CG1' ' A' ' 82' ' ' VAL . . . -111.1 127.1 55.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.445 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 74.2 ttt-85 -103.55 123.66 47.35 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.525 -179.68 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.568 HG22 HG22 ' A' ' 82' ' ' VAL . 66.1 t -77.5 123.51 34.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.621 -179.694 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 35.4 p80 -105.75 -16.37 14.69 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.741 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.472 HG21 ' CD2' ' A' ' 81' ' ' TYR . 32.6 m -128.45 129.33 45.96 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.692 179.666 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -65.71 109.65 2.5 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.557 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' PHE . . . . . 0.488 ' HB3' HD11 ' A' ' 49' ' ' ILE . 22.5 t80 -117.17 115.4 25.26 Favored 'General case' 0 C--O 1.241 0.611 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.372 179.557 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 95.5 m -131.08 128.28 22.2 Favored Pre-proline 0 N--CA 1.449 -0.502 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.754 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.5 166.41 29.9 Favored 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 123.012 2.475 . . . . 0.0 112.139 179.377 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 61.7 m -67.47 159.52 77.45 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.554 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_exo -55.62 -32.07 81.82 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.722 2.281 . . . . 0.0 112.183 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -95.51 11.45 32.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.763 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -106.69 108.73 20.38 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.339 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 5.0 t -113.51 -8.49 13.36 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.782 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 45.5 p-10 -75.59 -7.12 53.42 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.762 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 73.6 m -118.9 144.37 46.45 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-O 120.787 0.327 . . . . 0.0 110.504 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.413 HD21 ' HB2' ' A' ' 70' ' ' LEU . 9.5 tp -82.11 153.93 25.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.533 -179.776 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -96.2 130.61 43.23 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.573 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.488 HD11 ' HB3' ' A' ' 37' ' ' PHE . 34.2 pt -134.93 158.53 41.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.414 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.7 tttp -137.0 145.29 43.93 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.798 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 63.4 tttm -54.45 129.2 35.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.637 -179.782 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.57 -16.83 59.26 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 111.174 -0.77 . . . . 0.0 111.174 -179.692 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -74.87 148.41 40.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.786 0.327 . . . . 0.0 110.612 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 42.9 mm -109.93 126.63 67.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.392 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.423 HD11 ' CG2' ' A' ' 49' ' ' ILE . 82.9 mt -119.08 129.06 75.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.606 -179.606 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -77.11 122.77 25.44 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.326 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.4 mt -76.82 125.25 36.46 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.486 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.412 HD11 HG22 ' A' ' 67' ' ' THR . 30.6 pt -114.24 -27.98 2.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.461 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 10.4 t -167.35 161.82 14.41 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.647 -179.158 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -119.14 145.26 46.12 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.231 179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 25.5 m -94.89 134.32 25.09 Favored Pre-proline 0 CA--C 1.534 0.336 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.429 -179.134 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -50.73 -36.19 50.42 Favored 'Trans proline' 0 N--CA 1.494 1.546 0 C-N-CA 122.806 2.338 . . . . 0.0 112.068 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 60.6 ttm -59.03 -40.23 84.37 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.324 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 144.05 -31.78 1.83 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 97.5 mtp -62.54 146.59 51.38 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.014 0.435 . . . . 0.0 110.842 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 42.6 m0 -102.0 150.79 22.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.965 -179.186 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.412 HG22 HD11 ' A' ' 58' ' ' ILE . 93.2 m -110.55 136.73 49.22 Favored 'General case' 0 C--O 1.237 0.417 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.994 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -155.87 -171.56 22.43 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 111.095 -0.802 . . . . 0.0 111.095 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -123.35 147.65 46.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.991 0.424 . . . . 0.0 110.622 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.413 ' HB2' HD21 ' A' ' 47' ' ' LEU . 0.4 OUTLIER -151.09 117.37 5.64 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.69 -179.742 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 18.8 m120 51.22 52.83 14.07 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.142 179.413 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 80.7 m-20 59.68 26.18 15.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.237 -179.561 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.9 tttp -130.25 113.16 14.09 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.504 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 15.6 m -99.37 140.04 19.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.761 179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -171.42 -176.67 40.65 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -179.625 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 -104.12 150.4 24.36 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.077 0.465 . . . . 0.0 110.459 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.665 ' CD1' HG21 ' A' ' 82' ' ' VAL . 50.9 p90 -146.22 156.58 43.49 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.723 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 54.6 mttp -67.01 122.18 17.18 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.005 -179.591 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 55.9 p90 -68.64 -29.58 68.1 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.55 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 33.6 pt -60.46 -21.21 22.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.839 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.472 ' CD2' HG21 ' A' ' 35' ' ' THR . 22.4 m-85 -102.64 1.51 34.76 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.871 179.289 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.665 HG21 ' CD1' ' A' ' 77' ' ' PHE . 68.2 t -127.83 136.51 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 CA-C-O 121.109 0.48 . . . . 0.0 110.752 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 41.7 t0 -110.94 142.26 43.28 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.395 179.481 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.7 p -86.94 126.3 40.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.772 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 23.4 pt -127.19 163.32 30.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.714 179.84 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 28.7 t -104.74 130.32 52.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.581 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 7.9 tt0 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.554 179.916 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 84.1 m . . . . . 0 N--CA 1.453 -0.325 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 172.37 -140.53 5.79 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 21.0 mmm180 -110.14 148.13 32.37 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.887 0.375 . . . . 0.0 110.311 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -121.68 143.67 49.21 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.435 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 38.6 ptt180 -120.25 135.97 54.82 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.033 0.444 . . . . 0.0 110.427 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 43.4 t -84.54 135.53 24.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.982 -178.737 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 97.4 m-70 -107.28 -12.79 15.28 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.732 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 11.8 t -140.87 148.83 41.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.891 0.377 . . . . 0.0 110.375 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.3 p-10 -75.13 121.43 22.06 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.026 -179.515 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -119.28 118.24 30.73 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 178.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 89.6 m -126.56 94.69 39.8 Favored Pre-proline 0 CA--C 1.534 0.361 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.434 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -56.45 147.79 66.5 Favored 'Trans proline' 0 N--CA 1.499 1.804 0 C-N-CA 122.409 2.073 . . . . 0.0 112.023 -179.635 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 93.7 p -67.92 159.21 80.62 Favored Pre-proline 0 CA--C 1.532 0.255 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.709 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -56.8 -30.77 86.17 Favored 'Trans proline' 0 N--CA 1.499 1.812 0 C-N-CA 122.832 2.355 . . . . 0.0 112.154 -179.773 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -61.82 -22.96 65.93 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.062 -179.444 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -107.27 103.44 12.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.041 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.404 HG22 ' H ' ' A' ' 44' ' ' THR . 1.9 t -87.51 -33.89 18.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.367 179.762 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -63.37 -38.03 89.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.038 179.681 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 53.4 m -62.38 131.65 49.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.946 0.403 . . . . 0.0 110.647 -179.31 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 1.2 tt -87.55 150.84 23.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.755 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -98.22 123.52 42.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.263 -0.426 . . . . 0.0 109.926 179.092 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 47.3 pt -130.08 159.05 42.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 120.897 0.379 . . . . 0.0 110.902 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -135.71 141.99 44.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.704 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 22.8 pttp -53.35 138.86 31.76 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.982 0.42 . . . . 0.0 110.658 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.1 -17.9 56.42 Favored Glycine 0 CA--C 1.53 0.977 0 N-CA-C 111.2 -0.76 . . . . 0.0 111.2 -179.523 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -84.64 156.82 21.37 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.789 0.328 . . . . 0.0 110.921 179.569 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 47.4 mm -116.46 131.51 68.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.403 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.458 ' CG1' HD12 ' A' ' 70' ' ' LEU . 89.7 mt -118.25 132.04 69.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.282 -179.559 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 66.9 t0 -74.52 118.48 17.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.74 179.788 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 90.6 mt -69.34 122.4 20.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 120.902 0.382 . . . . 0.0 110.664 -179.433 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 82.6 mt -108.31 -59.44 3.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.183 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 94.2 m -140.87 142.93 34.46 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.479 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 12.2 pttp -154.26 123.21 6.33 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.926 0.393 . . . . 0.0 110.821 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.8 p -75.44 161.68 75.68 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.362 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_exo -52.28 -36.18 66.9 Favored 'Trans proline' 0 N--CA 1.495 1.607 0 C-N-CA 122.506 2.138 . . . . 0.0 111.833 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 14.9 tpt -149.71 97.0 2.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.476 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 168.85 -178.65 42.09 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 111.009 -0.836 . . . . 0.0 111.009 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.1 mtp -60.69 144.51 51.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.023 0.439 . . . . 0.0 110.738 -179.112 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 26.2 m0 -93.82 146.35 23.94 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.293 -179.57 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.9 m -112.59 135.49 53.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.986 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -160.59 -171.69 26.87 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 67.5 ttp -121.86 135.49 54.9 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.823 0.344 . . . . 0.0 110.407 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.458 HD12 ' CG1' ' A' ' 55' ' ' ILE . 4.2 tt -135.35 117.03 14.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.063 179.662 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ASN . . . . . 0.449 ' N ' HD23 ' A' ' 70' ' ' LEU . 64.8 t30 55.85 52.93 9.98 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.235 179.282 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 33.1 m120 57.94 35.08 25.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.657 0.265 . . . . 0.0 111.4 179.582 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -139.02 116.89 11.56 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.14 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 89.5 t -95.41 129.94 44.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.604 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -165.67 -174.08 34.85 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.337 -0.705 . . . . 0.0 111.337 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.1 m-80 -108.95 156.72 19.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.007 0.432 . . . . 0.0 110.912 -179.555 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -157.52 160.32 38.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.096 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -71.06 117.77 12.98 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.174 0.511 . . . . 0.0 111.119 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.456 ' HA ' HG12 ' A' ' 82' ' ' VAL . 55.6 p90 -63.15 -30.26 71.45 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.512 179.536 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.44 HG23 ' CE1' ' A' ' 79' ' ' PHE . 18.3 pt -62.43 -18.5 20.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.77 0.319 . . . . 0.0 110.724 179.344 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 15.3 m-30 -100.63 3.63 42.68 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.909 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.456 HG12 ' HA ' ' A' ' 79' ' ' PHE . 0.5 OUTLIER -132.58 159.94 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.758 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -127.59 144.47 51.07 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.526 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.7 p -93.65 128.63 44.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.579 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 44.0 pt -127.68 158.83 39.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.752 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 71.0 m -70.64 144.74 51.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.531 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.606 179.848 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 24.1 p . . . . . 0 N--CA 1.451 -0.423 0 CA-C-O 121.064 0.459 . . . . 0.0 110.195 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.97 -155.25 14.95 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 26.9 mmt85 -112.22 140.64 46.75 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.885 0.374 . . . . 0.0 110.481 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.6 117.15 30.08 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.496 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 75.5 ttt180 -91.34 124.57 35.64 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.615 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.584 HG22 HG22 ' A' ' 82' ' ' VAL . 82.5 t -82.26 129.33 37.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.6 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 37.0 m80 -107.1 -18.18 13.97 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.851 179.76 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.538 HG21 ' CD2' ' A' ' 81' ' ' TYR . 95.2 m -123.94 134.53 53.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.367 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -75.07 114.18 13.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.697 -179.577 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -118.22 125.18 49.65 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.345 179.8 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 10.0 t -132.28 134.18 24.66 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.673 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -72.97 166.41 30.11 Favored 'Trans proline' 0 N--CA 1.492 1.434 0 C-N-CA 122.894 2.396 . . . . 0.0 112.388 179.723 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 48.8 m -64.13 156.13 76.1 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.482 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -58.51 -27.39 82.07 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.621 2.214 . . . . 0.0 112.306 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -99.29 22.74 10.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.636 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -114.31 113.22 24.28 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.437 179.575 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 72.8 p -110.73 -15.14 13.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.683 179.729 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 56.7 p-10 -88.47 10.85 18.75 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.844 179.752 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 67.7 m -117.26 157.96 25.15 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 120.683 0.278 . . . . 0.0 110.3 -179.668 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 63.8 tp -104.56 136.7 43.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.321 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 13.3 tmtt? -96.72 124.94 40.85 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.385 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 49.3 pt -128.21 158.49 40.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.532 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 64.6 pttt -138.47 161.23 37.54 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.633 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 23.3 pttp -63.13 137.46 58.24 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.765 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.04 -11.6 71.7 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 111.024 -0.831 . . . . 0.0 111.024 -179.676 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 42.0 t0 -79.43 148.66 31.85 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-O 120.829 0.347 . . . . 0.0 110.463 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 39.0 mm -110.64 127.88 67.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.399 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 93.9 mt -115.22 134.34 58.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.803 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -82.17 111.9 18.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.559 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.5 mt -63.31 130.95 28.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.746 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 97.6 mt -112.57 -63.97 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.715 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.9 t -154.0 138.94 17.21 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.588 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -92.06 153.38 19.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.275 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 81.8 p -125.08 151.91 69.82 Favored Pre-proline 0 CA--C 1.532 0.252 0 C-N-CA 120.477 -0.489 . . . . 0.0 110.695 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -63.69 -18.85 65.92 Favored 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.908 2.406 . . . . 0.0 112.315 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 39.2 mmt -61.76 -37.41 84.19 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.195 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 125.18 -44.06 1.31 Allowed Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.074 -0.811 . . . . 0.0 111.074 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 33.5 mtt -61.85 141.76 57.76 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.98 0.419 . . . . 0.0 110.436 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 26.9 m0 -96.07 147.26 23.91 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.285 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 85.6 m -112.29 137.06 50.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.977 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -158.14 -172.53 25.41 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 37.2 ttm -119.69 140.49 50.58 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 120.734 0.302 . . . . 0.0 110.383 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -144.09 115.57 8.09 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.912 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 57.0 m-20 53.27 51.13 16.12 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.334 179.445 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 52.9 t30 60.75 28.79 18.51 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.545 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 13.0 tppt? -136.83 115.32 11.9 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.45 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.9 m -97.29 142.47 14.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.868 0.366 . . . . 0.0 110.804 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -171.18 -177.65 41.14 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 110.691 -0.963 . . . . 0.0 110.691 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -103.09 157.97 16.62 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 121.083 0.468 . . . . 0.0 110.644 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.571 ' CD1' HG21 ' A' ' 82' ' ' VAL . 2.1 p90 -154.35 161.56 41.68 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.194 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 12.4 tptt -62.17 117.47 6.08 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-O 121.488 0.661 . . . . 0.0 110.882 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -62.3 -23.22 66.6 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.353 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.419 HG23 ' N ' ' A' ' 81' ' ' TYR . 18.1 tt -73.28 -38.19 53.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.877 0.37 . . . . 0.0 110.812 179.591 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.538 ' CD2' HG21 ' A' ' 35' ' ' THR . 22.8 m-85 -80.3 -14.92 57.99 Favored 'General case' 0 C--O 1.24 0.582 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.765 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.584 HG22 HG22 ' A' ' 33' ' ' VAL . 67.2 t -111.78 137.08 45.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.223 0 CA-C-O 121.31 0.576 . . . . 0.0 110.61 179.843 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 41.5 t0 -121.04 149.47 42.65 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.743 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.3 p -87.85 132.38 33.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.447 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 2.4 tt -104.81 146.09 12.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.654 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 72.0 m -80.17 148.26 30.97 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.473 179.676 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 117.911 -1.042 . . . . 0.0 110.516 179.834 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 72.9 m . . . . . 0 CA--C 1.527 0.072 0 CA-C-O 120.832 0.349 . . . . 0.0 110.455 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 176.88 -123.76 0.92 Allowed Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -179.705 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 19.2 tpp180 -121.54 133.62 55.02 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.791 0.329 . . . . 0.0 110.448 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -104.28 122.94 46.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.694 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 78.3 ttt-85 -107.12 127.16 53.25 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.722 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.0 t -81.03 125.76 39.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.272 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 32.5 p80 -117.24 -13.1 10.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.699 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 97.2 m -125.51 134.37 52.05 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.538 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -69.22 122.98 19.93 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.672 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -71.59 137.69 48.18 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.222 179.642 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 82.1 m -120.01 93.27 47.72 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.424 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -73.59 151.69 47.35 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.864 2.376 . . . . 0.0 112.452 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 65.5 m -76.56 159.98 78.27 Favored Pre-proline 0 N--CA 1.452 -0.355 0 CA-C-O 121.263 0.554 . . . . 0.0 110.7 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -55.44 -37.47 94.81 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 122.733 2.289 . . . . 0.0 111.638 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.2 p90 -91.1 15.59 11.39 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.624 -179.702 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -108.81 94.83 5.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.276 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 71.2 p -104.42 -22.72 13.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.638 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -87.1 6.83 30.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.696 179.3 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 82.7 p -71.59 160.06 33.34 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-O 120.882 0.372 . . . . 0.0 110.42 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 55.8 tp -91.16 136.95 32.73 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.295 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 15.9 ptpt -93.64 123.33 36.89 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.762 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.0 pt -139.26 160.22 28.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.579 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.2 tttp -143.94 141.95 30.49 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.622 179.473 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 23.3 pttp -48.85 134.33 16.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.661 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.25 -19.61 53.81 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -74.32 153.66 39.23 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.784 0.326 . . . . 0.0 110.741 179.436 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 43.4 mm -114.47 126.62 72.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.367 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 87.1 mt -111.49 133.9 55.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.682 -179.528 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -80.11 112.17 17.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.593 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 97.5 mt -63.43 124.07 17.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.494 -179.657 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 97.3 mt -106.73 -54.87 5.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.634 179.827 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 32.0 p -161.51 171.27 18.41 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.61 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.02 146.14 42.4 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.499 179.828 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 62.1 p -101.45 155.02 36.87 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.515 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -63.27 -22.23 72.18 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 C-N-CA 122.957 2.438 . . . . 0.0 112.183 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 39.0 mmt -76.06 -10.56 59.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.877 179.485 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 104.08 -25.1 27.35 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 179.849 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 91.7 mmm -63.18 147.04 52.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.902 0.382 . . . . 0.0 110.426 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 33.1 m0 -103.95 143.38 32.94 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.827 -179.493 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 86.6 m -108.18 133.68 52.11 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.664 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -150.75 -179.05 26.18 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 -179.63 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 61.2 ttm -117.99 143.18 46.6 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-O 120.639 0.257 . . . . 0.0 110.557 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -142.04 117.14 10.02 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.574 179.74 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ASN . . . . . 0.454 ' O ' ' ND2' ' A' ' 71' ' ' ASN . 1.9 p-10 40.99 57.64 2.71 Favored 'General case' 0 N--CA 1.463 0.18 0 O-C-N 123.391 0.432 . . . . 0.0 111.019 -179.753 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 60.5 t30 60.62 38.56 18.57 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.909 -179.253 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 64.1 tttt -141.36 109.69 5.91 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.092 178.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 60.1 t -98.99 129.82 48.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.91 0.386 . . . . 0.0 110.772 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -163.63 -178.63 37.43 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 63.3 m-20 -101.17 160.52 14.33 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-O 120.643 0.259 . . . . 0.0 110.449 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 19.8 p90 -158.88 159.21 34.73 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.704 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 30.1 tttt -66.41 113.78 4.92 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.491 -179.402 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.428 ' HA ' HG12 ' A' ' 82' ' ' VAL . 49.4 p90 -59.22 -23.15 62.07 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.396 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 95.7 mt -68.54 -38.73 79.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.025 0.441 . . . . 0.0 110.19 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.7 m-30 -76.07 -5.43 46.45 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.815 -179.438 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.428 HG12 ' HA ' ' A' ' 79' ' ' PHE . 0.4 OUTLIER -126.82 165.43 25.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.629 -179.591 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -148.66 160.63 42.96 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.521 179.168 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.435 ' O ' HG23 ' A' ' 84' ' ' VAL . 23.6 m -94.52 129.34 44.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.624 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 43.1 pt -126.11 159.87 34.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.67 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 41.4 t -105.6 123.15 47.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.589 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 25.4 pt-20 . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.538 179.991 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 31.1 p . . . . . 0 N--CA 1.456 -0.157 0 CA-C-O 120.974 0.416 . . . . 0.0 110.143 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.63 -124.25 1.59 Allowed Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 14.7 mmp_? -111.2 147.0 35.91 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.681 0.277 . . . . 0.0 110.51 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -117.79 114.41 23.25 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.718 -0.393 . . . . 0.0 110.896 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.539 ' HD2' HD12 ' A' ' 85' ' ' ILE . 2.8 ptm85 -87.9 128.48 35.36 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.546 179.765 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.542 HG22 HG23 ' A' ' 82' ' ' VAL . 95.7 t -84.83 131.98 32.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.2 -179.313 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 30.3 m170 -114.17 -15.32 12.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.398 179.409 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.414 HG21 ' CD2' ' A' ' 81' ' ' TYR . 32.9 m -127.68 132.47 49.66 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.843 0.354 . . . . 0.0 110.712 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -65.79 145.1 56.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.736 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -98.65 134.92 40.9 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.004 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.48 HG23 ' O ' ' A' ' 38' ' ' THR . 2.7 t -121.22 93.52 48.81 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.752 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_endo -75.01 153.1 41.47 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.397 2.064 . . . . 0.0 112.319 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 65.6 m -72.01 158.97 86.69 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.525 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -53.82 -37.16 84.73 Favored 'Trans proline' 0 N--CA 1.497 1.723 0 C-N-CA 122.633 2.222 . . . . 0.0 112.039 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 41.1 p90 -97.43 16.36 20.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.869 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -96.6 88.16 4.58 Favored 'General case' 0 C--O 1.233 0.213 0 CA-C-O 121.039 0.447 . . . . 0.0 110.544 -179.726 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 6.9 t -93.24 -26.16 17.48 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.437 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 56.0 p-10 -79.5 -3.36 46.4 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.023 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 34.8 t -83.55 139.63 32.76 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.661 0.267 . . . . 0.0 110.536 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 60.2 tp -85.85 145.82 27.02 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.371 -0.377 . . . . 0.0 109.997 179.593 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 58.2 pttt -96.27 127.03 41.91 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.45 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 35.2 pt -144.12 150.2 17.01 Favored 'Isoleucine or valine' 0 C--O 1.237 0.436 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.339 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 63.7 tttp -132.72 145.88 51.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.331 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 64.8 pttt -48.93 138.15 11.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.953 0.406 . . . . 0.0 110.682 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 93.44 -13.27 67.94 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 -179.46 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -77.37 150.95 35.07 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-O 120.817 0.342 . . . . 0.0 110.636 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 36.1 mm -114.21 126.73 71.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.208 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.44 HG12 HD12 ' A' ' 70' ' ' LEU . 92.3 mt -117.93 133.14 65.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.83 -179.498 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -78.58 121.97 25.32 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.276 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.7 mt -69.5 120.39 17.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.914 0.388 . . . . 0.0 110.545 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.492 HD11 ' HB2' ' A' ' 69' ' ' MET . 93.3 mt -109.47 -50.65 6.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.451 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 95.3 m -140.26 151.42 45.11 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.437 179.483 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 37.8 mtmm -124.88 147.74 48.65 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.417 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 90.0 m -122.71 117.16 28.9 Favored Pre-proline 0 CA--C 1.537 0.466 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.202 179.569 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_exo -50.57 126.83 18.98 Favored 'Trans proline' 0 N--CA 1.497 1.715 0 C-N-CA 121.933 1.755 . . . . 0.0 111.971 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 93.7 mmm 47.15 40.62 10.27 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.613 179.677 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -151.77 176.37 30.17 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.152 -0.779 . . . . 0.0 111.152 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 98.9 mtp -60.0 148.33 35.81 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.006 0.432 . . . . 0.0 110.58 -179.088 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 16.1 m0 -94.89 158.25 15.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.057 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 96.2 m -118.93 138.0 53.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.238 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -160.73 -170.57 25.51 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' MET . . . . . 0.492 ' HB2' HD11 ' A' ' 58' ' ' ILE . 64.8 ttp -125.71 136.32 53.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.745 0.307 . . . . 0.0 110.337 -179.702 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.488 HD23 ' N ' ' A' ' 71' ' ' ASN . 4.4 tt -137.83 120.15 15.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.392 179.869 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ASN . . . . . 0.488 ' N ' HD23 ' A' ' 70' ' ' LEU . 67.2 t30 53.08 51.4 15.81 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.681 -0.408 . . . . 0.0 110.981 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 58.0 t30 58.87 36.26 24.57 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.653 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 4.0 tptm -139.12 113.76 9.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.37 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 91.7 t -94.54 127.36 46.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.846 0.355 . . . . 0.0 110.674 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -163.22 -178.82 37.29 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 -179.8 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -100.69 157.53 16.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.907 0.384 . . . . 0.0 110.729 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -155.88 161.21 40.62 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.841 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -73.54 121.96 21.45 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.859 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.626 ' HA ' HG12 ' A' ' 82' ' ' VAL . 51.2 p90 -67.69 -28.18 67.46 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.794 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.473 HG23 ' CE1' ' A' ' 79' ' ' PHE . 33.5 pt -63.82 -19.53 24.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.694 0.283 . . . . 0.0 111.073 179.656 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.414 ' CD2' HG21 ' A' ' 35' ' ' THR . 21.2 m-30 -102.23 5.39 40.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.942 0.401 . . . . 0.0 110.913 179.532 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.626 HG12 ' HA ' ' A' ' 79' ' ' PHE . 1.2 p -134.23 153.17 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.315 179.801 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -113.41 134.11 54.82 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.375 179.293 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.0 p -80.09 125.94 39.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.548 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.539 HD12 ' HD2' ' A' ' 32' ' ' ARG . 0.1 OUTLIER -122.76 134.42 66.0 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.418 -179.815 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 69.8 m -67.49 143.39 56.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.32 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.633 179.892 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 82.6 m . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.835 0.35 . . . . 0.0 110.378 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -175.34 -152.96 9.76 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 39.5 mmt180 -112.27 143.46 43.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.78 0.324 . . . . 0.0 110.657 -179.624 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -117.97 132.27 56.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.225 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.446 ' HA ' HD13 ' A' ' 54' ' ' ILE . 17.6 ptm180 -110.82 133.05 53.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.232 0.539 . . . . 0.0 110.733 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.502 HG22 HG23 ' A' ' 82' ' ' VAL . 86.5 t -85.68 133.44 29.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.511 -179.332 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.562 ' HD2' HG23 ' A' ' 35' ' ' THR . 0.3 OUTLIER -118.02 -7.31 10.88 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.171 179.792 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.562 HG23 ' HD2' ' A' ' 34' ' ' HIS . 72.9 p -130.65 158.82 39.0 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.892 0.377 . . . . 0.0 110.3 -179.836 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -91.35 104.06 16.63 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.599 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -119.24 121.4 39.58 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.571 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 8.7 t -130.3 139.67 36.33 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.809 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -73.59 166.01 30.91 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 122.779 2.319 . . . . 0.0 112.262 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 85.7 p -68.65 161.82 67.81 Favored Pre-proline 0 C--N 1.324 -0.525 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.653 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -56.23 -34.63 94.02 Favored 'Trans proline' 0 N--CA 1.5 1.893 0 C-N-CA 122.712 2.275 . . . . 0.0 112.098 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.3 p90 -87.75 9.42 21.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.923 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -112.38 114.73 27.61 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-O 120.684 0.278 . . . . 0.0 110.397 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 58.1 p -115.34 -30.57 6.22 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.933 0.397 . . . . 0.0 110.617 179.572 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -63.23 -37.32 86.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.548 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 66.7 m -58.85 152.83 18.42 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.606 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.521 HD13 ' H ' ' A' ' 48' ' ' LYS . 0.1 OUTLIER -91.72 132.51 36.33 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.51 -179.964 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.521 ' H ' HD13 ' A' ' 47' ' ' LEU . 62.4 mttp -87.4 124.38 33.34 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 179.181 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.493 ' CG2' HD11 ' A' ' 55' ' ' ILE . 47.5 pt -131.06 146.52 33.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.558 -179.572 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.7 mttp -135.08 159.98 39.8 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.427 -0.352 . . . . 0.0 110.274 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -55.81 121.98 10.44 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.989 0.423 . . . . 0.0 110.538 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 103.52 -21.21 39.73 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -67.01 143.09 56.98 Favored 'General case' 0 C--N 1.332 -0.194 0 C-N-CA 120.618 -0.433 . . . . 0.0 110.77 179.41 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.446 HD13 ' HA ' ' A' ' 32' ' ' ARG . 9.9 mm -112.69 128.71 69.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.599 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.493 HD11 ' CG2' ' A' ' 49' ' ' ILE . 2.5 mt -116.33 133.35 63.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.708 -179.417 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -79.95 117.63 20.97 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.15 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 92.0 mt -67.26 126.39 26.79 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.137 0 CA-C-O 120.919 0.39 . . . . 0.0 110.679 -179.524 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 93.3 mt -113.84 -59.27 3.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.47 179.721 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 94.7 m -144.77 168.8 19.34 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.938 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -115.98 141.48 48.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.187 179.573 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.9 m -98.86 137.52 20.55 Favored Pre-proline 0 CA--C 1.538 0.483 0 C-N-CA 120.149 -0.62 . . . . 0.0 110.343 -179.492 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -53.22 -36.84 79.24 Favored 'Trans proline' 0 N--CA 1.501 1.916 0 C-N-CA 122.414 2.076 . . . . 0.0 112.486 179.509 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' MET . . . . . 0.463 ' HG3' ' H ' ' A' ' 65' ' ' MET . 23.0 ptp -59.34 -18.67 40.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.885 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 119.41 -38.25 2.88 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 179.424 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' MET . . . . . 0.463 ' H ' ' HG3' ' A' ' 63' ' ' MET . 97.0 mtp -61.57 143.65 55.65 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.153 0.502 . . . . 0.0 110.59 -179.79 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 45.7 m0 -98.75 155.67 17.23 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.212 -179.312 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 93.0 m -115.92 135.21 54.2 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.901 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.6 -172.13 23.57 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 179.823 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 16.8 tmm? -122.04 139.8 53.26 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.847 0.356 . . . . 0.0 110.751 -179.701 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -139.25 111.72 7.64 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.618 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 14.0 m120 54.05 51.99 13.6 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.034 179.617 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 54.1 t30 62.41 37.3 13.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.792 0.33 . . . . 0.0 110.707 -179.387 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 46.9 tptt -137.33 113.29 9.75 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.034 179.266 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 88.9 t -100.46 127.28 53.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 C-N-CA 120.793 -0.363 . . . . 0.0 110.912 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.505 ' N ' HD23 ' A' ' 47' ' ' LEU . . . -164.92 -174.09 34.26 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -102.51 150.96 22.87 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.009 0.433 . . . . 0.0 110.483 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 44.0 p90 -150.84 158.75 44.52 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.757 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -72.29 117.36 13.85 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.94 -179.466 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -62.58 -27.51 69.23 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.683 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 13.7 tt -63.06 -33.27 59.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.999 0.428 . . . . 0.0 111.1 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -83.81 1.23 44.01 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.835 179.807 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.502 HG23 HG22 ' A' ' 33' ' ' VAL . 0.3 OUTLIER -132.66 161.42 41.56 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 CA-C-O 121.038 0.447 . . . . 0.0 110.464 179.815 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 53.3 t0 -124.1 137.64 54.54 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.133 179.39 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.5 p -87.52 124.64 40.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.773 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 41.4 pt -128.27 150.71 34.24 Favored 'Isoleucine or valine' 0 C--O 1.233 0.219 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.84 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 38.4 t -84.63 138.75 32.52 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.718 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.003 -0.998 . . . . 0.0 110.611 179.714 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 29.5 p . . . . . 0 N--CA 1.455 -0.219 0 CA-C-O 120.992 0.425 . . . . 0.0 110.424 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -174.16 -154.91 11.29 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -179.327 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 15.6 mmp_? -108.04 142.34 38.34 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.023 0.44 . . . . 0.0 110.469 -179.397 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.445 ' HB1' HG21 ' A' ' 82' ' ' VAL . . . -106.39 117.3 33.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.184 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 61.2 ttt180 -96.09 120.83 37.08 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.055 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 86.8 t -81.28 124.78 39.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.728 -179.4 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 35.2 p80 -115.81 -8.97 11.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.936 179.406 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 77.4 m -129.04 136.74 50.69 Favored 'General case' 0 C--O 1.231 0.099 0 CA-C-O 120.762 0.315 . . . . 0.0 110.625 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -69.49 119.69 14.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.493 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -65.47 136.91 57.04 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 92.1 m -118.45 94.85 47.96 Favored Pre-proline 0 CA--C 1.537 0.452 0 C-N-CA 120.958 -0.297 . . . . 0.0 110.762 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_endo -74.09 157.3 46.7 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 122.352 2.035 . . . . 0.0 112.201 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.1 m -79.78 158.03 73.54 Favored Pre-proline 0 CA--C 1.532 0.263 0 C-N-CA 120.661 -0.415 . . . . 0.0 110.797 -179.643 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -57.23 -40.27 83.87 Favored 'Trans proline' 0 N--CA 1.5 1.912 0 C-N-CA 122.381 2.054 . . . . 0.0 112.096 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.4 p90 -89.72 16.99 7.01 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.182 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -112.69 113.39 25.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.791 0.329 . . . . 0.0 110.626 179.425 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 55.7 p -112.42 -17.55 12.66 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.458 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 57.6 p-10 -87.59 6.13 35.99 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.13 179.64 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 74.9 m -70.28 151.17 45.6 Favored 'General case' 0 C--O 1.231 0.094 0 CA-C-O 120.86 0.362 . . . . 0.0 110.662 179.694 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 60.6 tp -84.66 135.93 33.96 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.154 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 62.6 mtpt -93.93 119.06 32.33 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.091 179.436 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.407 HG21 HD13 ' A' ' 49' ' ' ILE . 28.9 pt -136.64 168.02 22.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.316 -179.588 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 23.5 pttp -148.21 156.47 42.61 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.856 0.36 . . . . 0.0 110.385 179.255 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 65.3 tttm -56.96 129.9 43.66 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.313 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.13 -16.14 60.5 Favored Glycine 0 CA--C 1.53 1.004 0 N-CA-C 111.349 -0.7 . . . . 0.0 111.349 -179.633 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ASP . . . . . 0.483 ' OD2' HD11 ' A' ' 70' ' ' LEU . 17.5 t0 -71.33 146.61 48.74 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 110.321 -0.251 . . . . 0.0 110.321 179.663 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 48.2 mm -114.89 129.11 71.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.938 0.399 . . . . 0.0 110.291 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.473 HG12 HD12 ' A' ' 70' ' ' LEU . 90.9 mt -119.03 130.39 73.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.871 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -74.93 128.39 35.45 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.321 -0.552 . . . . 0.0 110.227 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.9 mt -74.11 121.52 25.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.165 0 CA-C-O 120.854 0.359 . . . . 0.0 110.514 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 12.7 tt -113.67 -35.99 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.656 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 85.7 m -147.68 152.16 37.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.589 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.3 mtpt -136.47 155.94 49.29 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.247 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 68.9 p -131.98 155.67 81.06 Favored Pre-proline 0 C--N 1.327 -0.373 0 C-N-CA 120.417 -0.513 . . . . 0.0 110.756 179.425 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -59.93 115.79 2.87 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 121.954 1.769 . . . . 0.0 111.882 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 99.3 mtp 43.75 32.92 0.63 Allowed 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.969 179.401 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -122.64 173.97 16.18 Favored Glycine 0 CA--C 1.519 0.336 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.614 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 10.6 ptm -60.07 149.61 31.89 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.83 0.348 . . . . 0.0 110.432 -179.243 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 45.4 m0 -94.55 150.55 20.13 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.968 -179.339 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.1 m -118.65 143.1 47.05 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.372 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -165.0 -168.5 27.25 Favored Glycine 0 CA--C 1.52 0.395 0 C-N-CA 120.167 -1.016 . . . . 0.0 111.68 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 60.9 ttm -114.86 135.94 53.64 Favored 'General case' 0 C--O 1.238 0.447 0 CA-C-O 120.969 0.414 . . . . 0.0 110.444 179.38 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.483 HD11 ' OD2' ' A' ' 53' ' ' ASP . 3.5 tt -136.71 113.68 10.49 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.596 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ASN . . . . . 0.423 ' N ' HD23 ' A' ' 70' ' ' LEU . 66.8 t30 53.39 52.33 13.66 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.678 -0.409 . . . . 0.0 111.356 178.764 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 59.71 28.48 17.93 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.921 0.391 . . . . 0.0 110.921 179.712 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -139.87 115.74 10.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.132 -0.486 . . . . 0.0 109.82 179.027 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.405 HG22 ' H ' ' A' ' 74' ' ' VAL . 19.4 m -92.28 141.88 13.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.622 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -165.9 177.68 40.92 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 -179.488 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 76.7 m-20 -107.96 144.66 34.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.919 0.39 . . . . 0.0 110.523 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.8 p90 -148.19 147.1 29.06 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.741 179.523 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 17.5 tptm -58.0 121.47 10.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.358 -179.094 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.7 p90 -61.28 -25.43 67.1 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.624 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 97.7 mt -64.0 -39.03 83.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-O 120.919 0.39 . . . . 0.0 110.503 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 12.7 m-30 -77.27 -1.78 31.42 Favored 'General case' 0 C--O 1.237 0.404 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.388 -179.14 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.445 HG21 ' HB1' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -128.5 161.6 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.68 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -130.02 143.88 51.03 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.4 ' H ' HG12 ' A' ' 84' ' ' VAL . 1.5 p -84.72 119.74 34.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.672 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 37.9 pt -127.84 158.96 39.28 Favored 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.77 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 35.2 t -110.66 127.37 55.25 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.234 179.724 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 118.048 -0.977 . . . . 0.0 110.488 -179.615 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 26.3 p . . . . . 0 N--CA 1.455 -0.222 0 CA-C-O 120.855 0.36 . . . . 0.0 110.317 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 162.32 -130.08 2.21 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 87.7 mmt-85 -112.11 145.31 40.0 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.943 0.401 . . . . 0.0 110.741 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.504 ' HB3' ' HB ' ' A' ' 55' ' ' ILE . . . -108.91 121.46 45.15 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.269 179.74 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 46.5 ttt-85 -97.09 125.43 41.55 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.896 0.379 . . . . 0.0 110.365 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.6 t -82.48 128.62 38.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.617 -179.143 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 4.0 m-70 -103.72 -10.3 18.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.192 179.61 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 12.2 t -144.76 145.39 31.65 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.927 0.394 . . . . 0.0 110.345 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -71.81 114.27 9.73 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.3 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 9.5 t80 -121.08 123.58 42.71 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.349 179.392 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 81.5 p -124.7 154.22 70.25 Favored Pre-proline 0 C--N 1.329 -0.29 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.824 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.14 159.22 30.21 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 C-N-CA 123.027 2.484 . . . . 0.0 112.487 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 72.4 m -82.28 158.41 66.66 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.377 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -52.86 -45.92 37.35 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 122.245 1.964 . . . . 0.0 111.981 -179.559 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -80.09 -20.78 44.29 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.91 0.386 . . . . 0.0 110.731 179.533 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -93.05 105.29 17.41 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.416 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 72.1 p -104.37 -23.55 13.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.314 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -63.2 -37.45 87.27 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.631 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.6 t -61.44 135.98 57.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.883 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 56.5 tp -80.57 146.03 31.46 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.419 -179.679 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.51 127.42 42.49 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.563 179.087 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.432 HG21 HD11 ' A' ' 55' ' ' ILE . 27.7 pt -139.24 160.45 28.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.565 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 19.6 ptpt -136.64 157.34 46.99 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.211 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -61.27 129.38 40.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.945 0.403 . . . . 0.0 111.071 -179.778 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.92 -16.31 59.64 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -76.55 146.47 38.34 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-O 120.776 0.322 . . . . 0.0 110.633 179.537 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 46.8 mm -108.89 127.55 65.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.004 0.431 . . . . 0.0 110.126 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.504 ' HB ' ' HB3' ' A' ' 31' ' ' ALA . 78.5 mt -108.58 130.62 61.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.728 -178.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -79.96 112.09 16.92 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.6 mt -65.9 118.2 8.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.908 0.385 . . . . 0.0 110.661 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.0 tt -101.93 -35.3 4.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.323 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 25.1 p -171.99 172.9 4.56 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.412 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 65.1 mttp -116.85 145.08 43.79 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 120.881 -0.328 . . . . 0.0 110.537 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 9.8 m -97.69 135.45 21.61 Favored Pre-proline 0 CA--C 1.536 0.417 0 C-N-CA 119.589 -0.844 . . . . 0.0 109.703 -179.379 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -58.7 -25.39 75.37 Favored 'Trans proline' 0 N--CA 1.501 1.915 0 C-N-CA 122.57 2.18 . . . . 0.0 112.614 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 39.2 mmt -65.19 -36.97 85.85 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.446 179.716 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 140.09 -39.56 1.49 Allowed Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 98.7 mtp -63.35 145.14 56.19 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.455 0.645 . . . . 0.0 111.198 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 22.4 m0 -96.35 146.95 24.3 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.828 -179.742 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 68.0 m -117.0 139.95 50.07 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 115.802 -0.636 . . . . 0.0 109.909 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.95 -172.02 23.71 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.166 -0.773 . . . . 0.0 111.166 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 67.8 ttp -116.18 143.09 45.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.152 0.501 . . . . 0.0 110.605 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -143.87 117.85 9.42 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.661 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ASN . . . . . 0.411 ' O ' ' ND2' ' A' ' 71' ' ' ASN . 1.0 OUTLIER 40.64 59.73 2.08 Favored 'General case' 0 N--CA 1.469 0.525 0 O-C-N 123.442 0.464 . . . . 0.0 111.033 179.806 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 33.7 m120 59.25 35.44 23.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.025 -179.8 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 19.3 tptp -140.56 111.49 7.02 Favored 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.399 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 95.5 t -99.53 127.41 52.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.758 -0.377 . . . . 0.0 110.425 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -159.77 -176.8 32.25 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.886 -0.885 . . . . 0.0 110.886 -179.634 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.0 m-20 -103.31 158.57 16.24 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.918 0.39 . . . . 0.0 110.467 -179.563 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -157.06 160.53 39.02 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.006 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 36.7 tptt -69.09 111.55 5.13 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.193 -179.445 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.3 p90 -59.17 -24.14 62.81 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.522 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.6 mt -67.9 -38.25 79.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.183 0.516 . . . . 0.0 110.654 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.2 m-30 -75.78 -5.94 48.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.834 -179.03 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.427 ' CG2' ' HB1' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -126.23 159.82 34.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 CA-C-O 121.042 0.449 . . . . 0.0 110.079 179.737 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 50.6 t0 -126.21 139.53 53.26 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.937 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.46 ' O ' HG13 ' A' ' 84' ' ' VAL . 8.8 p -82.45 121.03 35.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.953 0.406 . . . . 0.0 110.961 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 41.2 pt -128.3 160.4 38.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.613 179.669 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 29.9 t -106.25 132.1 52.7 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.441 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 54.2 tp10 . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 117.974 -1.013 . . . . 0.0 110.332 -179.987 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 77.3 m . . . . . 0 N--CA 1.457 -0.106 0 CA-C-O 120.95 0.405 . . . . 0.0 110.369 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 169.27 -142.25 7.22 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 2.9 mpp_? -112.25 146.2 38.6 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.879 0.371 . . . . 0.0 110.454 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.722 ' HB1' ' CG1' ' A' ' 82' ' ' VAL . . . -116.06 125.3 52.23 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.083 179.829 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 74.2 ttt-85 -92.74 119.83 32.51 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.387 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.54 HG22 HG22 ' A' ' 82' ' ' VAL . 96.4 t -78.29 125.54 37.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.829 0.347 . . . . 0.0 110.679 -179.511 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 33.2 p80 -112.51 -10.64 13.7 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.885 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 90.2 m -128.81 131.33 47.74 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.778 0.323 . . . . 0.0 110.396 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.6 t0 -68.27 131.34 45.18 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.629 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -88.28 137.22 32.52 Favored 'General case' 0 C--N 1.331 -0.2 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.167 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 43.2 p -126.82 93.79 41.36 Favored Pre-proline 0 CA--C 1.534 0.347 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.441 -179.792 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -73.27 155.79 51.25 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 122.172 1.915 . . . . 0.0 112.364 -179.022 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.6 m -73.47 157.96 87.16 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.801 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -55.83 -38.77 94.06 Favored 'Trans proline' 0 N--CA 1.498 1.766 0 C-N-CA 122.512 2.141 . . . . 0.0 112.046 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -88.6 6.54 37.69 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.066 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.22 101.15 12.09 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.752 0.311 . . . . 0.0 110.332 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 72.6 p -104.37 -27.52 11.91 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.883 0.373 . . . . 0.0 110.26 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -72.98 -21.27 60.88 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.775 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 41.4 t -59.62 141.36 55.15 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.404 -179.61 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 66.0 tp -80.27 138.84 36.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.147 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 30.2 mtpp -95.0 118.1 31.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.256 179.813 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.498 HG22 ' CD1' ' A' ' 70' ' ' LEU . 21.6 pt -138.42 146.68 26.3 Favored 'Isoleucine or valine' 0 C--O 1.237 0.419 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.186 179.676 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.04 167.23 14.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.909 0.385 . . . . 0.0 110.424 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -64.99 129.56 40.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.525 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.99 -20.83 47.41 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 111.214 -0.754 . . . . 0.0 111.214 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -69.88 148.51 48.94 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.387 179.219 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 86.5 mt -109.01 127.62 65.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.142 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 72.0 mt -109.96 130.16 63.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.447 -178.79 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -75.82 115.34 15.41 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.203 -0.599 . . . . 0.0 109.928 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.73 125.4 25.24 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 CA-C-O 120.823 0.344 . . . . 0.0 110.765 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 97.1 mt -108.73 -58.46 3.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.477 179.699 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 40.3 t -163.46 151.88 13.75 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.752 -179.691 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 59.0 mttm -96.85 157.78 15.74 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.073 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 74.9 p -112.29 156.95 41.31 Favored Pre-proline 0 C--N 1.329 -0.289 0 C-N-CA 120.618 -0.433 . . . . 0.0 110.784 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_exo -56.6 -33.73 93.82 Favored 'Trans proline' 0 N--CA 1.497 1.734 0 C-N-CA 122.68 2.254 . . . . 0.0 112.269 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 98.6 mtp -62.04 -38.48 88.89 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.514 -179.572 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 132.2 -32.38 2.86 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 98.5 mtp -62.4 143.8 56.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.002 0.429 . . . . 0.0 110.552 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 47.6 m0 -98.41 150.07 22.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.087 -178.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 90.0 m -110.0 135.18 51.25 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.657 179.553 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -152.66 -176.14 24.93 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 111.244 -0.742 . . . . 0.0 111.244 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.6 ttp -124.21 142.5 51.18 Favored 'General case' 0 C--O 1.237 0.432 0 CA-C-O 120.961 0.41 . . . . 0.0 110.672 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.498 ' CD1' HG22 ' A' ' 49' ' ' ILE . 2.1 mt -138.06 105.54 5.55 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.762 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 55.63 58.41 4.54 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.23 0.538 . . . . 0.0 109.705 178.775 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 58.5 t30 59.58 34.53 22.38 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.432 -179.515 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 8.9 tppt? -132.89 109.77 9.84 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.357 -0.383 . . . . 0.0 109.971 179.38 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 82.3 t -97.75 123.51 50.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 C-N-CA 120.706 -0.397 . . . . 0.0 110.499 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -156.83 179.12 32.88 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.62 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -105.69 154.54 20.31 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.958 0.409 . . . . 0.0 110.829 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.641 ' CD1' HG21 ' A' ' 82' ' ' VAL . 50.8 p90 -152.74 159.63 43.13 Favored 'General case' 0 C--O 1.237 0.443 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.823 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 30.6 tttt -68.65 116.46 9.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.209 -179.064 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -59.97 -25.71 65.45 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.571 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.6 mt -65.82 -38.46 82.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.713 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.1 m-30 -78.85 -7.32 57.79 Favored 'General case' 0 C--O 1.24 0.585 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.226 -178.909 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.722 ' CG1' ' HB1' ' A' ' 31' ' ' ALA . 66.5 t -121.39 138.68 50.93 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.283 0 CA-C-O 120.972 0.415 . . . . 0.0 110.991 -179.449 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -106.07 134.28 49.44 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.229 179.784 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.424 ' H ' HG12 ' A' ' 84' ' ' VAL . 1.4 p -76.44 118.21 22.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.188 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -106.39 148.0 11.24 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.126 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.253 -179.733 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 90.0 p -112.18 147.37 36.31 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.771 -0.372 . . . . 0.0 110.093 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.388 179.908 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 16.9 p . . . . . 0 N--CA 1.454 -0.266 0 CA-C-O 120.994 0.426 . . . . 0.0 110.269 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 174.85 -139.65 4.94 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -179.658 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 93.5 mtt-85 -126.24 151.73 47.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.776 0.322 . . . . 0.0 110.575 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -123.01 135.75 54.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.531 -179.86 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.437 ' HG2' HD12 ' A' ' 54' ' ' ILE . 57.3 mtm180 -101.88 123.53 45.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.254 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.66 HG22 HG23 ' A' ' 82' ' ' VAL . 99.0 t -81.22 129.04 38.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.485 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -113.06 -0.22 14.79 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.961 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 12.2 t -146.47 151.49 37.48 Favored 'General case' 0 N--CA 1.455 -0.214 0 CA-C-O 120.914 0.387 . . . . 0.0 110.547 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -88.46 107.59 18.95 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.529 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 6.2 t80 -118.67 119.34 34.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.621 179.678 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.412 ' O ' HG23 ' A' ' 38' ' ' THR . 9.8 t -126.79 131.38 23.87 Favored Pre-proline 0 N--CA 1.451 -0.398 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.669 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -73.33 163.47 37.75 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.873 2.382 . . . . 0.0 112.38 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.3 m -66.04 156.47 84.13 Favored Pre-proline 0 C--N 1.327 -0.383 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.607 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -57.69 -31.55 92.31 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 C-N-CA 122.778 2.319 . . . . 0.0 112.332 -179.571 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -73.11 -10.67 60.03 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.572 179.467 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 48.6 t0 -110.22 114.04 27.21 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.298 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.3 t -106.12 -28.67 10.35 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.728 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -62.23 -36.56 82.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.497 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 47.2 m -63.47 139.31 58.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.704 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.418 HD21 ' HB2' ' A' ' 70' ' ' LEU . 59.2 tp -91.79 143.36 26.6 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.41 -179.813 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 23.0 pttp -94.37 141.86 28.09 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.393 179.112 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.603 ' HB ' HG21 ' A' ' 33' ' ' VAL . 29.8 pt -132.0 147.5 32.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.559 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 40.7 ttmt -128.3 138.53 52.44 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.638 179.419 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -55.91 125.64 22.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.814 -179.679 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 105.51 -21.42 34.89 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.283 -0.727 . . . . 0.0 111.283 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -81.55 155.14 25.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.736 0.303 . . . . 0.0 110.806 179.29 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.437 HD12 ' HG2' ' A' ' 32' ' ' ARG . 46.7 mm -113.47 130.07 68.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.685 179.822 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.573 HD11 HG22 ' A' ' 49' ' ' ILE . 84.2 mt -112.49 129.06 68.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.498 -179.418 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 64.5 t0 -82.2 121.81 27.1 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.276 179.603 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 84.2 mt -70.21 128.74 33.94 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.116 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.419 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 88.8 mt -105.93 -53.49 6.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.709 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.8 t -163.84 150.66 11.89 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.78 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.7 mttp -109.29 155.34 21.27 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.251 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 81.5 p -136.05 155.09 77.85 Favored Pre-proline 0 N--CA 1.45 -0.471 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.853 179.651 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_exo -62.5 -21.23 72.55 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 122.863 2.375 . . . . 0.0 112.061 179.171 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 63.7 tpp -52.16 -31.6 32.11 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.417 -179.551 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 106.8 18.18 11.03 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 6.4 mtt -128.34 139.5 52.36 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.782 0.325 . . . . 0.0 110.474 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 33.5 m0 -93.36 139.45 30.66 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.775 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 93.0 m -98.39 131.16 44.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 109.897 179.688 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -154.52 -176.51 26.89 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -179.721 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 23.4 ptp -123.57 146.46 48.12 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.874 0.369 . . . . 0.0 110.667 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.418 ' HB2' HD21 ' A' ' 47' ' ' LEU . 0.5 OUTLIER -150.03 118.78 6.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.512 179.867 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 16.2 m120 53.59 49.71 18.83 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 54.3 t30 59.69 35.63 22.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.584 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 22.7 ttmm -138.64 117.62 12.48 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.459 179.292 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 96.9 t -99.45 131.03 47.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.733 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -158.03 177.57 34.7 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.807 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 81.7 m-20 -105.05 135.62 46.05 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.876 0.37 . . . . 0.0 110.564 -179.681 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -138.48 155.0 48.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.792 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -75.75 125.02 28.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.372 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.501 ' HA ' HG12 ' A' ' 82' ' ' VAL . 20.6 p90 -65.31 -20.42 66.4 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.706 -179.863 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 6.4 pt -61.01 -23.17 28.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.505 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 41.6 m-85 -102.4 10.18 39.21 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.644 179.443 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.66 HG23 HG22 ' A' ' 33' ' ' VAL . 0.3 OUTLIER -135.54 147.96 28.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.234 0 CA-C-O 120.863 0.363 . . . . 0.0 110.344 -179.609 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -105.62 131.95 52.37 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.302 179.679 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.402 HG12 ' H ' ' A' ' 84' ' ' VAL . 2.1 p -91.31 132.98 34.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-O 120.96 0.409 . . . . 0.0 110.795 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 37.5 pt -124.0 156.63 31.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.69 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 66.0 m -113.09 148.63 34.86 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.673 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.601 179.948 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.2 m . . . . . 0 N--CA 1.458 -0.075 0 CA-C-O 120.902 0.382 . . . . 0.0 110.403 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -175.92 -149.8 7.68 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -109.03 138.21 45.74 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.94 0.4 . . . . 0.0 110.496 -179.793 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.758 ' HB1' ' CG1' ' A' ' 82' ' ' VAL . . . -106.11 115.15 29.73 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.198 -179.822 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 45.4 ttp180 -96.59 120.54 37.1 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.195 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.46 HG22 HG22 ' A' ' 82' ' ' VAL . 90.3 t -76.17 124.32 34.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.48 -179.492 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 1.3 p80 -111.3 -15.87 13.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.537 179.548 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 53.0 m -131.97 135.5 46.62 Favored 'General case' 0 C--N 1.334 -0.103 0 CA-C-O 120.84 0.353 . . . . 0.0 110.833 179.6 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -64.44 133.91 53.47 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 120.716 -0.394 . . . . 0.0 110.49 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -120.8 135.77 55.07 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.276 179.618 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 57.0 p -135.44 90.76 19.7 Favored Pre-proline 0 CA--C 1.534 0.328 0 C-N-CA 120.92 -0.312 . . . . 0.0 110.304 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -69.83 150.6 68.01 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 122.66 2.24 . . . . 0.0 112.284 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 75.4 m -72.96 157.94 87.9 Favored Pre-proline 0 C--N 1.326 -0.439 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.653 -179.686 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -53.76 -23.09 25.34 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.835 2.357 . . . . 0.0 112.114 179.54 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -59.97 -23.05 63.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.204 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -65.8 125.87 26.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.35 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 82.8 p -70.68 -35.85 73.03 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.606 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.498 ' O ' ' C ' ' A' ' 46' ' ' SER . 88.5 m-20 -100.14 5.86 44.86 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 118.337 -0.84 . . . . 0.0 111.465 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.498 ' C ' ' O ' ' A' ' 45' ' ' ASP . 6.6 t -9.88 95.3 0.01 OUTLIER 'General case' 0 C--N 1.358 0.938 0 O-C-N 125.003 1.439 . . . . 0.0 111.311 -179.291 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 66.9 tp -111.34 131.72 54.96 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.232 -178.478 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -97.29 134.31 40.75 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.563 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 48.3 pt -126.65 162.47 30.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.509 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 39.8 ttpt -134.85 135.61 41.81 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.602 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -51.43 131.16 28.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.983 0.42 . . . . 0.0 110.448 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.51 -18.14 56.69 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 111.006 -0.838 . . . . 0.0 111.006 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -72.47 155.53 40.0 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.798 0.332 . . . . 0.0 110.702 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 48.5 mm -114.38 127.68 71.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.198 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.46 HG12 HD12 ' A' ' 70' ' ' LEU . 85.6 mt -117.9 129.41 74.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.683 -179.671 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -74.65 120.64 20.48 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.309 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 85.0 mt -69.76 126.03 29.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.764 0.316 . . . . 0.0 110.347 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.7 mt -110.71 -43.16 5.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.768 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 46.6 t -146.52 139.13 25.2 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.572 -179.607 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.3 mtpt -119.37 153.75 34.67 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.517 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 71.5 p -133.29 153.17 80.49 Favored Pre-proline 0 C--N 1.328 -0.34 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.746 179.753 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -62.62 114.32 2.34 Favored 'Trans proline' 0 N--CA 1.493 1.484 0 C-N-CA 122.53 2.153 . . . . 0.0 112.037 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 99.4 mtp 46.55 32.74 1.74 Allowed 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.274 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -123.45 172.65 16.24 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 8.5 ptm -60.98 148.33 40.35 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.819 0.342 . . . . 0.0 110.143 -179.479 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 41.9 m0 -95.51 149.58 21.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.239 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 84.9 m -115.3 138.33 51.07 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.734 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -162.43 -166.95 22.13 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 65.3 ttp -125.72 138.36 53.87 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.826 0.346 . . . . 0.0 110.258 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.478 HD23 ' C ' ' A' ' 70' ' ' LEU . 4.6 tt -134.31 115.47 14.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.426 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ASN . . . . . 0.419 ' N ' HD23 ' A' ' 70' ' ' LEU . 65.7 t30 53.17 56.93 6.8 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.87 179.039 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 56.82 36.94 28.43 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.477 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 5.1 tptt -139.29 111.9 7.74 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.245 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 89.4 t -93.43 127.75 45.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.827 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -162.58 -177.18 35.38 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.801 -0.919 . . . . 0.0 110.801 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 48.5 m-20 -107.78 156.3 19.27 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.98 0.419 . . . . 0.0 110.685 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.531 ' CD1' HG21 ' A' ' 82' ' ' VAL . 11.6 p90 -155.89 156.57 34.84 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.762 -0.653 . . . . 0.0 111.22 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.734 ' HE2' HD12 ' A' ' 80' ' ' ILE . 32.8 tttt -65.74 118.57 9.8 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.446 -179.243 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 36.5 p90 -61.18 -25.09 66.79 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.667 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.734 HD12 ' HE2' ' A' ' 78' ' ' LYS . 95.7 mt -63.08 -39.55 85.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 120.845 0.355 . . . . 0.0 110.634 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 18.3 m-85 -84.79 3.95 35.23 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.897 -179.54 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.758 ' CG1' ' HB1' ' A' ' 31' ' ' ALA . 86.3 t -126.22 136.09 61.86 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 CA-C-O 121.184 0.516 . . . . 0.0 110.914 179.801 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -111.17 142.48 43.3 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.422 179.461 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.466 ' O ' HG13 ' A' ' 84' ' ' VAL . 8.5 p -89.63 122.83 41.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.767 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 36.5 pt -128.92 158.96 41.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.719 179.557 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 29.3 t -90.1 124.73 35.04 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.457 179.638 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 . . . . . 0 C--O 1.219 -0.517 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.674 -179.874 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 17.0 p . . . . . 0 N--CA 1.448 -0.535 0 CA-C-O 121.103 0.478 . . . . 0.0 109.997 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 169.63 -138.3 4.97 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.024 -0.831 . . . . 0.0 111.024 -179.579 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 39.1 mmt180 -111.81 142.73 43.81 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.763 0.316 . . . . 0.0 110.361 -179.601 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -122.41 141.08 51.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.516 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -116.08 132.22 56.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.316 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 84.0 t -82.39 125.99 39.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.819 -179.086 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 28.2 p80 -114.14 -13.75 12.39 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.91 179.609 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 87.9 m -126.28 130.45 50.89 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.418 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.4 t0 -64.22 122.15 15.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.303 -179.771 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' PHE . . . . . 0.434 ' HB3' HD11 ' A' ' 49' ' ' ILE . 15.3 t80 -117.83 128.14 54.56 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.437 179.826 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 38' ' ' THR . 5.9 t -133.51 92.44 23.85 Favored Pre-proline 0 CA--C 1.539 0.53 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.485 179.561 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.85 151.45 62.86 Favored 'Trans proline' 0 N--CA 1.495 1.6 0 C-N-CA 121.955 1.77 . . . . 0.0 112.148 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 99.9 p -70.82 155.48 93.32 Favored Pre-proline 0 CA--C 1.533 0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.628 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -62.7 -21.89 73.4 Favored 'Trans proline' 0 N--CA 1.497 1.682 0 C-N-CA 122.491 2.127 . . . . 0.0 112.253 179.674 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -64.59 -25.16 67.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.442 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -64.89 143.71 57.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.356 179.442 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 61.9 p -84.39 -29.58 26.08 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.582 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.437 ' O ' ' C ' ' A' ' 46' ' ' SER . 97.9 m-20 -100.23 -0.86 37.81 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.716 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 45' ' ' ASP . 16.3 t -20.81 95.86 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.675 0 O-C-N 124.033 0.833 . . . . 0.0 112.697 -178.757 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 63.5 tp -104.98 134.05 48.74 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.933 -179.427 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -97.17 129.19 44.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.558 179.392 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.434 HD11 ' HB3' ' A' ' 37' ' ' PHE . 40.2 pt -136.62 160.4 37.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.429 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -137.25 134.57 36.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.648 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 5.4 ptmm? -49.58 137.02 16.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.775 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.98 -17.76 58.71 Favored Glycine 0 CA--C 1.528 0.863 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 -179.839 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -79.15 157.57 27.88 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.831 0.348 . . . . 0.0 110.452 179.541 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 47.9 mm -114.73 129.67 70.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.298 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 85.7 mt -111.1 132.58 59.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.725 -179.494 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -78.45 113.71 16.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.841 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.4 mt -68.23 125.93 26.98 Favored 'Isoleucine or valine' 0 C--O 1.232 0.178 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.472 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.457 HD11 ' HB2' ' A' ' 69' ' ' MET . 80.7 mt -105.34 -50.79 8.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.338 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 77.9 m -139.31 149.88 44.75 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.709 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.5 mtpt -132.07 159.64 38.28 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.612 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 82.4 p -132.0 158.57 75.15 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.537 179.697 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_exo -53.11 -39.23 80.72 Favored 'Trans proline' 0 N--CA 1.497 1.722 0 C-N-CA 122.488 2.125 . . . . 0.0 112.155 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 11.5 tpt -162.23 90.31 0.74 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.491 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 179.66 -178.18 48.5 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.1 mtp -62.49 147.59 48.36 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.02 0.438 . . . . 0.0 110.569 -179.406 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 43.8 m0 -95.86 147.05 24.06 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.462 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 96.8 m -107.62 132.75 52.96 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.882 179.513 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -151.3 -177.8 25.47 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' MET . . . . . 0.457 ' HB2' HD11 ' A' ' 58' ' ' ILE . 66.7 ttp -121.0 141.24 50.91 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 120.975 0.417 . . . . 0.0 110.631 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -140.93 110.84 6.52 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.4 179.785 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 15.3 m120 54.99 56.38 6.66 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.876 -0.33 . . . . 0.0 110.197 179.447 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 87.0 m-20 56.13 36.52 27.56 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.724 0.297 . . . . 0.0 110.781 -179.668 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 18.4 tptm -138.43 113.26 9.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.11 179.337 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 98.3 t -93.48 126.89 45.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 120.811 -0.356 . . . . 0.0 110.507 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -154.77 177.62 31.96 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.653 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -106.94 155.0 20.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.057 0.456 . . . . 0.0 110.953 -179.549 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 32.1 p90 -156.29 162.75 40.09 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.02 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 7.4 ttmm -76.67 115.98 16.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.72 -179.218 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.465 ' HA ' HG12 ' A' ' 82' ' ' VAL . 51.9 p90 -58.34 -22.61 53.95 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.818 179.856 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.6 mt -66.29 -39.35 83.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 121.062 0.458 . . . . 0.0 110.602 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.3 m-30 -79.65 -0.18 32.85 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.122 -179.017 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.465 HG12 ' HA ' ' A' ' 79' ' ' PHE . 0.5 OUTLIER -130.0 158.09 42.52 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 CA-C-O 120.857 0.36 . . . . 0.0 110.263 179.749 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -121.08 141.31 50.9 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.46 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.3 p -92.02 126.16 44.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.816 -179.782 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 44.4 pt -128.29 154.3 38.82 Favored 'Isoleucine or valine' 0 C--O 1.236 0.375 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.764 179.691 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 36.9 t -110.5 130.73 55.49 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.608 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.6 tm-20 . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.684 -179.977 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.1 m . . . . . 0 N--CA 1.456 -0.139 0 CA-C-O 120.853 0.359 . . . . 0.0 110.285 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 166.88 -140.31 6.23 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.5 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -117.29 154.96 30.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.348 . . . . 0.0 110.7 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.545 ' HB1' HG22 ' A' ' 82' ' ' VAL . . . -122.96 137.2 55.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.391 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.427 ' HE ' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -99.36 118.66 36.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.347 179.879 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 69.6 t -69.41 130.05 34.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.914 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 7.8 m80 -108.86 -22.52 12.16 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.811 179.389 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 50.7 p -125.99 158.4 35.38 Favored 'General case' 0 C--N 1.332 -0.177 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.348 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -91.27 116.55 28.92 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.823 -179.529 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 14.1 t80 -116.16 117.53 30.31 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.049 179.347 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 8.1 t -117.76 141.11 28.54 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.136 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -72.42 153.82 55.61 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.668 2.245 . . . . 0.0 112.456 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.5 p -72.91 166.17 45.67 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.036 -179.858 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -55.47 -42.14 71.02 Favored 'Trans proline' 0 N--CA 1.501 1.968 0 C-N-CA 122.906 2.404 . . . . 0.0 112.639 -179.461 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -97.37 11.43 36.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.879 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 65.2 t0 -112.19 112.07 23.42 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.768 0.318 . . . . 0.0 110.517 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 48.9 p -110.86 -24.16 10.58 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.484 179.241 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -63.36 -38.43 91.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.615 179.595 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.2 t -61.58 140.61 58.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.901 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 19.3 tp -89.39 143.71 26.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.748 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.8 pttt -97.03 137.55 35.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.452 179.093 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 2.4 pt -142.17 145.72 23.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.283 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.173 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 17.1 mttm -117.76 152.32 35.53 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.352 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -61.28 129.98 43.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.958 0.409 . . . . 0.0 110.285 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.19 -22.18 41.22 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -71.72 154.97 40.99 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.826 0.346 . . . . 0.0 110.609 179.186 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.427 HD11 ' HE ' ' A' ' 32' ' ' ARG . 76.2 mt -119.42 133.64 65.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.332 179.682 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 84.3 mt -117.66 132.04 68.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.913 -179.601 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -75.42 123.12 24.85 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 109.89 179.484 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 93.3 mt -69.11 129.34 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 O-C-N 123.881 0.738 . . . . 0.0 110.365 -179.662 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 89.9 mt -109.55 -54.53 5.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.66 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 44.1 t -163.99 147.65 9.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.189 -179.604 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -92.94 146.27 23.75 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.726 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.2 p -103.25 154.45 37.68 Favored Pre-proline 0 C--N 1.328 -0.346 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.514 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -62.11 -25.71 77.53 Favored 'Trans proline' 0 N--CA 1.497 1.704 0 C-N-CA 122.653 2.235 . . . . 0.0 112.159 179.332 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 96.4 mmm -70.17 -22.13 62.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.521 179.693 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 114.31 -26.26 9.87 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.4 mtp -64.95 147.04 54.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.983 0.421 . . . . 0.0 110.765 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 43.4 m0 -102.38 146.09 28.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.241 0.544 . . . . 0.0 111.321 -179.269 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 98.3 m -108.8 135.33 50.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.605 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -153.76 -176.93 26.7 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.9 ttp -118.46 140.29 50.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.933 0.397 . . . . 0.0 111.244 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -143.92 113.96 7.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.511 179.659 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 12.2 m120 56.98 55.31 6.21 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 32.6 m120 54.53 35.91 24.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.613 0.244 . . . . 0.0 110.491 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 36.6 ttpt -139.48 114.92 9.86 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 120.624 -0.43 . . . . 0.0 110.431 179.465 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 86.9 t -93.28 128.17 44.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.442 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -156.22 179.36 32.17 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 57.2 m-80 -104.38 158.46 16.45 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.222 0.534 . . . . 0.0 110.96 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 7.2 p90 -155.97 160.23 39.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.223 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -63.94 116.27 5.68 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.109 -179.141 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -58.24 -29.0 65.4 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.514 179.753 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.478 HG23 ' CD1' ' A' ' 81' ' ' TYR . 16.3 tt -74.6 -33.96 33.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.896 179.146 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.478 ' CD1' HG23 ' A' ' 80' ' ' ILE . 13.8 m-30 -72.1 -20.79 61.59 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.519 179.596 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.545 HG22 ' HB1' ' A' ' 31' ' ' ALA . 6.1 p -114.97 160.07 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.112 179.06 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ASP . . . . . 0.421 ' N ' HG22 ' A' ' 82' ' ' VAL . 8.3 t70 -128.92 149.39 50.81 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.688 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.3 p -92.85 135.19 28.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.594 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 23.2 pt -121.04 158.24 23.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.461 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 41.1 t -61.37 138.72 58.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.587 -179.74 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 20.0 tp10 . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.182 -0.913 . . . . 0.0 110.521 179.983 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.1 m . . . . . 0 N--CA 1.456 -0.139 0 CA-C-O 120.853 0.359 . . . . 0.0 110.285 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 166.88 -140.31 6.23 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.5 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -117.29 154.96 30.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.348 . . . . 0.0 110.7 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.545 ' HB1' HG22 ' A' ' 82' ' ' VAL . . . -122.96 137.2 55.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.391 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.427 ' HE ' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -99.36 118.66 36.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.347 179.879 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 69.6 t -69.41 130.05 34.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.914 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 7.8 m80 -108.86 -22.52 12.16 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.811 179.389 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 50.7 p -125.99 158.4 35.38 Favored 'General case' 0 C--N 1.332 -0.177 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.348 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -91.27 116.55 28.92 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.823 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 14.1 t80 -116.16 117.53 30.31 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.049 179.347 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 8.1 t -117.76 141.11 28.54 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.136 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -72.42 153.82 55.61 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.668 2.245 . . . . 0.0 112.456 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.5 p -72.91 166.17 45.67 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.036 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -55.47 -42.14 71.02 Favored 'Trans proline' 0 N--CA 1.501 1.968 0 C-N-CA 122.906 2.404 . . . . 0.0 112.639 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -97.37 11.43 36.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.879 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 65.2 t0 -112.19 112.07 23.42 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.768 0.318 . . . . 0.0 110.517 -179.714 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 48.9 p -110.86 -24.16 10.58 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.484 179.241 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -63.36 -38.43 91.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.615 179.595 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.2 t -61.58 140.61 58.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.901 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 19.3 tp -89.39 143.71 26.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.748 -179.704 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.8 pttt -97.03 137.55 35.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.452 179.093 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 2.4 pt -142.17 145.72 23.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.283 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.173 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 17.1 mttm -117.76 152.32 35.53 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.352 179.763 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -61.28 129.98 43.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.958 0.409 . . . . 0.0 110.285 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.19 -22.18 41.22 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -71.72 154.97 40.99 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.826 0.346 . . . . 0.0 110.609 179.186 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.427 HD11 ' HE ' ' A' ' 32' ' ' ARG . 76.2 mt -119.42 133.64 65.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.332 179.682 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 84.3 mt -117.66 132.04 68.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.913 -179.601 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -75.42 123.12 24.85 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 109.89 179.484 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 93.3 mt -69.11 129.34 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 O-C-N 123.881 0.738 . . . . 0.0 110.365 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 89.9 mt -109.55 -54.53 5.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.66 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 44.1 t -163.99 147.65 9.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.189 -179.604 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -92.94 146.27 23.75 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.726 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.2 p -103.25 154.45 37.68 Favored Pre-proline 0 C--N 1.328 -0.346 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.514 -179.668 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -62.11 -25.71 77.53 Favored 'Trans proline' 0 N--CA 1.497 1.704 0 C-N-CA 122.653 2.235 . . . . 0.0 112.159 179.332 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 96.4 mmm -70.17 -22.13 62.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.521 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 114.31 -26.26 9.87 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.4 mtp -64.95 147.04 54.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.983 0.421 . . . . 0.0 110.765 179.71 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 43.4 m0 -102.38 146.09 28.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.241 0.544 . . . . 0.0 111.321 -179.269 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 98.3 m -108.8 135.33 50.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.605 179.652 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -153.76 -176.93 26.7 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.9 ttp -118.46 140.29 50.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.933 0.397 . . . . 0.0 111.244 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -143.92 113.96 7.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.511 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 12.2 m120 56.98 55.31 6.21 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 32.6 m120 54.53 35.91 24.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.613 0.244 . . . . 0.0 110.491 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 36.6 ttpt -139.48 114.92 9.86 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 120.624 -0.43 . . . . 0.0 110.431 179.465 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 86.9 t -93.28 128.17 44.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.442 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -156.22 179.36 32.17 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 57.2 m-80 -104.38 158.46 16.45 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.222 0.534 . . . . 0.0 110.96 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 7.2 p90 -155.97 160.23 39.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.223 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -63.94 116.27 5.68 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.109 -179.141 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -58.24 -29.0 65.4 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.514 179.753 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.478 HG23 ' CD1' ' A' ' 81' ' ' TYR . 16.3 tt -74.6 -33.96 33.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.896 179.146 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.478 ' CD1' HG23 ' A' ' 80' ' ' ILE . 13.8 m-30 -72.1 -20.79 61.59 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.519 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.545 HG22 ' HB1' ' A' ' 31' ' ' ALA . 6.1 p -114.97 160.07 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.112 179.06 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ASP . . . . . 0.421 ' N ' HG22 ' A' ' 82' ' ' VAL . 8.3 t70 -128.92 149.39 50.81 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.688 179.819 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.3 p -92.85 135.19 28.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.594 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 23.2 pt -121.04 158.24 23.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.461 179.815 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 41.1 t -61.37 138.72 58.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.587 -179.74 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 20.0 tp10 . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.182 -0.913 . . . . 0.0 110.521 179.983 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 31.5 p . . . . . 0 N--CA 1.455 -0.193 0 CA-C-O 120.949 0.404 . . . . 0.0 110.132 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.424 ' H ' HD12 ' A' ' 57' ' ' ILE . . . 179.0 -125.45 0.98 Allowed Glycine 0 CA--C 1.523 0.537 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.237 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 28.4 mmt85 -129.56 141.72 50.91 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.053 0.454 . . . . 0.0 110.659 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.637 ' HB1' HG21 ' A' ' 82' ' ' VAL . . . -107.59 118.68 37.37 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.315 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 68.7 ttt180 -98.45 123.81 42.8 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.977 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.477 HG21 ' HB ' ' A' ' 49' ' ' ILE . 65.9 t -79.54 125.18 38.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.135 -178.76 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 33.2 p80 -105.77 -10.04 16.93 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.202 179.327 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 14.4 t -145.38 151.21 37.9 Favored 'General case' 0 C--O 1.231 0.1 0 CA-C-O 120.841 0.353 . . . . 0.0 110.174 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -80.8 110.42 16.29 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.938 -179.403 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 11.2 t80 -120.69 130.6 54.16 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.369 179.229 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 71.3 p -124.5 152.87 69.19 Favored Pre-proline 0 CA--C 1.53 0.2 0 C-N-CA 120.74 -0.384 . . . . 0.0 110.793 -179.816 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -76.45 159.91 35.73 Favored 'Trans proline' 0 N--CA 1.492 1.399 0 C-N-CA 122.72 2.28 . . . . 0.0 112.232 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 57.7 m -71.57 157.6 89.53 Favored Pre-proline 0 C--N 1.331 -0.213 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.663 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_exo -53.0 -43.39 57.31 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.241 1.961 . . . . 0.0 111.959 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -84.26 -13.96 51.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.963 179.647 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -91.3 104.13 16.71 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.288 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 71.7 p -102.15 -24.84 13.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.816 0.341 . . . . 0.0 110.53 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -63.08 -38.2 90.25 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.534 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.0 t -73.55 131.15 41.41 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.255 179.742 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 2.5 tp -88.5 161.58 16.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.231 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 23.6 pttm -97.35 145.72 25.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.401 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.546 HG22 HD11 ' A' ' 55' ' ' ILE . 27.3 pt -133.57 149.65 31.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.175 179.706 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 38.0 ttmt -130.71 150.64 51.8 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 57.3 mtmt -55.03 125.72 21.62 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.092 0.472 . . . . 0.0 110.819 -179.21 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.3 -17.36 57.02 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -71.77 142.8 49.71 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 116.923 0.362 . . . . 0.0 110.492 179.631 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 50.5 mm -114.89 128.18 72.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.106 179.76 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.546 HD11 HG22 ' A' ' 49' ' ' ILE . 85.9 mt -118.45 127.87 75.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.636 -179.596 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -78.44 135.22 37.34 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.479 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.424 HD12 ' H ' ' A' ' 29' ' ' GLY . 97.3 mt -76.91 120.9 28.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 C-N-CA 120.822 -0.351 . . . . 0.0 110.318 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.5 mt -107.75 -51.73 7.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.771 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 49.0 t -153.71 144.36 22.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.965 -179.553 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -96.5 142.58 28.41 Favored 'General case' 0 C--N 1.325 -0.46 0 C-N-CA 120.766 -0.374 . . . . 0.0 110.018 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 28.2 m -98.93 135.6 20.86 Favored Pre-proline 0 CA--C 1.54 0.563 0 C-N-CA 120.09 -0.644 . . . . 0.0 110.117 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -50.81 -32.57 37.56 Favored 'Trans proline' 0 N--CA 1.5 1.885 0 C-N-CA 122.373 2.049 . . . . 0.0 112.456 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 24.3 mmt -60.81 -38.85 86.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.273 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 140.67 -40.16 1.4 Allowed Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 179.745 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 96.5 mtp -61.83 145.92 51.2 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.129 0.49 . . . . 0.0 110.767 -179.359 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 42.5 m0 -98.64 153.89 18.35 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.703 -179.372 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.4 m -111.12 134.56 52.62 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 109.592 -0.522 . . . . 0.0 109.592 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.25 -174.22 25.77 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.333 -0.707 . . . . 0.0 111.333 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.1 ttp -119.33 138.16 53.23 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.831 0.348 . . . . 0.0 110.593 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -145.47 126.25 14.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.342 -179.879 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 6.5 p-10 43.46 56.13 4.52 Favored 'General case' 0 N--CA 1.466 0.371 0 O-C-N 123.441 0.463 . . . . 0.0 111.363 -179.525 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 55.08 34.16 21.95 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.935 0.397 . . . . 0.0 110.544 179.708 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.7 mmtp -142.34 115.04 8.59 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.392 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 16.0 m -97.68 139.4 20.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 C-N-CA 120.546 -0.462 . . . . 0.0 110.509 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -168.54 -177.42 39.52 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.415 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 -103.36 149.15 25.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.959 0.409 . . . . 0.0 110.701 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -146.71 157.97 43.81 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.334 179.765 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.524 ' HG2' HG22 ' A' ' 80' ' ' ILE . 23.0 ttmt -81.67 116.89 21.61 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.779 -178.564 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.438 ' HA ' HG12 ' A' ' 82' ' ' VAL . 36.5 p90 -57.98 -24.58 58.69 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.989 -179.658 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.524 HG22 ' HG2' ' A' ' 78' ' ' LYS . 10.6 tp -58.18 -25.17 26.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.883 0.373 . . . . 0.0 110.653 -179.667 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 25.1 m-85 -100.94 14.06 33.12 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.191 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.637 HG21 ' HB1' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -143.22 156.13 17.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.746 0.307 . . . . 0.0 110.311 -179.727 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -130.54 149.93 51.98 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.563 179.254 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.6 m -93.78 131.71 39.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.272 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 42.0 pt -126.53 149.77 31.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.832 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 83.7 p -75.85 163.37 27.29 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.732 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.018 -0.992 . . . . 0.0 110.546 179.712 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 28.1 p . . . . . 0 N--CA 1.457 -0.093 0 CA-C-O 120.887 0.375 . . . . 0.0 110.363 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.55 -146.6 6.61 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 -179.421 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 8.2 mmm180 -121.02 142.15 50.07 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.901 -0.32 . . . . 0.0 110.543 -179.516 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.11 127.68 56.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.532 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 17.9 mtp180 -105.14 128.26 53.29 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.46 179.782 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.9 t -86.28 131.26 35.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.327 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 64.4 m170 -111.89 -11.66 13.87 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.047 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.452 HG21 ' HD2' ' A' ' 81' ' ' TYR . 4.2 p -124.89 174.67 7.8 Favored 'General case' 0 N--CA 1.455 -0.188 0 CA-C-O 121.173 0.511 . . . . 0.0 110.419 -179.416 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -103.48 112.0 24.7 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.627 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 8.9 t80 -119.19 118.9 32.58 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-O 121.011 0.434 . . . . 0.0 110.253 179.62 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.517 HG23 ' O ' ' A' ' 38' ' ' THR . 4.8 t -133.61 95.2 18.0 Favored Pre-proline 0 CA--C 1.543 0.696 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.519 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -68.41 153.61 73.66 Favored 'Trans proline' 0 C--N 1.301 -1.924 0 C-N-CA 122.305 2.003 . . . . 0.0 112.313 -179.444 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 48.1 m -65.65 154.49 88.37 Favored Pre-proline 0 N--CA 1.453 -0.294 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.533 -179.564 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.15 -20.98 64.15 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.847 2.365 . . . . 0.0 112.0 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -66.94 -23.56 65.98 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.249 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -99.69 96.53 7.68 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.324 179.409 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' THR . . . . . 0.423 ' H ' HG22 ' A' ' 44' ' ' THR . 2.1 t -75.96 -32.8 59.69 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.614 179.617 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -66.85 -38.12 85.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.532 179.722 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 69.1 m -67.49 123.32 20.1 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.671 -179.477 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -85.08 156.31 21.12 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.586 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 60.4 mtpt -98.56 127.84 44.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.645 179.625 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 45.8 pt -138.48 148.37 24.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.509 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 28.2 mttm -127.4 163.44 24.04 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.537 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -61.37 124.61 21.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.52 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 107.42 -31.18 8.32 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.799 -0.92 . . . . 0.0 110.799 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -66.63 145.86 55.11 Favored 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 120.881 -0.328 . . . . 0.0 110.346 179.503 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 60.6 mt -116.49 132.23 66.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.51 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.449 HG12 HD12 ' A' ' 70' ' ' LEU . 2.7 mp -114.86 129.17 71.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.857 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -72.78 122.52 21.67 Favored 'General case' 0 CA--C 1.518 -0.286 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.122 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.96 127.02 28.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 120.986 0.422 . . . . 0.0 110.93 -179.484 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.5 mt -109.39 -54.64 5.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.247 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 20.4 p -162.64 172.6 15.1 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.614 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 31.1 mtpt -120.39 150.23 41.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.451 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 67.3 p -121.71 151.66 57.63 Favored Pre-proline 0 CA--C 1.535 0.386 0 C-N-CA 120.339 -0.545 . . . . 0.0 110.915 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -69.02 -20.73 37.92 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.682 2.255 . . . . 0.0 112.242 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 3.0 mpp? -60.0 -15.51 23.0 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.484 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 97.16 22.8 16.23 Favored Glycine 0 C--N 1.336 0.564 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 96.4 mmm -127.19 144.41 51.04 Favored 'General case' 0 C--O 1.236 0.379 0 CA-C-O 121.039 0.447 . . . . 0.0 110.671 179.726 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 6.0 m0 -98.4 142.49 29.96 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.469 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 89.0 m -105.97 132.1 52.47 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 116.01 -0.541 . . . . 0.0 109.875 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -151.66 -179.87 27.69 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 60.7 ttm -115.81 142.02 47.32 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.989 0.424 . . . . 0.0 110.878 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.449 HD12 HG12 ' A' ' 55' ' ' ILE . 0.6 OUTLIER -143.45 107.94 4.83 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.869 -179.89 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 18.0 m120 53.77 53.92 10.64 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.29 179.491 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 54.4 t30 61.07 30.75 19.67 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.64 -179.607 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 62.8 tttm -137.63 112.81 9.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.05 179.344 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 27.4 m -99.09 144.12 12.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.875 0.369 . . . . 0.0 110.648 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -170.09 -173.08 37.19 Favored Glycine 0 CA--C 1.528 0.901 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 -179.816 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 67.5 m-80 -103.4 148.29 26.08 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.985 0.421 . . . . 0.0 110.851 -179.287 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.8 p90 -153.21 160.1 42.75 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.727 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.473 ' HB3' HG12 ' A' ' 80' ' ' ILE . 96.7 mttt -79.71 122.34 26.45 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-O 121.433 0.635 . . . . 0.0 110.518 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 12.0 p90 -68.99 -24.11 64.19 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.199 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.473 HG12 ' HB3' ' A' ' 78' ' ' LYS . 28.4 pt -62.2 -19.69 22.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.833 0.349 . . . . 0.0 110.825 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.452 ' HD2' HG21 ' A' ' 35' ' ' THR . 30.6 m-85 -102.69 5.66 39.12 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.865 179.56 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -136.16 153.86 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 CA-C-O 121.109 0.481 . . . . 0.0 110.638 -179.697 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 -127.51 143.19 51.22 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.565 179.245 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.8 m -88.61 136.93 22.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.229 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 42.5 pt -120.23 157.79 22.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.803 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 83.3 p -72.95 160.77 31.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.656 179.764 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 118.015 -0.993 . . . . 0.0 110.543 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 79.9 m . . . . . 0 N--CA 1.458 -0.067 0 CA-C-O 120.887 0.375 . . . . 0.0 110.652 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -172.98 -153.29 9.36 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 -179.529 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 39.6 mmt180 -116.45 144.03 44.83 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.886 0.374 . . . . 0.0 110.58 -179.491 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -113.04 121.86 45.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.619 -179.651 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ARG . . . . . 0.476 ' HD2' HG21 ' A' ' 85' ' ' ILE . 94.8 mtt180 -95.77 121.4 37.46 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.51 178.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.431 HG21 ' HB ' ' A' ' 49' ' ' ILE . 67.2 t -76.64 119.84 25.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.352 -179.399 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.428 ' CE1' ' HG1' ' A' ' 35' ' ' THR . 13.7 p-80 -105.85 -16.05 14.76 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.438 179.716 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.54 HG21 ' CD2' ' A' ' 81' ' ' TYR . 1.3 m -126.34 142.56 51.49 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.579 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -77.33 104.57 7.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.978 0.418 . . . . 0.0 110.333 -179.474 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 26.0 t80 -116.52 115.25 25.43 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.63 179.674 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 10.2 t -129.76 137.42 30.88 Favored Pre-proline 0 N--CA 1.452 -0.375 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.605 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -73.49 160.79 43.77 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.855 2.37 . . . . 0.0 112.242 -179.462 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 89.1 p -70.39 161.22 77.81 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.467 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -55.35 -37.71 94.42 Favored 'Trans proline' 0 N--CA 1.496 1.652 0 C-N-CA 122.736 2.291 . . . . 0.0 112.189 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -85.59 1.49 48.9 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.72 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -107.25 108.88 20.5 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-O 120.855 0.36 . . . . 0.0 110.34 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 10.1 t -111.03 -27.26 8.84 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.77 179.809 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -62.44 -38.94 91.68 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.659 -179.684 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.5 t -69.53 141.59 53.82 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.579 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 59.8 tp -83.36 143.64 30.19 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.554 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 26.0 pttm -98.64 137.75 36.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.899 0.381 . . . . 0.0 110.74 178.893 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.431 ' HB ' HG21 ' A' ' 33' ' ' VAL . 46.3 pt -137.7 147.5 26.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.78 179.526 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -119.38 156.14 30.65 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.032 -179.735 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.7 ttpt -61.61 120.8 11.29 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.461 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 104.84 -22.19 34.32 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 111.092 -0.803 . . . . 0.0 111.092 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -65.81 147.54 53.21 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-O 120.884 0.373 . . . . 0.0 110.906 179.257 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 47.2 mm -108.73 126.72 65.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.661 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.4 mt -109.22 128.9 64.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.78 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -79.29 112.51 16.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.306 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.3 mt -65.35 126.5 24.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.606 -179.487 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.6 mt -112.41 -55.29 4.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.6 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.9 t -162.86 151.69 14.71 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.74 -179.439 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.4 156.08 17.83 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.46 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.4 p -110.38 154.56 42.91 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.319 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -60.03 -26.84 83.53 Favored 'Trans proline' 0 C--N 1.305 -1.735 0 C-N-CA 122.807 2.338 . . . . 0.0 112.286 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 78.9 mtm -63.99 -38.15 90.02 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.501 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 133.82 -35.55 2.24 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 8.7 mtt -63.0 147.31 51.03 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.918 0.389 . . . . 0.0 110.624 -179.601 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 21.6 m0 -101.88 151.58 21.93 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.865 -179.534 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.0 m -114.08 136.37 53.0 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.866 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -154.56 -174.54 24.7 Favored Glycine 0 CA--C 1.524 0.646 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 -179.651 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 65.3 ttp -117.83 141.36 48.5 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 120.624 0.249 . . . . 0.0 110.638 -179.771 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.421 ' O ' ' HB3' ' A' ' 73' ' ' LYS . 1.3 mt -143.46 110.44 5.65 Favored 'General case' 0 C--O 1.219 -0.512 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.58 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 54.27 54.16 9.9 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 178.926 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 59.79 28.57 18.06 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.369 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.421 ' HB3' ' O ' ' A' ' 70' ' ' LEU . 85.1 tttt -133.99 112.99 11.67 Favored 'General case' 0 C--O 1.225 -0.214 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.107 179.572 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 19.1 m -99.84 144.0 12.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.855 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -174.86 -173.84 41.03 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -179.536 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 78.1 m-20 -101.57 149.45 24.09 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.849 0.357 . . . . 0.0 110.646 -179.548 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -148.96 160.78 42.98 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.857 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.601 ' CG ' HG22 ' A' ' 80' ' ' ILE . 24.3 tptt -82.01 114.3 20.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.434 -179.168 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.472 ' HA ' HG12 ' A' ' 82' ' ' VAL . 49.0 p90 -62.9 -26.18 68.67 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.588 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.601 HG22 ' CG ' ' A' ' 78' ' ' LYS . 10.2 tt -58.94 -30.33 42.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.814 0.34 . . . . 0.0 110.917 -179.408 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.54 ' CD2' HG21 ' A' ' 35' ' ' THR . 25.2 m-85 -93.32 5.34 51.89 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.04 179.817 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.472 HG12 ' HA ' ' A' ' 79' ' ' PHE . 0.3 OUTLIER -131.42 156.44 42.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 CA-C-O 121.05 0.453 . . . . 0.0 110.68 -179.884 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 85.3 m-20 -123.6 140.07 53.36 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.436 179.352 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -93.84 142.83 12.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 120.949 0.404 . . . . 0.0 110.724 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.476 HG21 ' HD2' ' A' ' 32' ' ' ARG . 39.3 pt -128.6 159.02 40.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.82 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 99.1 p -106.61 160.67 15.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.598 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.569 179.966 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 81.0 m . . . . . 0 N--CA 1.454 -0.264 0 CA-C-O 121.006 0.431 . . . . 0.0 110.212 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -176.08 -144.36 5.09 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -117.83 142.87 46.82 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.694 0.283 . . . . 0.0 110.468 -179.726 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -116.44 137.1 52.43 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.853 0.359 . . . . 0.0 110.454 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 16.0 ptm180 -116.77 133.87 55.48 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.404 HG22 HD12 ' A' ' 49' ' ' ILE . 89.6 t -82.3 127.98 39.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.42 -178.669 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 88.5 m-70 -109.71 -17.13 13.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.435 179.267 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.44 HG21 ' HD2' ' A' ' 81' ' ' TYR . 7.4 p -120.22 173.79 6.9 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.879 0.371 . . . . 0.0 110.143 -179.548 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -101.03 107.71 19.23 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.803 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -117.82 109.84 17.05 Favored 'General case' 0 N--CA 1.463 0.217 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.129 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 90.8 m -128.62 128.23 23.54 Favored Pre-proline 0 CA--C 1.537 0.45 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.852 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -74.48 163.89 35.14 Favored 'Trans proline' 0 N--CA 1.489 1.25 0 C-N-CA 122.489 2.126 . . . . 0.0 112.165 179.612 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 69.7 m -70.57 158.61 87.41 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.565 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -54.4 -35.05 83.49 Favored 'Trans proline' 0 N--CA 1.499 1.807 0 C-N-CA 122.605 2.203 . . . . 0.0 112.128 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 35.5 p90 -90.56 4.11 52.15 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.212 179.803 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -108.58 111.57 23.47 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.551 -0.295 . . . . 0.0 110.364 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 61.4 p -112.89 -19.66 11.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.729 179.504 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -61.98 -38.74 89.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.665 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 58.2 m -80.3 144.19 33.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.682 179.79 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 47.1 tp -81.98 144.03 31.18 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.721 -179.612 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 7.1 ptpp? -98.34 118.56 35.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.622 178.977 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.404 HD12 HG22 ' A' ' 33' ' ' VAL . 20.1 pt -140.04 158.33 26.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.163 0.506 . . . . 0.0 110.926 -179.733 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.5 164.45 30.31 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.016 0.436 . . . . 0.0 110.679 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -60.59 129.1 39.87 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.914 -179.674 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 109.83 -20.39 26.9 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 111.361 -0.695 . . . . 0.0 111.361 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -85.18 147.41 26.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.003 0.43 . . . . 0.0 110.495 179.273 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 21.7 mm -112.49 129.33 68.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.316 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.417 HG21 ' CE2' ' A' ' 77' ' ' PHE . 75.9 mt -112.55 127.93 69.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.752 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.9 m-20 -78.62 124.94 28.7 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.232 -0.44 . . . . 0.0 109.877 179.591 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 93.4 mt -70.58 123.24 24.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 120.882 0.372 . . . . 0.0 110.478 -179.204 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.6 mt -106.34 -51.34 7.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.41 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 49.6 t -168.29 154.76 7.39 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.022 0.439 . . . . 0.0 110.975 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -90.15 136.15 33.22 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.083 179.26 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.5 t -123.45 148.02 54.34 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.87 -179.307 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -52.32 -169.67 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.454 0 C-N-CA 122.418 2.079 . . . . 0.0 112.126 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 91.6 mtp 63.64 15.85 9.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.376 -179.196 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 63.71 37.4 94.65 Favored Glycine 0 CA--C 1.522 0.471 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 179.466 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 75.0 mtp -126.46 150.68 48.54 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 120.411 -0.516 . . . . 0.0 111.387 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 10.7 m0 -110.82 147.9 33.53 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.625 179.625 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 85.1 m -104.99 131.26 52.74 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.716 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -155.94 -176.45 28.1 Favored Glycine 0 CA--C 1.522 0.487 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.487 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.4 ttp -122.46 138.31 54.59 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.757 0.313 . . . . 0.0 110.657 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -144.3 121.58 11.58 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.185 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 75.6 m-20 53.18 48.4 22.27 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 59.71 29.72 19.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.706 0.289 . . . . 0.0 110.354 -179.537 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 42.9 tptt -130.48 114.9 16.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.259 -0.428 . . . . 0.0 109.881 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 89.7 t -96.54 125.89 49.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.878 -0.329 . . . . 0.0 110.586 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -160.16 -179.71 35.12 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 -179.496 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 -98.83 149.79 22.53 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.026 0.441 . . . . 0.0 110.923 -179.695 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.417 ' CE2' HG21 ' A' ' 55' ' ' ILE . 48.8 p90 -152.17 159.16 43.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.692 179.731 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 1.5 mptp? -78.73 116.29 18.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.82 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.464 ' HA ' HG12 ' A' ' 82' ' ' VAL . 33.8 p90 -61.49 -25.11 67.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.629 179.809 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.436 HG23 ' CE1' ' A' ' 79' ' ' PHE . 40.9 pt -62.37 -20.12 23.89 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 CA-C-O 120.78 0.324 . . . . 0.0 110.8 179.634 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.44 ' HD2' HG21 ' A' ' 35' ' ' THR . 49.5 m-85 -100.18 3.61 43.87 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.805 179.002 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.464 HG12 ' HA ' ' A' ' 79' ' ' PHE . 0.3 OUTLIER -132.17 157.42 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 CA-C-O 120.86 0.362 . . . . 0.0 110.314 -179.544 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -120.06 133.16 55.6 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.714 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 3.2 m -88.05 137.61 20.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 C-N-CA 120.579 -0.448 . . . . 0.0 110.354 179.659 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 43.0 pt -129.71 158.79 42.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.756 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 67.2 m -112.57 143.96 42.86 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.507 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.556 179.875 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 28.4 p . . . . . 0 C--O 1.232 0.162 0 CA-C-O 120.84 0.352 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.99 -148.13 11.0 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 -179.377 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 1.7 mpt_? -113.01 141.91 46.31 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.95 0.405 . . . . 0.0 110.463 179.75 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -117.77 130.97 56.63 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.643 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 41.2 ttm180 -97.14 121.51 39.11 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.576 179.624 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.404 HG22 HG23 ' A' ' 82' ' ' VAL . 77.1 t -82.65 129.18 37.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.495 -179.872 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 51.0 m80 -112.88 8.63 18.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.974 179.452 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.0 p -137.12 166.87 22.69 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.74 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -108.56 104.74 14.12 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.356 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 16.1 t80 -118.72 119.19 33.69 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.628 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 82.4 p -120.74 152.28 55.66 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.609 -179.748 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -76.14 153.44 36.49 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.763 2.309 . . . . 0.0 112.406 -179.751 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 58.3 m -73.34 156.69 88.89 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.483 179.268 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -54.28 -39.4 86.93 Favored 'Trans proline' 0 C--N 1.301 -1.948 0 C-N-CA 122.858 2.372 . . . . 0.0 112.059 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -93.15 4.14 54.5 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.427 179.385 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -113.71 117.98 33.05 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.31 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 t -112.22 -25.13 9.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.79 179.592 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 -62.04 -38.43 88.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.595 -179.741 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 62.0 m -62.13 142.54 57.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.727 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 56.8 tp -90.38 142.49 27.68 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.423 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -94.73 121.84 36.73 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-O 120.939 0.399 . . . . 0.0 110.414 179.066 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.423 ' CG2' HD11 ' A' ' 55' ' ' ILE . 37.8 pt -131.1 155.21 41.75 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.62 -179.873 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 48.7 pttt -137.27 160.68 38.34 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.564 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -66.3 131.85 47.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.95 179.349 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 102.42 -18.75 50.31 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -82.87 152.01 25.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.823 0.344 . . . . 0.0 110.369 179.505 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 96.4 mt -116.29 133.11 63.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.62 179.69 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.423 HD11 ' CG2' ' A' ' 49' ' ' ILE . 82.5 mt -118.11 134.15 62.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.783 -179.294 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -80.49 122.94 27.62 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.189 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.3 mt -72.92 124.48 29.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.75 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 8.9 tt -107.0 -33.86 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.449 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 24.0 p -175.54 175.34 2.13 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.463 -179.324 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -126.35 151.8 47.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.536 179.464 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 31.0 p -105.18 153.42 39.56 Favored Pre-proline 0 N--CA 1.454 -0.261 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.611 -179.404 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -57.05 -35.93 99.1 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 C-N-CA 122.779 2.319 . . . . 0.0 112.227 179.717 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 98.2 mtp -61.29 -37.35 82.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.646 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 131.13 -25.46 4.1 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 96.4 mtp -62.15 139.67 58.46 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.027 0.441 . . . . 0.0 110.341 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 37.7 m0 -96.25 148.11 23.08 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.986 -179.371 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 58.3 m -119.48 140.49 50.38 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-N 116.022 -0.536 . . . . 0.0 109.885 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -164.81 -168.93 27.71 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -179.769 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.8 ttp -116.03 135.34 54.05 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-O 120.671 0.272 . . . . 0.0 110.739 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.471 HD23 ' C ' ' A' ' 70' ' ' LEU . 3.1 tt -135.7 112.51 10.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.371 179.702 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' ASN . . . . . 0.46 ' N ' HD23 ' A' ' 70' ' ' LEU . 66.9 t30 55.41 53.9 9.26 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.855 178.794 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 59.02 28.61 17.92 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.743 179.729 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -139.33 113.31 8.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.086 179.395 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 19.4 m -95.31 143.67 11.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.859 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -172.34 -173.39 38.95 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.664 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.2 m-20 -111.73 155.14 23.96 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.748 0.309 . . . . 0.0 110.451 -179.355 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 9.2 p90 -155.62 157.85 37.4 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.812 179.837 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.403 ' HB3' HG12 ' A' ' 80' ' ' ILE . 99.2 mttt -63.99 132.81 51.76 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.45 -179.639 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 29.6 p90 -67.08 -21.32 65.89 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.684 -179.17 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.403 HG12 ' HB3' ' A' ' 78' ' ' LYS . 12.5 pt -78.22 -27.0 14.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.334 -179.618 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.2 m-85 -84.3 1.16 46.21 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.71 179.724 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.404 HG23 HG22 ' A' ' 33' ' ' VAL . 7.1 p -139.33 157.88 28.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.31 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -132.22 147.41 52.41 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.392 179.798 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.1 p -83.36 131.21 34.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.597 179.744 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 61.1 mt -88.78 115.84 29.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.456 -178.854 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 70.8 p -79.4 165.34 23.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.488 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 78.2 mm-40 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.566 179.55 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 31.7 p . . . . . 0 N--CA 1.456 -0.147 0 CA-C-O 120.927 0.394 . . . . 0.0 110.342 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -166.86 -162.92 19.67 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 -179.375 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 10.9 mpt_? -119.6 147.55 44.37 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.764 0.316 . . . . 0.0 110.786 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.588 ' HB1' ' CG1' ' A' ' 82' ' ' VAL . . . -134.57 154.61 51.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.807 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 17.5 ptm180 -131.0 148.95 52.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.741 -179.589 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.444 HG22 HD12 ' A' ' 49' ' ' ILE . 58.8 t -86.26 128.71 39.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.301 -179.043 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 26.4 m170 -97.87 -16.98 19.54 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.517 178.922 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 13.1 t -144.53 142.8 30.48 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.885 -0.326 . . . . 0.0 110.145 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -62.59 117.45 6.26 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.777 -0.369 . . . . 0.0 110.731 -179.37 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -121.69 110.63 16.18 Favored 'General case' 0 C--O 1.233 0.201 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.945 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 88.0 m -129.14 94.73 32.91 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.057 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -54.78 152.7 27.36 Favored 'Trans proline' 0 N--CA 1.494 1.521 0 C-N-CA 122.358 2.039 . . . . 0.0 112.013 -179.596 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 39.0 m -59.14 154.73 38.59 Favored Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.474 -179.425 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -57.28 -24.65 60.86 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.554 2.17 . . . . 0.0 112.186 -179.434 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -65.87 -20.63 66.3 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.331 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 50.3 m-20 -96.11 59.68 1.96 Allowed 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 120.956 0.408 . . . . 0.0 110.521 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 12.8 t -60.46 -18.65 52.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.575 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 57.9 p-10 -90.1 7.23 38.91 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.314 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 67.8 m -106.57 144.41 33.28 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-O 120.917 0.389 . . . . 0.0 110.629 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 58.5 tp -81.6 142.03 33.16 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.536 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 1.6 mptm? -98.7 126.79 44.42 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.47 179.051 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.444 HD12 HG22 ' A' ' 33' ' ' VAL . 21.6 pt -131.49 148.5 32.65 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.631 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 39.3 ttpt -122.65 152.57 40.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.844 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 38.7 ttmt -57.11 128.35 36.56 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.058 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.38 -18.67 55.03 Favored Glycine 0 CA--C 1.524 0.635 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.451 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -72.23 144.96 48.27 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.796 0.332 . . . . 0.0 110.718 179.618 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 90.9 mt -111.96 129.08 68.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.35 179.243 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.416 ' CD1' HD12 ' A' ' 70' ' ' LEU . 81.3 mt -122.62 128.5 75.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.908 -179.172 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -76.9 134.03 39.08 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.367 179.349 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 85.9 mt -71.06 103.58 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.919 0.39 . . . . 0.0 110.16 -179.801 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.8 tt -89.09 -34.52 6.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.327 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 17.1 t -167.45 161.27 13.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.29 -179.46 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -120.57 144.7 47.95 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' THR . . . . . 0.459 HG22 ' H ' ' A' ' 63' ' ' MET . 27.6 m -101.67 135.69 19.72 Favored Pre-proline 0 CA--C 1.539 0.538 0 C-N-CA 120.232 -0.587 . . . . 0.0 109.98 -179.479 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -57.6 -25.7 68.7 Favored 'Trans proline' 0 N--CA 1.501 1.917 0 C-N-CA 122.359 2.039 . . . . 0.0 112.69 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' MET . . . . . 0.459 ' H ' HG22 ' A' ' 61' ' ' THR . 65.5 mtt -62.22 -38.74 90.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.959 0.409 . . . . 0.0 110.186 179.503 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 142.17 -40.12 1.32 Allowed Glycine 0 CA--C 1.524 0.634 0 N-CA-C 111.106 -0.798 . . . . 0.0 111.106 179.84 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 95.5 mtp -64.07 144.39 57.14 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.217 0.532 . . . . 0.0 111.108 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 38.4 m0 -97.4 156.31 16.52 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.369 -179.579 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 80.3 m -117.19 139.31 50.92 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.056 -179.719 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.23 -175.78 27.6 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 16.9 tmm? -121.31 141.55 50.81 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.723 0.297 . . . . 0.0 110.507 -179.697 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.416 HD12 ' CD1' ' A' ' 55' ' ' ILE . 0.5 OUTLIER -149.31 121.62 8.41 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.992 179.921 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 18.5 m120 50.31 49.96 19.6 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 53.0 t30 59.82 35.07 21.93 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.764 0.316 . . . . 0.0 110.708 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 24.3 tptp -134.26 115.94 14.71 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 179.43 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 97.1 t -105.78 129.03 59.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.446 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -165.86 -172.42 33.21 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.59 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.7 m-80 -101.43 153.18 19.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.024 0.44 . . . . 0.0 111.056 -179.508 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.538 ' CD1' HG21 ' A' ' 82' ' ' VAL . 53.4 p90 -149.93 160.43 43.61 Favored 'General case' 0 C--O 1.239 0.54 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.619 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 35.6 tptt -69.62 111.77 5.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.514 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 53.4 p90 -61.53 -24.31 66.53 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.8 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.9 mt -63.14 -39.24 84.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.022 0.439 . . . . 0.0 110.437 -179.807 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 20.6 m-85 -84.71 2.22 42.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.971 -179.581 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.588 ' CG1' ' HB1' ' A' ' 31' ' ' ALA . 85.6 t -126.02 136.9 59.43 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.147 0 CA-C-O 120.987 0.422 . . . . 0.0 110.813 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -124.41 148.42 47.59 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.373 -179.878 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 16.9 m -90.37 139.6 17.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 C-N-CA 120.662 -0.415 . . . . 0.0 110.58 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 38.9 pt -120.96 149.78 23.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.796 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 83.9 p -90.84 170.49 10.05 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.674 179.808 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.049 -0.977 . . . . 0.0 110.482 179.756 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.43 147.74 89.96 Favored 'Trans proline' 0 C--N 1.305 -1.75 0 C-N-CA 122.911 2.407 . . . . 0.0 111.907 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -114.89 139.21 49.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.49 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.4 m -119.76 149.8 41.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.484 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.51 -128.18 1.87 Allowed Glycine 0 CA--C 1.526 0.753 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 9.9 mpt_? -111.48 140.2 46.28 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.754 0.311 . . . . 0.0 110.7 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.464 ' HB1' ' CG1' ' A' ' 82' ' ' VAL . . . -111.1 127.1 55.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.445 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 74.2 ttt-85 -103.55 123.66 47.35 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.525 -179.68 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.568 HG22 HG22 ' A' ' 82' ' ' VAL . 66.1 t -77.5 123.51 34.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.621 -179.694 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 35.4 p80 -105.75 -16.37 14.69 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.741 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.472 HG21 ' CD2' ' A' ' 81' ' ' TYR . 32.6 m -128.45 129.33 45.96 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.692 179.666 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -65.71 109.65 2.5 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.557 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' PHE . . . . . 0.488 ' HB3' HD11 ' A' ' 49' ' ' ILE . 22.5 t80 -117.17 115.4 25.26 Favored 'General case' 0 C--O 1.241 0.611 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.372 179.557 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 95.5 m -131.08 128.28 22.2 Favored Pre-proline 0 N--CA 1.449 -0.502 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.754 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.5 166.41 29.9 Favored 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 123.012 2.475 . . . . 0.0 112.139 179.377 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 61.7 m -67.47 159.52 77.45 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.554 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_exo -55.62 -32.07 81.82 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.722 2.281 . . . . 0.0 112.183 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -95.51 11.45 32.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.763 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -106.69 108.73 20.38 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.339 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 5.0 t -113.51 -8.49 13.36 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.782 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 45.5 p-10 -75.59 -7.12 53.42 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.762 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 73.6 m -118.9 144.37 46.45 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-O 120.787 0.327 . . . . 0.0 110.504 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.413 HD21 ' HB2' ' A' ' 70' ' ' LEU . 9.5 tp -82.11 153.93 25.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.533 -179.776 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -96.2 130.61 43.23 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.573 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.488 HD11 ' HB3' ' A' ' 37' ' ' PHE . 34.2 pt -134.93 158.53 41.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.414 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.7 tttp -137.0 145.29 43.93 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.798 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 63.4 tttm -54.45 129.2 35.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.637 -179.782 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.57 -16.83 59.26 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 111.174 -0.77 . . . . 0.0 111.174 -179.692 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -74.87 148.41 40.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.786 0.327 . . . . 0.0 110.612 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 42.9 mm -109.93 126.63 67.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.392 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.423 HD11 ' CG2' ' A' ' 49' ' ' ILE . 82.9 mt -119.08 129.06 75.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.606 -179.606 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -77.11 122.77 25.44 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.326 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.4 mt -76.82 125.25 36.46 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.486 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.412 HD11 HG22 ' A' ' 67' ' ' THR . 30.6 pt -114.24 -27.98 2.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.461 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 10.4 t -167.35 161.82 14.41 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.647 -179.158 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -119.14 145.26 46.12 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.231 179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 25.5 m -94.89 134.32 25.09 Favored Pre-proline 0 CA--C 1.534 0.336 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.429 -179.134 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -50.73 -36.19 50.42 Favored 'Trans proline' 0 N--CA 1.494 1.546 0 C-N-CA 122.806 2.338 . . . . 0.0 112.068 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 60.6 ttm -59.03 -40.23 84.37 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.324 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 144.05 -31.78 1.83 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 97.5 mtp -62.54 146.59 51.38 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.014 0.435 . . . . 0.0 110.842 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 42.6 m0 -102.0 150.79 22.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.965 -179.186 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.412 HG22 HD11 ' A' ' 58' ' ' ILE . 93.2 m -110.55 136.73 49.22 Favored 'General case' 0 C--O 1.237 0.417 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.994 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -155.87 -171.56 22.43 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 111.095 -0.802 . . . . 0.0 111.095 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -123.35 147.65 46.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.991 0.424 . . . . 0.0 110.622 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.413 ' HB2' HD21 ' A' ' 47' ' ' LEU . 0.4 OUTLIER -151.09 117.37 5.64 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.69 -179.742 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 18.8 m120 51.22 52.83 14.07 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.142 179.413 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 80.7 m-20 59.68 26.18 15.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.237 -179.561 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.9 tttp -130.25 113.16 14.09 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.504 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 15.6 m -99.37 140.04 19.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.761 179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -171.42 -176.67 40.65 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -179.625 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 -104.12 150.4 24.36 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.077 0.465 . . . . 0.0 110.459 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.665 ' CD1' HG21 ' A' ' 82' ' ' VAL . 50.9 p90 -146.22 156.58 43.49 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.723 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 54.6 mttp -67.01 122.18 17.18 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.005 -179.591 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 55.9 p90 -68.64 -29.58 68.1 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.55 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 33.6 pt -60.46 -21.21 22.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.839 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.472 ' CD2' HG21 ' A' ' 35' ' ' THR . 22.4 m-85 -102.64 1.51 34.76 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.871 179.289 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.665 HG21 ' CD1' ' A' ' 77' ' ' PHE . 68.2 t -127.83 136.51 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 CA-C-O 121.109 0.48 . . . . 0.0 110.752 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 41.7 t0 -110.94 142.26 43.28 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.395 179.481 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.7 p -86.94 126.3 40.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.772 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 23.4 pt -127.19 163.32 30.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.714 179.84 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 28.7 t -104.74 130.32 52.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.581 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 7.9 tt0 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.554 179.916 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -68.34 143.93 60.1 Favored 'Trans proline' 0 C--N 1.305 -1.716 0 C-N-CA 122.746 2.297 . . . . 0.0 111.947 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 71.7 t80 -142.19 136.65 30.15 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.52 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 84.1 m -100.14 137.53 38.46 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.43 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 172.37 -140.53 5.79 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 21.0 mmm180 -110.14 148.13 32.37 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.887 0.375 . . . . 0.0 110.311 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -121.68 143.67 49.21 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.435 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 38.6 ptt180 -120.25 135.97 54.82 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.033 0.444 . . . . 0.0 110.427 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 43.4 t -84.54 135.53 24.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.982 -178.737 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 97.4 m-70 -107.28 -12.79 15.28 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.732 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 11.8 t -140.87 148.83 41.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.891 0.377 . . . . 0.0 110.375 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.3 p-10 -75.13 121.43 22.06 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.026 -179.515 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -119.28 118.24 30.73 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 178.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 89.6 m -126.56 94.69 39.8 Favored Pre-proline 0 CA--C 1.534 0.361 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.434 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -56.45 147.79 66.5 Favored 'Trans proline' 0 N--CA 1.499 1.804 0 C-N-CA 122.409 2.073 . . . . 0.0 112.023 -179.635 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 93.7 p -67.92 159.21 80.62 Favored Pre-proline 0 CA--C 1.532 0.255 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.709 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -56.8 -30.77 86.17 Favored 'Trans proline' 0 N--CA 1.499 1.812 0 C-N-CA 122.832 2.355 . . . . 0.0 112.154 -179.773 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -61.82 -22.96 65.93 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.062 -179.444 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -107.27 103.44 12.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.041 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.404 HG22 ' H ' ' A' ' 44' ' ' THR . 1.9 t -87.51 -33.89 18.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.367 179.762 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -63.37 -38.03 89.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.038 179.681 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 53.4 m -62.38 131.65 49.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.946 0.403 . . . . 0.0 110.647 -179.31 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 1.2 tt -87.55 150.84 23.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.755 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -98.22 123.52 42.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.263 -0.426 . . . . 0.0 109.926 179.092 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 47.3 pt -130.08 159.05 42.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 120.897 0.379 . . . . 0.0 110.902 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -135.71 141.99 44.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.704 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 22.8 pttp -53.35 138.86 31.76 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.982 0.42 . . . . 0.0 110.658 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.1 -17.9 56.42 Favored Glycine 0 CA--C 1.53 0.977 0 N-CA-C 111.2 -0.76 . . . . 0.0 111.2 -179.523 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -84.64 156.82 21.37 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.789 0.328 . . . . 0.0 110.921 179.569 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 47.4 mm -116.46 131.51 68.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.403 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.458 ' CG1' HD12 ' A' ' 70' ' ' LEU . 89.7 mt -118.25 132.04 69.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.282 -179.559 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 66.9 t0 -74.52 118.48 17.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.74 179.788 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 90.6 mt -69.34 122.4 20.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 120.902 0.382 . . . . 0.0 110.664 -179.433 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 82.6 mt -108.31 -59.44 3.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.183 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 94.2 m -140.87 142.93 34.46 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.479 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 12.2 pttp -154.26 123.21 6.33 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.926 0.393 . . . . 0.0 110.821 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.8 p -75.44 161.68 75.68 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.362 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_exo -52.28 -36.18 66.9 Favored 'Trans proline' 0 N--CA 1.495 1.607 0 C-N-CA 122.506 2.138 . . . . 0.0 111.833 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 14.9 tpt -149.71 97.0 2.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.476 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 168.85 -178.65 42.09 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 111.009 -0.836 . . . . 0.0 111.009 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.1 mtp -60.69 144.51 51.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.023 0.439 . . . . 0.0 110.738 -179.112 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 26.2 m0 -93.82 146.35 23.94 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.293 -179.57 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.9 m -112.59 135.49 53.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.986 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -160.59 -171.69 26.87 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 67.5 ttp -121.86 135.49 54.9 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.823 0.344 . . . . 0.0 110.407 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.458 HD12 ' CG1' ' A' ' 55' ' ' ILE . 4.2 tt -135.35 117.03 14.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.063 179.662 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ASN . . . . . 0.449 ' N ' HD23 ' A' ' 70' ' ' LEU . 64.8 t30 55.85 52.93 9.98 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.235 179.282 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 33.1 m120 57.94 35.08 25.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.657 0.265 . . . . 0.0 111.4 179.582 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -139.02 116.89 11.56 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.14 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 89.5 t -95.41 129.94 44.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.604 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -165.67 -174.08 34.85 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.337 -0.705 . . . . 0.0 111.337 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.1 m-80 -108.95 156.72 19.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.007 0.432 . . . . 0.0 110.912 -179.555 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -157.52 160.32 38.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.096 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -71.06 117.77 12.98 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.174 0.511 . . . . 0.0 111.119 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.456 ' HA ' HG12 ' A' ' 82' ' ' VAL . 55.6 p90 -63.15 -30.26 71.45 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.512 179.536 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.44 HG23 ' CE1' ' A' ' 79' ' ' PHE . 18.3 pt -62.43 -18.5 20.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.77 0.319 . . . . 0.0 110.724 179.344 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 15.3 m-30 -100.63 3.63 42.68 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.909 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.456 HG12 ' HA ' ' A' ' 79' ' ' PHE . 0.5 OUTLIER -132.58 159.94 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.758 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -127.59 144.47 51.07 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.526 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.7 p -93.65 128.63 44.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.579 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 44.0 pt -127.68 158.83 39.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.752 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 71.0 m -70.64 144.74 51.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.531 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.606 179.848 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.255 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -69.8 153.34 68.84 Favored 'Trans proline' 0 C--N 1.306 -1.706 0 C-N-CA 122.888 2.392 . . . . 0.0 112.201 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -114.12 133.5 55.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.607 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 24.1 p -66.45 151.66 46.72 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.064 0.459 . . . . 0.0 110.195 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.97 -155.25 14.95 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 26.9 mmt85 -112.22 140.64 46.75 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.885 0.374 . . . . 0.0 110.481 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.6 117.15 30.08 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.496 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 75.5 ttt180 -91.34 124.57 35.64 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.615 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.584 HG22 HG22 ' A' ' 82' ' ' VAL . 82.5 t -82.26 129.33 37.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.6 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 37.0 m80 -107.1 -18.18 13.97 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.851 179.76 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.538 HG21 ' CD2' ' A' ' 81' ' ' TYR . 95.2 m -123.94 134.53 53.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.367 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -75.07 114.18 13.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.697 -179.577 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -118.22 125.18 49.65 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.345 179.8 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 10.0 t -132.28 134.18 24.66 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.673 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -72.97 166.41 30.11 Favored 'Trans proline' 0 N--CA 1.492 1.434 0 C-N-CA 122.894 2.396 . . . . 0.0 112.388 179.723 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 48.8 m -64.13 156.13 76.1 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.482 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -58.51 -27.39 82.07 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.621 2.214 . . . . 0.0 112.306 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -99.29 22.74 10.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.636 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -114.31 113.22 24.28 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.437 179.575 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 72.8 p -110.73 -15.14 13.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.683 179.729 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 56.7 p-10 -88.47 10.85 18.75 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.844 179.752 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 67.7 m -117.26 157.96 25.15 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 120.683 0.278 . . . . 0.0 110.3 -179.668 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 63.8 tp -104.56 136.7 43.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.321 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 13.3 tmtt? -96.72 124.94 40.85 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.385 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 49.3 pt -128.21 158.49 40.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.532 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 64.6 pttt -138.47 161.23 37.54 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.633 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 23.3 pttp -63.13 137.46 58.24 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.765 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.04 -11.6 71.7 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 111.024 -0.831 . . . . 0.0 111.024 -179.676 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 42.0 t0 -79.43 148.66 31.85 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-O 120.829 0.347 . . . . 0.0 110.463 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 39.0 mm -110.64 127.88 67.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.399 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 93.9 mt -115.22 134.34 58.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.803 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -82.17 111.9 18.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.559 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.5 mt -63.31 130.95 28.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.746 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 97.6 mt -112.57 -63.97 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.715 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.9 t -154.0 138.94 17.21 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.588 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -92.06 153.38 19.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.275 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 81.8 p -125.08 151.91 69.82 Favored Pre-proline 0 CA--C 1.532 0.252 0 C-N-CA 120.477 -0.489 . . . . 0.0 110.695 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -63.69 -18.85 65.92 Favored 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.908 2.406 . . . . 0.0 112.315 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 39.2 mmt -61.76 -37.41 84.19 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.195 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 125.18 -44.06 1.31 Allowed Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.074 -0.811 . . . . 0.0 111.074 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 33.5 mtt -61.85 141.76 57.76 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.98 0.419 . . . . 0.0 110.436 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 26.9 m0 -96.07 147.26 23.91 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.285 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 85.6 m -112.29 137.06 50.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.977 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -158.14 -172.53 25.41 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 37.2 ttm -119.69 140.49 50.58 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 120.734 0.302 . . . . 0.0 110.383 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -144.09 115.57 8.09 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.912 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 57.0 m-20 53.27 51.13 16.12 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.334 179.445 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 52.9 t30 60.75 28.79 18.51 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.545 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 13.0 tppt? -136.83 115.32 11.9 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.45 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.9 m -97.29 142.47 14.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.868 0.366 . . . . 0.0 110.804 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -171.18 -177.65 41.14 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 110.691 -0.963 . . . . 0.0 110.691 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -103.09 157.97 16.62 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 121.083 0.468 . . . . 0.0 110.644 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.571 ' CD1' HG21 ' A' ' 82' ' ' VAL . 2.1 p90 -154.35 161.56 41.68 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.194 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 12.4 tptt -62.17 117.47 6.08 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-O 121.488 0.661 . . . . 0.0 110.882 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -62.3 -23.22 66.6 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.353 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.419 HG23 ' N ' ' A' ' 81' ' ' TYR . 18.1 tt -73.28 -38.19 53.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.877 0.37 . . . . 0.0 110.812 179.591 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.538 ' CD2' HG21 ' A' ' 35' ' ' THR . 22.8 m-85 -80.3 -14.92 57.99 Favored 'General case' 0 C--O 1.24 0.582 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.765 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.584 HG22 HG22 ' A' ' 33' ' ' VAL . 67.2 t -111.78 137.08 45.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.223 0 CA-C-O 121.31 0.576 . . . . 0.0 110.61 179.843 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 41.5 t0 -121.04 149.47 42.65 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.743 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.3 p -87.85 132.38 33.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.447 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 2.4 tt -104.81 146.09 12.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.654 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 72.0 m -80.17 148.26 30.97 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.473 179.676 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 117.911 -1.042 . . . . 0.0 110.516 179.834 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.308 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -69.88 149.78 66.6 Favored 'Trans proline' 0 C--N 1.306 -1.71 0 C-N-CA 122.789 2.326 . . . . 0.0 112.099 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -133.22 151.18 51.94 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.513 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 72.9 m -106.14 143.26 34.52 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.455 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 176.88 -123.76 0.92 Allowed Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -179.705 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 19.2 tpp180 -121.54 133.62 55.02 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.791 0.329 . . . . 0.0 110.448 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -104.28 122.94 46.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.694 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 78.3 ttt-85 -107.12 127.16 53.25 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.722 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.0 t -81.03 125.76 39.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.272 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 32.5 p80 -117.24 -13.1 10.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.699 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 97.2 m -125.51 134.37 52.05 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.538 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -69.22 122.98 19.93 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.672 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -71.59 137.69 48.18 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.222 179.642 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 82.1 m -120.01 93.27 47.72 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.424 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -73.59 151.69 47.35 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.864 2.376 . . . . 0.0 112.452 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 65.5 m -76.56 159.98 78.27 Favored Pre-proline 0 N--CA 1.452 -0.355 0 CA-C-O 121.263 0.554 . . . . 0.0 110.7 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -55.44 -37.47 94.81 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 122.733 2.289 . . . . 0.0 111.638 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.2 p90 -91.1 15.59 11.39 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.624 -179.702 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -108.81 94.83 5.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.276 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 71.2 p -104.42 -22.72 13.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.638 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -87.1 6.83 30.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.696 179.3 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 82.7 p -71.59 160.06 33.34 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-O 120.882 0.372 . . . . 0.0 110.42 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 55.8 tp -91.16 136.95 32.73 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.295 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 15.9 ptpt -93.64 123.33 36.89 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.762 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.0 pt -139.26 160.22 28.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.579 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.2 tttp -143.94 141.95 30.49 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.622 179.473 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 23.3 pttp -48.85 134.33 16.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.661 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.25 -19.61 53.81 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -74.32 153.66 39.23 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.784 0.326 . . . . 0.0 110.741 179.436 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 43.4 mm -114.47 126.62 72.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.367 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 87.1 mt -111.49 133.9 55.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.682 -179.528 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -80.11 112.17 17.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.593 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 97.5 mt -63.43 124.07 17.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.494 -179.657 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 97.3 mt -106.73 -54.87 5.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.634 179.827 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 32.0 p -161.51 171.27 18.41 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.61 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.02 146.14 42.4 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.499 179.828 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 62.1 p -101.45 155.02 36.87 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.515 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -63.27 -22.23 72.18 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 C-N-CA 122.957 2.438 . . . . 0.0 112.183 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 39.0 mmt -76.06 -10.56 59.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.877 179.485 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 104.08 -25.1 27.35 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 179.849 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 91.7 mmm -63.18 147.04 52.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.902 0.382 . . . . 0.0 110.426 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 33.1 m0 -103.95 143.38 32.94 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.827 -179.493 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 86.6 m -108.18 133.68 52.11 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.664 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -150.75 -179.05 26.18 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 -179.63 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 61.2 ttm -117.99 143.18 46.6 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-O 120.639 0.257 . . . . 0.0 110.557 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -142.04 117.14 10.02 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.574 179.74 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ASN . . . . . 0.454 ' O ' ' ND2' ' A' ' 71' ' ' ASN . 1.9 p-10 40.99 57.64 2.71 Favored 'General case' 0 N--CA 1.463 0.18 0 O-C-N 123.391 0.432 . . . . 0.0 111.019 -179.753 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 60.5 t30 60.62 38.56 18.57 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.909 -179.253 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 64.1 tttt -141.36 109.69 5.91 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.092 178.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 60.1 t -98.99 129.82 48.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.91 0.386 . . . . 0.0 110.772 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -163.63 -178.63 37.43 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 63.3 m-20 -101.17 160.52 14.33 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-O 120.643 0.259 . . . . 0.0 110.449 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 19.8 p90 -158.88 159.21 34.73 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.704 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 30.1 tttt -66.41 113.78 4.92 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.491 -179.402 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.428 ' HA ' HG12 ' A' ' 82' ' ' VAL . 49.4 p90 -59.22 -23.15 62.07 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.396 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 95.7 mt -68.54 -38.73 79.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.025 0.441 . . . . 0.0 110.19 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.7 m-30 -76.07 -5.43 46.45 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.815 -179.438 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.428 HG12 ' HA ' ' A' ' 79' ' ' PHE . 0.4 OUTLIER -126.82 165.43 25.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.629 -179.591 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -148.66 160.63 42.96 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.521 179.168 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.435 ' O ' HG23 ' A' ' 84' ' ' VAL . 23.6 m -94.52 129.34 44.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.624 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 43.1 pt -126.11 159.87 34.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.67 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 41.4 t -105.6 123.15 47.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.589 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 25.4 pt-20 . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.538 179.991 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.229 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_exo -58.18 142.28 97.09 Favored 'Trans proline' 0 C--N 1.307 -1.658 0 C-N-CA 122.805 2.336 . . . . 0.0 111.986 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -112.96 140.38 47.81 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.461 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 31.1 p -119.68 153.37 35.68 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.974 0.416 . . . . 0.0 110.143 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.63 -124.25 1.59 Allowed Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 14.7 mmp_? -111.2 147.0 35.91 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.681 0.277 . . . . 0.0 110.51 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -117.79 114.41 23.25 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.718 -0.393 . . . . 0.0 110.896 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.539 ' HD2' HD12 ' A' ' 85' ' ' ILE . 2.8 ptm85 -87.9 128.48 35.36 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.546 179.765 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.542 HG22 HG23 ' A' ' 82' ' ' VAL . 95.7 t -84.83 131.98 32.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.2 -179.313 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 30.3 m170 -114.17 -15.32 12.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.398 179.409 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.414 HG21 ' CD2' ' A' ' 81' ' ' TYR . 32.9 m -127.68 132.47 49.66 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.843 0.354 . . . . 0.0 110.712 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -65.79 145.1 56.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.736 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -98.65 134.92 40.9 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.004 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.48 HG23 ' O ' ' A' ' 38' ' ' THR . 2.7 t -121.22 93.52 48.81 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.752 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_endo -75.01 153.1 41.47 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.397 2.064 . . . . 0.0 112.319 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 65.6 m -72.01 158.97 86.69 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.525 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -53.82 -37.16 84.73 Favored 'Trans proline' 0 N--CA 1.497 1.723 0 C-N-CA 122.633 2.222 . . . . 0.0 112.039 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 41.1 p90 -97.43 16.36 20.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.869 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -96.6 88.16 4.58 Favored 'General case' 0 C--O 1.233 0.213 0 CA-C-O 121.039 0.447 . . . . 0.0 110.544 -179.726 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 6.9 t -93.24 -26.16 17.48 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.437 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 56.0 p-10 -79.5 -3.36 46.4 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.023 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 34.8 t -83.55 139.63 32.76 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.661 0.267 . . . . 0.0 110.536 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 60.2 tp -85.85 145.82 27.02 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.371 -0.377 . . . . 0.0 109.997 179.593 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 58.2 pttt -96.27 127.03 41.91 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.45 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 35.2 pt -144.12 150.2 17.01 Favored 'Isoleucine or valine' 0 C--O 1.237 0.436 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.339 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 63.7 tttp -132.72 145.88 51.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.331 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 64.8 pttt -48.93 138.15 11.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.953 0.406 . . . . 0.0 110.682 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 93.44 -13.27 67.94 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 -179.46 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -77.37 150.95 35.07 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-O 120.817 0.342 . . . . 0.0 110.636 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 36.1 mm -114.21 126.73 71.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.208 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.44 HG12 HD12 ' A' ' 70' ' ' LEU . 92.3 mt -117.93 133.14 65.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.83 -179.498 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -78.58 121.97 25.32 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.276 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.7 mt -69.5 120.39 17.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.914 0.388 . . . . 0.0 110.545 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.492 HD11 ' HB2' ' A' ' 69' ' ' MET . 93.3 mt -109.47 -50.65 6.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.451 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 95.3 m -140.26 151.42 45.11 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.437 179.483 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 37.8 mtmm -124.88 147.74 48.65 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.417 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 90.0 m -122.71 117.16 28.9 Favored Pre-proline 0 CA--C 1.537 0.466 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.202 179.569 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_exo -50.57 126.83 18.98 Favored 'Trans proline' 0 N--CA 1.497 1.715 0 C-N-CA 121.933 1.755 . . . . 0.0 111.971 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 93.7 mmm 47.15 40.62 10.27 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.613 179.677 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -151.77 176.37 30.17 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.152 -0.779 . . . . 0.0 111.152 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 98.9 mtp -60.0 148.33 35.81 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.006 0.432 . . . . 0.0 110.58 -179.088 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 16.1 m0 -94.89 158.25 15.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.057 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 96.2 m -118.93 138.0 53.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.238 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -160.73 -170.57 25.51 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' MET . . . . . 0.492 ' HB2' HD11 ' A' ' 58' ' ' ILE . 64.8 ttp -125.71 136.32 53.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.745 0.307 . . . . 0.0 110.337 -179.702 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.488 HD23 ' N ' ' A' ' 71' ' ' ASN . 4.4 tt -137.83 120.15 15.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.392 179.869 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ASN . . . . . 0.488 ' N ' HD23 ' A' ' 70' ' ' LEU . 67.2 t30 53.08 51.4 15.81 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.681 -0.408 . . . . 0.0 110.981 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 58.0 t30 58.87 36.26 24.57 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.653 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 4.0 tptm -139.12 113.76 9.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.37 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 91.7 t -94.54 127.36 46.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.846 0.355 . . . . 0.0 110.674 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -163.22 -178.82 37.29 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 -179.8 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -100.69 157.53 16.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.907 0.384 . . . . 0.0 110.729 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -155.88 161.21 40.62 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.841 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -73.54 121.96 21.45 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.859 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.626 ' HA ' HG12 ' A' ' 82' ' ' VAL . 51.2 p90 -67.69 -28.18 67.46 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.794 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.473 HG23 ' CE1' ' A' ' 79' ' ' PHE . 33.5 pt -63.82 -19.53 24.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.694 0.283 . . . . 0.0 111.073 179.656 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.414 ' CD2' HG21 ' A' ' 35' ' ' THR . 21.2 m-30 -102.23 5.39 40.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.942 0.401 . . . . 0.0 110.913 179.532 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.626 HG12 ' HA ' ' A' ' 79' ' ' PHE . 1.2 p -134.23 153.17 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.315 179.801 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -113.41 134.11 54.82 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.375 179.293 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.0 p -80.09 125.94 39.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.548 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.539 HD12 ' HD2' ' A' ' 32' ' ' ARG . 0.1 OUTLIER -122.76 134.42 66.0 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.418 -179.815 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 69.8 m -67.49 143.39 56.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.32 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.633 179.892 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.275 0 N-CA-C 109.601 -1.4 . . . . 0.0 109.601 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.49 144.28 97.05 Favored 'Trans proline' 0 N--CA 1.497 1.735 0 C-N-CA 122.852 2.368 . . . . 0.0 111.964 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -113.34 146.39 39.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.587 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 82.6 m -110.6 135.05 51.83 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.378 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -175.34 -152.96 9.76 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 39.5 mmt180 -112.27 143.46 43.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.78 0.324 . . . . 0.0 110.657 -179.624 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -117.97 132.27 56.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.225 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.446 ' HA ' HD13 ' A' ' 54' ' ' ILE . 17.6 ptm180 -110.82 133.05 53.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.232 0.539 . . . . 0.0 110.733 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.502 HG22 HG23 ' A' ' 82' ' ' VAL . 86.5 t -85.68 133.44 29.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.511 -179.332 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.562 ' HD2' HG23 ' A' ' 35' ' ' THR . 0.3 OUTLIER -118.02 -7.31 10.88 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.171 179.792 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.562 HG23 ' HD2' ' A' ' 34' ' ' HIS . 72.9 p -130.65 158.82 39.0 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.892 0.377 . . . . 0.0 110.3 -179.836 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -91.35 104.06 16.63 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.599 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -119.24 121.4 39.58 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.571 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 8.7 t -130.3 139.67 36.33 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.809 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -73.59 166.01 30.91 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 122.779 2.319 . . . . 0.0 112.262 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 85.7 p -68.65 161.82 67.81 Favored Pre-proline 0 C--N 1.324 -0.525 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.653 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -56.23 -34.63 94.02 Favored 'Trans proline' 0 N--CA 1.5 1.893 0 C-N-CA 122.712 2.275 . . . . 0.0 112.098 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.3 p90 -87.75 9.42 21.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.923 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -112.38 114.73 27.61 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-O 120.684 0.278 . . . . 0.0 110.397 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 58.1 p -115.34 -30.57 6.22 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.933 0.397 . . . . 0.0 110.617 179.572 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -63.23 -37.32 86.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.548 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 66.7 m -58.85 152.83 18.42 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.606 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.521 HD13 ' H ' ' A' ' 48' ' ' LYS . 0.1 OUTLIER -91.72 132.51 36.33 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.51 -179.964 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.521 ' H ' HD13 ' A' ' 47' ' ' LEU . 62.4 mttp -87.4 124.38 33.34 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 179.181 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.493 ' CG2' HD11 ' A' ' 55' ' ' ILE . 47.5 pt -131.06 146.52 33.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.558 -179.572 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.7 mttp -135.08 159.98 39.8 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.427 -0.352 . . . . 0.0 110.274 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -55.81 121.98 10.44 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.989 0.423 . . . . 0.0 110.538 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 103.52 -21.21 39.73 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -67.01 143.09 56.98 Favored 'General case' 0 C--N 1.332 -0.194 0 C-N-CA 120.618 -0.433 . . . . 0.0 110.77 179.41 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.446 HD13 ' HA ' ' A' ' 32' ' ' ARG . 9.9 mm -112.69 128.71 69.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.599 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.493 HD11 ' CG2' ' A' ' 49' ' ' ILE . 2.5 mt -116.33 133.35 63.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.708 -179.417 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -79.95 117.63 20.97 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.15 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 92.0 mt -67.26 126.39 26.79 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.137 0 CA-C-O 120.919 0.39 . . . . 0.0 110.679 -179.524 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 93.3 mt -113.84 -59.27 3.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.47 179.721 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 94.7 m -144.77 168.8 19.34 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.938 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -115.98 141.48 48.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.187 179.573 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.9 m -98.86 137.52 20.55 Favored Pre-proline 0 CA--C 1.538 0.483 0 C-N-CA 120.149 -0.62 . . . . 0.0 110.343 -179.492 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -53.22 -36.84 79.24 Favored 'Trans proline' 0 N--CA 1.501 1.916 0 C-N-CA 122.414 2.076 . . . . 0.0 112.486 179.509 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' MET . . . . . 0.463 ' HG3' ' H ' ' A' ' 65' ' ' MET . 23.0 ptp -59.34 -18.67 40.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.885 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 119.41 -38.25 2.88 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 179.424 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' MET . . . . . 0.463 ' H ' ' HG3' ' A' ' 63' ' ' MET . 97.0 mtp -61.57 143.65 55.65 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.153 0.502 . . . . 0.0 110.59 -179.79 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 45.7 m0 -98.75 155.67 17.23 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.212 -179.312 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 93.0 m -115.92 135.21 54.2 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.901 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.6 -172.13 23.57 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 179.823 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 16.8 tmm? -122.04 139.8 53.26 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.847 0.356 . . . . 0.0 110.751 -179.701 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -139.25 111.72 7.64 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.618 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 14.0 m120 54.05 51.99 13.6 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.034 179.617 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 54.1 t30 62.41 37.3 13.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.792 0.33 . . . . 0.0 110.707 -179.387 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 46.9 tptt -137.33 113.29 9.75 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.034 179.266 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 88.9 t -100.46 127.28 53.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 C-N-CA 120.793 -0.363 . . . . 0.0 110.912 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.505 ' N ' HD23 ' A' ' 47' ' ' LEU . . . -164.92 -174.09 34.26 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -102.51 150.96 22.87 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.009 0.433 . . . . 0.0 110.483 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 44.0 p90 -150.84 158.75 44.52 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.757 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -72.29 117.36 13.85 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.94 -179.466 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -62.58 -27.51 69.23 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.683 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 13.7 tt -63.06 -33.27 59.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.999 0.428 . . . . 0.0 111.1 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -83.81 1.23 44.01 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.835 179.807 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.502 HG23 HG22 ' A' ' 33' ' ' VAL . 0.3 OUTLIER -132.66 161.42 41.56 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 CA-C-O 121.038 0.447 . . . . 0.0 110.464 179.815 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 53.3 t0 -124.1 137.64 54.54 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.133 179.39 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.5 p -87.52 124.64 40.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.773 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 41.4 pt -128.27 150.71 34.24 Favored 'Isoleucine or valine' 0 C--O 1.233 0.219 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.84 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 38.4 t -84.63 138.75 32.52 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.718 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.003 -0.998 . . . . 0.0 110.611 179.714 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -69.78 151.62 68.98 Favored 'Trans proline' 0 C--N 1.305 -1.741 0 C-N-CA 122.849 2.366 . . . . 0.0 112.075 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 90.8 t80 -91.54 127.46 37.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.594 -179.72 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 29.5 p -100.09 129.91 46.18 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.992 0.425 . . . . 0.0 110.424 179.763 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -174.16 -154.91 11.29 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -179.327 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 15.6 mmp_? -108.04 142.34 38.34 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.023 0.44 . . . . 0.0 110.469 -179.397 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.445 ' HB1' HG21 ' A' ' 82' ' ' VAL . . . -106.39 117.3 33.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.184 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 61.2 ttt180 -96.09 120.83 37.08 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.055 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 86.8 t -81.28 124.78 39.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.728 -179.4 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 35.2 p80 -115.81 -8.97 11.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.936 179.406 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 77.4 m -129.04 136.74 50.69 Favored 'General case' 0 C--O 1.231 0.099 0 CA-C-O 120.762 0.315 . . . . 0.0 110.625 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -69.49 119.69 14.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.493 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -65.47 136.91 57.04 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 92.1 m -118.45 94.85 47.96 Favored Pre-proline 0 CA--C 1.537 0.452 0 C-N-CA 120.958 -0.297 . . . . 0.0 110.762 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_endo -74.09 157.3 46.7 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 122.352 2.035 . . . . 0.0 112.201 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.1 m -79.78 158.03 73.54 Favored Pre-proline 0 CA--C 1.532 0.263 0 C-N-CA 120.661 -0.415 . . . . 0.0 110.797 -179.643 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -57.23 -40.27 83.87 Favored 'Trans proline' 0 N--CA 1.5 1.912 0 C-N-CA 122.381 2.054 . . . . 0.0 112.096 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.4 p90 -89.72 16.99 7.01 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.182 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -112.69 113.39 25.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.791 0.329 . . . . 0.0 110.626 179.425 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 55.7 p -112.42 -17.55 12.66 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.458 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 57.6 p-10 -87.59 6.13 35.99 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.13 179.64 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 74.9 m -70.28 151.17 45.6 Favored 'General case' 0 C--O 1.231 0.094 0 CA-C-O 120.86 0.362 . . . . 0.0 110.662 179.694 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 60.6 tp -84.66 135.93 33.96 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.154 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 62.6 mtpt -93.93 119.06 32.33 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.091 179.436 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.407 HG21 HD13 ' A' ' 49' ' ' ILE . 28.9 pt -136.64 168.02 22.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.316 -179.588 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 23.5 pttp -148.21 156.47 42.61 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.856 0.36 . . . . 0.0 110.385 179.255 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 65.3 tttm -56.96 129.9 43.66 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.313 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.13 -16.14 60.5 Favored Glycine 0 CA--C 1.53 1.004 0 N-CA-C 111.349 -0.7 . . . . 0.0 111.349 -179.633 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ASP . . . . . 0.483 ' OD2' HD11 ' A' ' 70' ' ' LEU . 17.5 t0 -71.33 146.61 48.74 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 110.321 -0.251 . . . . 0.0 110.321 179.663 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 48.2 mm -114.89 129.11 71.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.938 0.399 . . . . 0.0 110.291 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.473 HG12 HD12 ' A' ' 70' ' ' LEU . 90.9 mt -119.03 130.39 73.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.871 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -74.93 128.39 35.45 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.321 -0.552 . . . . 0.0 110.227 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.9 mt -74.11 121.52 25.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.165 0 CA-C-O 120.854 0.359 . . . . 0.0 110.514 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 12.7 tt -113.67 -35.99 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.656 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 85.7 m -147.68 152.16 37.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.589 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.3 mtpt -136.47 155.94 49.29 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.247 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 68.9 p -131.98 155.67 81.06 Favored Pre-proline 0 C--N 1.327 -0.373 0 C-N-CA 120.417 -0.513 . . . . 0.0 110.756 179.425 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -59.93 115.79 2.87 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 121.954 1.769 . . . . 0.0 111.882 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 99.3 mtp 43.75 32.92 0.63 Allowed 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.969 179.401 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -122.64 173.97 16.18 Favored Glycine 0 CA--C 1.519 0.336 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.614 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 10.6 ptm -60.07 149.61 31.89 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.83 0.348 . . . . 0.0 110.432 -179.243 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 45.4 m0 -94.55 150.55 20.13 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.968 -179.339 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.1 m -118.65 143.1 47.05 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.372 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -165.0 -168.5 27.25 Favored Glycine 0 CA--C 1.52 0.395 0 C-N-CA 120.167 -1.016 . . . . 0.0 111.68 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 60.9 ttm -114.86 135.94 53.64 Favored 'General case' 0 C--O 1.238 0.447 0 CA-C-O 120.969 0.414 . . . . 0.0 110.444 179.38 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.483 HD11 ' OD2' ' A' ' 53' ' ' ASP . 3.5 tt -136.71 113.68 10.49 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.596 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ASN . . . . . 0.423 ' N ' HD23 ' A' ' 70' ' ' LEU . 66.8 t30 53.39 52.33 13.66 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.678 -0.409 . . . . 0.0 111.356 178.764 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 59.71 28.48 17.93 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.921 0.391 . . . . 0.0 110.921 179.712 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -139.87 115.74 10.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.132 -0.486 . . . . 0.0 109.82 179.027 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.405 HG22 ' H ' ' A' ' 74' ' ' VAL . 19.4 m -92.28 141.88 13.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.622 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -165.9 177.68 40.92 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 -179.488 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 76.7 m-20 -107.96 144.66 34.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.919 0.39 . . . . 0.0 110.523 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.8 p90 -148.19 147.1 29.06 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.741 179.523 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 17.5 tptm -58.0 121.47 10.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.358 -179.094 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.7 p90 -61.28 -25.43 67.1 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.624 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 97.7 mt -64.0 -39.03 83.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-O 120.919 0.39 . . . . 0.0 110.503 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 12.7 m-30 -77.27 -1.78 31.42 Favored 'General case' 0 C--O 1.237 0.404 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.388 -179.14 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.445 HG21 ' HB1' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -128.5 161.6 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.68 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -130.02 143.88 51.03 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.4 ' H ' HG12 ' A' ' 84' ' ' VAL . 1.5 p -84.72 119.74 34.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.672 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 37.9 pt -127.84 158.96 39.28 Favored 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.77 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 35.2 t -110.66 127.37 55.25 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.234 179.724 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 118.048 -0.977 . . . . 0.0 110.488 -179.615 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.304 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -69.79 154.47 67.57 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 C-N-CA 122.841 2.361 . . . . 0.0 112.278 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -126.96 151.98 47.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.577 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 26.3 p -116.51 152.9 33.14 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.317 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 162.32 -130.08 2.21 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 87.7 mmt-85 -112.11 145.31 40.0 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.943 0.401 . . . . 0.0 110.741 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.504 ' HB3' ' HB ' ' A' ' 55' ' ' ILE . . . -108.91 121.46 45.15 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.269 179.74 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 46.5 ttt-85 -97.09 125.43 41.55 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.896 0.379 . . . . 0.0 110.365 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.6 t -82.48 128.62 38.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.617 -179.143 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 4.0 m-70 -103.72 -10.3 18.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.192 179.61 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 12.2 t -144.76 145.39 31.65 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.927 0.394 . . . . 0.0 110.345 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -71.81 114.27 9.73 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.3 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 9.5 t80 -121.08 123.58 42.71 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.349 179.392 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 81.5 p -124.7 154.22 70.25 Favored Pre-proline 0 C--N 1.329 -0.29 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.824 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.14 159.22 30.21 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 C-N-CA 123.027 2.484 . . . . 0.0 112.487 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 72.4 m -82.28 158.41 66.66 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.377 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -52.86 -45.92 37.35 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 122.245 1.964 . . . . 0.0 111.981 -179.559 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -80.09 -20.78 44.29 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.91 0.386 . . . . 0.0 110.731 179.533 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -93.05 105.29 17.41 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.416 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 72.1 p -104.37 -23.55 13.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.314 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -63.2 -37.45 87.27 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.631 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.6 t -61.44 135.98 57.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.883 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 56.5 tp -80.57 146.03 31.46 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.419 -179.679 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.51 127.42 42.49 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.563 179.087 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.432 HG21 HD11 ' A' ' 55' ' ' ILE . 27.7 pt -139.24 160.45 28.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.565 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 19.6 ptpt -136.64 157.34 46.99 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.211 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -61.27 129.38 40.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.945 0.403 . . . . 0.0 111.071 -179.778 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.92 -16.31 59.64 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -76.55 146.47 38.34 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-O 120.776 0.322 . . . . 0.0 110.633 179.537 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 46.8 mm -108.89 127.55 65.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.004 0.431 . . . . 0.0 110.126 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.504 ' HB ' ' HB3' ' A' ' 31' ' ' ALA . 78.5 mt -108.58 130.62 61.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.728 -178.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -79.96 112.09 16.92 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.6 mt -65.9 118.2 8.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.908 0.385 . . . . 0.0 110.661 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.0 tt -101.93 -35.3 4.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.323 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 25.1 p -171.99 172.9 4.56 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.412 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 65.1 mttp -116.85 145.08 43.79 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 120.881 -0.328 . . . . 0.0 110.537 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 9.8 m -97.69 135.45 21.61 Favored Pre-proline 0 CA--C 1.536 0.417 0 C-N-CA 119.589 -0.844 . . . . 0.0 109.703 -179.379 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -58.7 -25.39 75.37 Favored 'Trans proline' 0 N--CA 1.501 1.915 0 C-N-CA 122.57 2.18 . . . . 0.0 112.614 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 39.2 mmt -65.19 -36.97 85.85 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.446 179.716 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 140.09 -39.56 1.49 Allowed Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 98.7 mtp -63.35 145.14 56.19 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.455 0.645 . . . . 0.0 111.198 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 22.4 m0 -96.35 146.95 24.3 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.828 -179.742 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 68.0 m -117.0 139.95 50.07 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 115.802 -0.636 . . . . 0.0 109.909 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.95 -172.02 23.71 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.166 -0.773 . . . . 0.0 111.166 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 67.8 ttp -116.18 143.09 45.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.152 0.501 . . . . 0.0 110.605 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -143.87 117.85 9.42 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.661 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ASN . . . . . 0.411 ' O ' ' ND2' ' A' ' 71' ' ' ASN . 1.0 OUTLIER 40.64 59.73 2.08 Favored 'General case' 0 N--CA 1.469 0.525 0 O-C-N 123.442 0.464 . . . . 0.0 111.033 179.806 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 33.7 m120 59.25 35.44 23.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.025 -179.8 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 19.3 tptp -140.56 111.49 7.02 Favored 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.399 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 95.5 t -99.53 127.41 52.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.758 -0.377 . . . . 0.0 110.425 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -159.77 -176.8 32.25 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.886 -0.885 . . . . 0.0 110.886 -179.634 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.0 m-20 -103.31 158.57 16.24 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.918 0.39 . . . . 0.0 110.467 -179.563 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -157.06 160.53 39.02 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.006 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 36.7 tptt -69.09 111.55 5.13 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.193 -179.445 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.3 p90 -59.17 -24.14 62.81 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.522 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.6 mt -67.9 -38.25 79.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.183 0.516 . . . . 0.0 110.654 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.2 m-30 -75.78 -5.94 48.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.834 -179.03 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.427 ' CG2' ' HB1' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -126.23 159.82 34.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 CA-C-O 121.042 0.449 . . . . 0.0 110.079 179.737 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 50.6 t0 -126.21 139.53 53.26 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.937 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.46 ' O ' HG13 ' A' ' 84' ' ' VAL . 8.8 p -82.45 121.03 35.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.953 0.406 . . . . 0.0 110.961 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 41.2 pt -128.3 160.4 38.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.613 179.669 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 29.9 t -106.25 132.1 52.7 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.441 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 54.2 tp10 . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 117.974 -1.013 . . . . 0.0 110.332 -179.987 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -58.11 142.7 97.17 Favored 'Trans proline' 0 C--N 1.305 -1.745 0 C-N-CA 122.859 2.373 . . . . 0.0 111.876 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 81.0 m-85 -112.68 143.06 44.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.413 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 77.3 m -116.91 144.7 44.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.95 0.405 . . . . 0.0 110.369 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 169.27 -142.25 7.22 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 2.9 mpp_? -112.25 146.2 38.6 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.879 0.371 . . . . 0.0 110.454 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.722 ' HB1' ' CG1' ' A' ' 82' ' ' VAL . . . -116.06 125.3 52.23 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.083 179.829 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 74.2 ttt-85 -92.74 119.83 32.51 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.387 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.54 HG22 HG22 ' A' ' 82' ' ' VAL . 96.4 t -78.29 125.54 37.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.829 0.347 . . . . 0.0 110.679 -179.511 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 33.2 p80 -112.51 -10.64 13.7 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.885 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 90.2 m -128.81 131.33 47.74 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.778 0.323 . . . . 0.0 110.396 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.6 t0 -68.27 131.34 45.18 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.629 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -88.28 137.22 32.52 Favored 'General case' 0 C--N 1.331 -0.2 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.167 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 43.2 p -126.82 93.79 41.36 Favored Pre-proline 0 CA--C 1.534 0.347 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.441 -179.792 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -73.27 155.79 51.25 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 122.172 1.915 . . . . 0.0 112.364 -179.022 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.6 m -73.47 157.96 87.16 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.801 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -55.83 -38.77 94.06 Favored 'Trans proline' 0 N--CA 1.498 1.766 0 C-N-CA 122.512 2.141 . . . . 0.0 112.046 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -88.6 6.54 37.69 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.066 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.22 101.15 12.09 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.752 0.311 . . . . 0.0 110.332 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 72.6 p -104.37 -27.52 11.91 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.883 0.373 . . . . 0.0 110.26 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -72.98 -21.27 60.88 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.775 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 41.4 t -59.62 141.36 55.15 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.404 -179.61 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 66.0 tp -80.27 138.84 36.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.147 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 30.2 mtpp -95.0 118.1 31.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.256 179.813 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.498 HG22 ' CD1' ' A' ' 70' ' ' LEU . 21.6 pt -138.42 146.68 26.3 Favored 'Isoleucine or valine' 0 C--O 1.237 0.419 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.186 179.676 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.04 167.23 14.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.909 0.385 . . . . 0.0 110.424 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -64.99 129.56 40.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.525 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.99 -20.83 47.41 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 111.214 -0.754 . . . . 0.0 111.214 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -69.88 148.51 48.94 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.387 179.219 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 86.5 mt -109.01 127.62 65.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.142 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 72.0 mt -109.96 130.16 63.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.447 -178.79 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -75.82 115.34 15.41 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.203 -0.599 . . . . 0.0 109.928 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.73 125.4 25.24 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 CA-C-O 120.823 0.344 . . . . 0.0 110.765 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 97.1 mt -108.73 -58.46 3.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.477 179.699 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 40.3 t -163.46 151.88 13.75 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.752 -179.691 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 59.0 mttm -96.85 157.78 15.74 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.073 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 74.9 p -112.29 156.95 41.31 Favored Pre-proline 0 C--N 1.329 -0.289 0 C-N-CA 120.618 -0.433 . . . . 0.0 110.784 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_exo -56.6 -33.73 93.82 Favored 'Trans proline' 0 N--CA 1.497 1.734 0 C-N-CA 122.68 2.254 . . . . 0.0 112.269 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 98.6 mtp -62.04 -38.48 88.89 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.514 -179.572 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 132.2 -32.38 2.86 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 98.5 mtp -62.4 143.8 56.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.002 0.429 . . . . 0.0 110.552 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 47.6 m0 -98.41 150.07 22.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.087 -178.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 90.0 m -110.0 135.18 51.25 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.657 179.553 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -152.66 -176.14 24.93 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 111.244 -0.742 . . . . 0.0 111.244 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.6 ttp -124.21 142.5 51.18 Favored 'General case' 0 C--O 1.237 0.432 0 CA-C-O 120.961 0.41 . . . . 0.0 110.672 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.498 ' CD1' HG22 ' A' ' 49' ' ' ILE . 2.1 mt -138.06 105.54 5.55 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.762 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 55.63 58.41 4.54 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.23 0.538 . . . . 0.0 109.705 178.775 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 58.5 t30 59.58 34.53 22.38 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.432 -179.515 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 8.9 tppt? -132.89 109.77 9.84 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.357 -0.383 . . . . 0.0 109.971 179.38 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 82.3 t -97.75 123.51 50.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 C-N-CA 120.706 -0.397 . . . . 0.0 110.499 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -156.83 179.12 32.88 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.62 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -105.69 154.54 20.31 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.958 0.409 . . . . 0.0 110.829 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.641 ' CD1' HG21 ' A' ' 82' ' ' VAL . 50.8 p90 -152.74 159.63 43.13 Favored 'General case' 0 C--O 1.237 0.443 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.823 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 30.6 tttt -68.65 116.46 9.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.209 -179.064 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -59.97 -25.71 65.45 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.571 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.6 mt -65.82 -38.46 82.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.713 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.1 m-30 -78.85 -7.32 57.79 Favored 'General case' 0 C--O 1.24 0.585 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.226 -178.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.722 ' CG1' ' HB1' ' A' ' 31' ' ' ALA . 66.5 t -121.39 138.68 50.93 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.283 0 CA-C-O 120.972 0.415 . . . . 0.0 110.991 -179.449 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -106.07 134.28 49.44 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.229 179.784 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.424 ' H ' HG12 ' A' ' 84' ' ' VAL . 1.4 p -76.44 118.21 22.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.188 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -106.39 148.0 11.24 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.126 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.253 -179.733 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 90.0 p -112.18 147.37 36.31 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.771 -0.372 . . . . 0.0 110.093 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.388 179.908 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -69.74 152.31 69.39 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 C-N-CA 122.819 2.346 . . . . 0.0 112.146 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -126.67 153.9 44.79 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.737 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 16.9 p -60.27 151.67 26.87 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-O 120.994 0.426 . . . . 0.0 110.269 -179.642 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 174.85 -139.65 4.94 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -179.658 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 93.5 mtt-85 -126.24 151.73 47.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.776 0.322 . . . . 0.0 110.575 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -123.01 135.75 54.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.531 -179.86 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.437 ' HG2' HD12 ' A' ' 54' ' ' ILE . 57.3 mtm180 -101.88 123.53 45.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.254 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.66 HG22 HG23 ' A' ' 82' ' ' VAL . 99.0 t -81.22 129.04 38.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.485 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -113.06 -0.22 14.79 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.961 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 12.2 t -146.47 151.49 37.48 Favored 'General case' 0 N--CA 1.455 -0.214 0 CA-C-O 120.914 0.387 . . . . 0.0 110.547 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -88.46 107.59 18.95 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.529 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 6.2 t80 -118.67 119.34 34.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.621 179.678 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.412 ' O ' HG23 ' A' ' 38' ' ' THR . 9.8 t -126.79 131.38 23.87 Favored Pre-proline 0 N--CA 1.451 -0.398 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.669 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -73.33 163.47 37.75 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.873 2.382 . . . . 0.0 112.38 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.3 m -66.04 156.47 84.13 Favored Pre-proline 0 C--N 1.327 -0.383 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.607 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -57.69 -31.55 92.31 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 C-N-CA 122.778 2.319 . . . . 0.0 112.332 -179.571 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -73.11 -10.67 60.03 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.572 179.467 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 48.6 t0 -110.22 114.04 27.21 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.298 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.3 t -106.12 -28.67 10.35 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.728 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -62.23 -36.56 82.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.497 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 47.2 m -63.47 139.31 58.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.704 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.418 HD21 ' HB2' ' A' ' 70' ' ' LEU . 59.2 tp -91.79 143.36 26.6 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.41 -179.813 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 23.0 pttp -94.37 141.86 28.09 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.393 179.112 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.603 ' HB ' HG21 ' A' ' 33' ' ' VAL . 29.8 pt -132.0 147.5 32.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.559 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 40.7 ttmt -128.3 138.53 52.44 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.638 179.419 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -55.91 125.64 22.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.814 -179.679 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 105.51 -21.42 34.89 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.283 -0.727 . . . . 0.0 111.283 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -81.55 155.14 25.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.736 0.303 . . . . 0.0 110.806 179.29 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.437 HD12 ' HG2' ' A' ' 32' ' ' ARG . 46.7 mm -113.47 130.07 68.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.685 179.822 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.573 HD11 HG22 ' A' ' 49' ' ' ILE . 84.2 mt -112.49 129.06 68.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.498 -179.418 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 64.5 t0 -82.2 121.81 27.1 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.276 179.603 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 84.2 mt -70.21 128.74 33.94 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.116 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.419 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 88.8 mt -105.93 -53.49 6.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.709 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.8 t -163.84 150.66 11.89 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.78 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.7 mttp -109.29 155.34 21.27 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.251 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 81.5 p -136.05 155.09 77.85 Favored Pre-proline 0 N--CA 1.45 -0.471 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.853 179.651 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_exo -62.5 -21.23 72.55 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 122.863 2.375 . . . . 0.0 112.061 179.171 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 63.7 tpp -52.16 -31.6 32.11 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.417 -179.551 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 106.8 18.18 11.03 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 6.4 mtt -128.34 139.5 52.36 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.782 0.325 . . . . 0.0 110.474 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 33.5 m0 -93.36 139.45 30.66 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.775 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 93.0 m -98.39 131.16 44.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 109.897 179.688 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -154.52 -176.51 26.89 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -179.721 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 23.4 ptp -123.57 146.46 48.12 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.874 0.369 . . . . 0.0 110.667 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.418 ' HB2' HD21 ' A' ' 47' ' ' LEU . 0.5 OUTLIER -150.03 118.78 6.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.512 179.867 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 16.2 m120 53.59 49.71 18.83 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 54.3 t30 59.69 35.63 22.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.584 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 22.7 ttmm -138.64 117.62 12.48 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.459 179.292 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 96.9 t -99.45 131.03 47.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.733 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -158.03 177.57 34.7 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.807 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 81.7 m-20 -105.05 135.62 46.05 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.876 0.37 . . . . 0.0 110.564 -179.681 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -138.48 155.0 48.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.792 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -75.75 125.02 28.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.372 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.501 ' HA ' HG12 ' A' ' 82' ' ' VAL . 20.6 p90 -65.31 -20.42 66.4 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.706 -179.863 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 6.4 pt -61.01 -23.17 28.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.505 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 41.6 m-85 -102.4 10.18 39.21 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.644 179.443 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.66 HG23 HG22 ' A' ' 33' ' ' VAL . 0.3 OUTLIER -135.54 147.96 28.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.234 0 CA-C-O 120.863 0.363 . . . . 0.0 110.344 -179.609 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -105.62 131.95 52.37 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.302 179.679 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.402 HG12 ' H ' ' A' ' 84' ' ' VAL . 2.1 p -91.31 132.98 34.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-O 120.96 0.409 . . . . 0.0 110.795 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 37.5 pt -124.0 156.63 31.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.69 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 66.0 m -113.09 148.63 34.86 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.673 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.601 179.948 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.318 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -69.55 151.25 70.25 Favored 'Trans proline' 0 C--N 1.305 -1.745 0 C-N-CA 122.815 2.344 . . . . 0.0 112.164 179.886 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -141.81 145.6 34.92 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.36 -179.733 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.2 m -101.81 136.77 41.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.403 179.706 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -175.92 -149.8 7.68 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -109.03 138.21 45.74 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.94 0.4 . . . . 0.0 110.496 -179.793 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.758 ' HB1' ' CG1' ' A' ' 82' ' ' VAL . . . -106.11 115.15 29.73 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.198 -179.822 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 45.4 ttp180 -96.59 120.54 37.1 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.195 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.46 HG22 HG22 ' A' ' 82' ' ' VAL . 90.3 t -76.17 124.32 34.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.48 -179.492 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 1.3 p80 -111.3 -15.87 13.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.537 179.548 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 53.0 m -131.97 135.5 46.62 Favored 'General case' 0 C--N 1.334 -0.103 0 CA-C-O 120.84 0.353 . . . . 0.0 110.833 179.6 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -64.44 133.91 53.47 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 120.716 -0.394 . . . . 0.0 110.49 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -120.8 135.77 55.07 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.276 179.618 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 57.0 p -135.44 90.76 19.7 Favored Pre-proline 0 CA--C 1.534 0.328 0 C-N-CA 120.92 -0.312 . . . . 0.0 110.304 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -69.83 150.6 68.01 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 122.66 2.24 . . . . 0.0 112.284 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 75.4 m -72.96 157.94 87.9 Favored Pre-proline 0 C--N 1.326 -0.439 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.653 -179.686 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -53.76 -23.09 25.34 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.835 2.357 . . . . 0.0 112.114 179.54 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -59.97 -23.05 63.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.204 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -65.8 125.87 26.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.35 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 82.8 p -70.68 -35.85 73.03 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.606 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.498 ' O ' ' C ' ' A' ' 46' ' ' SER . 88.5 m-20 -100.14 5.86 44.86 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 118.337 -0.84 . . . . 0.0 111.465 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.498 ' C ' ' O ' ' A' ' 45' ' ' ASP . 6.6 t -9.88 95.3 0.01 OUTLIER 'General case' 0 C--N 1.358 0.938 0 O-C-N 125.003 1.439 . . . . 0.0 111.311 -179.291 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 66.9 tp -111.34 131.72 54.96 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.232 -178.478 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -97.29 134.31 40.75 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.563 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 48.3 pt -126.65 162.47 30.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.509 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 39.8 ttpt -134.85 135.61 41.81 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.602 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -51.43 131.16 28.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.983 0.42 . . . . 0.0 110.448 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.51 -18.14 56.69 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 111.006 -0.838 . . . . 0.0 111.006 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -72.47 155.53 40.0 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.798 0.332 . . . . 0.0 110.702 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 48.5 mm -114.38 127.68 71.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.198 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.46 HG12 HD12 ' A' ' 70' ' ' LEU . 85.6 mt -117.9 129.41 74.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.683 -179.671 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -74.65 120.64 20.48 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.309 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 85.0 mt -69.76 126.03 29.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.764 0.316 . . . . 0.0 110.347 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.7 mt -110.71 -43.16 5.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.768 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 46.6 t -146.52 139.13 25.2 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.572 -179.607 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.3 mtpt -119.37 153.75 34.67 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.517 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 71.5 p -133.29 153.17 80.49 Favored Pre-proline 0 C--N 1.328 -0.34 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.746 179.753 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -62.62 114.32 2.34 Favored 'Trans proline' 0 N--CA 1.493 1.484 0 C-N-CA 122.53 2.153 . . . . 0.0 112.037 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 99.4 mtp 46.55 32.74 1.74 Allowed 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.274 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -123.45 172.65 16.24 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 8.5 ptm -60.98 148.33 40.35 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.819 0.342 . . . . 0.0 110.143 -179.479 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 41.9 m0 -95.51 149.58 21.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.239 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 84.9 m -115.3 138.33 51.07 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.734 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -162.43 -166.95 22.13 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 65.3 ttp -125.72 138.36 53.87 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.826 0.346 . . . . 0.0 110.258 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.478 HD23 ' C ' ' A' ' 70' ' ' LEU . 4.6 tt -134.31 115.47 14.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.426 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ASN . . . . . 0.419 ' N ' HD23 ' A' ' 70' ' ' LEU . 65.7 t30 53.17 56.93 6.8 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.87 179.039 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 56.82 36.94 28.43 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.477 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 5.1 tptt -139.29 111.9 7.74 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.245 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 89.4 t -93.43 127.75 45.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.827 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -162.58 -177.18 35.38 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.801 -0.919 . . . . 0.0 110.801 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 48.5 m-20 -107.78 156.3 19.27 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.98 0.419 . . . . 0.0 110.685 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.531 ' CD1' HG21 ' A' ' 82' ' ' VAL . 11.6 p90 -155.89 156.57 34.84 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.762 -0.653 . . . . 0.0 111.22 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.734 ' HE2' HD12 ' A' ' 80' ' ' ILE . 32.8 tttt -65.74 118.57 9.8 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.446 -179.243 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 36.5 p90 -61.18 -25.09 66.79 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.667 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.734 HD12 ' HE2' ' A' ' 78' ' ' LYS . 95.7 mt -63.08 -39.55 85.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 120.845 0.355 . . . . 0.0 110.634 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 18.3 m-85 -84.79 3.95 35.23 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.897 -179.54 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.758 ' CG1' ' HB1' ' A' ' 31' ' ' ALA . 86.3 t -126.22 136.09 61.86 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 CA-C-O 121.184 0.516 . . . . 0.0 110.914 179.801 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -111.17 142.48 43.3 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.422 179.461 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.466 ' O ' HG13 ' A' ' 84' ' ' VAL . 8.5 p -89.63 122.83 41.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.767 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 36.5 pt -128.92 158.96 41.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.719 179.557 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 29.3 t -90.1 124.73 35.04 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.457 179.638 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 . . . . . 0 C--O 1.219 -0.517 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.674 -179.874 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.329 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -72.9 142.82 35.69 Favored 'Trans proline' 0 C--N 1.305 -1.711 0 C-N-CA 122.738 2.292 . . . . 0.0 112.183 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -138.38 151.17 47.25 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.793 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 17.0 p -69.52 162.81 26.75 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-O 121.103 0.478 . . . . 0.0 109.997 179.608 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 169.63 -138.3 4.97 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.024 -0.831 . . . . 0.0 111.024 -179.579 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 39.1 mmt180 -111.81 142.73 43.81 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.763 0.316 . . . . 0.0 110.361 -179.601 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -122.41 141.08 51.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.516 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -116.08 132.22 56.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.316 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 84.0 t -82.39 125.99 39.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.819 -179.086 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 28.2 p80 -114.14 -13.75 12.39 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.91 179.609 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 87.9 m -126.28 130.45 50.89 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.418 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.4 t0 -64.22 122.15 15.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.303 -179.771 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' PHE . . . . . 0.434 ' HB3' HD11 ' A' ' 49' ' ' ILE . 15.3 t80 -117.83 128.14 54.56 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.437 179.826 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 38' ' ' THR . 5.9 t -133.51 92.44 23.85 Favored Pre-proline 0 CA--C 1.539 0.53 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.485 179.561 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.85 151.45 62.86 Favored 'Trans proline' 0 N--CA 1.495 1.6 0 C-N-CA 121.955 1.77 . . . . 0.0 112.148 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 99.9 p -70.82 155.48 93.32 Favored Pre-proline 0 CA--C 1.533 0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.628 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -62.7 -21.89 73.4 Favored 'Trans proline' 0 N--CA 1.497 1.682 0 C-N-CA 122.491 2.127 . . . . 0.0 112.253 179.674 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -64.59 -25.16 67.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.442 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -64.89 143.71 57.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.356 179.442 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 61.9 p -84.39 -29.58 26.08 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.582 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.437 ' O ' ' C ' ' A' ' 46' ' ' SER . 97.9 m-20 -100.23 -0.86 37.81 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.716 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 45' ' ' ASP . 16.3 t -20.81 95.86 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.675 0 O-C-N 124.033 0.833 . . . . 0.0 112.697 -178.757 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 63.5 tp -104.98 134.05 48.74 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.933 -179.427 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -97.17 129.19 44.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.558 179.392 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.434 HD11 ' HB3' ' A' ' 37' ' ' PHE . 40.2 pt -136.62 160.4 37.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.429 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -137.25 134.57 36.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.648 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 5.4 ptmm? -49.58 137.02 16.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.775 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.98 -17.76 58.71 Favored Glycine 0 CA--C 1.528 0.863 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 -179.839 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -79.15 157.57 27.88 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.831 0.348 . . . . 0.0 110.452 179.541 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 47.9 mm -114.73 129.67 70.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.298 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 85.7 mt -111.1 132.58 59.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.725 -179.494 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -78.45 113.71 16.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.841 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.4 mt -68.23 125.93 26.98 Favored 'Isoleucine or valine' 0 C--O 1.232 0.178 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.472 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.457 HD11 ' HB2' ' A' ' 69' ' ' MET . 80.7 mt -105.34 -50.79 8.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.338 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 77.9 m -139.31 149.88 44.75 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.709 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.5 mtpt -132.07 159.64 38.28 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.612 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 82.4 p -132.0 158.57 75.15 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.537 179.697 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_exo -53.11 -39.23 80.72 Favored 'Trans proline' 0 N--CA 1.497 1.722 0 C-N-CA 122.488 2.125 . . . . 0.0 112.155 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 11.5 tpt -162.23 90.31 0.74 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.491 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 179.66 -178.18 48.5 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.1 mtp -62.49 147.59 48.36 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.02 0.438 . . . . 0.0 110.569 -179.406 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 43.8 m0 -95.86 147.05 24.06 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.462 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 96.8 m -107.62 132.75 52.96 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.882 179.513 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -151.3 -177.8 25.47 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' MET . . . . . 0.457 ' HB2' HD11 ' A' ' 58' ' ' ILE . 66.7 ttp -121.0 141.24 50.91 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 120.975 0.417 . . . . 0.0 110.631 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -140.93 110.84 6.52 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.4 179.785 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 15.3 m120 54.99 56.38 6.66 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.876 -0.33 . . . . 0.0 110.197 179.447 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 87.0 m-20 56.13 36.52 27.56 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.724 0.297 . . . . 0.0 110.781 -179.668 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 18.4 tptm -138.43 113.26 9.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.11 179.337 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 98.3 t -93.48 126.89 45.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 120.811 -0.356 . . . . 0.0 110.507 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -154.77 177.62 31.96 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.653 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -106.94 155.0 20.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.057 0.456 . . . . 0.0 110.953 -179.549 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 32.1 p90 -156.29 162.75 40.09 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.02 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 7.4 ttmm -76.67 115.98 16.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.72 -179.218 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.465 ' HA ' HG12 ' A' ' 82' ' ' VAL . 51.9 p90 -58.34 -22.61 53.95 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.818 179.856 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.6 mt -66.29 -39.35 83.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 121.062 0.458 . . . . 0.0 110.602 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.3 m-30 -79.65 -0.18 32.85 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.122 -179.017 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.465 HG12 ' HA ' ' A' ' 79' ' ' PHE . 0.5 OUTLIER -130.0 158.09 42.52 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 CA-C-O 120.857 0.36 . . . . 0.0 110.263 179.749 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -121.08 141.31 50.9 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.46 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.3 p -92.02 126.16 44.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.816 -179.782 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 44.4 pt -128.29 154.3 38.82 Favored 'Isoleucine or valine' 0 C--O 1.236 0.375 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.764 179.691 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 36.9 t -110.5 130.73 55.49 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.608 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.6 tm-20 . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.684 -179.977 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -58.73 145.03 97.47 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 123.037 2.491 . . . . 0.0 111.952 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -112.55 138.67 48.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.421 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.1 m -115.02 145.46 42.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.285 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 166.88 -140.31 6.23 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.5 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -117.29 154.96 30.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.348 . . . . 0.0 110.7 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.545 ' HB1' HG22 ' A' ' 82' ' ' VAL . . . -122.96 137.2 55.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.391 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.427 ' HE ' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -99.36 118.66 36.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.347 179.879 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 69.6 t -69.41 130.05 34.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.914 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 7.8 m80 -108.86 -22.52 12.16 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.811 179.389 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 50.7 p -125.99 158.4 35.38 Favored 'General case' 0 C--N 1.332 -0.177 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.348 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -91.27 116.55 28.92 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.823 -179.529 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 14.1 t80 -116.16 117.53 30.31 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.049 179.347 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 8.1 t -117.76 141.11 28.54 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.136 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -72.42 153.82 55.61 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.668 2.245 . . . . 0.0 112.456 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.5 p -72.91 166.17 45.67 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.036 -179.858 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -55.47 -42.14 71.02 Favored 'Trans proline' 0 N--CA 1.501 1.968 0 C-N-CA 122.906 2.404 . . . . 0.0 112.639 -179.461 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -97.37 11.43 36.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.879 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 65.2 t0 -112.19 112.07 23.42 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.768 0.318 . . . . 0.0 110.517 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 48.9 p -110.86 -24.16 10.58 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.484 179.241 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -63.36 -38.43 91.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.615 179.595 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.2 t -61.58 140.61 58.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.901 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 19.3 tp -89.39 143.71 26.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.748 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.8 pttt -97.03 137.55 35.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.452 179.093 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 2.4 pt -142.17 145.72 23.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.283 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.173 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 17.1 mttm -117.76 152.32 35.53 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.352 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -61.28 129.98 43.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.958 0.409 . . . . 0.0 110.285 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.19 -22.18 41.22 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -71.72 154.97 40.99 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.826 0.346 . . . . 0.0 110.609 179.186 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.427 HD11 ' HE ' ' A' ' 32' ' ' ARG . 76.2 mt -119.42 133.64 65.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.332 179.682 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 84.3 mt -117.66 132.04 68.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.913 -179.601 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -75.42 123.12 24.85 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 109.89 179.484 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 93.3 mt -69.11 129.34 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 O-C-N 123.881 0.738 . . . . 0.0 110.365 -179.662 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 89.9 mt -109.55 -54.53 5.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.66 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 44.1 t -163.99 147.65 9.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.189 -179.604 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -92.94 146.27 23.75 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.726 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.2 p -103.25 154.45 37.68 Favored Pre-proline 0 C--N 1.328 -0.346 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.514 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -62.11 -25.71 77.53 Favored 'Trans proline' 0 N--CA 1.497 1.704 0 C-N-CA 122.653 2.235 . . . . 0.0 112.159 179.332 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 96.4 mmm -70.17 -22.13 62.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.521 179.693 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 114.31 -26.26 9.87 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.4 mtp -64.95 147.04 54.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.983 0.421 . . . . 0.0 110.765 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 43.4 m0 -102.38 146.09 28.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.241 0.544 . . . . 0.0 111.321 -179.269 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 98.3 m -108.8 135.33 50.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.605 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -153.76 -176.93 26.7 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.9 ttp -118.46 140.29 50.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.933 0.397 . . . . 0.0 111.244 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -143.92 113.96 7.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.511 179.659 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 12.2 m120 56.98 55.31 6.21 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 32.6 m120 54.53 35.91 24.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.613 0.244 . . . . 0.0 110.491 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 36.6 ttpt -139.48 114.92 9.86 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 120.624 -0.43 . . . . 0.0 110.431 179.465 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 86.9 t -93.28 128.17 44.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.442 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -156.22 179.36 32.17 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 57.2 m-80 -104.38 158.46 16.45 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.222 0.534 . . . . 0.0 110.96 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 7.2 p90 -155.97 160.23 39.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.223 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -63.94 116.27 5.68 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.109 -179.141 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -58.24 -29.0 65.4 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.514 179.753 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.478 HG23 ' CD1' ' A' ' 81' ' ' TYR . 16.3 tt -74.6 -33.96 33.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.896 179.146 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.478 ' CD1' HG23 ' A' ' 80' ' ' ILE . 13.8 m-30 -72.1 -20.79 61.59 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.519 179.596 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.545 HG22 ' HB1' ' A' ' 31' ' ' ALA . 6.1 p -114.97 160.07 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.112 179.06 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ASP . . . . . 0.421 ' N ' HG22 ' A' ' 82' ' ' VAL . 8.3 t70 -128.92 149.39 50.81 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.688 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.3 p -92.85 135.19 28.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.594 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 23.2 pt -121.04 158.24 23.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.461 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 41.1 t -61.37 138.72 58.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.587 -179.74 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 20.0 tp10 . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.182 -0.913 . . . . 0.0 110.521 179.983 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -58.73 145.03 97.47 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 123.037 2.491 . . . . 0.0 111.952 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -112.55 138.67 48.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.421 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.1 m -115.02 145.46 42.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.285 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 166.88 -140.31 6.23 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.5 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -117.29 154.96 30.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.348 . . . . 0.0 110.7 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.545 ' HB1' HG22 ' A' ' 82' ' ' VAL . . . -122.96 137.2 55.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.391 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.427 ' HE ' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -99.36 118.66 36.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.347 179.879 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 69.6 t -69.41 130.05 34.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.914 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 7.8 m80 -108.86 -22.52 12.16 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.811 179.389 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 50.7 p -125.99 158.4 35.38 Favored 'General case' 0 C--N 1.332 -0.177 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.348 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -91.27 116.55 28.92 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.823 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 14.1 t80 -116.16 117.53 30.31 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.049 179.347 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 8.1 t -117.76 141.11 28.54 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.136 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -72.42 153.82 55.61 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.668 2.245 . . . . 0.0 112.456 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.5 p -72.91 166.17 45.67 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.036 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -55.47 -42.14 71.02 Favored 'Trans proline' 0 N--CA 1.501 1.968 0 C-N-CA 122.906 2.404 . . . . 0.0 112.639 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -97.37 11.43 36.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.879 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 65.2 t0 -112.19 112.07 23.42 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.768 0.318 . . . . 0.0 110.517 -179.714 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 48.9 p -110.86 -24.16 10.58 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.484 179.241 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -63.36 -38.43 91.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.615 179.595 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.2 t -61.58 140.61 58.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.901 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 19.3 tp -89.39 143.71 26.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.748 -179.704 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.8 pttt -97.03 137.55 35.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.452 179.093 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 2.4 pt -142.17 145.72 23.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.283 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.173 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 17.1 mttm -117.76 152.32 35.53 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.352 179.763 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -61.28 129.98 43.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.958 0.409 . . . . 0.0 110.285 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.19 -22.18 41.22 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -71.72 154.97 40.99 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.826 0.346 . . . . 0.0 110.609 179.186 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.427 HD11 ' HE ' ' A' ' 32' ' ' ARG . 76.2 mt -119.42 133.64 65.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.332 179.682 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 84.3 mt -117.66 132.04 68.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.913 -179.601 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -75.42 123.12 24.85 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 109.89 179.484 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 93.3 mt -69.11 129.34 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 O-C-N 123.881 0.738 . . . . 0.0 110.365 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 89.9 mt -109.55 -54.53 5.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.66 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 44.1 t -163.99 147.65 9.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.189 -179.604 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -92.94 146.27 23.75 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.726 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.2 p -103.25 154.45 37.68 Favored Pre-proline 0 C--N 1.328 -0.346 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.514 -179.668 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -62.11 -25.71 77.53 Favored 'Trans proline' 0 N--CA 1.497 1.704 0 C-N-CA 122.653 2.235 . . . . 0.0 112.159 179.332 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 96.4 mmm -70.17 -22.13 62.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.521 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 114.31 -26.26 9.87 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.4 mtp -64.95 147.04 54.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.983 0.421 . . . . 0.0 110.765 179.71 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 43.4 m0 -102.38 146.09 28.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.241 0.544 . . . . 0.0 111.321 -179.269 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 98.3 m -108.8 135.33 50.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.605 179.652 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -153.76 -176.93 26.7 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.9 ttp -118.46 140.29 50.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.933 0.397 . . . . 0.0 111.244 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -143.92 113.96 7.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.511 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 12.2 m120 56.98 55.31 6.21 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 32.6 m120 54.53 35.91 24.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.613 0.244 . . . . 0.0 110.491 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 36.6 ttpt -139.48 114.92 9.86 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 120.624 -0.43 . . . . 0.0 110.431 179.465 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 86.9 t -93.28 128.17 44.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.442 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -156.22 179.36 32.17 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 57.2 m-80 -104.38 158.46 16.45 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.222 0.534 . . . . 0.0 110.96 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 7.2 p90 -155.97 160.23 39.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.223 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -63.94 116.27 5.68 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.109 -179.141 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -58.24 -29.0 65.4 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.514 179.753 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.478 HG23 ' CD1' ' A' ' 81' ' ' TYR . 16.3 tt -74.6 -33.96 33.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.896 179.146 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.478 ' CD1' HG23 ' A' ' 80' ' ' ILE . 13.8 m-30 -72.1 -20.79 61.59 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.519 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.545 HG22 ' HB1' ' A' ' 31' ' ' ALA . 6.1 p -114.97 160.07 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.112 179.06 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ASP . . . . . 0.421 ' N ' HG22 ' A' ' 82' ' ' VAL . 8.3 t70 -128.92 149.39 50.81 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.688 179.819 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.3 p -92.85 135.19 28.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.594 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 23.2 pt -121.04 158.24 23.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.461 179.815 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 41.1 t -61.37 138.72 58.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.587 -179.74 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 20.0 tp10 . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.182 -0.913 . . . . 0.0 110.521 179.983 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.208 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -59.03 146.81 92.97 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 122.992 2.461 . . . . 0.0 112.022 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -117.35 150.31 39.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.41 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 31.5 p -126.69 154.0 44.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.132 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.424 ' H ' HD12 ' A' ' 57' ' ' ILE . . . 179.0 -125.45 0.98 Allowed Glycine 0 CA--C 1.523 0.537 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.237 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 28.4 mmt85 -129.56 141.72 50.91 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.053 0.454 . . . . 0.0 110.659 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.637 ' HB1' HG21 ' A' ' 82' ' ' VAL . . . -107.59 118.68 37.37 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.315 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 68.7 ttt180 -98.45 123.81 42.8 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.977 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.477 HG21 ' HB ' ' A' ' 49' ' ' ILE . 65.9 t -79.54 125.18 38.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.135 -178.76 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 33.2 p80 -105.77 -10.04 16.93 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.202 179.327 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 14.4 t -145.38 151.21 37.9 Favored 'General case' 0 C--O 1.231 0.1 0 CA-C-O 120.841 0.353 . . . . 0.0 110.174 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -80.8 110.42 16.29 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.938 -179.403 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 11.2 t80 -120.69 130.6 54.16 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.369 179.229 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 71.3 p -124.5 152.87 69.19 Favored Pre-proline 0 CA--C 1.53 0.2 0 C-N-CA 120.74 -0.384 . . . . 0.0 110.793 -179.816 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -76.45 159.91 35.73 Favored 'Trans proline' 0 N--CA 1.492 1.399 0 C-N-CA 122.72 2.28 . . . . 0.0 112.232 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 57.7 m -71.57 157.6 89.53 Favored Pre-proline 0 C--N 1.331 -0.213 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.663 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_exo -53.0 -43.39 57.31 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.241 1.961 . . . . 0.0 111.959 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -84.26 -13.96 51.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.963 179.647 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -91.3 104.13 16.71 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.288 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 71.7 p -102.15 -24.84 13.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.816 0.341 . . . . 0.0 110.53 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -63.08 -38.2 90.25 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.534 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.0 t -73.55 131.15 41.41 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.255 179.742 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 2.5 tp -88.5 161.58 16.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.231 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 23.6 pttm -97.35 145.72 25.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.401 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.546 HG22 HD11 ' A' ' 55' ' ' ILE . 27.3 pt -133.57 149.65 31.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.175 179.706 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 38.0 ttmt -130.71 150.64 51.8 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 57.3 mtmt -55.03 125.72 21.62 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.092 0.472 . . . . 0.0 110.819 -179.21 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.3 -17.36 57.02 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -71.77 142.8 49.71 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 116.923 0.362 . . . . 0.0 110.492 179.631 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 50.5 mm -114.89 128.18 72.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.106 179.76 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.546 HD11 HG22 ' A' ' 49' ' ' ILE . 85.9 mt -118.45 127.87 75.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.636 -179.596 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -78.44 135.22 37.34 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.479 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.424 HD12 ' H ' ' A' ' 29' ' ' GLY . 97.3 mt -76.91 120.9 28.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 C-N-CA 120.822 -0.351 . . . . 0.0 110.318 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.5 mt -107.75 -51.73 7.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.771 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 49.0 t -153.71 144.36 22.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.965 -179.553 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -96.5 142.58 28.41 Favored 'General case' 0 C--N 1.325 -0.46 0 C-N-CA 120.766 -0.374 . . . . 0.0 110.018 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 28.2 m -98.93 135.6 20.86 Favored Pre-proline 0 CA--C 1.54 0.563 0 C-N-CA 120.09 -0.644 . . . . 0.0 110.117 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -50.81 -32.57 37.56 Favored 'Trans proline' 0 N--CA 1.5 1.885 0 C-N-CA 122.373 2.049 . . . . 0.0 112.456 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 24.3 mmt -60.81 -38.85 86.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.273 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 140.67 -40.16 1.4 Allowed Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 179.745 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 96.5 mtp -61.83 145.92 51.2 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.129 0.49 . . . . 0.0 110.767 -179.359 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 42.5 m0 -98.64 153.89 18.35 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.703 -179.372 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.4 m -111.12 134.56 52.62 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 109.592 -0.522 . . . . 0.0 109.592 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.25 -174.22 25.77 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.333 -0.707 . . . . 0.0 111.333 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.1 ttp -119.33 138.16 53.23 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.831 0.348 . . . . 0.0 110.593 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -145.47 126.25 14.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.342 -179.879 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 6.5 p-10 43.46 56.13 4.52 Favored 'General case' 0 N--CA 1.466 0.371 0 O-C-N 123.441 0.463 . . . . 0.0 111.363 -179.525 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 55.08 34.16 21.95 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.935 0.397 . . . . 0.0 110.544 179.708 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.7 mmtp -142.34 115.04 8.59 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.392 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 16.0 m -97.68 139.4 20.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 C-N-CA 120.546 -0.462 . . . . 0.0 110.509 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -168.54 -177.42 39.52 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.415 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 -103.36 149.15 25.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.959 0.409 . . . . 0.0 110.701 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -146.71 157.97 43.81 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.334 179.765 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.524 ' HG2' HG22 ' A' ' 80' ' ' ILE . 23.0 ttmt -81.67 116.89 21.61 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.779 -178.564 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.438 ' HA ' HG12 ' A' ' 82' ' ' VAL . 36.5 p90 -57.98 -24.58 58.69 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.989 -179.658 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.524 HG22 ' HG2' ' A' ' 78' ' ' LYS . 10.6 tp -58.18 -25.17 26.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.883 0.373 . . . . 0.0 110.653 -179.667 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 25.1 m-85 -100.94 14.06 33.12 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.191 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.637 HG21 ' HB1' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -143.22 156.13 17.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.746 0.307 . . . . 0.0 110.311 -179.727 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -130.54 149.93 51.98 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.563 179.254 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.6 m -93.78 131.71 39.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.272 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 42.0 pt -126.53 149.77 31.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.832 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 83.7 p -75.85 163.37 27.29 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.732 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.018 -0.992 . . . . 0.0 110.546 179.712 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -70.72 156.7 60.34 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 C-N-CA 122.943 2.429 . . . . 0.0 112.138 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 -125.88 150.52 47.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.502 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 28.1 p -116.45 142.4 46.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.363 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.55 -146.6 6.61 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 -179.421 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 8.2 mmm180 -121.02 142.15 50.07 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.901 -0.32 . . . . 0.0 110.543 -179.516 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.11 127.68 56.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.532 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 17.9 mtp180 -105.14 128.26 53.29 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.46 179.782 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.9 t -86.28 131.26 35.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.327 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 64.4 m170 -111.89 -11.66 13.87 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.047 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.452 HG21 ' HD2' ' A' ' 81' ' ' TYR . 4.2 p -124.89 174.67 7.8 Favored 'General case' 0 N--CA 1.455 -0.188 0 CA-C-O 121.173 0.511 . . . . 0.0 110.419 -179.416 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -103.48 112.0 24.7 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.627 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 8.9 t80 -119.19 118.9 32.58 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-O 121.011 0.434 . . . . 0.0 110.253 179.62 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.517 HG23 ' O ' ' A' ' 38' ' ' THR . 4.8 t -133.61 95.2 18.0 Favored Pre-proline 0 CA--C 1.543 0.696 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.519 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -68.41 153.61 73.66 Favored 'Trans proline' 0 C--N 1.301 -1.924 0 C-N-CA 122.305 2.003 . . . . 0.0 112.313 -179.444 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 48.1 m -65.65 154.49 88.37 Favored Pre-proline 0 N--CA 1.453 -0.294 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.533 -179.564 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.15 -20.98 64.15 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.847 2.365 . . . . 0.0 112.0 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -66.94 -23.56 65.98 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.249 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -99.69 96.53 7.68 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.324 179.409 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.423 ' H ' HG22 ' A' ' 44' ' ' THR . 2.1 t -75.96 -32.8 59.69 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.614 179.617 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -66.85 -38.12 85.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.532 179.722 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 69.1 m -67.49 123.32 20.1 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.671 -179.477 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -85.08 156.31 21.12 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.586 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 60.4 mtpt -98.56 127.84 44.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.645 179.625 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 45.8 pt -138.48 148.37 24.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.509 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 28.2 mttm -127.4 163.44 24.04 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.537 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -61.37 124.61 21.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.52 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 107.42 -31.18 8.32 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.799 -0.92 . . . . 0.0 110.799 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -66.63 145.86 55.11 Favored 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 120.881 -0.328 . . . . 0.0 110.346 179.503 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 60.6 mt -116.49 132.23 66.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.51 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.449 HG12 HD12 ' A' ' 70' ' ' LEU . 2.7 mp -114.86 129.17 71.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.857 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -72.78 122.52 21.67 Favored 'General case' 0 CA--C 1.518 -0.286 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.122 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.96 127.02 28.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 120.986 0.422 . . . . 0.0 110.93 -179.484 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.5 mt -109.39 -54.64 5.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.247 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 20.4 p -162.64 172.6 15.1 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.614 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 31.1 mtpt -120.39 150.23 41.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.451 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 67.3 p -121.71 151.66 57.63 Favored Pre-proline 0 CA--C 1.535 0.386 0 C-N-CA 120.339 -0.545 . . . . 0.0 110.915 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -69.02 -20.73 37.92 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.682 2.255 . . . . 0.0 112.242 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 3.0 mpp? -60.0 -15.51 23.0 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.484 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 97.16 22.8 16.23 Favored Glycine 0 C--N 1.336 0.564 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 96.4 mmm -127.19 144.41 51.04 Favored 'General case' 0 C--O 1.236 0.379 0 CA-C-O 121.039 0.447 . . . . 0.0 110.671 179.726 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 6.0 m0 -98.4 142.49 29.96 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.469 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 89.0 m -105.97 132.1 52.47 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 116.01 -0.541 . . . . 0.0 109.875 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -151.66 -179.87 27.69 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 60.7 ttm -115.81 142.02 47.32 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.989 0.424 . . . . 0.0 110.878 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.449 HD12 HG12 ' A' ' 55' ' ' ILE . 0.6 OUTLIER -143.45 107.94 4.83 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.869 -179.89 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 18.0 m120 53.77 53.92 10.64 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.29 179.491 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 54.4 t30 61.07 30.75 19.67 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.64 -179.607 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 62.8 tttm -137.63 112.81 9.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.05 179.344 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 27.4 m -99.09 144.12 12.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.875 0.369 . . . . 0.0 110.648 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -170.09 -173.08 37.19 Favored Glycine 0 CA--C 1.528 0.901 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 -179.816 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 67.5 m-80 -103.4 148.29 26.08 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.985 0.421 . . . . 0.0 110.851 -179.287 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.8 p90 -153.21 160.1 42.75 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.727 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.473 ' HB3' HG12 ' A' ' 80' ' ' ILE . 96.7 mttt -79.71 122.34 26.45 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-O 121.433 0.635 . . . . 0.0 110.518 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 12.0 p90 -68.99 -24.11 64.19 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.199 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.473 HG12 ' HB3' ' A' ' 78' ' ' LYS . 28.4 pt -62.2 -19.69 22.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.833 0.349 . . . . 0.0 110.825 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.452 ' HD2' HG21 ' A' ' 35' ' ' THR . 30.6 m-85 -102.69 5.66 39.12 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.865 179.56 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -136.16 153.86 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 CA-C-O 121.109 0.481 . . . . 0.0 110.638 -179.697 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 -127.51 143.19 51.22 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.565 179.245 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.8 m -88.61 136.93 22.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.229 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 42.5 pt -120.23 157.79 22.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.803 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 83.3 p -72.95 160.77 31.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.656 179.764 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 118.015 -0.993 . . . . 0.0 110.543 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -69.39 154.56 69.03 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 C-N-CA 122.855 2.37 . . . . 0.0 112.203 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 32.9 t80 -121.09 139.56 53.16 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.277 -179.487 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 79.9 m -107.38 135.03 49.56 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.652 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -172.98 -153.29 9.36 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 -179.529 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 39.6 mmt180 -116.45 144.03 44.83 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.886 0.374 . . . . 0.0 110.58 -179.491 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -113.04 121.86 45.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.619 -179.651 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.476 ' HD2' HG21 ' A' ' 85' ' ' ILE . 94.8 mtt180 -95.77 121.4 37.46 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.51 178.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.431 HG21 ' HB ' ' A' ' 49' ' ' ILE . 67.2 t -76.64 119.84 25.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.352 -179.399 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.428 ' CE1' ' HG1' ' A' ' 35' ' ' THR . 13.7 p-80 -105.85 -16.05 14.76 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.438 179.716 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.54 HG21 ' CD2' ' A' ' 81' ' ' TYR . 1.3 m -126.34 142.56 51.49 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.579 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -77.33 104.57 7.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.978 0.418 . . . . 0.0 110.333 -179.474 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 26.0 t80 -116.52 115.25 25.43 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.63 179.674 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 10.2 t -129.76 137.42 30.88 Favored Pre-proline 0 N--CA 1.452 -0.375 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.605 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -73.49 160.79 43.77 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.855 2.37 . . . . 0.0 112.242 -179.462 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 89.1 p -70.39 161.22 77.81 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.467 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -55.35 -37.71 94.42 Favored 'Trans proline' 0 N--CA 1.496 1.652 0 C-N-CA 122.736 2.291 . . . . 0.0 112.189 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -85.59 1.49 48.9 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.72 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -107.25 108.88 20.5 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-O 120.855 0.36 . . . . 0.0 110.34 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 10.1 t -111.03 -27.26 8.84 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.77 179.809 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -62.44 -38.94 91.68 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.659 -179.684 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.5 t -69.53 141.59 53.82 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.579 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 59.8 tp -83.36 143.64 30.19 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.554 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 26.0 pttm -98.64 137.75 36.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.899 0.381 . . . . 0.0 110.74 178.893 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.431 ' HB ' HG21 ' A' ' 33' ' ' VAL . 46.3 pt -137.7 147.5 26.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.78 179.526 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -119.38 156.14 30.65 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.032 -179.735 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.7 ttpt -61.61 120.8 11.29 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.461 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 104.84 -22.19 34.32 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 111.092 -0.803 . . . . 0.0 111.092 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -65.81 147.54 53.21 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-O 120.884 0.373 . . . . 0.0 110.906 179.257 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 47.2 mm -108.73 126.72 65.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.661 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.4 mt -109.22 128.9 64.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.78 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -79.29 112.51 16.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.306 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.3 mt -65.35 126.5 24.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.606 -179.487 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.6 mt -112.41 -55.29 4.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.6 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.9 t -162.86 151.69 14.71 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.74 -179.439 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.4 156.08 17.83 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.46 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.4 p -110.38 154.56 42.91 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.319 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -60.03 -26.84 83.53 Favored 'Trans proline' 0 C--N 1.305 -1.735 0 C-N-CA 122.807 2.338 . . . . 0.0 112.286 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 78.9 mtm -63.99 -38.15 90.02 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.501 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 133.82 -35.55 2.24 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 8.7 mtt -63.0 147.31 51.03 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.918 0.389 . . . . 0.0 110.624 -179.601 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 21.6 m0 -101.88 151.58 21.93 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.865 -179.534 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.0 m -114.08 136.37 53.0 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.866 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -154.56 -174.54 24.7 Favored Glycine 0 CA--C 1.524 0.646 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 -179.651 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 65.3 ttp -117.83 141.36 48.5 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 120.624 0.249 . . . . 0.0 110.638 -179.771 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.421 ' O ' ' HB3' ' A' ' 73' ' ' LYS . 1.3 mt -143.46 110.44 5.65 Favored 'General case' 0 C--O 1.219 -0.512 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.58 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 54.27 54.16 9.9 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 178.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 59.79 28.57 18.06 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.369 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.421 ' HB3' ' O ' ' A' ' 70' ' ' LEU . 85.1 tttt -133.99 112.99 11.67 Favored 'General case' 0 C--O 1.225 -0.214 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.107 179.572 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 19.1 m -99.84 144.0 12.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.855 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -174.86 -173.84 41.03 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -179.536 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 78.1 m-20 -101.57 149.45 24.09 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.849 0.357 . . . . 0.0 110.646 -179.548 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -148.96 160.78 42.98 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.857 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.601 ' CG ' HG22 ' A' ' 80' ' ' ILE . 24.3 tptt -82.01 114.3 20.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.434 -179.168 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.472 ' HA ' HG12 ' A' ' 82' ' ' VAL . 49.0 p90 -62.9 -26.18 68.67 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.588 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.601 HG22 ' CG ' ' A' ' 78' ' ' LYS . 10.2 tt -58.94 -30.33 42.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.814 0.34 . . . . 0.0 110.917 -179.408 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.54 ' CD2' HG21 ' A' ' 35' ' ' THR . 25.2 m-85 -93.32 5.34 51.89 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.04 179.817 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.472 HG12 ' HA ' ' A' ' 79' ' ' PHE . 0.3 OUTLIER -131.42 156.44 42.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 CA-C-O 121.05 0.453 . . . . 0.0 110.68 -179.884 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 85.3 m-20 -123.6 140.07 53.36 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.436 179.352 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -93.84 142.83 12.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 120.949 0.404 . . . . 0.0 110.724 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.476 HG21 ' HD2' ' A' ' 32' ' ' ARG . 39.3 pt -128.6 159.02 40.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.82 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 99.1 p -106.61 160.67 15.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.598 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.569 179.966 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -69.57 148.09 65.52 Favored 'Trans proline' 0 C--N 1.305 -1.741 0 C-N-CA 122.768 2.312 . . . . 0.0 112.084 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 83.4 t80 -137.22 130.39 30.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.478 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 81.0 m -105.9 133.73 50.15 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.006 0.431 . . . . 0.0 110.212 179.736 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -176.08 -144.36 5.09 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -117.83 142.87 46.82 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.694 0.283 . . . . 0.0 110.468 -179.726 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -116.44 137.1 52.43 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.853 0.359 . . . . 0.0 110.454 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 16.0 ptm180 -116.77 133.87 55.48 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.404 HG22 HD12 ' A' ' 49' ' ' ILE . 89.6 t -82.3 127.98 39.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.42 -178.669 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 88.5 m-70 -109.71 -17.13 13.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.435 179.267 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.44 HG21 ' HD2' ' A' ' 81' ' ' TYR . 7.4 p -120.22 173.79 6.9 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.879 0.371 . . . . 0.0 110.143 -179.548 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -101.03 107.71 19.23 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.803 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -117.82 109.84 17.05 Favored 'General case' 0 N--CA 1.463 0.217 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.129 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 90.8 m -128.62 128.23 23.54 Favored Pre-proline 0 CA--C 1.537 0.45 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.852 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -74.48 163.89 35.14 Favored 'Trans proline' 0 N--CA 1.489 1.25 0 C-N-CA 122.489 2.126 . . . . 0.0 112.165 179.612 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 69.7 m -70.57 158.61 87.41 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.565 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -54.4 -35.05 83.49 Favored 'Trans proline' 0 N--CA 1.499 1.807 0 C-N-CA 122.605 2.203 . . . . 0.0 112.128 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 35.5 p90 -90.56 4.11 52.15 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.212 179.803 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -108.58 111.57 23.47 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.551 -0.295 . . . . 0.0 110.364 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 61.4 p -112.89 -19.66 11.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.729 179.504 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -61.98 -38.74 89.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.665 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 58.2 m -80.3 144.19 33.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.682 179.79 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 47.1 tp -81.98 144.03 31.18 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.721 -179.612 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 7.1 ptpp? -98.34 118.56 35.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.622 178.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.404 HD12 HG22 ' A' ' 33' ' ' VAL . 20.1 pt -140.04 158.33 26.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.163 0.506 . . . . 0.0 110.926 -179.733 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.5 164.45 30.31 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.016 0.436 . . . . 0.0 110.679 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -60.59 129.1 39.87 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.914 -179.674 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 109.83 -20.39 26.9 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 111.361 -0.695 . . . . 0.0 111.361 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -85.18 147.41 26.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.003 0.43 . . . . 0.0 110.495 179.273 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 21.7 mm -112.49 129.33 68.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.316 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.417 HG21 ' CE2' ' A' ' 77' ' ' PHE . 75.9 mt -112.55 127.93 69.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.752 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.9 m-20 -78.62 124.94 28.7 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.232 -0.44 . . . . 0.0 109.877 179.591 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 93.4 mt -70.58 123.24 24.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 120.882 0.372 . . . . 0.0 110.478 -179.204 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.6 mt -106.34 -51.34 7.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.41 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 49.6 t -168.29 154.76 7.39 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.022 0.439 . . . . 0.0 110.975 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -90.15 136.15 33.22 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.083 179.26 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.5 t -123.45 148.02 54.34 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.87 -179.307 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -52.32 -169.67 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.454 0 C-N-CA 122.418 2.079 . . . . 0.0 112.126 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 91.6 mtp 63.64 15.85 9.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.376 -179.196 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 63.71 37.4 94.65 Favored Glycine 0 CA--C 1.522 0.471 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 179.466 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 75.0 mtp -126.46 150.68 48.54 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 120.411 -0.516 . . . . 0.0 111.387 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 10.7 m0 -110.82 147.9 33.53 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.625 179.625 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 85.1 m -104.99 131.26 52.74 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.716 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -155.94 -176.45 28.1 Favored Glycine 0 CA--C 1.522 0.487 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.487 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.4 ttp -122.46 138.31 54.59 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.757 0.313 . . . . 0.0 110.657 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -144.3 121.58 11.58 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.185 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 75.6 m-20 53.18 48.4 22.27 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 59.71 29.72 19.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.706 0.289 . . . . 0.0 110.354 -179.537 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 42.9 tptt -130.48 114.9 16.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.259 -0.428 . . . . 0.0 109.881 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 89.7 t -96.54 125.89 49.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.878 -0.329 . . . . 0.0 110.586 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -160.16 -179.71 35.12 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 -179.496 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 -98.83 149.79 22.53 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.026 0.441 . . . . 0.0 110.923 -179.695 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.417 ' CE2' HG21 ' A' ' 55' ' ' ILE . 48.8 p90 -152.17 159.16 43.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.692 179.731 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 1.5 mptp? -78.73 116.29 18.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.82 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.464 ' HA ' HG12 ' A' ' 82' ' ' VAL . 33.8 p90 -61.49 -25.11 67.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.629 179.809 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.436 HG23 ' CE1' ' A' ' 79' ' ' PHE . 40.9 pt -62.37 -20.12 23.89 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 CA-C-O 120.78 0.324 . . . . 0.0 110.8 179.634 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.44 ' HD2' HG21 ' A' ' 35' ' ' THR . 49.5 m-85 -100.18 3.61 43.87 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.805 179.002 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.464 HG12 ' HA ' ' A' ' 79' ' ' PHE . 0.3 OUTLIER -132.17 157.42 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 CA-C-O 120.86 0.362 . . . . 0.0 110.314 -179.544 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -120.06 133.16 55.6 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.714 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 3.2 m -88.05 137.61 20.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 C-N-CA 120.579 -0.448 . . . . 0.0 110.354 179.659 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 43.0 pt -129.71 158.79 42.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.756 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 67.2 m -112.57 143.96 42.86 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.507 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.556 179.875 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -58.9 145.56 96.6 Favored 'Trans proline' 0 C--N 1.304 -1.783 0 C-N-CA 122.901 2.401 . . . . 0.0 112.057 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -119.7 148.26 43.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.601 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 28.4 p -124.88 149.16 47.82 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.575 -179.612 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.99 -148.13 11.0 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 -179.377 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 1.7 mpt_? -113.01 141.91 46.31 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.95 0.405 . . . . 0.0 110.463 179.75 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -117.77 130.97 56.63 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.643 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 41.2 ttm180 -97.14 121.51 39.11 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.576 179.624 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.404 HG22 HG23 ' A' ' 82' ' ' VAL . 77.1 t -82.65 129.18 37.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.495 -179.872 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 51.0 m80 -112.88 8.63 18.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.974 179.452 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.0 p -137.12 166.87 22.69 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.74 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -108.56 104.74 14.12 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.356 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 16.1 t80 -118.72 119.19 33.69 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.628 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 82.4 p -120.74 152.28 55.66 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.609 -179.748 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -76.14 153.44 36.49 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.763 2.309 . . . . 0.0 112.406 -179.751 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 58.3 m -73.34 156.69 88.89 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.483 179.268 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -54.28 -39.4 86.93 Favored 'Trans proline' 0 C--N 1.301 -1.948 0 C-N-CA 122.858 2.372 . . . . 0.0 112.059 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -93.15 4.14 54.5 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.427 179.385 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -113.71 117.98 33.05 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.31 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 t -112.22 -25.13 9.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.79 179.592 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 -62.04 -38.43 88.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.595 -179.741 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 62.0 m -62.13 142.54 57.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.727 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 56.8 tp -90.38 142.49 27.68 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.423 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -94.73 121.84 36.73 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-O 120.939 0.399 . . . . 0.0 110.414 179.066 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.423 ' CG2' HD11 ' A' ' 55' ' ' ILE . 37.8 pt -131.1 155.21 41.75 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.62 -179.873 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 48.7 pttt -137.27 160.68 38.34 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.564 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -66.3 131.85 47.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.95 179.349 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 102.42 -18.75 50.31 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -82.87 152.01 25.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.823 0.344 . . . . 0.0 110.369 179.505 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 96.4 mt -116.29 133.11 63.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.62 179.69 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.423 HD11 ' CG2' ' A' ' 49' ' ' ILE . 82.5 mt -118.11 134.15 62.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.783 -179.294 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -80.49 122.94 27.62 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.189 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.3 mt -72.92 124.48 29.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.75 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 8.9 tt -107.0 -33.86 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.449 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 24.0 p -175.54 175.34 2.13 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.463 -179.324 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -126.35 151.8 47.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.536 179.464 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 31.0 p -105.18 153.42 39.56 Favored Pre-proline 0 N--CA 1.454 -0.261 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.611 -179.404 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -57.05 -35.93 99.1 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 C-N-CA 122.779 2.319 . . . . 0.0 112.227 179.717 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 98.2 mtp -61.29 -37.35 82.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.646 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 131.13 -25.46 4.1 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 96.4 mtp -62.15 139.67 58.46 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.027 0.441 . . . . 0.0 110.341 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 37.7 m0 -96.25 148.11 23.08 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.986 -179.371 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 58.3 m -119.48 140.49 50.38 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-N 116.022 -0.536 . . . . 0.0 109.885 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -164.81 -168.93 27.71 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -179.769 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.8 ttp -116.03 135.34 54.05 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-O 120.671 0.272 . . . . 0.0 110.739 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.471 HD23 ' C ' ' A' ' 70' ' ' LEU . 3.1 tt -135.7 112.51 10.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.371 179.702 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ASN . . . . . 0.46 ' N ' HD23 ' A' ' 70' ' ' LEU . 66.9 t30 55.41 53.9 9.26 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.855 178.794 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 59.02 28.61 17.92 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.743 179.729 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -139.33 113.31 8.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.086 179.395 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 19.4 m -95.31 143.67 11.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.859 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -172.34 -173.39 38.95 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.664 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.2 m-20 -111.73 155.14 23.96 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.748 0.309 . . . . 0.0 110.451 -179.355 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 9.2 p90 -155.62 157.85 37.4 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.812 179.837 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.403 ' HB3' HG12 ' A' ' 80' ' ' ILE . 99.2 mttt -63.99 132.81 51.76 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.45 -179.639 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 29.6 p90 -67.08 -21.32 65.89 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.684 -179.17 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.403 HG12 ' HB3' ' A' ' 78' ' ' LYS . 12.5 pt -78.22 -27.0 14.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.334 -179.618 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.2 m-85 -84.3 1.16 46.21 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.71 179.724 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.404 HG23 HG22 ' A' ' 33' ' ' VAL . 7.1 p -139.33 157.88 28.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.31 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -132.22 147.41 52.41 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.392 179.798 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.1 p -83.36 131.21 34.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.597 179.744 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 61.1 mt -88.78 115.84 29.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.456 -178.854 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 70.8 p -79.4 165.34 23.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.488 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 78.2 mm-40 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.566 179.55 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.231 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.71 147.43 87.91 Favored 'Trans proline' 0 C--N 1.303 -1.844 0 C-N-CA 123.063 2.509 . . . . 0.0 112.069 179.854 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -118.57 152.7 35.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.27 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 31.7 p -116.94 140.32 49.61 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.927 0.394 . . . . 0.0 110.342 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -166.86 -162.92 19.67 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 -179.375 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 10.9 mpt_? -119.6 147.55 44.37 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.764 0.316 . . . . 0.0 110.786 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.588 ' HB1' ' CG1' ' A' ' 82' ' ' VAL . . . -134.57 154.61 51.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.807 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 17.5 ptm180 -131.0 148.95 52.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.741 -179.589 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.444 HG22 HD12 ' A' ' 49' ' ' ILE . 58.8 t -86.26 128.71 39.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.301 -179.043 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 26.4 m170 -97.87 -16.98 19.54 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.517 178.922 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 13.1 t -144.53 142.8 30.48 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.885 -0.326 . . . . 0.0 110.145 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -62.59 117.45 6.26 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.777 -0.369 . . . . 0.0 110.731 -179.37 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -121.69 110.63 16.18 Favored 'General case' 0 C--O 1.233 0.201 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.945 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 88.0 m -129.14 94.73 32.91 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.057 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -54.78 152.7 27.36 Favored 'Trans proline' 0 N--CA 1.494 1.521 0 C-N-CA 122.358 2.039 . . . . 0.0 112.013 -179.596 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 39.0 m -59.14 154.73 38.59 Favored Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.474 -179.425 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -57.28 -24.65 60.86 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.554 2.17 . . . . 0.0 112.186 -179.434 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -65.87 -20.63 66.3 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.331 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 50.3 m-20 -96.11 59.68 1.96 Allowed 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 120.956 0.408 . . . . 0.0 110.521 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 12.8 t -60.46 -18.65 52.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.575 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 57.9 p-10 -90.1 7.23 38.91 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.314 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 67.8 m -106.57 144.41 33.28 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-O 120.917 0.389 . . . . 0.0 110.629 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 58.5 tp -81.6 142.03 33.16 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.536 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 1.6 mptm? -98.7 126.79 44.42 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.47 179.051 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.444 HD12 HG22 ' A' ' 33' ' ' VAL . 21.6 pt -131.49 148.5 32.65 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.631 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 39.3 ttpt -122.65 152.57 40.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.844 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 38.7 ttmt -57.11 128.35 36.56 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.058 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.38 -18.67 55.03 Favored Glycine 0 CA--C 1.524 0.635 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.451 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -72.23 144.96 48.27 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.796 0.332 . . . . 0.0 110.718 179.618 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 90.9 mt -111.96 129.08 68.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.35 179.243 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.416 ' CD1' HD12 ' A' ' 70' ' ' LEU . 81.3 mt -122.62 128.5 75.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.908 -179.172 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -76.9 134.03 39.08 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.367 179.349 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 85.9 mt -71.06 103.58 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.919 0.39 . . . . 0.0 110.16 -179.801 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.8 tt -89.09 -34.52 6.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.327 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 17.1 t -167.45 161.27 13.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.29 -179.46 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -120.57 144.7 47.95 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' THR . . . . . 0.459 HG22 ' H ' ' A' ' 63' ' ' MET . 27.6 m -101.67 135.69 19.72 Favored Pre-proline 0 CA--C 1.539 0.538 0 C-N-CA 120.232 -0.587 . . . . 0.0 109.98 -179.479 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -57.6 -25.7 68.7 Favored 'Trans proline' 0 N--CA 1.501 1.917 0 C-N-CA 122.359 2.039 . . . . 0.0 112.69 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' MET . . . . . 0.459 ' H ' HG22 ' A' ' 61' ' ' THR . 65.5 mtt -62.22 -38.74 90.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.959 0.409 . . . . 0.0 110.186 179.503 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 142.17 -40.12 1.32 Allowed Glycine 0 CA--C 1.524 0.634 0 N-CA-C 111.106 -0.798 . . . . 0.0 111.106 179.84 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 95.5 mtp -64.07 144.39 57.14 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.217 0.532 . . . . 0.0 111.108 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 38.4 m0 -97.4 156.31 16.52 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.369 -179.579 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 80.3 m -117.19 139.31 50.92 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.056 -179.719 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.23 -175.78 27.6 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 16.9 tmm? -121.31 141.55 50.81 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.723 0.297 . . . . 0.0 110.507 -179.697 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.416 HD12 ' CD1' ' A' ' 55' ' ' ILE . 0.5 OUTLIER -149.31 121.62 8.41 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.992 179.921 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 18.5 m120 50.31 49.96 19.6 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 53.0 t30 59.82 35.07 21.93 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.764 0.316 . . . . 0.0 110.708 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 24.3 tptp -134.26 115.94 14.71 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 179.43 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 97.1 t -105.78 129.03 59.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.446 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -165.86 -172.42 33.21 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.59 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.7 m-80 -101.43 153.18 19.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.024 0.44 . . . . 0.0 111.056 -179.508 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.538 ' CD1' HG21 ' A' ' 82' ' ' VAL . 53.4 p90 -149.93 160.43 43.61 Favored 'General case' 0 C--O 1.239 0.54 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.619 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 35.6 tptt -69.62 111.77 5.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.514 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 53.4 p90 -61.53 -24.31 66.53 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.8 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.9 mt -63.14 -39.24 84.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.022 0.439 . . . . 0.0 110.437 -179.807 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 20.6 m-85 -84.71 2.22 42.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.971 -179.581 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.588 ' CG1' ' HB1' ' A' ' 31' ' ' ALA . 85.6 t -126.02 136.9 59.43 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.147 0 CA-C-O 120.987 0.422 . . . . 0.0 110.813 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -124.41 148.42 47.59 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.373 -179.878 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 16.9 m -90.37 139.6 17.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 C-N-CA 120.662 -0.415 . . . . 0.0 110.58 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 38.9 pt -120.96 149.78 23.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.796 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 83.9 p -90.84 170.49 10.05 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.674 179.808 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.049 -0.977 . . . . 0.0 110.482 179.756 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.4 m . . . . . 0 N--CA 1.456 -0.132 0 CA-C-O 120.844 0.354 . . . . 0.0 110.484 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.51 -128.18 1.87 Allowed Glycine 0 CA--C 1.526 0.753 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 9.9 mpt_? -111.48 140.2 46.28 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.754 0.311 . . . . 0.0 110.7 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.464 ' HB1' ' CG1' ' A' ' 82' ' ' VAL . . . -111.1 127.1 55.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.445 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 74.2 ttt-85 -103.55 123.66 47.35 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.525 -179.68 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.568 HG22 HG22 ' A' ' 82' ' ' VAL . 66.1 t -77.5 123.51 34.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.621 -179.694 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 35.4 p80 -105.75 -16.37 14.69 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.741 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.472 HG21 ' CD2' ' A' ' 81' ' ' TYR . 32.6 m -128.45 129.33 45.96 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.692 179.666 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -65.71 109.65 2.5 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.557 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . 0.488 ' HB3' HD11 ' A' ' 49' ' ' ILE . 22.5 t80 -117.17 115.4 25.26 Favored 'General case' 0 C--O 1.241 0.611 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.372 179.557 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 95.5 m -131.08 128.28 22.2 Favored Pre-proline 0 N--CA 1.449 -0.502 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.754 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.5 166.41 29.9 Favored 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 123.012 2.475 . . . . 0.0 112.139 179.377 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 61.7 m -67.47 159.52 77.45 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.554 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_exo -55.62 -32.07 81.82 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.722 2.281 . . . . 0.0 112.183 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -95.51 11.45 32.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.763 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -106.69 108.73 20.38 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.339 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 5.0 t -113.51 -8.49 13.36 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.782 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 45.5 p-10 -75.59 -7.12 53.42 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.762 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 73.6 m -118.9 144.37 46.45 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-O 120.787 0.327 . . . . 0.0 110.504 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.413 HD21 ' HB2' ' A' ' 70' ' ' LEU . 9.5 tp -82.11 153.93 25.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.533 -179.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -96.2 130.61 43.23 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.573 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.488 HD11 ' HB3' ' A' ' 37' ' ' PHE . 34.2 pt -134.93 158.53 41.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.414 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.7 tttp -137.0 145.29 43.93 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.798 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 63.4 tttm -54.45 129.2 35.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.637 -179.782 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.57 -16.83 59.26 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 111.174 -0.77 . . . . 0.0 111.174 -179.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -74.87 148.41 40.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.786 0.327 . . . . 0.0 110.612 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 42.9 mm -109.93 126.63 67.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.392 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.423 HD11 ' CG2' ' A' ' 49' ' ' ILE . 82.9 mt -119.08 129.06 75.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.606 -179.606 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -77.11 122.77 25.44 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.326 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.4 mt -76.82 125.25 36.46 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.486 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.412 HD11 HG22 ' A' ' 67' ' ' THR . 30.6 pt -114.24 -27.98 2.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.461 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 10.4 t -167.35 161.82 14.41 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.647 -179.158 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -119.14 145.26 46.12 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.231 179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 25.5 m -94.89 134.32 25.09 Favored Pre-proline 0 CA--C 1.534 0.336 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.429 -179.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -50.73 -36.19 50.42 Favored 'Trans proline' 0 N--CA 1.494 1.546 0 C-N-CA 122.806 2.338 . . . . 0.0 112.068 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 60.6 ttm -59.03 -40.23 84.37 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.324 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 144.05 -31.78 1.83 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 97.5 mtp -62.54 146.59 51.38 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.014 0.435 . . . . 0.0 110.842 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 42.6 m0 -102.0 150.79 22.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.965 -179.186 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.412 HG22 HD11 ' A' ' 58' ' ' ILE . 93.2 m -110.55 136.73 49.22 Favored 'General case' 0 C--O 1.237 0.417 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.994 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -155.87 -171.56 22.43 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 111.095 -0.802 . . . . 0.0 111.095 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -123.35 147.65 46.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.991 0.424 . . . . 0.0 110.622 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.435 HD22 ' ND2' ' A' ' 71' ' ' ASN . 0.4 OUTLIER -151.09 117.37 5.64 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.69 -179.742 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . 0.435 ' ND2' HD22 ' A' ' 70' ' ' LEU . 67.5 m-20 51.22 52.83 14.07 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.142 179.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 80.7 m-20 59.68 26.18 15.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.237 -179.561 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.9 tttp -130.25 113.16 14.09 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.504 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 15.6 m -99.37 140.04 19.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.761 179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -171.42 -176.67 40.65 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -179.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 -104.12 150.4 24.36 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.077 0.465 . . . . 0.0 110.459 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.665 ' CD1' HG21 ' A' ' 82' ' ' VAL . 50.9 p90 -146.22 156.58 43.49 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.723 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 54.6 mttp -67.01 122.18 17.18 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.005 -179.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 55.9 p90 -68.64 -29.58 68.1 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.55 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 33.6 pt -60.46 -21.21 22.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.839 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.472 ' CD2' HG21 ' A' ' 35' ' ' THR . 22.4 m-85 -102.64 1.51 34.76 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.871 179.289 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.665 HG21 ' CD1' ' A' ' 77' ' ' PHE . 68.2 t -127.83 136.51 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 CA-C-O 121.109 0.48 . . . . 0.0 110.752 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 41.7 t0 -110.94 142.26 43.28 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.395 179.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.7 p -86.94 126.3 40.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.772 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 23.4 pt -127.19 163.32 30.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.714 179.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 28.7 t -104.74 130.32 52.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.581 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 7.9 tt0 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.554 179.916 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 84.1 m . . . . . 0 N--CA 1.453 -0.325 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 172.37 -140.53 5.79 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 21.0 mmm180 -110.14 148.13 32.37 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.887 0.375 . . . . 0.0 110.311 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -121.68 143.67 49.21 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.435 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 38.6 ptt180 -120.25 135.97 54.82 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.033 0.444 . . . . 0.0 110.427 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 43.4 t -84.54 135.53 24.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.982 -178.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 97.4 m-70 -107.28 -12.79 15.28 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.732 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 11.8 t -140.87 148.83 41.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.891 0.377 . . . . 0.0 110.375 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.3 p-10 -75.13 121.43 22.06 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.026 -179.515 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -119.28 118.24 30.73 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 178.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 89.6 m -126.56 94.69 39.8 Favored Pre-proline 0 CA--C 1.534 0.361 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.434 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -56.45 147.79 66.5 Favored 'Trans proline' 0 N--CA 1.499 1.804 0 C-N-CA 122.409 2.073 . . . . 0.0 112.023 -179.635 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 93.7 p -67.92 159.21 80.62 Favored Pre-proline 0 CA--C 1.532 0.255 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.709 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -56.8 -30.77 86.17 Favored 'Trans proline' 0 N--CA 1.499 1.812 0 C-N-CA 122.832 2.355 . . . . 0.0 112.154 -179.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -61.82 -22.96 65.93 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.062 -179.444 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -107.27 103.44 12.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.041 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.404 HG22 ' H ' ' A' ' 44' ' ' THR . 1.9 t -87.51 -33.89 18.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.367 179.762 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -63.37 -38.03 89.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.038 179.681 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 53.4 m -62.38 131.65 49.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.946 0.403 . . . . 0.0 110.647 -179.31 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 1.2 tt -87.55 150.84 23.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.755 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -98.22 123.52 42.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.263 -0.426 . . . . 0.0 109.926 179.092 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 47.3 pt -130.08 159.05 42.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 120.897 0.379 . . . . 0.0 110.902 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -135.71 141.99 44.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.704 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 22.8 pttp -53.35 138.86 31.76 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.982 0.42 . . . . 0.0 110.658 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.1 -17.9 56.42 Favored Glycine 0 CA--C 1.53 0.977 0 N-CA-C 111.2 -0.76 . . . . 0.0 111.2 -179.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -84.64 156.82 21.37 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.789 0.328 . . . . 0.0 110.921 179.569 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 47.4 mm -116.46 131.51 68.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.403 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.458 ' CG1' HD12 ' A' ' 70' ' ' LEU . 89.7 mt -118.25 132.04 69.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.282 -179.559 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 66.9 t0 -74.52 118.48 17.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.74 179.788 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 90.6 mt -69.34 122.4 20.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 120.902 0.382 . . . . 0.0 110.664 -179.433 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 82.6 mt -108.31 -59.44 3.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.183 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 94.2 m -140.87 142.93 34.46 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.479 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 12.2 pttp -154.26 123.21 6.33 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.926 0.393 . . . . 0.0 110.821 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.8 p -75.44 161.68 75.68 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.362 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_exo -52.28 -36.18 66.9 Favored 'Trans proline' 0 N--CA 1.495 1.607 0 C-N-CA 122.506 2.138 . . . . 0.0 111.833 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 14.9 tpt -149.71 97.0 2.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.476 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 168.85 -178.65 42.09 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 111.009 -0.836 . . . . 0.0 111.009 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.1 mtp -60.69 144.51 51.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.023 0.439 . . . . 0.0 110.738 -179.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 26.2 m0 -93.82 146.35 23.94 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.293 -179.57 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.9 m -112.59 135.49 53.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.986 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -160.59 -171.69 26.87 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 67.5 ttp -121.86 135.49 54.9 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.823 0.344 . . . . 0.0 110.407 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.458 HD12 ' CG1' ' A' ' 55' ' ' ILE . 4.2 tt -135.35 117.03 14.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.063 179.662 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . 0.449 ' N ' HD23 ' A' ' 70' ' ' LEU . 64.8 t30 55.85 52.93 9.98 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.235 179.282 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 33.1 m120 57.94 35.08 25.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.657 0.265 . . . . 0.0 111.4 179.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -139.02 116.89 11.56 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.14 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 89.5 t -95.41 129.94 44.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.604 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -165.67 -174.08 34.85 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.337 -0.705 . . . . 0.0 111.337 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -108.95 156.72 19.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.007 0.432 . . . . 0.0 110.912 -179.555 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -157.52 160.32 38.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.096 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -71.06 117.77 12.98 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.174 0.511 . . . . 0.0 111.119 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.456 ' HA ' HG12 ' A' ' 82' ' ' VAL . 55.6 p90 -63.15 -30.26 71.45 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.512 179.536 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.44 HG23 ' CE1' ' A' ' 79' ' ' PHE . 18.3 pt -62.43 -18.5 20.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.77 0.319 . . . . 0.0 110.724 179.344 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 15.3 m-30 -100.63 3.63 42.68 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.909 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.456 HG12 ' HA ' ' A' ' 79' ' ' PHE . 0.5 OUTLIER -132.58 159.94 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.758 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -127.59 144.47 51.07 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.526 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.7 p -93.65 128.63 44.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.579 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 44.0 pt -127.68 158.83 39.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.752 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 71.0 m -70.64 144.74 51.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.531 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.606 179.848 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 24.1 p . . . . . 0 N--CA 1.451 -0.423 0 CA-C-O 121.064 0.459 . . . . 0.0 110.195 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.97 -155.25 14.95 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 26.9 mmt85 -112.22 140.64 46.75 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.885 0.374 . . . . 0.0 110.481 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.6 117.15 30.08 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.496 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 75.5 ttt180 -91.34 124.57 35.64 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.615 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.584 HG22 HG22 ' A' ' 82' ' ' VAL . 82.5 t -82.26 129.33 37.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.6 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 88.0 m-70 -107.1 -18.18 13.97 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.851 179.76 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.538 HG21 ' CD2' ' A' ' 81' ' ' TYR . 95.2 m -123.94 134.53 53.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.367 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -75.07 114.18 13.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.697 -179.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -118.22 125.18 49.65 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.345 179.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 10.0 t -132.28 134.18 24.66 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.673 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -72.97 166.41 30.11 Favored 'Trans proline' 0 N--CA 1.492 1.434 0 C-N-CA 122.894 2.396 . . . . 0.0 112.388 179.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 48.8 m -64.13 156.13 76.1 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.482 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -58.51 -27.39 82.07 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.621 2.214 . . . . 0.0 112.306 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -99.29 22.74 10.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.636 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -114.31 113.22 24.28 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.437 179.575 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 72.8 p -110.73 -15.14 13.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.683 179.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 56.7 p-10 -88.47 10.85 18.75 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.844 179.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 67.7 m -117.26 157.96 25.15 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 120.683 0.278 . . . . 0.0 110.3 -179.668 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 63.8 tp -104.56 136.7 43.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.321 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 13.3 tmtt? -96.72 124.94 40.85 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.385 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 49.3 pt -128.21 158.49 40.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.532 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 64.6 pttt -138.47 161.23 37.54 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.633 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 23.3 pttp -63.13 137.46 58.24 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.765 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.04 -11.6 71.7 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 111.024 -0.831 . . . . 0.0 111.024 -179.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 42.0 t0 -79.43 148.66 31.85 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-O 120.829 0.347 . . . . 0.0 110.463 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 39.0 mm -110.64 127.88 67.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.399 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 93.9 mt -115.22 134.34 58.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.803 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -82.17 111.9 18.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.559 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.5 mt -63.31 130.95 28.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.746 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 97.6 mt -112.57 -63.97 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.715 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.9 t -154.0 138.94 17.21 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.588 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -92.06 153.38 19.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.275 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 81.8 p -125.08 151.91 69.82 Favored Pre-proline 0 CA--C 1.532 0.252 0 C-N-CA 120.477 -0.489 . . . . 0.0 110.695 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -63.69 -18.85 65.92 Favored 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.908 2.406 . . . . 0.0 112.315 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 39.2 mmt -61.76 -37.41 84.19 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.195 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 125.18 -44.06 1.31 Allowed Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.074 -0.811 . . . . 0.0 111.074 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 33.5 mtt -61.85 141.76 57.76 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.98 0.419 . . . . 0.0 110.436 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 26.9 m0 -96.07 147.26 23.91 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.285 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 85.6 m -112.29 137.06 50.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.977 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -158.14 -172.53 25.41 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 37.2 ttm -119.69 140.49 50.58 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 120.734 0.302 . . . . 0.0 110.383 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -144.09 115.57 8.09 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.912 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 57.0 m-20 53.27 51.13 16.12 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.334 179.445 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 52.9 t30 60.75 28.79 18.51 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.545 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 13.0 tppt? -136.83 115.32 11.9 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.45 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.9 m -97.29 142.47 14.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.868 0.366 . . . . 0.0 110.804 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -171.18 -177.65 41.14 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 110.691 -0.963 . . . . 0.0 110.691 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -103.09 157.97 16.62 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 121.083 0.468 . . . . 0.0 110.644 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.571 ' CD1' HG21 ' A' ' 82' ' ' VAL . 2.1 p90 -154.35 161.56 41.68 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.194 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 12.4 tptt -62.17 117.47 6.08 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-O 121.488 0.661 . . . . 0.0 110.882 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -62.3 -23.22 66.6 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.353 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.419 HG23 ' N ' ' A' ' 81' ' ' TYR . 18.1 tt -73.28 -38.19 53.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.877 0.37 . . . . 0.0 110.812 179.591 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.538 ' CD2' HG21 ' A' ' 35' ' ' THR . 22.8 m-85 -80.3 -14.92 57.99 Favored 'General case' 0 C--O 1.24 0.582 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.765 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.584 HG22 HG22 ' A' ' 33' ' ' VAL . 67.2 t -111.78 137.08 45.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.223 0 CA-C-O 121.31 0.576 . . . . 0.0 110.61 179.843 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 41.5 t0 -121.04 149.47 42.65 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.743 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.3 p -87.85 132.38 33.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.447 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 2.4 tt -104.81 146.09 12.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.654 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 72.0 m -80.17 148.26 30.97 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.473 179.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 117.911 -1.042 . . . . 0.0 110.516 179.834 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 72.9 m . . . . . 0 CA--C 1.527 0.072 0 CA-C-O 120.832 0.349 . . . . 0.0 110.455 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 176.88 -123.76 0.92 Allowed Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -179.705 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 19.2 tpp180 -121.54 133.62 55.02 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.791 0.329 . . . . 0.0 110.448 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -104.28 122.94 46.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.694 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 78.3 ttt-85 -107.12 127.16 53.25 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.722 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.0 t -81.03 125.76 39.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.272 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 32.5 p80 -117.24 -13.1 10.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.699 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 97.2 m -125.51 134.37 52.05 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.538 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -69.22 122.98 19.93 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.672 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -71.59 137.69 48.18 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.222 179.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 82.1 m -120.01 93.27 47.72 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.424 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -73.59 151.69 47.35 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.864 2.376 . . . . 0.0 112.452 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 65.5 m -76.56 159.98 78.27 Favored Pre-proline 0 N--CA 1.452 -0.355 0 CA-C-O 121.263 0.554 . . . . 0.0 110.7 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -55.44 -37.47 94.81 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 122.733 2.289 . . . . 0.0 111.638 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.2 p90 -91.1 15.59 11.39 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.624 -179.702 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -108.81 94.83 5.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.276 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 71.2 p -104.42 -22.72 13.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.638 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -87.1 6.83 30.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.696 179.3 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 82.7 p -71.59 160.06 33.34 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-O 120.882 0.372 . . . . 0.0 110.42 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 55.8 tp -91.16 136.95 32.73 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.295 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 15.9 ptpt -93.64 123.33 36.89 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.762 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.0 pt -139.26 160.22 28.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.579 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.2 tttp -143.94 141.95 30.49 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.622 179.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 23.3 pttp -48.85 134.33 16.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.661 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.25 -19.61 53.81 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -74.32 153.66 39.23 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.784 0.326 . . . . 0.0 110.741 179.436 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 43.4 mm -114.47 126.62 72.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.367 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 87.1 mt -111.49 133.9 55.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.682 -179.528 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -80.11 112.17 17.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.593 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 97.5 mt -63.43 124.07 17.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.494 -179.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 97.3 mt -106.73 -54.87 5.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.634 179.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 32.0 p -161.51 171.27 18.41 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.61 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.02 146.14 42.4 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.499 179.828 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 62.1 p -101.45 155.02 36.87 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.515 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -63.27 -22.23 72.18 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 C-N-CA 122.957 2.438 . . . . 0.0 112.183 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 39.0 mmt -76.06 -10.56 59.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.877 179.485 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 104.08 -25.1 27.35 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 179.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 91.7 mmm -63.18 147.04 52.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.902 0.382 . . . . 0.0 110.426 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 33.1 m0 -103.95 143.38 32.94 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.827 -179.493 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 86.6 m -108.18 133.68 52.11 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.664 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -150.75 -179.05 26.18 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 -179.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 61.2 ttm -117.99 143.18 46.6 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-O 120.639 0.257 . . . . 0.0 110.557 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -142.04 117.14 10.02 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.574 179.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 9.1 p30 40.99 57.64 2.71 Favored 'General case' 0 N--CA 1.463 0.18 0 O-C-N 123.391 0.432 . . . . 0.0 111.019 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 60.5 t30 60.62 38.56 18.57 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.909 -179.253 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 64.1 tttt -141.36 109.69 5.91 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.092 178.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 60.1 t -98.99 129.82 48.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.91 0.386 . . . . 0.0 110.772 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -163.63 -178.63 37.43 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -101.17 160.52 14.33 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-O 120.643 0.259 . . . . 0.0 110.449 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 19.8 p90 -158.88 159.21 34.73 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.704 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 30.1 tttt -66.41 113.78 4.92 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.491 -179.402 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.428 ' HA ' HG12 ' A' ' 82' ' ' VAL . 49.4 p90 -59.22 -23.15 62.07 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.396 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 95.7 mt -68.54 -38.73 79.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.025 0.441 . . . . 0.0 110.19 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.7 m-30 -76.07 -5.43 46.45 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.815 -179.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.428 HG12 ' HA ' ' A' ' 79' ' ' PHE . 0.4 OUTLIER -126.82 165.43 25.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.629 -179.591 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -148.66 160.63 42.96 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.521 179.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.435 ' O ' HG23 ' A' ' 84' ' ' VAL . 23.6 m -94.52 129.34 44.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.624 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 43.1 pt -126.11 159.87 34.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.67 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 41.4 t -105.6 123.15 47.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.589 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 25.4 pt-20 . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.538 179.991 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 31.1 p . . . . . 0 N--CA 1.456 -0.157 0 CA-C-O 120.974 0.416 . . . . 0.0 110.143 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.63 -124.25 1.59 Allowed Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 14.7 mmp_? -111.2 147.0 35.91 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.681 0.277 . . . . 0.0 110.51 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -117.79 114.41 23.25 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.718 -0.393 . . . . 0.0 110.896 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.539 ' HD2' HD12 ' A' ' 85' ' ' ILE . 2.8 ptm85 -87.9 128.48 35.36 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.546 179.765 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.542 HG22 HG23 ' A' ' 82' ' ' VAL . 95.7 t -84.83 131.98 32.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.2 -179.313 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 30.3 m170 -114.17 -15.32 12.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.398 179.409 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.414 HG21 ' CD2' ' A' ' 81' ' ' TYR . 32.9 m -127.68 132.47 49.66 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.843 0.354 . . . . 0.0 110.712 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -65.79 145.1 56.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.736 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -98.65 134.92 40.9 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.004 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.48 HG23 ' O ' ' A' ' 38' ' ' THR . 2.7 t -121.22 93.52 48.81 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.752 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_endo -75.01 153.1 41.47 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.397 2.064 . . . . 0.0 112.319 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 65.6 m -72.01 158.97 86.69 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.525 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -53.82 -37.16 84.73 Favored 'Trans proline' 0 N--CA 1.497 1.723 0 C-N-CA 122.633 2.222 . . . . 0.0 112.039 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 41.1 p90 -97.43 16.36 20.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.869 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -96.6 88.16 4.58 Favored 'General case' 0 C--O 1.233 0.213 0 CA-C-O 121.039 0.447 . . . . 0.0 110.544 -179.726 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 6.9 t -93.24 -26.16 17.48 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.437 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 56.0 p-10 -79.5 -3.36 46.4 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.023 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 34.8 t -83.55 139.63 32.76 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.661 0.267 . . . . 0.0 110.536 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 60.2 tp -85.85 145.82 27.02 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.371 -0.377 . . . . 0.0 109.997 179.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 58.2 pttt -96.27 127.03 41.91 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.45 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 35.2 pt -144.12 150.2 17.01 Favored 'Isoleucine or valine' 0 C--O 1.237 0.436 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.339 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 63.7 tttp -132.72 145.88 51.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.331 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 64.8 pttt -48.93 138.15 11.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.953 0.406 . . . . 0.0 110.682 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 93.44 -13.27 67.94 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 -179.46 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -77.37 150.95 35.07 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-O 120.817 0.342 . . . . 0.0 110.636 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 36.1 mm -114.21 126.73 71.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.208 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.44 HG12 HD12 ' A' ' 70' ' ' LEU . 92.3 mt -117.93 133.14 65.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.83 -179.498 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -78.58 121.97 25.32 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.276 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.7 mt -69.5 120.39 17.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.914 0.388 . . . . 0.0 110.545 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.492 HD11 ' HB2' ' A' ' 69' ' ' MET . 93.3 mt -109.47 -50.65 6.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.451 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 95.3 m -140.26 151.42 45.11 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.437 179.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 37.8 mtmm -124.88 147.74 48.65 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.417 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 90.0 m -122.71 117.16 28.9 Favored Pre-proline 0 CA--C 1.537 0.466 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.202 179.569 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_exo -50.57 126.83 18.98 Favored 'Trans proline' 0 N--CA 1.497 1.715 0 C-N-CA 121.933 1.755 . . . . 0.0 111.971 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 93.7 mmm 47.15 40.62 10.27 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.613 179.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -151.77 176.37 30.17 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.152 -0.779 . . . . 0.0 111.152 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 98.9 mtp -60.0 148.33 35.81 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.006 0.432 . . . . 0.0 110.58 -179.088 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 16.1 m0 -94.89 158.25 15.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.057 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 96.2 m -118.93 138.0 53.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.238 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -160.73 -170.57 25.51 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . 0.492 ' HB2' HD11 ' A' ' 58' ' ' ILE . 64.8 ttp -125.71 136.32 53.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.745 0.307 . . . . 0.0 110.337 -179.702 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.488 HD23 ' N ' ' A' ' 71' ' ' ASN . 4.4 tt -137.83 120.15 15.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.392 179.869 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . 0.488 ' N ' HD23 ' A' ' 70' ' ' LEU . 67.2 t30 53.08 51.4 15.81 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.681 -0.408 . . . . 0.0 110.981 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 58.0 t30 58.87 36.26 24.57 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.653 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 4.0 tptm -139.12 113.76 9.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.37 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 91.7 t -94.54 127.36 46.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.846 0.355 . . . . 0.0 110.674 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -163.22 -178.82 37.29 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 -179.8 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -100.69 157.53 16.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.907 0.384 . . . . 0.0 110.729 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -155.88 161.21 40.62 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.841 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -73.54 121.96 21.45 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.859 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.626 ' HA ' HG12 ' A' ' 82' ' ' VAL . 51.2 p90 -67.69 -28.18 67.46 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.794 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.473 HG23 ' CE1' ' A' ' 79' ' ' PHE . 33.5 pt -63.82 -19.53 24.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.694 0.283 . . . . 0.0 111.073 179.656 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.414 ' CD2' HG21 ' A' ' 35' ' ' THR . 21.2 m-30 -102.23 5.39 40.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.942 0.401 . . . . 0.0 110.913 179.532 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.626 HG12 ' HA ' ' A' ' 79' ' ' PHE . 1.2 p -134.23 153.17 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.315 179.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -113.41 134.11 54.82 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.375 179.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.0 p -80.09 125.94 39.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.548 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.539 HD12 ' HD2' ' A' ' 32' ' ' ARG . 0.1 OUTLIER -122.76 134.42 66.0 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.418 -179.815 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 69.8 m -67.49 143.39 56.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.32 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.633 179.892 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 82.6 m . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.835 0.35 . . . . 0.0 110.378 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -175.34 -152.96 9.76 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 39.5 mmt180 -112.27 143.46 43.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.78 0.324 . . . . 0.0 110.657 -179.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -117.97 132.27 56.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.225 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.446 ' HA ' HD13 ' A' ' 54' ' ' ILE . 17.6 ptm180 -110.82 133.05 53.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.232 0.539 . . . . 0.0 110.733 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.502 HG22 HG23 ' A' ' 82' ' ' VAL . 86.5 t -85.68 133.44 29.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.511 -179.332 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.562 ' HD2' HG23 ' A' ' 35' ' ' THR . 0.3 OUTLIER -118.02 -7.31 10.88 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.171 179.792 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.562 HG23 ' HD2' ' A' ' 34' ' ' HIS . 72.9 p -130.65 158.82 39.0 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.892 0.377 . . . . 0.0 110.3 -179.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -91.35 104.06 16.63 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.599 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -119.24 121.4 39.58 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.571 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 8.7 t -130.3 139.67 36.33 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.809 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -73.59 166.01 30.91 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 122.779 2.319 . . . . 0.0 112.262 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 85.7 p -68.65 161.82 67.81 Favored Pre-proline 0 C--N 1.324 -0.525 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.653 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -56.23 -34.63 94.02 Favored 'Trans proline' 0 N--CA 1.5 1.893 0 C-N-CA 122.712 2.275 . . . . 0.0 112.098 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.3 p90 -87.75 9.42 21.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.923 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -112.38 114.73 27.61 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-O 120.684 0.278 . . . . 0.0 110.397 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 58.1 p -115.34 -30.57 6.22 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.933 0.397 . . . . 0.0 110.617 179.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -63.23 -37.32 86.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.548 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 66.7 m -58.85 152.83 18.42 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.606 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.521 HD13 ' H ' ' A' ' 48' ' ' LYS . 0.1 OUTLIER -91.72 132.51 36.33 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.51 -179.964 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.521 ' H ' HD13 ' A' ' 47' ' ' LEU . 62.4 mttp -87.4 124.38 33.34 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 179.181 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.493 ' CG2' HD11 ' A' ' 55' ' ' ILE . 47.5 pt -131.06 146.52 33.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.558 -179.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.7 mttp -135.08 159.98 39.8 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.427 -0.352 . . . . 0.0 110.274 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -55.81 121.98 10.44 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.989 0.423 . . . . 0.0 110.538 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 103.52 -21.21 39.73 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -67.01 143.09 56.98 Favored 'General case' 0 C--N 1.332 -0.194 0 C-N-CA 120.618 -0.433 . . . . 0.0 110.77 179.41 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.446 HD13 ' HA ' ' A' ' 32' ' ' ARG . 9.9 mm -112.69 128.71 69.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.599 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.493 HD11 ' CG2' ' A' ' 49' ' ' ILE . 2.5 mt -116.33 133.35 63.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.708 -179.417 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -79.95 117.63 20.97 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.15 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 92.0 mt -67.26 126.39 26.79 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.137 0 CA-C-O 120.919 0.39 . . . . 0.0 110.679 -179.524 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 93.3 mt -113.84 -59.27 3.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.47 179.721 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 94.7 m -144.77 168.8 19.34 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.938 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -115.98 141.48 48.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.187 179.573 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.9 m -98.86 137.52 20.55 Favored Pre-proline 0 CA--C 1.538 0.483 0 C-N-CA 120.149 -0.62 . . . . 0.0 110.343 -179.492 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -53.22 -36.84 79.24 Favored 'Trans proline' 0 N--CA 1.501 1.916 0 C-N-CA 122.414 2.076 . . . . 0.0 112.486 179.509 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . 0.463 ' HG3' ' H ' ' A' ' 65' ' ' MET . 23.0 ptp -59.34 -18.67 40.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.885 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 119.41 -38.25 2.88 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 179.424 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' MET . . . . . 0.463 ' H ' ' HG3' ' A' ' 63' ' ' MET . 97.0 mtp -61.57 143.65 55.65 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.153 0.502 . . . . 0.0 110.59 -179.79 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 45.7 m0 -98.75 155.67 17.23 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.212 -179.312 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 93.0 m -115.92 135.21 54.2 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.901 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.6 -172.13 23.57 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 179.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 16.8 tmm? -122.04 139.8 53.26 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.847 0.356 . . . . 0.0 110.751 -179.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.433 HD22 ' ND2' ' A' ' 71' ' ' ASN . 0.4 OUTLIER -139.25 111.72 7.64 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.618 179.812 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . 0.433 ' ND2' HD22 ' A' ' 70' ' ' LEU . 47.2 m-20 54.05 51.99 13.6 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.034 179.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 54.1 t30 62.41 37.3 13.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.792 0.33 . . . . 0.0 110.707 -179.387 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 46.9 tptt -137.33 113.29 9.75 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.034 179.266 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 88.9 t -100.46 127.28 53.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 C-N-CA 120.793 -0.363 . . . . 0.0 110.912 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.505 ' N ' HD23 ' A' ' 47' ' ' LEU . . . -164.92 -174.09 34.26 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -102.51 150.96 22.87 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.009 0.433 . . . . 0.0 110.483 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 44.0 p90 -150.84 158.75 44.52 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.757 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -72.29 117.36 13.85 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.94 -179.466 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -62.58 -27.51 69.23 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.683 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 13.7 tt -63.06 -33.27 59.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.999 0.428 . . . . 0.0 111.1 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -83.81 1.23 44.01 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.835 179.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.502 HG23 HG22 ' A' ' 33' ' ' VAL . 0.3 OUTLIER -132.66 161.42 41.56 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 CA-C-O 121.038 0.447 . . . . 0.0 110.464 179.815 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 53.3 t0 -124.1 137.64 54.54 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.133 179.39 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.5 p -87.52 124.64 40.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.773 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 41.4 pt -128.27 150.71 34.24 Favored 'Isoleucine or valine' 0 C--O 1.233 0.219 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.84 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 38.4 t -84.63 138.75 32.52 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.718 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.003 -0.998 . . . . 0.0 110.611 179.714 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 29.5 p . . . . . 0 N--CA 1.455 -0.219 0 CA-C-O 120.992 0.425 . . . . 0.0 110.424 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -174.16 -154.91 11.29 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -179.327 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 15.6 mmp_? -108.04 142.34 38.34 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.023 0.44 . . . . 0.0 110.469 -179.397 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.445 ' HB1' HG21 ' A' ' 82' ' ' VAL . . . -106.39 117.3 33.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.184 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 61.2 ttt180 -96.09 120.83 37.08 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.055 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 86.8 t -81.28 124.78 39.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.728 -179.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 35.2 p80 -115.81 -8.97 11.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.936 179.406 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 77.4 m -129.04 136.74 50.69 Favored 'General case' 0 C--O 1.231 0.099 0 CA-C-O 120.762 0.315 . . . . 0.0 110.625 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -69.49 119.69 14.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.493 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -65.47 136.91 57.04 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 92.1 m -118.45 94.85 47.96 Favored Pre-proline 0 CA--C 1.537 0.452 0 C-N-CA 120.958 -0.297 . . . . 0.0 110.762 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_endo -74.09 157.3 46.7 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 122.352 2.035 . . . . 0.0 112.201 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.1 m -79.78 158.03 73.54 Favored Pre-proline 0 CA--C 1.532 0.263 0 C-N-CA 120.661 -0.415 . . . . 0.0 110.797 -179.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -57.23 -40.27 83.87 Favored 'Trans proline' 0 N--CA 1.5 1.912 0 C-N-CA 122.381 2.054 . . . . 0.0 112.096 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.4 p90 -89.72 16.99 7.01 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.182 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -112.69 113.39 25.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.791 0.329 . . . . 0.0 110.626 179.425 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 55.7 p -112.42 -17.55 12.66 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.458 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 57.6 p-10 -87.59 6.13 35.99 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.13 179.64 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 74.9 m -70.28 151.17 45.6 Favored 'General case' 0 C--O 1.231 0.094 0 CA-C-O 120.86 0.362 . . . . 0.0 110.662 179.694 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 60.6 tp -84.66 135.93 33.96 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.154 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 62.6 mtpt -93.93 119.06 32.33 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.091 179.436 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.407 HG21 HD13 ' A' ' 49' ' ' ILE . 28.9 pt -136.64 168.02 22.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.316 -179.588 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 23.5 pttp -148.21 156.47 42.61 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.856 0.36 . . . . 0.0 110.385 179.255 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 65.3 tttm -56.96 129.9 43.66 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.313 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.13 -16.14 60.5 Favored Glycine 0 CA--C 1.53 1.004 0 N-CA-C 111.349 -0.7 . . . . 0.0 111.349 -179.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . 0.483 ' OD2' HD11 ' A' ' 70' ' ' LEU . 17.5 t0 -71.33 146.61 48.74 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 110.321 -0.251 . . . . 0.0 110.321 179.663 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 48.2 mm -114.89 129.11 71.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.938 0.399 . . . . 0.0 110.291 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.473 HG12 HD12 ' A' ' 70' ' ' LEU . 90.9 mt -119.03 130.39 73.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.871 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -74.93 128.39 35.45 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.321 -0.552 . . . . 0.0 110.227 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.9 mt -74.11 121.52 25.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.165 0 CA-C-O 120.854 0.359 . . . . 0.0 110.514 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 12.7 tt -113.67 -35.99 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.656 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 85.7 m -147.68 152.16 37.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.589 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.3 mtpt -136.47 155.94 49.29 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.247 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 68.9 p -131.98 155.67 81.06 Favored Pre-proline 0 C--N 1.327 -0.373 0 C-N-CA 120.417 -0.513 . . . . 0.0 110.756 179.425 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -59.93 115.79 2.87 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 121.954 1.769 . . . . 0.0 111.882 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 99.3 mtp 43.75 32.92 0.63 Allowed 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.969 179.401 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -122.64 173.97 16.18 Favored Glycine 0 CA--C 1.519 0.336 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 10.6 ptm -60.07 149.61 31.89 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.83 0.348 . . . . 0.0 110.432 -179.243 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 45.4 m0 -94.55 150.55 20.13 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.968 -179.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.1 m -118.65 143.1 47.05 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.372 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -165.0 -168.5 27.25 Favored Glycine 0 CA--C 1.52 0.395 0 C-N-CA 120.167 -1.016 . . . . 0.0 111.68 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 60.9 ttm -114.86 135.94 53.64 Favored 'General case' 0 C--O 1.238 0.447 0 CA-C-O 120.969 0.414 . . . . 0.0 110.444 179.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.483 HD11 ' OD2' ' A' ' 53' ' ' ASP . 3.5 tt -136.71 113.68 10.49 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.596 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . 0.423 ' N ' HD23 ' A' ' 70' ' ' LEU . 66.8 t30 53.39 52.33 13.66 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.678 -0.409 . . . . 0.0 111.356 178.764 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 59.71 28.48 17.93 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.921 0.391 . . . . 0.0 110.921 179.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -139.87 115.74 10.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.132 -0.486 . . . . 0.0 109.82 179.027 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.405 HG22 ' H ' ' A' ' 74' ' ' VAL . 19.4 m -92.28 141.88 13.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.622 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -165.9 177.68 40.92 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 -179.488 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 76.7 m-20 -107.96 144.66 34.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.919 0.39 . . . . 0.0 110.523 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.8 p90 -148.19 147.1 29.06 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.741 179.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 17.5 tptm -58.0 121.47 10.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.358 -179.094 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.7 p90 -61.28 -25.43 67.1 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.624 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 97.7 mt -64.0 -39.03 83.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-O 120.919 0.39 . . . . 0.0 110.503 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 12.7 m-30 -77.27 -1.78 31.42 Favored 'General case' 0 C--O 1.237 0.404 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.388 -179.14 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.445 HG21 ' HB1' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -128.5 161.6 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.68 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -130.02 143.88 51.03 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.4 ' H ' HG12 ' A' ' 84' ' ' VAL . 1.5 p -84.72 119.74 34.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.672 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 37.9 pt -127.84 158.96 39.28 Favored 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.77 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 35.2 t -110.66 127.37 55.25 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.234 179.724 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 118.048 -0.977 . . . . 0.0 110.488 -179.615 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 26.3 p . . . . . 0 N--CA 1.455 -0.222 0 CA-C-O 120.855 0.36 . . . . 0.0 110.317 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 162.32 -130.08 2.21 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 87.7 mmt-85 -112.11 145.31 40.0 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.943 0.401 . . . . 0.0 110.741 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.504 ' HB3' ' HB ' ' A' ' 55' ' ' ILE . . . -108.91 121.46 45.15 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.269 179.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 46.5 ttt-85 -97.09 125.43 41.55 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.896 0.379 . . . . 0.0 110.365 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.6 t -82.48 128.62 38.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.617 -179.143 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 65.6 m170 -103.72 -10.3 18.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.192 179.61 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 12.2 t -144.76 145.39 31.65 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.927 0.394 . . . . 0.0 110.345 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -71.81 114.27 9.73 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.3 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 9.5 t80 -121.08 123.58 42.71 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.349 179.392 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 81.5 p -124.7 154.22 70.25 Favored Pre-proline 0 C--N 1.329 -0.29 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.824 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.14 159.22 30.21 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 C-N-CA 123.027 2.484 . . . . 0.0 112.487 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 72.4 m -82.28 158.41 66.66 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.377 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -52.86 -45.92 37.35 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 122.245 1.964 . . . . 0.0 111.981 -179.559 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -80.09 -20.78 44.29 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.91 0.386 . . . . 0.0 110.731 179.533 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -93.05 105.29 17.41 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.416 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 72.1 p -104.37 -23.55 13.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.314 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -63.2 -37.45 87.27 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.631 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.6 t -61.44 135.98 57.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.883 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 56.5 tp -80.57 146.03 31.46 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.419 -179.679 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.51 127.42 42.49 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.563 179.087 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.432 HG21 HD11 ' A' ' 55' ' ' ILE . 27.7 pt -139.24 160.45 28.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.565 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 19.6 ptpt -136.64 157.34 46.99 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.211 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -61.27 129.38 40.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.945 0.403 . . . . 0.0 111.071 -179.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.92 -16.31 59.64 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -76.55 146.47 38.34 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-O 120.776 0.322 . . . . 0.0 110.633 179.537 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 46.8 mm -108.89 127.55 65.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.004 0.431 . . . . 0.0 110.126 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.504 ' HB ' ' HB3' ' A' ' 31' ' ' ALA . 78.5 mt -108.58 130.62 61.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.728 -178.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -79.96 112.09 16.92 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.6 mt -65.9 118.2 8.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.908 0.385 . . . . 0.0 110.661 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.0 tt -101.93 -35.3 4.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.323 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 25.1 p -171.99 172.9 4.56 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.412 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 65.1 mttp -116.85 145.08 43.79 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 120.881 -0.328 . . . . 0.0 110.537 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 9.8 m -97.69 135.45 21.61 Favored Pre-proline 0 CA--C 1.536 0.417 0 C-N-CA 119.589 -0.844 . . . . 0.0 109.703 -179.379 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -58.7 -25.39 75.37 Favored 'Trans proline' 0 N--CA 1.501 1.915 0 C-N-CA 122.57 2.18 . . . . 0.0 112.614 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 39.2 mmt -65.19 -36.97 85.85 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.446 179.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 140.09 -39.56 1.49 Allowed Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 98.7 mtp -63.35 145.14 56.19 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.455 0.645 . . . . 0.0 111.198 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 22.4 m0 -96.35 146.95 24.3 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.828 -179.742 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 68.0 m -117.0 139.95 50.07 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 115.802 -0.636 . . . . 0.0 109.909 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.95 -172.02 23.71 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.166 -0.773 . . . . 0.0 111.166 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 67.8 ttp -116.18 143.09 45.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.152 0.501 . . . . 0.0 110.605 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -143.87 117.85 9.42 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.661 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 8.9 p30 40.64 59.73 2.08 Favored 'General case' 0 N--CA 1.469 0.525 0 O-C-N 123.442 0.464 . . . . 0.0 111.033 179.806 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 33.7 m120 59.25 35.44 23.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.025 -179.8 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 19.3 tptp -140.56 111.49 7.02 Favored 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.399 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 95.5 t -99.53 127.41 52.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.758 -0.377 . . . . 0.0 110.425 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -159.77 -176.8 32.25 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.886 -0.885 . . . . 0.0 110.886 -179.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.4 m120 -103.31 158.57 16.24 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.918 0.39 . . . . 0.0 110.467 -179.563 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -157.06 160.53 39.02 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.006 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 36.7 tptt -69.09 111.55 5.13 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.193 -179.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.3 p90 -59.17 -24.14 62.81 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.522 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.6 mt -67.9 -38.25 79.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.183 0.516 . . . . 0.0 110.654 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.2 m-30 -75.78 -5.94 48.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.834 -179.03 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.427 ' CG2' ' HB1' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -126.23 159.82 34.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 CA-C-O 121.042 0.449 . . . . 0.0 110.079 179.737 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 50.6 t0 -126.21 139.53 53.26 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.937 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.46 HG13 ' O ' ' A' ' 84' ' ' VAL . 8.8 p -82.45 121.03 35.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.953 0.406 . . . . 0.0 110.961 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 41.2 pt -128.3 160.4 38.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.613 179.669 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 29.9 t -106.25 132.1 52.7 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.441 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 54.2 tp10 . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 117.974 -1.013 . . . . 0.0 110.332 -179.987 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 77.3 m . . . . . 0 N--CA 1.457 -0.106 0 CA-C-O 120.95 0.405 . . . . 0.0 110.369 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 169.27 -142.25 7.22 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 2.9 mpp_? -112.25 146.2 38.6 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.879 0.371 . . . . 0.0 110.454 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.722 ' HB1' ' CG1' ' A' ' 82' ' ' VAL . . . -116.06 125.3 52.23 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.083 179.829 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 74.2 ttt-85 -92.74 119.83 32.51 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.387 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.54 HG22 HG22 ' A' ' 82' ' ' VAL . 96.4 t -78.29 125.54 37.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.829 0.347 . . . . 0.0 110.679 -179.511 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 33.2 p80 -112.51 -10.64 13.7 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.885 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 90.2 m -128.81 131.33 47.74 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.778 0.323 . . . . 0.0 110.396 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.6 t0 -68.27 131.34 45.18 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.629 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -88.28 137.22 32.52 Favored 'General case' 0 C--N 1.331 -0.2 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.167 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 43.2 p -126.82 93.79 41.36 Favored Pre-proline 0 CA--C 1.534 0.347 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.441 -179.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -73.27 155.79 51.25 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 122.172 1.915 . . . . 0.0 112.364 -179.022 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.6 m -73.47 157.96 87.16 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.801 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -55.83 -38.77 94.06 Favored 'Trans proline' 0 N--CA 1.498 1.766 0 C-N-CA 122.512 2.141 . . . . 0.0 112.046 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -88.6 6.54 37.69 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.066 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.22 101.15 12.09 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.752 0.311 . . . . 0.0 110.332 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 72.6 p -104.37 -27.52 11.91 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.883 0.373 . . . . 0.0 110.26 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -72.98 -21.27 60.88 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.775 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 41.4 t -59.62 141.36 55.15 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.404 -179.61 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 66.0 tp -80.27 138.84 36.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.147 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 30.2 mtpp -95.0 118.1 31.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.256 179.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.498 HG22 ' CD1' ' A' ' 70' ' ' LEU . 21.6 pt -138.42 146.68 26.3 Favored 'Isoleucine or valine' 0 C--O 1.237 0.419 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.186 179.676 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.04 167.23 14.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.909 0.385 . . . . 0.0 110.424 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -64.99 129.56 40.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.525 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.99 -20.83 47.41 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 111.214 -0.754 . . . . 0.0 111.214 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -69.88 148.51 48.94 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.387 179.219 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 86.5 mt -109.01 127.62 65.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.142 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 72.0 mt -109.96 130.16 63.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.447 -178.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -75.82 115.34 15.41 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.203 -0.599 . . . . 0.0 109.928 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.73 125.4 25.24 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 CA-C-O 120.823 0.344 . . . . 0.0 110.765 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 97.1 mt -108.73 -58.46 3.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.477 179.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 40.3 t -163.46 151.88 13.75 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.752 -179.691 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 59.0 mttm -96.85 157.78 15.74 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.073 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 74.9 p -112.29 156.95 41.31 Favored Pre-proline 0 C--N 1.329 -0.289 0 C-N-CA 120.618 -0.433 . . . . 0.0 110.784 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_exo -56.6 -33.73 93.82 Favored 'Trans proline' 0 N--CA 1.497 1.734 0 C-N-CA 122.68 2.254 . . . . 0.0 112.269 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 98.6 mtp -62.04 -38.48 88.89 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.514 -179.572 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 132.2 -32.38 2.86 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 98.5 mtp -62.4 143.8 56.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.002 0.429 . . . . 0.0 110.552 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 47.6 m0 -98.41 150.07 22.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.087 -178.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 90.0 m -110.0 135.18 51.25 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.657 179.553 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -152.66 -176.14 24.93 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 111.244 -0.742 . . . . 0.0 111.244 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.6 ttp -124.21 142.5 51.18 Favored 'General case' 0 C--O 1.237 0.432 0 CA-C-O 120.961 0.41 . . . . 0.0 110.672 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.498 ' CD1' HG22 ' A' ' 49' ' ' ILE . 2.1 mt -138.06 105.54 5.55 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.762 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 55.63 58.41 4.54 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.23 0.538 . . . . 0.0 109.705 178.775 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 58.5 t30 59.58 34.53 22.38 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.432 -179.515 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 8.9 tppt? -132.89 109.77 9.84 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.357 -0.383 . . . . 0.0 109.971 179.38 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 82.3 t -97.75 123.51 50.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 C-N-CA 120.706 -0.397 . . . . 0.0 110.499 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -156.83 179.12 32.88 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -105.69 154.54 20.31 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.958 0.409 . . . . 0.0 110.829 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.641 ' CD1' HG21 ' A' ' 82' ' ' VAL . 50.8 p90 -152.74 159.63 43.13 Favored 'General case' 0 C--O 1.237 0.443 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.823 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 30.6 tttt -68.65 116.46 9.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.209 -179.064 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -59.97 -25.71 65.45 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.571 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.6 mt -65.82 -38.46 82.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.713 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.1 m-30 -78.85 -7.32 57.79 Favored 'General case' 0 C--O 1.24 0.585 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.226 -178.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.722 ' CG1' ' HB1' ' A' ' 31' ' ' ALA . 66.5 t -121.39 138.68 50.93 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.283 0 CA-C-O 120.972 0.415 . . . . 0.0 110.991 -179.449 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -106.07 134.28 49.44 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.229 179.784 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.424 ' H ' HG12 ' A' ' 84' ' ' VAL . 1.4 p -76.44 118.21 22.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.188 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -106.39 148.0 11.24 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.126 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.253 -179.733 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 90.0 p -112.18 147.37 36.31 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.771 -0.372 . . . . 0.0 110.093 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.388 179.908 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 16.9 p . . . . . 0 N--CA 1.454 -0.266 0 CA-C-O 120.994 0.426 . . . . 0.0 110.269 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 174.85 -139.65 4.94 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -179.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 93.5 mtt-85 -126.24 151.73 47.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.776 0.322 . . . . 0.0 110.575 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -123.01 135.75 54.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.531 -179.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.437 ' HG2' HD12 ' A' ' 54' ' ' ILE . 57.3 mtm180 -101.88 123.53 45.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.254 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.66 HG22 HG23 ' A' ' 82' ' ' VAL . 99.0 t -81.22 129.04 38.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.485 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -113.06 -0.22 14.79 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.961 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 12.2 t -146.47 151.49 37.48 Favored 'General case' 0 N--CA 1.455 -0.214 0 CA-C-O 120.914 0.387 . . . . 0.0 110.547 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -88.46 107.59 18.95 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.529 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 6.2 t80 -118.67 119.34 34.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.621 179.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.412 ' O ' HG23 ' A' ' 38' ' ' THR . 9.8 t -126.79 131.38 23.87 Favored Pre-proline 0 N--CA 1.451 -0.398 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.669 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -73.33 163.47 37.75 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.873 2.382 . . . . 0.0 112.38 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.3 m -66.04 156.47 84.13 Favored Pre-proline 0 C--N 1.327 -0.383 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.607 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -57.69 -31.55 92.31 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 C-N-CA 122.778 2.319 . . . . 0.0 112.332 -179.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -73.11 -10.67 60.03 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.572 179.467 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 48.6 t0 -110.22 114.04 27.21 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.298 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.3 t -106.12 -28.67 10.35 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.728 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -62.23 -36.56 82.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.497 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 47.2 m -63.47 139.31 58.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.704 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.418 HD21 ' HB2' ' A' ' 70' ' ' LEU . 59.2 tp -91.79 143.36 26.6 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.41 -179.813 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 23.0 pttp -94.37 141.86 28.09 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.393 179.112 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.603 ' HB ' HG21 ' A' ' 33' ' ' VAL . 29.8 pt -132.0 147.5 32.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.559 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 40.7 ttmt -128.3 138.53 52.44 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.638 179.419 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -55.91 125.64 22.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.814 -179.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 105.51 -21.42 34.89 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.283 -0.727 . . . . 0.0 111.283 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -81.55 155.14 25.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.736 0.303 . . . . 0.0 110.806 179.29 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.437 HD12 ' HG2' ' A' ' 32' ' ' ARG . 46.7 mm -113.47 130.07 68.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.685 179.822 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.573 HD11 HG22 ' A' ' 49' ' ' ILE . 84.2 mt -112.49 129.06 68.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.498 -179.418 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 64.5 t0 -82.2 121.81 27.1 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.276 179.603 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 84.2 mt -70.21 128.74 33.94 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.116 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.419 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 88.8 mt -105.93 -53.49 6.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.709 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.8 t -163.84 150.66 11.89 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.78 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.7 mttp -109.29 155.34 21.27 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.251 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 81.5 p -136.05 155.09 77.85 Favored Pre-proline 0 N--CA 1.45 -0.471 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.853 179.651 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_exo -62.5 -21.23 72.55 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 122.863 2.375 . . . . 0.0 112.061 179.171 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 63.7 tpp -52.16 -31.6 32.11 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.417 -179.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 106.8 18.18 11.03 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 6.4 mtt -128.34 139.5 52.36 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.782 0.325 . . . . 0.0 110.474 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 33.5 m0 -93.36 139.45 30.66 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.775 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 93.0 m -98.39 131.16 44.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 109.897 179.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -154.52 -176.51 26.89 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -179.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 23.4 ptp -123.57 146.46 48.12 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.874 0.369 . . . . 0.0 110.667 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.418 ' HB2' HD21 ' A' ' 47' ' ' LEU . 0.5 OUTLIER -150.03 118.78 6.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.512 179.867 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 54.8 m-20 53.59 49.71 18.83 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 54.3 t30 59.69 35.63 22.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.584 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 22.7 ttmm -138.64 117.62 12.48 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.459 179.292 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 96.9 t -99.45 131.03 47.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.733 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -158.03 177.57 34.7 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 81.7 m-20 -105.05 135.62 46.05 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.876 0.37 . . . . 0.0 110.564 -179.681 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -138.48 155.0 48.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.792 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -75.75 125.02 28.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.372 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.501 ' HA ' HG12 ' A' ' 82' ' ' VAL . 20.6 p90 -65.31 -20.42 66.4 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.706 -179.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 6.4 pt -61.01 -23.17 28.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.505 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 41.6 m-85 -102.4 10.18 39.21 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.644 179.443 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.66 HG23 HG22 ' A' ' 33' ' ' VAL . 0.3 OUTLIER -135.54 147.96 28.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.234 0 CA-C-O 120.863 0.363 . . . . 0.0 110.344 -179.609 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -105.62 131.95 52.37 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.302 179.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.402 HG12 ' H ' ' A' ' 84' ' ' VAL . 2.1 p -91.31 132.98 34.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-O 120.96 0.409 . . . . 0.0 110.795 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 37.5 pt -124.0 156.63 31.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.69 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 66.0 m -113.09 148.63 34.86 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.673 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.601 179.948 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.2 m . . . . . 0 N--CA 1.458 -0.075 0 CA-C-O 120.902 0.382 . . . . 0.0 110.403 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -175.92 -149.8 7.68 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -109.03 138.21 45.74 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.94 0.4 . . . . 0.0 110.496 -179.793 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.758 ' HB1' ' CG1' ' A' ' 82' ' ' VAL . . . -106.11 115.15 29.73 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.198 -179.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 45.4 ttp180 -96.59 120.54 37.1 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.195 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.46 HG22 HG22 ' A' ' 82' ' ' VAL . 90.3 t -76.17 124.32 34.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.48 -179.492 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 1.3 p80 -111.3 -15.87 13.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.537 179.548 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 53.0 m -131.97 135.5 46.62 Favored 'General case' 0 C--N 1.334 -0.103 0 CA-C-O 120.84 0.353 . . . . 0.0 110.833 179.6 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -64.44 133.91 53.47 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 120.716 -0.394 . . . . 0.0 110.49 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -120.8 135.77 55.07 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.276 179.618 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 57.0 p -135.44 90.76 19.7 Favored Pre-proline 0 CA--C 1.534 0.328 0 C-N-CA 120.92 -0.312 . . . . 0.0 110.304 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -69.83 150.6 68.01 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 122.66 2.24 . . . . 0.0 112.284 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 75.4 m -72.96 157.94 87.9 Favored Pre-proline 0 C--N 1.326 -0.439 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.653 -179.686 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -53.76 -23.09 25.34 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.835 2.357 . . . . 0.0 112.114 179.54 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -59.97 -23.05 63.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.204 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -65.8 125.87 26.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.35 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 82.8 p -70.68 -35.85 73.03 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.606 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.498 ' O ' ' C ' ' A' ' 46' ' ' SER . 88.5 m-20 -100.14 5.86 44.86 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 118.337 -0.84 . . . . 0.0 111.465 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.498 ' C ' ' O ' ' A' ' 45' ' ' ASP . 6.6 t -9.88 95.3 0.01 OUTLIER 'General case' 0 C--N 1.358 0.938 0 O-C-N 125.003 1.439 . . . . 0.0 111.311 -179.291 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 66.9 tp -111.34 131.72 54.96 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.232 -178.478 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -97.29 134.31 40.75 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.563 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 48.3 pt -126.65 162.47 30.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.509 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 39.8 ttpt -134.85 135.61 41.81 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.602 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -51.43 131.16 28.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.983 0.42 . . . . 0.0 110.448 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.51 -18.14 56.69 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 111.006 -0.838 . . . . 0.0 111.006 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -72.47 155.53 40.0 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.798 0.332 . . . . 0.0 110.702 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 48.5 mm -114.38 127.68 71.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.198 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.46 HG12 HD12 ' A' ' 70' ' ' LEU . 85.6 mt -117.9 129.41 74.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.683 -179.671 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -74.65 120.64 20.48 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.309 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 85.0 mt -69.76 126.03 29.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.764 0.316 . . . . 0.0 110.347 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.7 mt -110.71 -43.16 5.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.768 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 46.6 t -146.52 139.13 25.2 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.572 -179.607 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.3 mtpt -119.37 153.75 34.67 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.517 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 71.5 p -133.29 153.17 80.49 Favored Pre-proline 0 C--N 1.328 -0.34 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.746 179.753 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -62.62 114.32 2.34 Favored 'Trans proline' 0 N--CA 1.493 1.484 0 C-N-CA 122.53 2.153 . . . . 0.0 112.037 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 99.4 mtp 46.55 32.74 1.74 Allowed 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.274 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -123.45 172.65 16.24 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 8.5 ptm -60.98 148.33 40.35 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.819 0.342 . . . . 0.0 110.143 -179.479 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 41.9 m0 -95.51 149.58 21.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.239 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 84.9 m -115.3 138.33 51.07 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.734 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -162.43 -166.95 22.13 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 65.3 ttp -125.72 138.36 53.87 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.826 0.346 . . . . 0.0 110.258 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.478 ' C ' HD23 ' A' ' 70' ' ' LEU . 4.6 tt -134.31 115.47 14.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.426 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . 0.419 ' N ' HD23 ' A' ' 70' ' ' LEU . 65.7 t30 53.17 56.93 6.8 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.87 179.039 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 56.82 36.94 28.43 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.477 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 5.1 tptt -139.29 111.9 7.74 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.245 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 89.4 t -93.43 127.75 45.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.827 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -162.58 -177.18 35.38 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.801 -0.919 . . . . 0.0 110.801 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -107.78 156.3 19.27 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.98 0.419 . . . . 0.0 110.685 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.531 ' CD1' HG21 ' A' ' 82' ' ' VAL . 11.6 p90 -155.89 156.57 34.84 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.762 -0.653 . . . . 0.0 111.22 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.734 ' HE2' HD12 ' A' ' 80' ' ' ILE . 32.8 tttt -65.74 118.57 9.8 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.446 -179.243 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 36.5 p90 -61.18 -25.09 66.79 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.667 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.734 HD12 ' HE2' ' A' ' 78' ' ' LYS . 95.7 mt -63.08 -39.55 85.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 120.845 0.355 . . . . 0.0 110.634 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 18.3 m-85 -84.79 3.95 35.23 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.897 -179.54 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.758 ' CG1' ' HB1' ' A' ' 31' ' ' ALA . 86.3 t -126.22 136.09 61.86 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 CA-C-O 121.184 0.516 . . . . 0.0 110.914 179.801 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -111.17 142.48 43.3 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.422 179.461 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.466 HG13 ' O ' ' A' ' 84' ' ' VAL . 8.5 p -89.63 122.83 41.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.767 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 36.5 pt -128.92 158.96 41.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.719 179.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 29.3 t -90.1 124.73 35.04 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.457 179.638 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 . . . . . 0 C--O 1.219 -0.517 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.674 -179.874 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 17.0 p . . . . . 0 N--CA 1.448 -0.535 0 CA-C-O 121.103 0.478 . . . . 0.0 109.997 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 169.63 -138.3 4.97 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.024 -0.831 . . . . 0.0 111.024 -179.579 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 39.1 mmt180 -111.81 142.73 43.81 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.763 0.316 . . . . 0.0 110.361 -179.601 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -122.41 141.08 51.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.516 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -116.08 132.22 56.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.316 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 84.0 t -82.39 125.99 39.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.819 -179.086 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 28.2 p80 -114.14 -13.75 12.39 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.91 179.609 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 87.9 m -126.28 130.45 50.89 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.418 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.4 t0 -64.22 122.15 15.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.303 -179.771 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . 0.434 ' HB3' HD11 ' A' ' 49' ' ' ILE . 15.3 t80 -117.83 128.14 54.56 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.437 179.826 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 38' ' ' THR . 5.9 t -133.51 92.44 23.85 Favored Pre-proline 0 CA--C 1.539 0.53 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.485 179.561 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.85 151.45 62.86 Favored 'Trans proline' 0 N--CA 1.495 1.6 0 C-N-CA 121.955 1.77 . . . . 0.0 112.148 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 99.9 p -70.82 155.48 93.32 Favored Pre-proline 0 CA--C 1.533 0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.628 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -62.7 -21.89 73.4 Favored 'Trans proline' 0 N--CA 1.497 1.682 0 C-N-CA 122.491 2.127 . . . . 0.0 112.253 179.674 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -64.59 -25.16 67.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.442 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -64.89 143.71 57.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.356 179.442 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 61.9 p -84.39 -29.58 26.08 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.582 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.437 ' O ' ' C ' ' A' ' 46' ' ' SER . 97.9 m-20 -100.23 -0.86 37.81 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.716 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 45' ' ' ASP . 16.3 t -20.81 95.86 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.675 0 O-C-N 124.033 0.833 . . . . 0.0 112.697 -178.757 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 63.5 tp -104.98 134.05 48.74 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.933 -179.427 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -97.17 129.19 44.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.558 179.392 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.434 HD11 ' HB3' ' A' ' 37' ' ' PHE . 40.2 pt -136.62 160.4 37.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.429 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -137.25 134.57 36.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.648 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 5.4 ptmm? -49.58 137.02 16.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.775 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.98 -17.76 58.71 Favored Glycine 0 CA--C 1.528 0.863 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 -179.839 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -79.15 157.57 27.88 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.831 0.348 . . . . 0.0 110.452 179.541 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 47.9 mm -114.73 129.67 70.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.298 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 85.7 mt -111.1 132.58 59.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.725 -179.494 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -78.45 113.71 16.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.841 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.4 mt -68.23 125.93 26.98 Favored 'Isoleucine or valine' 0 C--O 1.232 0.178 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.472 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.457 HD11 ' HB2' ' A' ' 69' ' ' MET . 80.7 mt -105.34 -50.79 8.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.338 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 77.9 m -139.31 149.88 44.75 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.709 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.5 mtpt -132.07 159.64 38.28 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.612 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 82.4 p -132.0 158.57 75.15 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.537 179.697 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_exo -53.11 -39.23 80.72 Favored 'Trans proline' 0 N--CA 1.497 1.722 0 C-N-CA 122.488 2.125 . . . . 0.0 112.155 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 11.5 tpt -162.23 90.31 0.74 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.491 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 179.66 -178.18 48.5 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.1 mtp -62.49 147.59 48.36 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.02 0.438 . . . . 0.0 110.569 -179.406 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 43.8 m0 -95.86 147.05 24.06 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.462 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 96.8 m -107.62 132.75 52.96 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.882 179.513 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -151.3 -177.8 25.47 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . 0.457 ' HB2' HD11 ' A' ' 58' ' ' ILE . 66.7 ttp -121.0 141.24 50.91 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 120.975 0.417 . . . . 0.0 110.631 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.436 HD22 ' ND2' ' A' ' 71' ' ' ASN . 0.5 OUTLIER -140.93 110.84 6.52 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.4 179.785 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . 0.436 ' ND2' HD22 ' A' ' 70' ' ' LEU . 50.9 m-20 54.99 56.38 6.66 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.876 -0.33 . . . . 0.0 110.197 179.447 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 87.0 m-20 56.13 36.52 27.56 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.724 0.297 . . . . 0.0 110.781 -179.668 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 18.4 tptm -138.43 113.26 9.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.11 179.337 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 98.3 t -93.48 126.89 45.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 120.811 -0.356 . . . . 0.0 110.507 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -154.77 177.62 31.96 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.653 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -106.94 155.0 20.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.057 0.456 . . . . 0.0 110.953 -179.549 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 32.1 p90 -156.29 162.75 40.09 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.02 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 7.4 ttmm -76.67 115.98 16.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.72 -179.218 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.465 ' HA ' HG12 ' A' ' 82' ' ' VAL . 51.9 p90 -58.34 -22.61 53.95 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.818 179.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.6 mt -66.29 -39.35 83.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 121.062 0.458 . . . . 0.0 110.602 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.3 m-30 -79.65 -0.18 32.85 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.122 -179.017 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.465 HG12 ' HA ' ' A' ' 79' ' ' PHE . 0.5 OUTLIER -130.0 158.09 42.52 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 CA-C-O 120.857 0.36 . . . . 0.0 110.263 179.749 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -121.08 141.31 50.9 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.46 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.3 p -92.02 126.16 44.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.816 -179.782 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 44.4 pt -128.29 154.3 38.82 Favored 'Isoleucine or valine' 0 C--O 1.236 0.375 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.764 179.691 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 36.9 t -110.5 130.73 55.49 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.608 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.6 tm-20 . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.684 -179.977 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.1 m . . . . . 0 N--CA 1.456 -0.139 0 CA-C-O 120.853 0.359 . . . . 0.0 110.285 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 166.88 -140.31 6.23 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.5 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -117.29 154.96 30.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.348 . . . . 0.0 110.7 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.545 ' HB1' HG22 ' A' ' 82' ' ' VAL . . . -122.96 137.2 55.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.391 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.427 ' HE ' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -99.36 118.66 36.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.347 179.879 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 69.6 t -69.41 130.05 34.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.914 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 23.9 m-70 -108.86 -22.52 12.16 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.811 179.389 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 50.7 p -125.99 158.4 35.38 Favored 'General case' 0 C--N 1.332 -0.177 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.348 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -91.27 116.55 28.92 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.823 -179.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 14.1 t80 -116.16 117.53 30.31 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.049 179.347 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 8.1 t -117.76 141.11 28.54 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.136 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -72.42 153.82 55.61 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.668 2.245 . . . . 0.0 112.456 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.5 p -72.91 166.17 45.67 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.036 -179.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -55.47 -42.14 71.02 Favored 'Trans proline' 0 N--CA 1.501 1.968 0 C-N-CA 122.906 2.404 . . . . 0.0 112.639 -179.461 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -97.37 11.43 36.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.879 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 65.2 t0 -112.19 112.07 23.42 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.768 0.318 . . . . 0.0 110.517 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 48.9 p -110.86 -24.16 10.58 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.484 179.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -63.36 -38.43 91.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.615 179.595 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.2 t -61.58 140.61 58.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.901 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 19.3 tp -89.39 143.71 26.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.748 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.8 pttt -97.03 137.55 35.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.452 179.093 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 2.4 pt -142.17 145.72 23.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.283 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.173 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 17.1 mttm -117.76 152.32 35.53 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.352 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -61.28 129.98 43.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.958 0.409 . . . . 0.0 110.285 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.19 -22.18 41.22 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -71.72 154.97 40.99 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.826 0.346 . . . . 0.0 110.609 179.186 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.427 HD11 ' HE ' ' A' ' 32' ' ' ARG . 76.2 mt -119.42 133.64 65.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.332 179.682 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 84.3 mt -117.66 132.04 68.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.913 -179.601 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -75.42 123.12 24.85 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 109.89 179.484 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 93.3 mt -69.11 129.34 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 O-C-N 123.881 0.738 . . . . 0.0 110.365 -179.662 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 89.9 mt -109.55 -54.53 5.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.66 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 44.1 t -163.99 147.65 9.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.189 -179.604 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -92.94 146.27 23.75 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.726 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.2 p -103.25 154.45 37.68 Favored Pre-proline 0 C--N 1.328 -0.346 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.514 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -62.11 -25.71 77.53 Favored 'Trans proline' 0 N--CA 1.497 1.704 0 C-N-CA 122.653 2.235 . . . . 0.0 112.159 179.332 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 96.4 mmm -70.17 -22.13 62.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.521 179.693 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 114.31 -26.26 9.87 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.4 mtp -64.95 147.04 54.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.983 0.421 . . . . 0.0 110.765 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 43.4 m0 -102.38 146.09 28.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.241 0.544 . . . . 0.0 111.321 -179.269 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 98.3 m -108.8 135.33 50.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.605 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -153.76 -176.93 26.7 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.9 ttp -118.46 140.29 50.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.933 0.397 . . . . 0.0 111.244 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.457 HD22 ' ND2' ' A' ' 71' ' ' ASN . 0.4 OUTLIER -143.92 113.96 7.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.511 179.659 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . 0.457 ' ND2' HD22 ' A' ' 70' ' ' LEU . 47.0 m-20 56.98 55.31 6.21 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 32.6 m120 54.53 35.91 24.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.613 0.244 . . . . 0.0 110.491 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 36.6 ttpt -139.48 114.92 9.86 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 120.624 -0.43 . . . . 0.0 110.431 179.465 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 86.9 t -93.28 128.17 44.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.442 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -156.22 179.36 32.17 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 57.2 m-80 -104.38 158.46 16.45 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.222 0.534 . . . . 0.0 110.96 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 7.2 p90 -155.97 160.23 39.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.223 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -63.94 116.27 5.68 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.109 -179.141 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -58.24 -29.0 65.4 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.514 179.753 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.478 HG23 ' CD1' ' A' ' 81' ' ' TYR . 16.3 tt -74.6 -33.96 33.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.896 179.146 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.478 ' CD1' HG23 ' A' ' 80' ' ' ILE . 13.8 m-30 -72.1 -20.79 61.59 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.519 179.596 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.545 HG22 ' HB1' ' A' ' 31' ' ' ALA . 6.1 p -114.97 160.07 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.112 179.06 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . 0.421 ' N ' HG22 ' A' ' 82' ' ' VAL . 8.3 t70 -128.92 149.39 50.81 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.688 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.3 p -92.85 135.19 28.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.594 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 23.2 pt -121.04 158.24 23.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.461 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 41.1 t -61.37 138.72 58.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.587 -179.74 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 20.0 tp10 . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.182 -0.913 . . . . 0.0 110.521 179.983 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.1 m . . . . . 0 N--CA 1.456 -0.139 0 CA-C-O 120.853 0.359 . . . . 0.0 110.285 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 166.88 -140.31 6.23 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.5 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -117.29 154.96 30.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.348 . . . . 0.0 110.7 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.545 ' HB1' HG22 ' A' ' 82' ' ' VAL . . . -122.96 137.2 55.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.391 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.427 ' HE ' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -99.36 118.66 36.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.347 179.879 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 69.6 t -69.41 130.05 34.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.914 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 23.9 m-70 -108.86 -22.52 12.16 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.811 179.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 50.7 p -125.99 158.4 35.38 Favored 'General case' 0 C--N 1.332 -0.177 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.348 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -91.27 116.55 28.92 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.823 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 14.1 t80 -116.16 117.53 30.31 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.049 179.347 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 8.1 t -117.76 141.11 28.54 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.136 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -72.42 153.82 55.61 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.668 2.245 . . . . 0.0 112.456 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.5 p -72.91 166.17 45.67 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.036 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -55.47 -42.14 71.02 Favored 'Trans proline' 0 N--CA 1.501 1.968 0 C-N-CA 122.906 2.404 . . . . 0.0 112.639 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -97.37 11.43 36.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.879 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 65.2 t0 -112.19 112.07 23.42 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.768 0.318 . . . . 0.0 110.517 -179.714 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 48.9 p -110.86 -24.16 10.58 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.484 179.241 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -63.36 -38.43 91.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.615 179.595 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.2 t -61.58 140.61 58.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.901 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 19.3 tp -89.39 143.71 26.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.748 -179.704 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.8 pttt -97.03 137.55 35.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.452 179.093 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 2.4 pt -142.17 145.72 23.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.283 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.173 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 17.1 mttm -117.76 152.32 35.53 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.352 179.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -61.28 129.98 43.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.958 0.409 . . . . 0.0 110.285 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.19 -22.18 41.22 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -71.72 154.97 40.99 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.826 0.346 . . . . 0.0 110.609 179.186 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.427 HD11 ' HE ' ' A' ' 32' ' ' ARG . 76.2 mt -119.42 133.64 65.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.332 179.682 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 84.3 mt -117.66 132.04 68.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.913 -179.601 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -75.42 123.12 24.85 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 109.89 179.484 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 93.3 mt -69.11 129.34 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 O-C-N 123.881 0.738 . . . . 0.0 110.365 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 89.9 mt -109.55 -54.53 5.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.66 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 44.1 t -163.99 147.65 9.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.189 -179.604 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -92.94 146.27 23.75 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.726 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.2 p -103.25 154.45 37.68 Favored Pre-proline 0 C--N 1.328 -0.346 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.514 -179.668 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -62.11 -25.71 77.53 Favored 'Trans proline' 0 N--CA 1.497 1.704 0 C-N-CA 122.653 2.235 . . . . 0.0 112.159 179.332 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 96.4 mmm -70.17 -22.13 62.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.521 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 114.31 -26.26 9.87 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.4 mtp -64.95 147.04 54.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.983 0.421 . . . . 0.0 110.765 179.71 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 43.4 m0 -102.38 146.09 28.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.241 0.544 . . . . 0.0 111.321 -179.269 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 98.3 m -108.8 135.33 50.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.605 179.652 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -153.76 -176.93 26.7 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.9 ttp -118.46 140.29 50.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.933 0.397 . . . . 0.0 111.244 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.457 HD22 ' ND2' ' A' ' 71' ' ' ASN . 0.4 OUTLIER -143.92 113.96 7.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.511 179.659 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . 0.457 ' ND2' HD22 ' A' ' 70' ' ' LEU . 47.0 m-20 56.98 55.31 6.21 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 32.6 m120 54.53 35.91 24.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.613 0.244 . . . . 0.0 110.491 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 36.6 ttpt -139.48 114.92 9.86 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 120.624 -0.43 . . . . 0.0 110.431 179.465 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 86.9 t -93.28 128.17 44.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.442 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -156.22 179.36 32.17 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 57.2 m-80 -104.38 158.46 16.45 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.222 0.534 . . . . 0.0 110.96 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 7.2 p90 -155.97 160.23 39.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.223 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -63.94 116.27 5.68 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.109 -179.141 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -58.24 -29.0 65.4 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.514 179.753 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.478 HG23 ' CD1' ' A' ' 81' ' ' TYR . 16.3 tt -74.6 -33.96 33.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.896 179.146 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.478 ' CD1' HG23 ' A' ' 80' ' ' ILE . 13.8 m-30 -72.1 -20.79 61.59 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.519 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.545 HG22 ' HB1' ' A' ' 31' ' ' ALA . 6.1 p -114.97 160.07 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.112 179.06 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . 0.421 ' N ' HG22 ' A' ' 82' ' ' VAL . 8.3 t70 -128.92 149.39 50.81 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.688 179.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.3 p -92.85 135.19 28.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.594 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 23.2 pt -121.04 158.24 23.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.461 179.815 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 41.1 t -61.37 138.72 58.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.587 -179.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 20.0 tp10 . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.182 -0.913 . . . . 0.0 110.521 179.983 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 31.5 p . . . . . 0 N--CA 1.455 -0.193 0 CA-C-O 120.949 0.404 . . . . 0.0 110.132 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.424 ' H ' HD12 ' A' ' 57' ' ' ILE . . . 179.0 -125.45 0.98 Allowed Glycine 0 CA--C 1.523 0.537 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.237 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 28.4 mmt85 -129.56 141.72 50.91 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.053 0.454 . . . . 0.0 110.659 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.637 ' HB1' HG21 ' A' ' 82' ' ' VAL . . . -107.59 118.68 37.37 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.315 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 68.7 ttt180 -98.45 123.81 42.8 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.977 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.477 HG21 ' HB ' ' A' ' 49' ' ' ILE . 65.9 t -79.54 125.18 38.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.135 -178.76 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 33.2 p80 -105.77 -10.04 16.93 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.202 179.327 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 14.4 t -145.38 151.21 37.9 Favored 'General case' 0 C--O 1.231 0.1 0 CA-C-O 120.841 0.353 . . . . 0.0 110.174 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -80.8 110.42 16.29 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.938 -179.403 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 11.2 t80 -120.69 130.6 54.16 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.369 179.229 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 71.3 p -124.5 152.87 69.19 Favored Pre-proline 0 CA--C 1.53 0.2 0 C-N-CA 120.74 -0.384 . . . . 0.0 110.793 -179.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -76.45 159.91 35.73 Favored 'Trans proline' 0 N--CA 1.492 1.399 0 C-N-CA 122.72 2.28 . . . . 0.0 112.232 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 57.7 m -71.57 157.6 89.53 Favored Pre-proline 0 C--N 1.331 -0.213 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.663 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_exo -53.0 -43.39 57.31 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.241 1.961 . . . . 0.0 111.959 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -84.26 -13.96 51.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.963 179.647 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -91.3 104.13 16.71 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.288 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 71.7 p -102.15 -24.84 13.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.816 0.341 . . . . 0.0 110.53 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -63.08 -38.2 90.25 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.534 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.0 t -73.55 131.15 41.41 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.255 179.742 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 2.5 tp -88.5 161.58 16.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.231 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 23.6 pttm -97.35 145.72 25.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.401 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.546 HG22 HD11 ' A' ' 55' ' ' ILE . 27.3 pt -133.57 149.65 31.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.175 179.706 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 38.0 ttmt -130.71 150.64 51.8 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 57.3 mtmt -55.03 125.72 21.62 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.092 0.472 . . . . 0.0 110.819 -179.21 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.3 -17.36 57.02 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -71.77 142.8 49.71 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 116.923 0.362 . . . . 0.0 110.492 179.631 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 50.5 mm -114.89 128.18 72.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.106 179.76 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.546 HD11 HG22 ' A' ' 49' ' ' ILE . 85.9 mt -118.45 127.87 75.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.636 -179.596 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -78.44 135.22 37.34 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.479 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.424 HD12 ' H ' ' A' ' 29' ' ' GLY . 97.3 mt -76.91 120.9 28.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 C-N-CA 120.822 -0.351 . . . . 0.0 110.318 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.5 mt -107.75 -51.73 7.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.771 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 49.0 t -153.71 144.36 22.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.965 -179.553 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -96.5 142.58 28.41 Favored 'General case' 0 C--N 1.325 -0.46 0 C-N-CA 120.766 -0.374 . . . . 0.0 110.018 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 28.2 m -98.93 135.6 20.86 Favored Pre-proline 0 CA--C 1.54 0.563 0 C-N-CA 120.09 -0.644 . . . . 0.0 110.117 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -50.81 -32.57 37.56 Favored 'Trans proline' 0 N--CA 1.5 1.885 0 C-N-CA 122.373 2.049 . . . . 0.0 112.456 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 24.3 mmt -60.81 -38.85 86.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.273 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 140.67 -40.16 1.4 Allowed Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 179.745 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 96.5 mtp -61.83 145.92 51.2 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.129 0.49 . . . . 0.0 110.767 -179.359 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 42.5 m0 -98.64 153.89 18.35 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.703 -179.372 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.4 m -111.12 134.56 52.62 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 109.592 -0.522 . . . . 0.0 109.592 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.25 -174.22 25.77 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.333 -0.707 . . . . 0.0 111.333 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.1 ttp -119.33 138.16 53.23 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.831 0.348 . . . . 0.0 110.593 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -145.47 126.25 14.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.342 -179.879 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 6.5 p-10 43.46 56.13 4.52 Favored 'General case' 0 N--CA 1.466 0.371 0 O-C-N 123.441 0.463 . . . . 0.0 111.363 -179.525 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 55.08 34.16 21.95 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.935 0.397 . . . . 0.0 110.544 179.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.7 mmtp -142.34 115.04 8.59 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.392 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 16.0 m -97.68 139.4 20.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 C-N-CA 120.546 -0.462 . . . . 0.0 110.509 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -168.54 -177.42 39.52 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.415 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 -103.36 149.15 25.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.959 0.409 . . . . 0.0 110.701 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -146.71 157.97 43.81 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.334 179.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.524 ' HG2' HG22 ' A' ' 80' ' ' ILE . 23.0 ttmt -81.67 116.89 21.61 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.779 -178.564 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.438 ' HA ' HG12 ' A' ' 82' ' ' VAL . 36.5 p90 -57.98 -24.58 58.69 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.989 -179.658 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.524 HG22 ' HG2' ' A' ' 78' ' ' LYS . 10.6 tp -58.18 -25.17 26.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.883 0.373 . . . . 0.0 110.653 -179.667 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 25.1 m-85 -100.94 14.06 33.12 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.191 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.637 HG21 ' HB1' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -143.22 156.13 17.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.746 0.307 . . . . 0.0 110.311 -179.727 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -130.54 149.93 51.98 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.563 179.254 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.6 m -93.78 131.71 39.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.272 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 42.0 pt -126.53 149.77 31.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.832 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 83.7 p -75.85 163.37 27.29 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.732 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.018 -0.992 . . . . 0.0 110.546 179.712 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 28.1 p . . . . . 0 N--CA 1.457 -0.093 0 CA-C-O 120.887 0.375 . . . . 0.0 110.363 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.55 -146.6 6.61 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 -179.421 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 8.2 mmm180 -121.02 142.15 50.07 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.901 -0.32 . . . . 0.0 110.543 -179.516 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.11 127.68 56.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.532 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 17.9 mtp180 -105.14 128.26 53.29 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.46 179.782 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.9 t -86.28 131.26 35.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.327 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 64.4 m170 -111.89 -11.66 13.87 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.047 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.452 HG21 ' HD2' ' A' ' 81' ' ' TYR . 4.2 p -124.89 174.67 7.8 Favored 'General case' 0 N--CA 1.455 -0.188 0 CA-C-O 121.173 0.511 . . . . 0.0 110.419 -179.416 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -103.48 112.0 24.7 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.627 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 8.9 t80 -119.19 118.9 32.58 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-O 121.011 0.434 . . . . 0.0 110.253 179.62 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.517 HG23 ' O ' ' A' ' 38' ' ' THR . 4.8 t -133.61 95.2 18.0 Favored Pre-proline 0 CA--C 1.543 0.696 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.519 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -68.41 153.61 73.66 Favored 'Trans proline' 0 C--N 1.301 -1.924 0 C-N-CA 122.305 2.003 . . . . 0.0 112.313 -179.444 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 48.1 m -65.65 154.49 88.37 Favored Pre-proline 0 N--CA 1.453 -0.294 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.533 -179.564 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.15 -20.98 64.15 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.847 2.365 . . . . 0.0 112.0 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -66.94 -23.56 65.98 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.249 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -99.69 96.53 7.68 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.324 179.409 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . 0.423 ' H ' HG22 ' A' ' 44' ' ' THR . 2.1 t -75.96 -32.8 59.69 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.614 179.617 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -66.85 -38.12 85.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.532 179.722 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 69.1 m -67.49 123.32 20.1 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.671 -179.477 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -85.08 156.31 21.12 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.586 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 60.4 mtpt -98.56 127.84 44.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.645 179.625 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 45.8 pt -138.48 148.37 24.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.509 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 28.2 mttm -127.4 163.44 24.04 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.537 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -61.37 124.61 21.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.52 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 107.42 -31.18 8.32 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.799 -0.92 . . . . 0.0 110.799 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -66.63 145.86 55.11 Favored 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 120.881 -0.328 . . . . 0.0 110.346 179.503 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 60.6 mt -116.49 132.23 66.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.51 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.449 HG12 HD12 ' A' ' 70' ' ' LEU . 2.7 mp -114.86 129.17 71.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.857 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -72.78 122.52 21.67 Favored 'General case' 0 CA--C 1.518 -0.286 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.122 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.96 127.02 28.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 120.986 0.422 . . . . 0.0 110.93 -179.484 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.5 mt -109.39 -54.64 5.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.247 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 20.4 p -162.64 172.6 15.1 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.614 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 31.1 mtpt -120.39 150.23 41.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.451 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 67.3 p -121.71 151.66 57.63 Favored Pre-proline 0 CA--C 1.535 0.386 0 C-N-CA 120.339 -0.545 . . . . 0.0 110.915 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -69.02 -20.73 37.92 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.682 2.255 . . . . 0.0 112.242 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 3.0 mpp? -60.0 -15.51 23.0 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.484 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 97.16 22.8 16.23 Favored Glycine 0 C--N 1.336 0.564 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 96.4 mmm -127.19 144.41 51.04 Favored 'General case' 0 C--O 1.236 0.379 0 CA-C-O 121.039 0.447 . . . . 0.0 110.671 179.726 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 6.0 m0 -98.4 142.49 29.96 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.469 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 89.0 m -105.97 132.1 52.47 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 116.01 -0.541 . . . . 0.0 109.875 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -151.66 -179.87 27.69 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 60.7 ttm -115.81 142.02 47.32 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.989 0.424 . . . . 0.0 110.878 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.449 HD12 HG12 ' A' ' 55' ' ' ILE . 0.6 OUTLIER -143.45 107.94 4.83 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.869 -179.89 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 53.77 53.92 10.64 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.29 179.491 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 54.4 t30 61.07 30.75 19.67 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.64 -179.607 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 62.8 tttm -137.63 112.81 9.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.05 179.344 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 27.4 m -99.09 144.12 12.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.875 0.369 . . . . 0.0 110.648 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -170.09 -173.08 37.19 Favored Glycine 0 CA--C 1.528 0.901 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 -179.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 35.4 m120 -103.4 148.29 26.08 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.985 0.421 . . . . 0.0 110.851 -179.287 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.8 p90 -153.21 160.1 42.75 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.727 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.473 ' HB3' HG12 ' A' ' 80' ' ' ILE . 96.7 mttt -79.71 122.34 26.45 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-O 121.433 0.635 . . . . 0.0 110.518 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 12.0 p90 -68.99 -24.11 64.19 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.199 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.473 HG12 ' HB3' ' A' ' 78' ' ' LYS . 28.4 pt -62.2 -19.69 22.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.833 0.349 . . . . 0.0 110.825 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.452 ' HD2' HG21 ' A' ' 35' ' ' THR . 30.6 m-85 -102.69 5.66 39.12 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.865 179.56 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -136.16 153.86 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 CA-C-O 121.109 0.481 . . . . 0.0 110.638 -179.697 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 -127.51 143.19 51.22 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.565 179.245 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.8 m -88.61 136.93 22.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.229 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 42.5 pt -120.23 157.79 22.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.803 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 83.3 p -72.95 160.77 31.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.656 179.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 118.015 -0.993 . . . . 0.0 110.543 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 79.9 m . . . . . 0 N--CA 1.458 -0.067 0 CA-C-O 120.887 0.375 . . . . 0.0 110.652 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -172.98 -153.29 9.36 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 -179.529 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 39.6 mmt180 -116.45 144.03 44.83 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.886 0.374 . . . . 0.0 110.58 -179.491 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -113.04 121.86 45.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.619 -179.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . 0.476 ' HD2' HG21 ' A' ' 85' ' ' ILE . 94.8 mtt180 -95.77 121.4 37.46 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.51 178.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.431 HG21 ' HB ' ' A' ' 49' ' ' ILE . 67.2 t -76.64 119.84 25.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.352 -179.399 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 4.3 p80 -105.85 -16.05 14.76 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.438 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.54 HG21 ' CD2' ' A' ' 81' ' ' TYR . 1.3 m -126.34 142.56 51.49 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.579 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -77.33 104.57 7.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.978 0.418 . . . . 0.0 110.333 -179.474 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 26.0 t80 -116.52 115.25 25.43 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.63 179.674 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 10.2 t -129.76 137.42 30.88 Favored Pre-proline 0 N--CA 1.452 -0.375 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.605 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -73.49 160.79 43.77 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.855 2.37 . . . . 0.0 112.242 -179.462 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 89.1 p -70.39 161.22 77.81 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.467 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -55.35 -37.71 94.42 Favored 'Trans proline' 0 N--CA 1.496 1.652 0 C-N-CA 122.736 2.291 . . . . 0.0 112.189 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -85.59 1.49 48.9 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.72 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -107.25 108.88 20.5 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-O 120.855 0.36 . . . . 0.0 110.34 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 10.1 t -111.03 -27.26 8.84 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.77 179.809 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -62.44 -38.94 91.68 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.659 -179.684 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.5 t -69.53 141.59 53.82 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.579 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 59.8 tp -83.36 143.64 30.19 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.554 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 26.0 pttm -98.64 137.75 36.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.899 0.381 . . . . 0.0 110.74 178.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.431 ' HB ' HG21 ' A' ' 33' ' ' VAL . 46.3 pt -137.7 147.5 26.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.78 179.526 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -119.38 156.14 30.65 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.032 -179.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.7 ttpt -61.61 120.8 11.29 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.461 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 104.84 -22.19 34.32 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 111.092 -0.803 . . . . 0.0 111.092 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -65.81 147.54 53.21 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-O 120.884 0.373 . . . . 0.0 110.906 179.257 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 47.2 mm -108.73 126.72 65.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.661 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.4 mt -109.22 128.9 64.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.78 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -79.29 112.51 16.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.306 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.3 mt -65.35 126.5 24.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.606 -179.487 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.6 mt -112.41 -55.29 4.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.6 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.9 t -162.86 151.69 14.71 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.74 -179.439 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.4 156.08 17.83 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.46 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.4 p -110.38 154.56 42.91 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.319 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -60.03 -26.84 83.53 Favored 'Trans proline' 0 C--N 1.305 -1.735 0 C-N-CA 122.807 2.338 . . . . 0.0 112.286 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 78.9 mtm -63.99 -38.15 90.02 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.501 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 133.82 -35.55 2.24 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 8.7 mtt -63.0 147.31 51.03 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.918 0.389 . . . . 0.0 110.624 -179.601 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 21.6 m0 -101.88 151.58 21.93 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.865 -179.534 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.0 m -114.08 136.37 53.0 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.866 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -154.56 -174.54 24.7 Favored Glycine 0 CA--C 1.524 0.646 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 -179.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 65.3 ttp -117.83 141.36 48.5 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 120.624 0.249 . . . . 0.0 110.638 -179.771 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.421 ' O ' ' HB3' ' A' ' 73' ' ' LYS . 1.3 mt -143.46 110.44 5.65 Favored 'General case' 0 C--O 1.219 -0.512 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.58 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . 0.4 ' ND2' ' N ' ' A' ' 71' ' ' ASN . 0.1 OUTLIER 54.27 54.16 9.9 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 178.926 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 59.79 28.57 18.06 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.369 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.421 ' HB3' ' O ' ' A' ' 70' ' ' LEU . 85.1 tttt -133.99 112.99 11.67 Favored 'General case' 0 C--O 1.225 -0.214 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.107 179.572 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 19.1 m -99.84 144.0 12.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.855 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -174.86 -173.84 41.03 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -179.536 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 78.1 m-20 -101.57 149.45 24.09 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.849 0.357 . . . . 0.0 110.646 -179.548 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -148.96 160.78 42.98 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.857 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.601 ' CG ' HG22 ' A' ' 80' ' ' ILE . 24.3 tptt -82.01 114.3 20.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.434 -179.168 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.472 ' HA ' HG12 ' A' ' 82' ' ' VAL . 49.0 p90 -62.9 -26.18 68.67 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.588 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.601 HG22 ' CG ' ' A' ' 78' ' ' LYS . 10.2 tt -58.94 -30.33 42.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.814 0.34 . . . . 0.0 110.917 -179.408 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.54 ' CD2' HG21 ' A' ' 35' ' ' THR . 25.2 m-85 -93.32 5.34 51.89 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.04 179.817 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.472 HG12 ' HA ' ' A' ' 79' ' ' PHE . 0.3 OUTLIER -131.42 156.44 42.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 CA-C-O 121.05 0.453 . . . . 0.0 110.68 -179.884 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 85.3 m-20 -123.6 140.07 53.36 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.436 179.352 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -93.84 142.83 12.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 120.949 0.404 . . . . 0.0 110.724 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.476 HG21 ' HD2' ' A' ' 32' ' ' ARG . 39.3 pt -128.6 159.02 40.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.82 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 99.1 p -106.61 160.67 15.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.598 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.569 179.966 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 81.0 m . . . . . 0 N--CA 1.454 -0.264 0 CA-C-O 121.006 0.431 . . . . 0.0 110.212 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -176.08 -144.36 5.09 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -117.83 142.87 46.82 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.694 0.283 . . . . 0.0 110.468 -179.726 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -116.44 137.1 52.43 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.853 0.359 . . . . 0.0 110.454 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 16.0 ptm180 -116.77 133.87 55.48 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.404 HG22 HD12 ' A' ' 49' ' ' ILE . 89.6 t -82.3 127.98 39.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.42 -178.669 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 88.5 m-70 -109.71 -17.13 13.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.435 179.267 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.44 HG21 ' HD2' ' A' ' 81' ' ' TYR . 7.4 p -120.22 173.79 6.9 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.879 0.371 . . . . 0.0 110.143 -179.548 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -101.03 107.71 19.23 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.803 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -117.82 109.84 17.05 Favored 'General case' 0 N--CA 1.463 0.217 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.129 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 90.8 m -128.62 128.23 23.54 Favored Pre-proline 0 CA--C 1.537 0.45 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.852 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -74.48 163.89 35.14 Favored 'Trans proline' 0 N--CA 1.489 1.25 0 C-N-CA 122.489 2.126 . . . . 0.0 112.165 179.612 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 69.7 m -70.57 158.61 87.41 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.565 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -54.4 -35.05 83.49 Favored 'Trans proline' 0 N--CA 1.499 1.807 0 C-N-CA 122.605 2.203 . . . . 0.0 112.128 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 35.5 p90 -90.56 4.11 52.15 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.212 179.803 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -108.58 111.57 23.47 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.551 -0.295 . . . . 0.0 110.364 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 61.4 p -112.89 -19.66 11.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.729 179.504 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -61.98 -38.74 89.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.665 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 58.2 m -80.3 144.19 33.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.682 179.79 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 47.1 tp -81.98 144.03 31.18 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.721 -179.612 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 7.1 ptpp? -98.34 118.56 35.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.622 178.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.404 HD12 HG22 ' A' ' 33' ' ' VAL . 20.1 pt -140.04 158.33 26.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.163 0.506 . . . . 0.0 110.926 -179.733 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.5 164.45 30.31 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.016 0.436 . . . . 0.0 110.679 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -60.59 129.1 39.87 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.914 -179.674 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 109.83 -20.39 26.9 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 111.361 -0.695 . . . . 0.0 111.361 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -85.18 147.41 26.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.003 0.43 . . . . 0.0 110.495 179.273 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 21.7 mm -112.49 129.33 68.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.316 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.417 HG21 ' CE2' ' A' ' 77' ' ' PHE . 75.9 mt -112.55 127.93 69.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.752 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.9 m-20 -78.62 124.94 28.7 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.232 -0.44 . . . . 0.0 109.877 179.591 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 93.4 mt -70.58 123.24 24.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 120.882 0.372 . . . . 0.0 110.478 -179.204 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.6 mt -106.34 -51.34 7.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.41 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 49.6 t -168.29 154.76 7.39 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.022 0.439 . . . . 0.0 110.975 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -90.15 136.15 33.22 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.083 179.26 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.5 t -123.45 148.02 54.34 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.87 -179.307 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -52.32 -169.67 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.454 0 C-N-CA 122.418 2.079 . . . . 0.0 112.126 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 91.6 mtp 63.64 15.85 9.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.376 -179.196 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 63.71 37.4 94.65 Favored Glycine 0 CA--C 1.522 0.471 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 179.466 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 75.0 mtp -126.46 150.68 48.54 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 120.411 -0.516 . . . . 0.0 111.387 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 10.7 m0 -110.82 147.9 33.53 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.625 179.625 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 85.1 m -104.99 131.26 52.74 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.716 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -155.94 -176.45 28.1 Favored Glycine 0 CA--C 1.522 0.487 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.487 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.4 ttp -122.46 138.31 54.59 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.757 0.313 . . . . 0.0 110.657 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -144.3 121.58 11.58 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.185 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 75.6 m-20 53.18 48.4 22.27 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 59.71 29.72 19.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.706 0.289 . . . . 0.0 110.354 -179.537 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 42.9 tptt -130.48 114.9 16.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.259 -0.428 . . . . 0.0 109.881 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 89.7 t -96.54 125.89 49.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.878 -0.329 . . . . 0.0 110.586 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -160.16 -179.71 35.12 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 -179.496 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 -98.83 149.79 22.53 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.026 0.441 . . . . 0.0 110.923 -179.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.417 ' CE2' HG21 ' A' ' 55' ' ' ILE . 48.8 p90 -152.17 159.16 43.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.692 179.731 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 1.5 mptp? -78.73 116.29 18.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.82 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.464 ' HA ' HG12 ' A' ' 82' ' ' VAL . 33.8 p90 -61.49 -25.11 67.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.629 179.809 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.436 HG23 ' CE1' ' A' ' 79' ' ' PHE . 40.9 pt -62.37 -20.12 23.89 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 CA-C-O 120.78 0.324 . . . . 0.0 110.8 179.634 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.44 ' HD2' HG21 ' A' ' 35' ' ' THR . 49.5 m-85 -100.18 3.61 43.87 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.805 179.002 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.464 HG12 ' HA ' ' A' ' 79' ' ' PHE . 0.3 OUTLIER -132.17 157.42 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 CA-C-O 120.86 0.362 . . . . 0.0 110.314 -179.544 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -120.06 133.16 55.6 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.714 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 3.2 m -88.05 137.61 20.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 C-N-CA 120.579 -0.448 . . . . 0.0 110.354 179.659 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 43.0 pt -129.71 158.79 42.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.756 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 67.2 m -112.57 143.96 42.86 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.507 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.556 179.875 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 28.4 p . . . . . 0 C--O 1.232 0.162 0 CA-C-O 120.84 0.352 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.99 -148.13 11.0 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 -179.377 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 1.7 mpt_? -113.01 141.91 46.31 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.95 0.405 . . . . 0.0 110.463 179.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -117.77 130.97 56.63 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.643 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 41.2 ttm180 -97.14 121.51 39.11 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.576 179.624 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.404 HG22 HG23 ' A' ' 82' ' ' VAL . 77.1 t -82.65 129.18 37.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.495 -179.872 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -112.88 8.63 18.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.974 179.452 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.0 p -137.12 166.87 22.69 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.74 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -108.56 104.74 14.12 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.356 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 16.1 t80 -118.72 119.19 33.69 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.628 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 82.4 p -120.74 152.28 55.66 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.609 -179.748 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -76.14 153.44 36.49 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.763 2.309 . . . . 0.0 112.406 -179.751 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 58.3 m -73.34 156.69 88.89 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.483 179.268 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -54.28 -39.4 86.93 Favored 'Trans proline' 0 C--N 1.301 -1.948 0 C-N-CA 122.858 2.372 . . . . 0.0 112.059 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -93.15 4.14 54.5 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.427 179.385 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -113.71 117.98 33.05 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.31 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 t -112.22 -25.13 9.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.79 179.592 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 -62.04 -38.43 88.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.595 -179.741 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 62.0 m -62.13 142.54 57.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.727 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 56.8 tp -90.38 142.49 27.68 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.423 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -94.73 121.84 36.73 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-O 120.939 0.399 . . . . 0.0 110.414 179.066 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.423 ' CG2' HD11 ' A' ' 55' ' ' ILE . 37.8 pt -131.1 155.21 41.75 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.62 -179.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 48.7 pttt -137.27 160.68 38.34 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.564 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -66.3 131.85 47.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.95 179.349 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 102.42 -18.75 50.31 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -82.87 152.01 25.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.823 0.344 . . . . 0.0 110.369 179.505 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 96.4 mt -116.29 133.11 63.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.62 179.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.423 HD11 ' CG2' ' A' ' 49' ' ' ILE . 82.5 mt -118.11 134.15 62.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.783 -179.294 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -80.49 122.94 27.62 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.189 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.3 mt -72.92 124.48 29.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.75 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 8.9 tt -107.0 -33.86 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.449 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 24.0 p -175.54 175.34 2.13 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.463 -179.324 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -126.35 151.8 47.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.536 179.464 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 31.0 p -105.18 153.42 39.56 Favored Pre-proline 0 N--CA 1.454 -0.261 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.611 -179.404 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -57.05 -35.93 99.1 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 C-N-CA 122.779 2.319 . . . . 0.0 112.227 179.717 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 98.2 mtp -61.29 -37.35 82.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.646 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 131.13 -25.46 4.1 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 96.4 mtp -62.15 139.67 58.46 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.027 0.441 . . . . 0.0 110.341 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 37.7 m0 -96.25 148.11 23.08 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.986 -179.371 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 58.3 m -119.48 140.49 50.38 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-N 116.022 -0.536 . . . . 0.0 109.885 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -164.81 -168.93 27.71 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -179.769 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.8 ttp -116.03 135.34 54.05 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-O 120.671 0.272 . . . . 0.0 110.739 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.471 ' C ' HD23 ' A' ' 70' ' ' LEU . 3.1 tt -135.7 112.51 10.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.371 179.702 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . 0.46 ' N ' HD23 ' A' ' 70' ' ' LEU . 66.9 t30 55.41 53.9 9.26 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.855 178.794 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 59.02 28.61 17.92 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.743 179.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -139.33 113.31 8.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.086 179.395 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 19.4 m -95.31 143.67 11.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.859 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -172.34 -173.39 38.95 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.664 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -111.73 155.14 23.96 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.748 0.309 . . . . 0.0 110.451 -179.355 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 9.2 p90 -155.62 157.85 37.4 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.812 179.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.403 ' HB3' HG12 ' A' ' 80' ' ' ILE . 99.2 mttt -63.99 132.81 51.76 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.45 -179.639 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 29.6 p90 -67.08 -21.32 65.89 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.684 -179.17 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.403 HG12 ' HB3' ' A' ' 78' ' ' LYS . 12.5 pt -78.22 -27.0 14.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.334 -179.618 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.2 m-85 -84.3 1.16 46.21 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.71 179.724 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.404 HG23 HG22 ' A' ' 33' ' ' VAL . 7.1 p -139.33 157.88 28.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.31 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -132.22 147.41 52.41 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.392 179.798 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.1 p -83.36 131.21 34.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.597 179.744 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 61.1 mt -88.78 115.84 29.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.456 -178.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 70.8 p -79.4 165.34 23.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.488 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 78.2 mm-40 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.566 179.55 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 31.7 p . . . . . 0 N--CA 1.456 -0.147 0 CA-C-O 120.927 0.394 . . . . 0.0 110.342 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -166.86 -162.92 19.67 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 -179.375 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 10.9 mpt_? -119.6 147.55 44.37 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.764 0.316 . . . . 0.0 110.786 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.588 ' HB1' ' CG1' ' A' ' 82' ' ' VAL . . . -134.57 154.61 51.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.807 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 17.5 ptm180 -131.0 148.95 52.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.741 -179.589 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.444 HG22 HD12 ' A' ' 49' ' ' ILE . 58.8 t -86.26 128.71 39.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.301 -179.043 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 26.4 m170 -97.87 -16.98 19.54 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.517 178.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 13.1 t -144.53 142.8 30.48 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.885 -0.326 . . . . 0.0 110.145 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -62.59 117.45 6.26 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.777 -0.369 . . . . 0.0 110.731 -179.37 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -121.69 110.63 16.18 Favored 'General case' 0 C--O 1.233 0.201 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 88.0 m -129.14 94.73 32.91 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.057 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -54.78 152.7 27.36 Favored 'Trans proline' 0 N--CA 1.494 1.521 0 C-N-CA 122.358 2.039 . . . . 0.0 112.013 -179.596 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 39.0 m -59.14 154.73 38.59 Favored Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.474 -179.425 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -57.28 -24.65 60.86 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.554 2.17 . . . . 0.0 112.186 -179.434 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -65.87 -20.63 66.3 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.331 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 50.3 m-20 -96.11 59.68 1.96 Allowed 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 120.956 0.408 . . . . 0.0 110.521 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 12.8 t -60.46 -18.65 52.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.575 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 57.9 p-10 -90.1 7.23 38.91 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.314 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 67.8 m -106.57 144.41 33.28 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-O 120.917 0.389 . . . . 0.0 110.629 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 58.5 tp -81.6 142.03 33.16 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.536 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 1.6 mptm? -98.7 126.79 44.42 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.47 179.051 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.444 HD12 HG22 ' A' ' 33' ' ' VAL . 21.6 pt -131.49 148.5 32.65 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.631 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 39.3 ttpt -122.65 152.57 40.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.844 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 38.7 ttmt -57.11 128.35 36.56 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.058 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.38 -18.67 55.03 Favored Glycine 0 CA--C 1.524 0.635 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.451 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -72.23 144.96 48.27 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.796 0.332 . . . . 0.0 110.718 179.618 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 90.9 mt -111.96 129.08 68.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.35 179.243 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.416 ' CD1' HD12 ' A' ' 70' ' ' LEU . 81.3 mt -122.62 128.5 75.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.908 -179.172 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -76.9 134.03 39.08 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.367 179.349 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 85.9 mt -71.06 103.58 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.919 0.39 . . . . 0.0 110.16 -179.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.8 tt -89.09 -34.52 6.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.327 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 17.1 t -167.45 161.27 13.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.29 -179.46 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -120.57 144.7 47.95 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . 0.459 HG22 ' H ' ' A' ' 63' ' ' MET . 27.6 m -101.67 135.69 19.72 Favored Pre-proline 0 CA--C 1.539 0.538 0 C-N-CA 120.232 -0.587 . . . . 0.0 109.98 -179.479 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -57.6 -25.7 68.7 Favored 'Trans proline' 0 N--CA 1.501 1.917 0 C-N-CA 122.359 2.039 . . . . 0.0 112.69 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' MET . . . . . 0.459 ' H ' HG22 ' A' ' 61' ' ' THR . 65.5 mtt -62.22 -38.74 90.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.959 0.409 . . . . 0.0 110.186 179.503 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 142.17 -40.12 1.32 Allowed Glycine 0 CA--C 1.524 0.634 0 N-CA-C 111.106 -0.798 . . . . 0.0 111.106 179.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 95.5 mtp -64.07 144.39 57.14 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.217 0.532 . . . . 0.0 111.108 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 38.4 m0 -97.4 156.31 16.52 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.369 -179.579 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 80.3 m -117.19 139.31 50.92 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.056 -179.719 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.23 -175.78 27.6 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 16.9 tmm? -121.31 141.55 50.81 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.723 0.297 . . . . 0.0 110.507 -179.697 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.459 HD22 ' ND2' ' A' ' 71' ' ' ASN . 0.5 OUTLIER -149.31 121.62 8.41 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.992 179.921 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . 0.459 ' ND2' HD22 ' A' ' 70' ' ' LEU . 69.5 m-20 50.31 49.96 19.6 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.714 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 53.0 t30 59.82 35.07 21.93 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.764 0.316 . . . . 0.0 110.708 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 24.3 tptp -134.26 115.94 14.71 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 179.43 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 97.1 t -105.78 129.03 59.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.446 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -165.86 -172.42 33.21 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.59 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.7 m-80 -101.43 153.18 19.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.024 0.44 . . . . 0.0 111.056 -179.508 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.538 ' CD1' HG21 ' A' ' 82' ' ' VAL . 53.4 p90 -149.93 160.43 43.61 Favored 'General case' 0 C--O 1.239 0.54 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.619 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 35.6 tptt -69.62 111.77 5.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.514 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 53.4 p90 -61.53 -24.31 66.53 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.8 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.9 mt -63.14 -39.24 84.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.022 0.439 . . . . 0.0 110.437 -179.807 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 20.6 m-85 -84.71 2.22 42.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.971 -179.581 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.588 ' CG1' ' HB1' ' A' ' 31' ' ' ALA . 85.6 t -126.02 136.9 59.43 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.147 0 CA-C-O 120.987 0.422 . . . . 0.0 110.813 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -124.41 148.42 47.59 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.373 -179.878 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 16.9 m -90.37 139.6 17.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 C-N-CA 120.662 -0.415 . . . . 0.0 110.58 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 38.9 pt -120.96 149.78 23.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.796 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 83.9 p -90.84 170.49 10.05 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.674 179.808 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.049 -0.977 . . . . 0.0 110.482 179.756 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.43 147.74 89.96 Favored 'Trans proline' 0 C--N 1.305 -1.75 0 C-N-CA 122.911 2.407 . . . . 0.0 111.907 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -114.89 139.21 49.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.49 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.4 m -119.76 149.8 41.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.484 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.51 -128.18 1.87 Allowed Glycine 0 CA--C 1.526 0.753 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 9.9 mpt_? -111.48 140.2 46.28 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.754 0.311 . . . . 0.0 110.7 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.464 ' HB1' ' CG1' ' A' ' 82' ' ' VAL . . . -111.1 127.1 55.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.445 179.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 74.2 ttt-85 -103.55 123.66 47.35 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.525 -179.68 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.568 HG22 HG22 ' A' ' 82' ' ' VAL . 66.1 t -77.5 123.51 34.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.621 -179.694 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 35.4 p80 -105.75 -16.37 14.69 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.741 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.472 HG21 ' CD2' ' A' ' 81' ' ' TYR . 32.6 m -128.45 129.33 45.96 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.692 179.666 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -65.71 109.65 2.5 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.557 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . 0.488 ' HB3' HD11 ' A' ' 49' ' ' ILE . 22.5 t80 -117.17 115.4 25.26 Favored 'General case' 0 C--O 1.241 0.611 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.372 179.557 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 95.5 m -131.08 128.28 22.2 Favored Pre-proline 0 N--CA 1.449 -0.502 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.754 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -72.5 166.41 29.9 Favored 'Trans proline' 0 C--N 1.308 -1.597 0 C-N-CA 123.012 2.475 . . . . 0.0 112.139 179.377 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 61.7 m -67.47 159.52 77.45 Favored Pre-proline 0 C--N 1.327 -0.393 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.554 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_exo -55.62 -32.07 81.82 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.722 2.281 . . . . 0.0 112.183 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -95.51 11.45 32.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.763 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -106.69 108.73 20.38 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.339 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 5.0 t -113.51 -8.49 13.36 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.782 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 45.5 p-10 -75.59 -7.12 53.42 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.762 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 73.6 m -118.9 144.37 46.45 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-O 120.787 0.327 . . . . 0.0 110.504 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.413 HD21 ' HB2' ' A' ' 70' ' ' LEU . 9.5 tp -82.11 153.93 25.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.533 -179.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -96.2 130.61 43.23 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.573 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.488 HD11 ' HB3' ' A' ' 37' ' ' PHE . 34.2 pt -134.93 158.53 41.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.414 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.7 tttp -137.0 145.29 43.93 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.798 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 63.4 tttm -54.45 129.2 35.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.637 -179.782 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.57 -16.83 59.26 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 111.174 -0.77 . . . . 0.0 111.174 -179.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -74.87 148.41 40.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.786 0.327 . . . . 0.0 110.612 179.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 42.9 mm -109.93 126.63 67.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.392 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.423 HD11 ' CG2' ' A' ' 49' ' ' ILE . 82.9 mt -119.08 129.06 75.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.606 -179.606 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -77.11 122.77 25.44 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.326 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.4 mt -76.82 125.25 36.46 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.486 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.412 HD11 HG22 ' A' ' 67' ' ' THR . 30.6 pt -114.24 -27.98 2.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.461 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 10.4 t -167.35 161.82 14.41 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.647 -179.158 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -119.14 145.26 46.12 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.231 179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 25.5 m -94.89 134.32 25.09 Favored Pre-proline 0 CA--C 1.534 0.336 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.429 -179.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -50.73 -36.19 50.42 Favored 'Trans proline' 0 N--CA 1.494 1.546 0 C-N-CA 122.806 2.338 . . . . 0.0 112.068 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 60.6 ttm -59.03 -40.23 84.37 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.324 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 144.05 -31.78 1.83 Allowed Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 97.5 mtp -62.54 146.59 51.38 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.014 0.435 . . . . 0.0 110.842 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 42.6 m0 -102.0 150.79 22.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.965 -179.186 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.412 HG22 HD11 ' A' ' 58' ' ' ILE . 93.2 m -110.55 136.73 49.22 Favored 'General case' 0 C--O 1.237 0.417 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.994 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -155.87 -171.56 22.43 Favored Glycine 0 CA--C 1.523 0.573 0 N-CA-C 111.095 -0.802 . . . . 0.0 111.095 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -123.35 147.65 46.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.991 0.424 . . . . 0.0 110.622 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.435 HD22 ' ND2' ' A' ' 71' ' ' ASN . 0.4 OUTLIER -151.09 117.37 5.64 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.69 -179.742 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . 0.435 ' ND2' HD22 ' A' ' 70' ' ' LEU . 67.5 m-20 51.22 52.83 14.07 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.142 179.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 80.7 m-20 59.68 26.18 15.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.237 -179.561 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.9 tttp -130.25 113.16 14.09 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.504 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 15.6 m -99.37 140.04 19.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.761 179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -171.42 -176.67 40.65 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -179.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 -104.12 150.4 24.36 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.077 0.465 . . . . 0.0 110.459 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.665 ' CD1' HG21 ' A' ' 82' ' ' VAL . 50.9 p90 -146.22 156.58 43.49 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.723 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 54.6 mttp -67.01 122.18 17.18 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.005 -179.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 55.9 p90 -68.64 -29.58 68.1 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.55 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 33.6 pt -60.46 -21.21 22.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.839 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.472 ' CD2' HG21 ' A' ' 35' ' ' THR . 22.4 m-85 -102.64 1.51 34.76 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.871 179.289 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.665 HG21 ' CD1' ' A' ' 77' ' ' PHE . 68.2 t -127.83 136.51 60.16 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 CA-C-O 121.109 0.48 . . . . 0.0 110.752 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 41.7 t0 -110.94 142.26 43.28 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.395 179.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.7 p -86.94 126.3 40.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.772 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 23.4 pt -127.19 163.32 30.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.714 179.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 28.7 t -104.74 130.32 52.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.581 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 7.9 tt0 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.554 179.916 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -68.34 143.93 60.1 Favored 'Trans proline' 0 C--N 1.305 -1.716 0 C-N-CA 122.746 2.297 . . . . 0.0 111.947 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 71.7 t80 -142.19 136.65 30.15 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.52 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 84.1 m -100.14 137.53 38.46 Favored 'General case' 0 C--N 1.327 -0.384 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.43 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 172.37 -140.53 5.79 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 21.0 mmm180 -110.14 148.13 32.37 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.887 0.375 . . . . 0.0 110.311 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -121.68 143.67 49.21 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.435 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 38.6 ptt180 -120.25 135.97 54.82 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.033 0.444 . . . . 0.0 110.427 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 43.4 t -84.54 135.53 24.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.982 -178.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 97.4 m-70 -107.28 -12.79 15.28 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.732 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 11.8 t -140.87 148.83 41.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.891 0.377 . . . . 0.0 110.375 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 11.3 p-10 -75.13 121.43 22.06 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.026 -179.515 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -119.28 118.24 30.73 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 178.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 89.6 m -126.56 94.69 39.8 Favored Pre-proline 0 CA--C 1.534 0.361 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.434 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -56.45 147.79 66.5 Favored 'Trans proline' 0 N--CA 1.499 1.804 0 C-N-CA 122.409 2.073 . . . . 0.0 112.023 -179.635 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 93.7 p -67.92 159.21 80.62 Favored Pre-proline 0 CA--C 1.532 0.255 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.709 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -56.8 -30.77 86.17 Favored 'Trans proline' 0 N--CA 1.499 1.812 0 C-N-CA 122.832 2.355 . . . . 0.0 112.154 -179.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -61.82 -22.96 65.93 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.062 -179.444 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -107.27 103.44 12.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.041 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.404 HG22 ' H ' ' A' ' 44' ' ' THR . 1.9 t -87.51 -33.89 18.82 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.367 179.762 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -63.37 -38.03 89.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.038 179.681 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 53.4 m -62.38 131.65 49.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.946 0.403 . . . . 0.0 110.647 -179.31 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 1.2 tt -87.55 150.84 23.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.755 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -98.22 123.52 42.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.263 -0.426 . . . . 0.0 109.926 179.092 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 47.3 pt -130.08 159.05 42.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 120.897 0.379 . . . . 0.0 110.902 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -135.71 141.99 44.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.704 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 22.8 pttp -53.35 138.86 31.76 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.982 0.42 . . . . 0.0 110.658 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.1 -17.9 56.42 Favored Glycine 0 CA--C 1.53 0.977 0 N-CA-C 111.2 -0.76 . . . . 0.0 111.2 -179.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -84.64 156.82 21.37 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.789 0.328 . . . . 0.0 110.921 179.569 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 47.4 mm -116.46 131.51 68.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.403 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.458 ' CG1' HD12 ' A' ' 70' ' ' LEU . 89.7 mt -118.25 132.04 69.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.282 -179.559 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 66.9 t0 -74.52 118.48 17.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.74 179.788 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 90.6 mt -69.34 122.4 20.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 120.902 0.382 . . . . 0.0 110.664 -179.433 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 82.6 mt -108.31 -59.44 3.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.183 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 94.2 m -140.87 142.93 34.46 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.479 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 12.2 pttp -154.26 123.21 6.33 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.926 0.393 . . . . 0.0 110.821 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.8 p -75.44 161.68 75.68 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.362 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_exo -52.28 -36.18 66.9 Favored 'Trans proline' 0 N--CA 1.495 1.607 0 C-N-CA 122.506 2.138 . . . . 0.0 111.833 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 14.9 tpt -149.71 97.0 2.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.476 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 168.85 -178.65 42.09 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 111.009 -0.836 . . . . 0.0 111.009 179.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.1 mtp -60.69 144.51 51.96 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.023 0.439 . . . . 0.0 110.738 -179.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 26.2 m0 -93.82 146.35 23.94 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.293 -179.57 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.9 m -112.59 135.49 53.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.986 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -160.59 -171.69 26.87 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 67.5 ttp -121.86 135.49 54.9 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.823 0.344 . . . . 0.0 110.407 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.458 HD12 ' CG1' ' A' ' 55' ' ' ILE . 4.2 tt -135.35 117.03 14.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.063 179.662 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . 0.449 ' N ' HD23 ' A' ' 70' ' ' LEU . 64.8 t30 55.85 52.93 9.98 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.265 -0.574 . . . . 0.0 111.235 179.282 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 33.1 m120 57.94 35.08 25.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.657 0.265 . . . . 0.0 111.4 179.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -139.02 116.89 11.56 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.14 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 89.5 t -95.41 129.94 44.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.604 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -165.67 -174.08 34.85 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.337 -0.705 . . . . 0.0 111.337 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -108.95 156.72 19.38 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.007 0.432 . . . . 0.0 110.912 -179.555 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -157.52 160.32 38.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.096 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -71.06 117.77 12.98 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.174 0.511 . . . . 0.0 111.119 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.456 ' HA ' HG12 ' A' ' 82' ' ' VAL . 55.6 p90 -63.15 -30.26 71.45 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.512 179.536 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.44 HG23 ' CE1' ' A' ' 79' ' ' PHE . 18.3 pt -62.43 -18.5 20.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.77 0.319 . . . . 0.0 110.724 179.344 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 15.3 m-30 -100.63 3.63 42.68 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.909 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.456 HG12 ' HA ' ' A' ' 79' ' ' PHE . 0.5 OUTLIER -132.58 159.94 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.758 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -127.59 144.47 51.07 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.526 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.7 p -93.65 128.63 44.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.579 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 44.0 pt -127.68 158.83 39.03 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.752 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 71.0 m -70.64 144.74 51.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.531 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.606 179.848 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.255 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -69.8 153.34 68.84 Favored 'Trans proline' 0 C--N 1.306 -1.706 0 C-N-CA 122.888 2.392 . . . . 0.0 112.201 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -114.12 133.5 55.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.607 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 24.1 p -66.45 151.66 46.72 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.064 0.459 . . . . 0.0 110.195 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.97 -155.25 14.95 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 111.143 -0.783 . . . . 0.0 111.143 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 26.9 mmt85 -112.22 140.64 46.75 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.885 0.374 . . . . 0.0 110.481 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.6 117.15 30.08 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.496 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 75.5 ttt180 -91.34 124.57 35.64 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.615 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.584 HG22 HG22 ' A' ' 82' ' ' VAL . 82.5 t -82.26 129.33 37.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.6 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 88.0 m-70 -107.1 -18.18 13.97 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.851 179.76 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.538 HG21 ' CD2' ' A' ' 81' ' ' TYR . 95.2 m -123.94 134.53 53.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.367 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -75.07 114.18 13.26 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.697 -179.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -118.22 125.18 49.65 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.345 179.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 10.0 t -132.28 134.18 24.66 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.673 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -72.97 166.41 30.11 Favored 'Trans proline' 0 N--CA 1.492 1.434 0 C-N-CA 122.894 2.396 . . . . 0.0 112.388 179.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 48.8 m -64.13 156.13 76.1 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.482 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -58.51 -27.39 82.07 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.621 2.214 . . . . 0.0 112.306 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -99.29 22.74 10.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.636 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -114.31 113.22 24.28 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.437 179.575 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 72.8 p -110.73 -15.14 13.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.683 179.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 56.7 p-10 -88.47 10.85 18.75 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.844 179.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 67.7 m -117.26 157.96 25.15 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-O 120.683 0.278 . . . . 0.0 110.3 -179.668 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 63.8 tp -104.56 136.7 43.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.321 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 13.3 tmtt? -96.72 124.94 40.85 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.385 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 49.3 pt -128.21 158.49 40.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.532 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 64.6 pttt -138.47 161.23 37.54 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.633 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 23.3 pttp -63.13 137.46 58.24 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.765 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.04 -11.6 71.7 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 111.024 -0.831 . . . . 0.0 111.024 -179.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 42.0 t0 -79.43 148.66 31.85 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-O 120.829 0.347 . . . . 0.0 110.463 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 39.0 mm -110.64 127.88 67.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.399 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 93.9 mt -115.22 134.34 58.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.803 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -82.17 111.9 18.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.559 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.5 mt -63.31 130.95 28.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.746 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 97.6 mt -112.57 -63.97 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.715 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 41.9 t -154.0 138.94 17.21 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.588 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -92.06 153.38 19.44 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.275 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 81.8 p -125.08 151.91 69.82 Favored Pre-proline 0 CA--C 1.532 0.252 0 C-N-CA 120.477 -0.489 . . . . 0.0 110.695 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -63.69 -18.85 65.92 Favored 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.908 2.406 . . . . 0.0 112.315 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 39.2 mmt -61.76 -37.41 84.19 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.195 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 125.18 -44.06 1.31 Allowed Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.074 -0.811 . . . . 0.0 111.074 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 33.5 mtt -61.85 141.76 57.76 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.98 0.419 . . . . 0.0 110.436 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 26.9 m0 -96.07 147.26 23.91 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.285 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 85.6 m -112.29 137.06 50.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.977 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -158.14 -172.53 25.41 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 37.2 ttm -119.69 140.49 50.58 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-O 120.734 0.302 . . . . 0.0 110.383 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -144.09 115.57 8.09 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.912 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 57.0 m-20 53.27 51.13 16.12 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.334 179.445 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 52.9 t30 60.75 28.79 18.51 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.545 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 13.0 tppt? -136.83 115.32 11.9 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.45 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.9 m -97.29 142.47 14.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.868 0.366 . . . . 0.0 110.804 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -171.18 -177.65 41.14 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 110.691 -0.963 . . . . 0.0 110.691 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -103.09 157.97 16.62 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 121.083 0.468 . . . . 0.0 110.644 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.571 ' CD1' HG21 ' A' ' 82' ' ' VAL . 2.1 p90 -154.35 161.56 41.68 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.194 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 12.4 tptt -62.17 117.47 6.08 Favored 'General case' 0 C--O 1.237 0.436 0 CA-C-O 121.488 0.661 . . . . 0.0 110.882 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -62.3 -23.22 66.6 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.353 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.419 HG23 ' N ' ' A' ' 81' ' ' TYR . 18.1 tt -73.28 -38.19 53.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.877 0.37 . . . . 0.0 110.812 179.591 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.538 ' CD2' HG21 ' A' ' 35' ' ' THR . 22.8 m-85 -80.3 -14.92 57.99 Favored 'General case' 0 C--O 1.24 0.582 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.765 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.584 HG22 HG22 ' A' ' 33' ' ' VAL . 67.2 t -111.78 137.08 45.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.223 0 CA-C-O 121.31 0.576 . . . . 0.0 110.61 179.843 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 41.5 t0 -121.04 149.47 42.65 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.743 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.3 p -87.85 132.38 33.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.447 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 2.4 tt -104.81 146.09 12.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.654 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 72.0 m -80.17 148.26 30.97 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.473 179.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 117.911 -1.042 . . . . 0.0 110.516 179.834 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.308 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -69.88 149.78 66.6 Favored 'Trans proline' 0 C--N 1.306 -1.71 0 C-N-CA 122.789 2.326 . . . . 0.0 112.099 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -133.22 151.18 51.94 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.513 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 72.9 m -106.14 143.26 34.52 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.455 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 176.88 -123.76 0.92 Allowed Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -179.705 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 19.2 tpp180 -121.54 133.62 55.02 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.791 0.329 . . . . 0.0 110.448 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -104.28 122.94 46.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.694 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 78.3 ttt-85 -107.12 127.16 53.25 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.722 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.0 t -81.03 125.76 39.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.272 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 32.5 p80 -117.24 -13.1 10.47 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.699 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 97.2 m -125.51 134.37 52.05 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.538 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -69.22 122.98 19.93 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.672 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -71.59 137.69 48.18 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.222 179.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 82.1 m -120.01 93.27 47.72 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.424 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -73.59 151.69 47.35 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.864 2.376 . . . . 0.0 112.452 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 65.5 m -76.56 159.98 78.27 Favored Pre-proline 0 N--CA 1.452 -0.355 0 CA-C-O 121.263 0.554 . . . . 0.0 110.7 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -55.44 -37.47 94.81 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 122.733 2.289 . . . . 0.0 111.638 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 38.2 p90 -91.1 15.59 11.39 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.624 -179.702 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -108.81 94.83 5.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.276 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 71.2 p -104.42 -22.72 13.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.638 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -87.1 6.83 30.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.696 179.3 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 82.7 p -71.59 160.06 33.34 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-O 120.882 0.372 . . . . 0.0 110.42 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 55.8 tp -91.16 136.95 32.73 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.295 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 15.9 ptpt -93.64 123.33 36.89 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.762 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.0 pt -139.26 160.22 28.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.579 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 65.2 tttp -143.94 141.95 30.49 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.622 179.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 23.3 pttp -48.85 134.33 16.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.661 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.25 -19.61 53.81 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -74.32 153.66 39.23 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.784 0.326 . . . . 0.0 110.741 179.436 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 43.4 mm -114.47 126.62 72.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.367 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 87.1 mt -111.49 133.9 55.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.682 -179.528 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -80.11 112.17 17.16 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.593 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 97.5 mt -63.43 124.07 17.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.494 -179.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 97.3 mt -106.73 -54.87 5.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.634 179.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 32.0 p -161.51 171.27 18.41 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.61 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.02 146.14 42.4 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.499 179.828 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 62.1 p -101.45 155.02 36.87 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.515 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -63.27 -22.23 72.18 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 C-N-CA 122.957 2.438 . . . . 0.0 112.183 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 39.0 mmt -76.06 -10.56 59.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.877 179.485 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 104.08 -25.1 27.35 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 179.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 91.7 mmm -63.18 147.04 52.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.902 0.382 . . . . 0.0 110.426 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 33.1 m0 -103.95 143.38 32.94 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.827 -179.493 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 86.6 m -108.18 133.68 52.11 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.664 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -150.75 -179.05 26.18 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 -179.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 61.2 ttm -117.99 143.18 46.6 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-O 120.639 0.257 . . . . 0.0 110.557 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -142.04 117.14 10.02 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.574 179.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 9.1 p30 40.99 57.64 2.71 Favored 'General case' 0 N--CA 1.463 0.18 0 O-C-N 123.391 0.432 . . . . 0.0 111.019 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 60.5 t30 60.62 38.56 18.57 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.909 -179.253 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 64.1 tttt -141.36 109.69 5.91 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.092 178.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 60.1 t -98.99 129.82 48.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.91 0.386 . . . . 0.0 110.772 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -163.63 -178.63 37.43 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -101.17 160.52 14.33 Favored 'General case' 0 CA--C 1.531 0.22 0 CA-C-O 120.643 0.259 . . . . 0.0 110.449 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 19.8 p90 -158.88 159.21 34.73 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.704 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 30.1 tttt -66.41 113.78 4.92 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.491 -179.402 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.428 ' HA ' HG12 ' A' ' 82' ' ' VAL . 49.4 p90 -59.22 -23.15 62.07 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.396 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 95.7 mt -68.54 -38.73 79.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.025 0.441 . . . . 0.0 110.19 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.7 m-30 -76.07 -5.43 46.45 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.815 -179.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.428 HG12 ' HA ' ' A' ' 79' ' ' PHE . 0.4 OUTLIER -126.82 165.43 25.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.629 -179.591 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -148.66 160.63 42.96 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.521 179.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.435 ' O ' HG23 ' A' ' 84' ' ' VAL . 23.6 m -94.52 129.34 44.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.624 179.809 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 43.1 pt -126.11 159.87 34.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.67 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 41.4 t -105.6 123.15 47.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.589 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 25.4 pt-20 . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.538 179.991 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.229 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_exo -58.18 142.28 97.09 Favored 'Trans proline' 0 C--N 1.307 -1.658 0 C-N-CA 122.805 2.336 . . . . 0.0 111.986 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -112.96 140.38 47.81 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.461 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 31.1 p -119.68 153.37 35.68 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.974 0.416 . . . . 0.0 110.143 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.63 -124.25 1.59 Allowed Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 -179.59 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 14.7 mmp_? -111.2 147.0 35.91 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.681 0.277 . . . . 0.0 110.51 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -117.79 114.41 23.25 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.718 -0.393 . . . . 0.0 110.896 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.539 ' HD2' HD12 ' A' ' 85' ' ' ILE . 2.8 ptm85 -87.9 128.48 35.36 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.546 179.765 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.542 HG22 HG23 ' A' ' 82' ' ' VAL . 95.7 t -84.83 131.98 32.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.2 -179.313 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 30.3 m170 -114.17 -15.32 12.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.398 179.409 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.414 HG21 ' CD2' ' A' ' 81' ' ' TYR . 32.9 m -127.68 132.47 49.66 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.843 0.354 . . . . 0.0 110.712 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -65.79 145.1 56.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.736 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -98.65 134.92 40.9 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.004 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.48 HG23 ' O ' ' A' ' 38' ' ' THR . 2.7 t -121.22 93.52 48.81 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.752 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_endo -75.01 153.1 41.47 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.397 2.064 . . . . 0.0 112.319 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 65.6 m -72.01 158.97 86.69 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.525 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -53.82 -37.16 84.73 Favored 'Trans proline' 0 N--CA 1.497 1.723 0 C-N-CA 122.633 2.222 . . . . 0.0 112.039 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 41.1 p90 -97.43 16.36 20.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.869 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -96.6 88.16 4.58 Favored 'General case' 0 C--O 1.233 0.213 0 CA-C-O 121.039 0.447 . . . . 0.0 110.544 -179.726 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 6.9 t -93.24 -26.16 17.48 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.437 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 56.0 p-10 -79.5 -3.36 46.4 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.023 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 34.8 t -83.55 139.63 32.76 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.661 0.267 . . . . 0.0 110.536 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 60.2 tp -85.85 145.82 27.02 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.371 -0.377 . . . . 0.0 109.997 179.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 58.2 pttt -96.27 127.03 41.91 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.45 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 35.2 pt -144.12 150.2 17.01 Favored 'Isoleucine or valine' 0 C--O 1.237 0.436 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.339 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 63.7 tttp -132.72 145.88 51.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.331 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 64.8 pttt -48.93 138.15 11.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.953 0.406 . . . . 0.0 110.682 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 93.44 -13.27 67.94 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 -179.46 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -77.37 150.95 35.07 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-O 120.817 0.342 . . . . 0.0 110.636 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 36.1 mm -114.21 126.73 71.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.208 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.44 HG12 HD12 ' A' ' 70' ' ' LEU . 92.3 mt -117.93 133.14 65.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.83 -179.498 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -78.58 121.97 25.32 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.276 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.7 mt -69.5 120.39 17.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.914 0.388 . . . . 0.0 110.545 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.492 HD11 ' HB2' ' A' ' 69' ' ' MET . 93.3 mt -109.47 -50.65 6.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.451 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 95.3 m -140.26 151.42 45.11 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.437 179.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 37.8 mtmm -124.88 147.74 48.65 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.417 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 90.0 m -122.71 117.16 28.9 Favored Pre-proline 0 CA--C 1.537 0.466 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.202 179.569 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_exo -50.57 126.83 18.98 Favored 'Trans proline' 0 N--CA 1.497 1.715 0 C-N-CA 121.933 1.755 . . . . 0.0 111.971 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 93.7 mmm 47.15 40.62 10.27 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.613 179.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -151.77 176.37 30.17 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.152 -0.779 . . . . 0.0 111.152 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 98.9 mtp -60.0 148.33 35.81 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.006 0.432 . . . . 0.0 110.58 -179.088 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 16.1 m0 -94.89 158.25 15.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.057 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 96.2 m -118.93 138.0 53.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.238 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -160.73 -170.57 25.51 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . 0.492 ' HB2' HD11 ' A' ' 58' ' ' ILE . 64.8 ttp -125.71 136.32 53.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.745 0.307 . . . . 0.0 110.337 -179.702 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.488 HD23 ' N ' ' A' ' 71' ' ' ASN . 4.4 tt -137.83 120.15 15.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.392 179.869 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . 0.488 ' N ' HD23 ' A' ' 70' ' ' LEU . 67.2 t30 53.08 51.4 15.81 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.681 -0.408 . . . . 0.0 110.981 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 58.0 t30 58.87 36.26 24.57 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.653 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 4.0 tptm -139.12 113.76 9.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.37 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 91.7 t -94.54 127.36 46.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.846 0.355 . . . . 0.0 110.674 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -163.22 -178.82 37.29 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 -179.8 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -100.69 157.53 16.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.907 0.384 . . . . 0.0 110.729 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -155.88 161.21 40.62 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.841 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -73.54 121.96 21.45 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.859 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.626 ' HA ' HG12 ' A' ' 82' ' ' VAL . 51.2 p90 -67.69 -28.18 67.46 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.794 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.473 HG23 ' CE1' ' A' ' 79' ' ' PHE . 33.5 pt -63.82 -19.53 24.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.694 0.283 . . . . 0.0 111.073 179.656 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.414 ' CD2' HG21 ' A' ' 35' ' ' THR . 21.2 m-30 -102.23 5.39 40.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.942 0.401 . . . . 0.0 110.913 179.532 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.626 HG12 ' HA ' ' A' ' 79' ' ' PHE . 1.2 p -134.23 153.17 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.315 179.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -113.41 134.11 54.82 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.375 179.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.0 p -80.09 125.94 39.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.548 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.539 HD12 ' HD2' ' A' ' 32' ' ' ARG . 0.1 OUTLIER -122.76 134.42 66.0 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.418 -179.815 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 69.8 m -67.49 143.39 56.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.32 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 10.7 tt0 . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.633 179.892 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.275 0 N-CA-C 109.601 -1.4 . . . . 0.0 109.601 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.49 144.28 97.05 Favored 'Trans proline' 0 N--CA 1.497 1.735 0 C-N-CA 122.852 2.368 . . . . 0.0 111.964 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -113.34 146.39 39.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.587 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 82.6 m -110.6 135.05 51.83 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.378 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -175.34 -152.96 9.76 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 39.5 mmt180 -112.27 143.46 43.31 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.78 0.324 . . . . 0.0 110.657 -179.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -117.97 132.27 56.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.225 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.446 ' HA ' HD13 ' A' ' 54' ' ' ILE . 17.6 ptm180 -110.82 133.05 53.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.232 0.539 . . . . 0.0 110.733 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.502 HG22 HG23 ' A' ' 82' ' ' VAL . 86.5 t -85.68 133.44 29.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.511 -179.332 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.562 ' HD2' HG23 ' A' ' 35' ' ' THR . 0.3 OUTLIER -118.02 -7.31 10.88 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.171 179.792 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.562 HG23 ' HD2' ' A' ' 34' ' ' HIS . 72.9 p -130.65 158.82 39.0 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.892 0.377 . . . . 0.0 110.3 -179.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -91.35 104.06 16.63 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.599 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -119.24 121.4 39.58 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.571 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 8.7 t -130.3 139.67 36.33 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.809 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -73.59 166.01 30.91 Favored 'Trans proline' 0 N--CA 1.494 1.51 0 C-N-CA 122.779 2.319 . . . . 0.0 112.262 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 85.7 p -68.65 161.82 67.81 Favored Pre-proline 0 C--N 1.324 -0.525 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.653 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_exo -56.23 -34.63 94.02 Favored 'Trans proline' 0 N--CA 1.5 1.893 0 C-N-CA 122.712 2.275 . . . . 0.0 112.098 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.3 p90 -87.75 9.42 21.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.923 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -112.38 114.73 27.61 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-O 120.684 0.278 . . . . 0.0 110.397 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 58.1 p -115.34 -30.57 6.22 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.933 0.397 . . . . 0.0 110.617 179.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -63.23 -37.32 86.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.548 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 66.7 m -58.85 152.83 18.42 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.606 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.521 HD13 ' H ' ' A' ' 48' ' ' LYS . 0.1 OUTLIER -91.72 132.51 36.33 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.51 -179.964 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.521 ' H ' HD13 ' A' ' 47' ' ' LEU . 62.4 mttp -87.4 124.38 33.34 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 179.181 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.493 ' CG2' HD11 ' A' ' 55' ' ' ILE . 47.5 pt -131.06 146.52 33.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.558 -179.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 32.7 mttp -135.08 159.98 39.8 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.427 -0.352 . . . . 0.0 110.274 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -55.81 121.98 10.44 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.989 0.423 . . . . 0.0 110.538 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 103.52 -21.21 39.73 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -67.01 143.09 56.98 Favored 'General case' 0 C--N 1.332 -0.194 0 C-N-CA 120.618 -0.433 . . . . 0.0 110.77 179.41 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.446 HD13 ' HA ' ' A' ' 32' ' ' ARG . 9.9 mm -112.69 128.71 69.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.599 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.493 HD11 ' CG2' ' A' ' 49' ' ' ILE . 2.5 mt -116.33 133.35 63.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.708 -179.417 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -79.95 117.63 20.97 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.15 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 92.0 mt -67.26 126.39 26.79 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.137 0 CA-C-O 120.919 0.39 . . . . 0.0 110.679 -179.524 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 93.3 mt -113.84 -59.27 3.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.47 179.721 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 94.7 m -144.77 168.8 19.34 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.938 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -115.98 141.48 48.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.187 179.573 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.9 m -98.86 137.52 20.55 Favored Pre-proline 0 CA--C 1.538 0.483 0 C-N-CA 120.149 -0.62 . . . . 0.0 110.343 -179.492 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -53.22 -36.84 79.24 Favored 'Trans proline' 0 N--CA 1.501 1.916 0 C-N-CA 122.414 2.076 . . . . 0.0 112.486 179.509 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . 0.463 ' HG3' ' H ' ' A' ' 65' ' ' MET . 23.0 ptp -59.34 -18.67 40.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.885 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 119.41 -38.25 2.88 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.136 -0.786 . . . . 0.0 111.136 179.424 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' MET . . . . . 0.463 ' H ' ' HG3' ' A' ' 63' ' ' MET . 97.0 mtp -61.57 143.65 55.65 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.153 0.502 . . . . 0.0 110.59 -179.79 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 45.7 m0 -98.75 155.67 17.23 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.212 -179.312 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 93.0 m -115.92 135.21 54.2 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.901 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.6 -172.13 23.57 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 179.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 16.8 tmm? -122.04 139.8 53.26 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.847 0.356 . . . . 0.0 110.751 -179.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.433 HD22 ' ND2' ' A' ' 71' ' ' ASN . 0.4 OUTLIER -139.25 111.72 7.64 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.618 179.812 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . 0.433 ' ND2' HD22 ' A' ' 70' ' ' LEU . 47.2 m-20 54.05 51.99 13.6 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.034 179.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 54.1 t30 62.41 37.3 13.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.792 0.33 . . . . 0.0 110.707 -179.387 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 46.9 tptt -137.33 113.29 9.75 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.034 179.266 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 88.9 t -100.46 127.28 53.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 C-N-CA 120.793 -0.363 . . . . 0.0 110.912 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.505 ' N ' HD23 ' A' ' 47' ' ' LEU . . . -164.92 -174.09 34.26 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -102.51 150.96 22.87 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.009 0.433 . . . . 0.0 110.483 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 44.0 p90 -150.84 158.75 44.52 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.757 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -72.29 117.36 13.85 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.94 -179.466 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -62.58 -27.51 69.23 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.683 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 13.7 tt -63.06 -33.27 59.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.999 0.428 . . . . 0.0 111.1 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -83.81 1.23 44.01 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.835 179.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.502 HG23 HG22 ' A' ' 33' ' ' VAL . 0.3 OUTLIER -132.66 161.42 41.56 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 CA-C-O 121.038 0.447 . . . . 0.0 110.464 179.815 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 53.3 t0 -124.1 137.64 54.54 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.133 179.39 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 1.5 p -87.52 124.64 40.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.773 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 41.4 pt -128.27 150.71 34.24 Favored 'Isoleucine or valine' 0 C--O 1.233 0.219 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.84 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 38.4 t -84.63 138.75 32.52 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.718 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.003 -0.998 . . . . 0.0 110.611 179.714 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -69.78 151.62 68.98 Favored 'Trans proline' 0 C--N 1.305 -1.741 0 C-N-CA 122.849 2.366 . . . . 0.0 112.075 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 90.8 t80 -91.54 127.46 37.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.594 -179.72 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 29.5 p -100.09 129.91 46.18 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.992 0.425 . . . . 0.0 110.424 179.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -174.16 -154.91 11.29 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -179.327 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 15.6 mmp_? -108.04 142.34 38.34 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.023 0.44 . . . . 0.0 110.469 -179.397 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.445 ' HB1' HG21 ' A' ' 82' ' ' VAL . . . -106.39 117.3 33.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.184 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 61.2 ttt180 -96.09 120.83 37.08 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.055 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 86.8 t -81.28 124.78 39.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.728 -179.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 35.2 p80 -115.81 -8.97 11.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.936 179.406 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 77.4 m -129.04 136.74 50.69 Favored 'General case' 0 C--O 1.231 0.099 0 CA-C-O 120.762 0.315 . . . . 0.0 110.625 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -69.49 119.69 14.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.493 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -65.47 136.91 57.04 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 92.1 m -118.45 94.85 47.96 Favored Pre-proline 0 CA--C 1.537 0.452 0 C-N-CA 120.958 -0.297 . . . . 0.0 110.762 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_endo -74.09 157.3 46.7 Favored 'Trans proline' 0 N--CA 1.497 1.705 0 C-N-CA 122.352 2.035 . . . . 0.0 112.201 -179.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.1 m -79.78 158.03 73.54 Favored Pre-proline 0 CA--C 1.532 0.263 0 C-N-CA 120.661 -0.415 . . . . 0.0 110.797 -179.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -57.23 -40.27 83.87 Favored 'Trans proline' 0 N--CA 1.5 1.912 0 C-N-CA 122.381 2.054 . . . . 0.0 112.096 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.4 p90 -89.72 16.99 7.01 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.182 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -112.69 113.39 25.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.791 0.329 . . . . 0.0 110.626 179.425 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 55.7 p -112.42 -17.55 12.66 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.458 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 57.6 p-10 -87.59 6.13 35.99 Favored 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.13 179.64 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 74.9 m -70.28 151.17 45.6 Favored 'General case' 0 C--O 1.231 0.094 0 CA-C-O 120.86 0.362 . . . . 0.0 110.662 179.694 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 60.6 tp -84.66 135.93 33.96 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.154 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 62.6 mtpt -93.93 119.06 32.33 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.091 179.436 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.407 HG21 HD13 ' A' ' 49' ' ' ILE . 28.9 pt -136.64 168.02 22.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.316 -179.588 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 23.5 pttp -148.21 156.47 42.61 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.856 0.36 . . . . 0.0 110.385 179.255 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 65.3 tttm -56.96 129.9 43.66 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.313 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.13 -16.14 60.5 Favored Glycine 0 CA--C 1.53 1.004 0 N-CA-C 111.349 -0.7 . . . . 0.0 111.349 -179.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . 0.483 ' OD2' HD11 ' A' ' 70' ' ' LEU . 17.5 t0 -71.33 146.61 48.74 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 110.321 -0.251 . . . . 0.0 110.321 179.663 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 48.2 mm -114.89 129.11 71.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.938 0.399 . . . . 0.0 110.291 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.473 HG12 HD12 ' A' ' 70' ' ' LEU . 90.9 mt -119.03 130.39 73.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.871 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -74.93 128.39 35.45 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.321 -0.552 . . . . 0.0 110.227 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.9 mt -74.11 121.52 25.41 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.165 0 CA-C-O 120.854 0.359 . . . . 0.0 110.514 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 12.7 tt -113.67 -35.99 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.656 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 85.7 m -147.68 152.16 37.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.589 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.3 mtpt -136.47 155.94 49.29 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.247 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 68.9 p -131.98 155.67 81.06 Favored Pre-proline 0 C--N 1.327 -0.373 0 C-N-CA 120.417 -0.513 . . . . 0.0 110.756 179.425 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -59.93 115.79 2.87 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 121.954 1.769 . . . . 0.0 111.882 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 99.3 mtp 43.75 32.92 0.63 Allowed 'General case' 0 C--O 1.234 0.259 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.969 179.401 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -122.64 173.97 16.18 Favored Glycine 0 CA--C 1.519 0.336 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 10.6 ptm -60.07 149.61 31.89 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.83 0.348 . . . . 0.0 110.432 -179.243 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 45.4 m0 -94.55 150.55 20.13 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.968 -179.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.1 m -118.65 143.1 47.05 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.372 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -165.0 -168.5 27.25 Favored Glycine 0 CA--C 1.52 0.395 0 C-N-CA 120.167 -1.016 . . . . 0.0 111.68 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 60.9 ttm -114.86 135.94 53.64 Favored 'General case' 0 C--O 1.238 0.447 0 CA-C-O 120.969 0.414 . . . . 0.0 110.444 179.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.483 HD11 ' OD2' ' A' ' 53' ' ' ASP . 3.5 tt -136.71 113.68 10.49 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.596 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . 0.423 ' N ' HD23 ' A' ' 70' ' ' LEU . 66.8 t30 53.39 52.33 13.66 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.678 -0.409 . . . . 0.0 111.356 178.764 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 59.71 28.48 17.93 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.921 0.391 . . . . 0.0 110.921 179.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 38.5 ttpt -139.87 115.74 10.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.132 -0.486 . . . . 0.0 109.82 179.027 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.405 HG22 ' H ' ' A' ' 74' ' ' VAL . 19.4 m -92.28 141.88 13.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.622 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -165.9 177.68 40.92 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 -179.488 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 76.7 m-20 -107.96 144.66 34.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.919 0.39 . . . . 0.0 110.523 -179.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.8 p90 -148.19 147.1 29.06 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.741 179.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 17.5 tptm -58.0 121.47 10.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.358 -179.094 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.7 p90 -61.28 -25.43 67.1 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.624 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 97.7 mt -64.0 -39.03 83.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-O 120.919 0.39 . . . . 0.0 110.503 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 12.7 m-30 -77.27 -1.78 31.42 Favored 'General case' 0 C--O 1.237 0.404 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.388 -179.14 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.445 HG21 ' HB1' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -128.5 161.6 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.68 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -130.02 143.88 51.03 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.4 ' H ' HG12 ' A' ' 84' ' ' VAL . 1.5 p -84.72 119.74 34.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.672 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 37.9 pt -127.84 158.96 39.28 Favored 'Isoleucine or valine' 0 C--O 1.232 0.172 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.77 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 35.2 t -110.66 127.37 55.25 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.234 179.724 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 118.048 -0.977 . . . . 0.0 110.488 -179.615 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.304 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -69.79 154.47 67.57 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 C-N-CA 122.841 2.361 . . . . 0.0 112.278 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -126.96 151.98 47.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.577 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 26.3 p -116.51 152.9 33.14 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.317 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 162.32 -130.08 2.21 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.904 -0.879 . . . . 0.0 110.904 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 87.7 mmt-85 -112.11 145.31 40.0 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.943 0.401 . . . . 0.0 110.741 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.504 ' HB3' ' HB ' ' A' ' 55' ' ' ILE . . . -108.91 121.46 45.15 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.269 179.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 46.5 ttt-85 -97.09 125.43 41.55 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.896 0.379 . . . . 0.0 110.365 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.6 t -82.48 128.62 38.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.617 -179.143 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 65.6 m170 -103.72 -10.3 18.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.192 179.61 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 12.2 t -144.76 145.39 31.65 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.927 0.394 . . . . 0.0 110.345 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -71.81 114.27 9.73 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.3 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 9.5 t80 -121.08 123.58 42.71 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.349 179.392 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 81.5 p -124.7 154.22 70.25 Favored Pre-proline 0 C--N 1.329 -0.29 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.824 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.14 159.22 30.21 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 C-N-CA 123.027 2.484 . . . . 0.0 112.487 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 72.4 m -82.28 158.41 66.66 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.377 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -52.86 -45.92 37.35 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 122.245 1.964 . . . . 0.0 111.981 -179.559 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -80.09 -20.78 44.29 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.91 0.386 . . . . 0.0 110.731 179.533 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -93.05 105.29 17.41 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.416 -179.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 72.1 p -104.37 -23.55 13.18 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.314 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -63.2 -37.45 87.27 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.631 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.6 t -61.44 135.98 57.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.883 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 56.5 tp -80.57 146.03 31.46 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.419 -179.679 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.51 127.42 42.49 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.563 179.087 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.432 HG21 HD11 ' A' ' 55' ' ' ILE . 27.7 pt -139.24 160.45 28.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.565 -179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 19.6 ptpt -136.64 157.34 46.99 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.211 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -61.27 129.38 40.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.945 0.403 . . . . 0.0 111.071 -179.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 98.92 -16.31 59.64 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -76.55 146.47 38.34 Favored 'General case' 0 C--O 1.233 0.22 0 CA-C-O 120.776 0.322 . . . . 0.0 110.633 179.537 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 46.8 mm -108.89 127.55 65.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.004 0.431 . . . . 0.0 110.126 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.504 ' HB ' ' HB3' ' A' ' 31' ' ' ALA . 78.5 mt -108.58 130.62 61.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.728 -178.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -79.96 112.09 16.92 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.6 mt -65.9 118.2 8.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.908 0.385 . . . . 0.0 110.661 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.0 tt -101.93 -35.3 4.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.323 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 25.1 p -171.99 172.9 4.56 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.412 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 65.1 mttp -116.85 145.08 43.79 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 120.881 -0.328 . . . . 0.0 110.537 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 9.8 m -97.69 135.45 21.61 Favored Pre-proline 0 CA--C 1.536 0.417 0 C-N-CA 119.589 -0.844 . . . . 0.0 109.703 -179.379 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -58.7 -25.39 75.37 Favored 'Trans proline' 0 N--CA 1.501 1.915 0 C-N-CA 122.57 2.18 . . . . 0.0 112.614 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 39.2 mmt -65.19 -36.97 85.85 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.446 179.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 140.09 -39.56 1.49 Allowed Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 98.7 mtp -63.35 145.14 56.19 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.455 0.645 . . . . 0.0 111.198 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 22.4 m0 -96.35 146.95 24.3 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.828 -179.742 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 68.0 m -117.0 139.95 50.07 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 115.802 -0.636 . . . . 0.0 109.909 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.95 -172.02 23.71 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.166 -0.773 . . . . 0.0 111.166 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 67.8 ttp -116.18 143.09 45.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.152 0.501 . . . . 0.0 110.605 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -143.87 117.85 9.42 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.661 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 8.9 p30 40.64 59.73 2.08 Favored 'General case' 0 N--CA 1.469 0.525 0 O-C-N 123.442 0.464 . . . . 0.0 111.033 179.806 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 33.7 m120 59.25 35.44 23.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.025 -179.8 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 19.3 tptp -140.56 111.49 7.02 Favored 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.399 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 95.5 t -99.53 127.41 52.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.758 -0.377 . . . . 0.0 110.425 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -159.77 -176.8 32.25 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.886 -0.885 . . . . 0.0 110.886 -179.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 8.4 m120 -103.31 158.57 16.24 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.918 0.39 . . . . 0.0 110.467 -179.563 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.4 p90 -157.06 160.53 39.02 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.006 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 36.7 tptt -69.09 111.55 5.13 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.193 -179.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.3 p90 -59.17 -24.14 62.81 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.522 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.6 mt -67.9 -38.25 79.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 121.183 0.516 . . . . 0.0 110.654 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.2 m-30 -75.78 -5.94 48.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.834 -179.03 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.427 ' CG2' ' HB1' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -126.23 159.82 34.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 CA-C-O 121.042 0.449 . . . . 0.0 110.079 179.737 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 50.6 t0 -126.21 139.53 53.26 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.937 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.46 HG13 ' O ' ' A' ' 84' ' ' VAL . 8.8 p -82.45 121.03 35.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.953 0.406 . . . . 0.0 110.961 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 41.2 pt -128.3 160.4 38.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.613 179.669 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 29.9 t -106.25 132.1 52.7 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.441 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 54.2 tp10 . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 117.974 -1.013 . . . . 0.0 110.332 -179.987 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -58.11 142.7 97.17 Favored 'Trans proline' 0 C--N 1.305 -1.745 0 C-N-CA 122.859 2.373 . . . . 0.0 111.876 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 81.0 m-85 -112.68 143.06 44.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.413 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 77.3 m -116.91 144.7 44.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.95 0.405 . . . . 0.0 110.369 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 169.27 -142.25 7.22 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 2.9 mpp_? -112.25 146.2 38.6 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.879 0.371 . . . . 0.0 110.454 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.722 ' HB1' ' CG1' ' A' ' 82' ' ' VAL . . . -116.06 125.3 52.23 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.083 179.829 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 74.2 ttt-85 -92.74 119.83 32.51 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.387 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.54 HG22 HG22 ' A' ' 82' ' ' VAL . 96.4 t -78.29 125.54 37.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.829 0.347 . . . . 0.0 110.679 -179.511 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 33.2 p80 -112.51 -10.64 13.7 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.885 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 90.2 m -128.81 131.33 47.74 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.778 0.323 . . . . 0.0 110.396 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.6 t0 -68.27 131.34 45.18 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.629 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -88.28 137.22 32.52 Favored 'General case' 0 C--N 1.331 -0.2 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.167 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 43.2 p -126.82 93.79 41.36 Favored Pre-proline 0 CA--C 1.534 0.347 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.441 -179.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -73.27 155.79 51.25 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 122.172 1.915 . . . . 0.0 112.364 -179.022 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 68.6 m -73.47 157.96 87.16 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.801 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -55.83 -38.77 94.06 Favored 'Trans proline' 0 N--CA 1.498 1.766 0 C-N-CA 122.512 2.141 . . . . 0.0 112.046 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -88.6 6.54 37.69 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.066 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -100.22 101.15 12.09 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.752 0.311 . . . . 0.0 110.332 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 72.6 p -104.37 -27.52 11.91 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.883 0.373 . . . . 0.0 110.26 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -72.98 -21.27 60.88 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.775 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 41.4 t -59.62 141.36 55.15 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.404 -179.61 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 66.0 tp -80.27 138.84 36.84 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.147 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 30.2 mtpp -95.0 118.1 31.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.256 179.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.498 HG22 ' CD1' ' A' ' 70' ' ' LEU . 21.6 pt -138.42 146.68 26.3 Favored 'Isoleucine or valine' 0 C--O 1.237 0.419 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.186 179.676 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.04 167.23 14.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.909 0.385 . . . . 0.0 110.424 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -64.99 129.56 40.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.525 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.99 -20.83 47.41 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 111.214 -0.754 . . . . 0.0 111.214 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -69.88 148.51 48.94 Favored 'General case' 0 C--N 1.331 -0.203 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.387 179.219 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 86.5 mt -109.01 127.62 65.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.142 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 72.0 mt -109.96 130.16 63.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.447 -178.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -75.82 115.34 15.41 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.203 -0.599 . . . . 0.0 109.928 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.73 125.4 25.24 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.124 0 CA-C-O 120.823 0.344 . . . . 0.0 110.765 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 97.1 mt -108.73 -58.46 3.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.477 179.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 40.3 t -163.46 151.88 13.75 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.752 -179.691 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 59.0 mttm -96.85 157.78 15.74 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.073 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 74.9 p -112.29 156.95 41.31 Favored Pre-proline 0 C--N 1.329 -0.289 0 C-N-CA 120.618 -0.433 . . . . 0.0 110.784 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_exo -56.6 -33.73 93.82 Favored 'Trans proline' 0 N--CA 1.497 1.734 0 C-N-CA 122.68 2.254 . . . . 0.0 112.269 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 98.6 mtp -62.04 -38.48 88.89 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.514 -179.572 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 132.2 -32.38 2.86 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 98.5 mtp -62.4 143.8 56.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.002 0.429 . . . . 0.0 110.552 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 47.6 m0 -98.41 150.07 22.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.751 -0.659 . . . . 0.0 111.087 -178.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 90.0 m -110.0 135.18 51.25 Favored 'General case' 0 C--O 1.237 0.398 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.657 179.553 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -152.66 -176.14 24.93 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 111.244 -0.742 . . . . 0.0 111.244 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.6 ttp -124.21 142.5 51.18 Favored 'General case' 0 C--O 1.237 0.432 0 CA-C-O 120.961 0.41 . . . . 0.0 110.672 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.498 ' CD1' HG22 ' A' ' 49' ' ' ILE . 2.1 mt -138.06 105.54 5.55 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.762 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 55.63 58.41 4.54 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.23 0.538 . . . . 0.0 109.705 178.775 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 58.5 t30 59.58 34.53 22.38 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.432 -179.515 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 8.9 tppt? -132.89 109.77 9.84 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.357 -0.383 . . . . 0.0 109.971 179.38 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 82.3 t -97.75 123.51 50.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 C-N-CA 120.706 -0.397 . . . . 0.0 110.499 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -156.83 179.12 32.88 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -105.69 154.54 20.31 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.958 0.409 . . . . 0.0 110.829 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.641 ' CD1' HG21 ' A' ' 82' ' ' VAL . 50.8 p90 -152.74 159.63 43.13 Favored 'General case' 0 C--O 1.237 0.443 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.823 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 30.6 tttt -68.65 116.46 9.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.209 -179.064 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 43.8 p90 -59.97 -25.71 65.45 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.571 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.6 mt -65.82 -38.46 82.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.713 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.1 m-30 -78.85 -7.32 57.79 Favored 'General case' 0 C--O 1.24 0.585 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.226 -178.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.722 ' CG1' ' HB1' ' A' ' 31' ' ' ALA . 66.5 t -121.39 138.68 50.93 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.283 0 CA-C-O 120.972 0.415 . . . . 0.0 110.991 -179.449 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -106.07 134.28 49.44 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.229 179.784 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.424 ' H ' HG12 ' A' ' 84' ' ' VAL . 1.4 p -76.44 118.21 22.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.188 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -106.39 148.0 11.24 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.126 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.253 -179.733 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 90.0 p -112.18 147.37 36.31 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.771 -0.372 . . . . 0.0 110.093 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.388 179.908 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -69.74 152.31 69.39 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 C-N-CA 122.819 2.346 . . . . 0.0 112.146 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -126.67 153.9 44.79 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.737 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 16.9 p -60.27 151.67 26.87 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-O 120.994 0.426 . . . . 0.0 110.269 -179.642 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 174.85 -139.65 4.94 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -179.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 93.5 mtt-85 -126.24 151.73 47.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.776 0.322 . . . . 0.0 110.575 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -123.01 135.75 54.58 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.531 -179.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.437 ' HG2' HD12 ' A' ' 54' ' ' ILE . 57.3 mtm180 -101.88 123.53 45.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.254 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.66 HG22 HG23 ' A' ' 82' ' ' VAL . 99.0 t -81.22 129.04 38.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.485 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -113.06 -0.22 14.79 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.961 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 12.2 t -146.47 151.49 37.48 Favored 'General case' 0 N--CA 1.455 -0.214 0 CA-C-O 120.914 0.387 . . . . 0.0 110.547 -179.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -88.46 107.59 18.95 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.529 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 6.2 t80 -118.67 119.34 34.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.621 179.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.412 ' O ' HG23 ' A' ' 38' ' ' THR . 9.8 t -126.79 131.38 23.87 Favored Pre-proline 0 N--CA 1.451 -0.398 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.669 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -73.33 163.47 37.75 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.873 2.382 . . . . 0.0 112.38 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.3 m -66.04 156.47 84.13 Favored Pre-proline 0 C--N 1.327 -0.383 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.607 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -57.69 -31.55 92.31 Favored 'Trans proline' 0 C--N 1.305 -1.756 0 C-N-CA 122.778 2.319 . . . . 0.0 112.332 -179.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -73.11 -10.67 60.03 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.572 179.467 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 48.6 t0 -110.22 114.04 27.21 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.298 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.3 t -106.12 -28.67 10.35 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.728 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -62.23 -36.56 82.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.497 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 47.2 m -63.47 139.31 58.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.704 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.418 HD21 ' HB2' ' A' ' 70' ' ' LEU . 59.2 tp -91.79 143.36 26.6 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.41 -179.813 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 23.0 pttp -94.37 141.86 28.09 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.393 179.112 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.603 ' HB ' HG21 ' A' ' 33' ' ' VAL . 29.8 pt -132.0 147.5 32.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.559 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 40.7 ttmt -128.3 138.53 52.44 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.638 179.419 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -55.91 125.64 22.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.814 -179.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 105.51 -21.42 34.89 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.283 -0.727 . . . . 0.0 111.283 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -81.55 155.14 25.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.736 0.303 . . . . 0.0 110.806 179.29 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.437 HD12 ' HG2' ' A' ' 32' ' ' ARG . 46.7 mm -113.47 130.07 68.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.685 179.822 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.573 HD11 HG22 ' A' ' 49' ' ' ILE . 84.2 mt -112.49 129.06 68.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.498 -179.418 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 64.5 t0 -82.2 121.81 27.1 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.276 179.603 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 84.2 mt -70.21 128.74 33.94 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.116 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.419 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 88.8 mt -105.93 -53.49 6.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.709 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.8 t -163.84 150.66 11.89 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.78 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.7 mttp -109.29 155.34 21.27 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.251 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 81.5 p -136.05 155.09 77.85 Favored Pre-proline 0 N--CA 1.45 -0.471 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.853 179.651 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_exo -62.5 -21.23 72.55 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 122.863 2.375 . . . . 0.0 112.061 179.171 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 63.7 tpp -52.16 -31.6 32.11 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.417 -179.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 106.8 18.18 11.03 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 6.4 mtt -128.34 139.5 52.36 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.782 0.325 . . . . 0.0 110.474 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 33.5 m0 -93.36 139.45 30.66 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.775 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 93.0 m -98.39 131.16 44.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 109.897 179.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -154.52 -176.51 26.89 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -179.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 23.4 ptp -123.57 146.46 48.12 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.874 0.369 . . . . 0.0 110.667 -179.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.418 ' HB2' HD21 ' A' ' 47' ' ' LEU . 0.5 OUTLIER -150.03 118.78 6.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.512 179.867 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 54.8 m-20 53.59 49.71 18.83 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 54.3 t30 59.69 35.63 22.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.584 -179.684 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 22.7 ttmm -138.64 117.62 12.48 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.459 179.292 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 96.9 t -99.45 131.03 47.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.733 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -158.03 177.57 34.7 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 81.7 m-20 -105.05 135.62 46.05 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.876 0.37 . . . . 0.0 110.564 -179.681 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -138.48 155.0 48.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.792 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -75.75 125.02 28.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.372 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.501 ' HA ' HG12 ' A' ' 82' ' ' VAL . 20.6 p90 -65.31 -20.42 66.4 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.706 -179.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 6.4 pt -61.01 -23.17 28.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.505 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 41.6 m-85 -102.4 10.18 39.21 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.644 179.443 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.66 HG23 HG22 ' A' ' 33' ' ' VAL . 0.3 OUTLIER -135.54 147.96 28.55 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.234 0 CA-C-O 120.863 0.363 . . . . 0.0 110.344 -179.609 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -105.62 131.95 52.37 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.302 179.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.402 HG12 ' H ' ' A' ' 84' ' ' VAL . 2.1 p -91.31 132.98 34.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-O 120.96 0.409 . . . . 0.0 110.795 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 37.5 pt -124.0 156.63 31.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.69 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 66.0 m -113.09 148.63 34.86 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.673 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.601 179.948 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.318 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -69.55 151.25 70.25 Favored 'Trans proline' 0 C--N 1.305 -1.745 0 C-N-CA 122.815 2.344 . . . . 0.0 112.164 179.886 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -141.81 145.6 34.92 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.36 -179.733 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.2 m -101.81 136.77 41.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.403 179.706 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -175.92 -149.8 7.68 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -109.03 138.21 45.74 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.94 0.4 . . . . 0.0 110.496 -179.793 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.758 ' HB1' ' CG1' ' A' ' 82' ' ' VAL . . . -106.11 115.15 29.73 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.198 -179.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 45.4 ttp180 -96.59 120.54 37.1 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.195 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.46 HG22 HG22 ' A' ' 82' ' ' VAL . 90.3 t -76.17 124.32 34.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.48 -179.492 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 1.3 p80 -111.3 -15.87 13.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.537 179.548 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 53.0 m -131.97 135.5 46.62 Favored 'General case' 0 C--N 1.334 -0.103 0 CA-C-O 120.84 0.353 . . . . 0.0 110.833 179.6 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -64.44 133.91 53.47 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 120.716 -0.394 . . . . 0.0 110.49 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -120.8 135.77 55.07 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.276 179.618 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 57.0 p -135.44 90.76 19.7 Favored Pre-proline 0 CA--C 1.534 0.328 0 C-N-CA 120.92 -0.312 . . . . 0.0 110.304 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -69.83 150.6 68.01 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 122.66 2.24 . . . . 0.0 112.284 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 75.4 m -72.96 157.94 87.9 Favored Pre-proline 0 C--N 1.326 -0.439 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.653 -179.686 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -53.76 -23.09 25.34 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.835 2.357 . . . . 0.0 112.114 179.54 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -59.97 -23.05 63.3 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.204 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -65.8 125.87 26.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.35 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 82.8 p -70.68 -35.85 73.03 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.606 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.498 ' O ' ' C ' ' A' ' 46' ' ' SER . 88.5 m-20 -100.14 5.86 44.86 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 118.337 -0.84 . . . . 0.0 111.465 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.498 ' C ' ' O ' ' A' ' 45' ' ' ASP . 6.6 t -9.88 95.3 0.01 OUTLIER 'General case' 0 C--N 1.358 0.938 0 O-C-N 125.003 1.439 . . . . 0.0 111.311 -179.291 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 66.9 tp -111.34 131.72 54.96 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.232 -178.478 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -97.29 134.31 40.75 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.563 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 48.3 pt -126.65 162.47 30.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.509 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 39.8 ttpt -134.85 135.61 41.81 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.602 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -51.43 131.16 28.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.983 0.42 . . . . 0.0 110.448 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.51 -18.14 56.69 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 111.006 -0.838 . . . . 0.0 111.006 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -72.47 155.53 40.0 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.798 0.332 . . . . 0.0 110.702 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 48.5 mm -114.38 127.68 71.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.198 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.46 HG12 HD12 ' A' ' 70' ' ' LEU . 85.6 mt -117.9 129.41 74.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.683 -179.671 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 59.8 t0 -74.65 120.64 20.48 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.309 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 85.0 mt -69.76 126.03 29.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.764 0.316 . . . . 0.0 110.347 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.7 mt -110.71 -43.16 5.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.768 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 46.6 t -146.52 139.13 25.2 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.572 -179.607 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.3 mtpt -119.37 153.75 34.67 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.517 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 71.5 p -133.29 153.17 80.49 Favored Pre-proline 0 C--N 1.328 -0.34 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.746 179.753 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -62.62 114.32 2.34 Favored 'Trans proline' 0 N--CA 1.493 1.484 0 C-N-CA 122.53 2.153 . . . . 0.0 112.037 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 99.4 mtp 46.55 32.74 1.74 Allowed 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.274 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -123.45 172.65 16.24 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 8.5 ptm -60.98 148.33 40.35 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.819 0.342 . . . . 0.0 110.143 -179.479 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 41.9 m0 -95.51 149.58 21.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.239 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 84.9 m -115.3 138.33 51.07 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.734 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -162.43 -166.95 22.13 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 65.3 ttp -125.72 138.36 53.87 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.826 0.346 . . . . 0.0 110.258 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.478 ' C ' HD23 ' A' ' 70' ' ' LEU . 4.6 tt -134.31 115.47 14.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.426 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . 0.419 ' N ' HD23 ' A' ' 70' ' ' LEU . 65.7 t30 53.17 56.93 6.8 Favored 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.87 179.039 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 56.82 36.94 28.43 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.477 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 5.1 tptt -139.29 111.9 7.74 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.245 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 89.4 t -93.43 127.75 45.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.827 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -162.58 -177.18 35.38 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.801 -0.919 . . . . 0.0 110.801 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -107.78 156.3 19.27 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.98 0.419 . . . . 0.0 110.685 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.531 ' CD1' HG21 ' A' ' 82' ' ' VAL . 11.6 p90 -155.89 156.57 34.84 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.762 -0.653 . . . . 0.0 111.22 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.734 ' HE2' HD12 ' A' ' 80' ' ' ILE . 32.8 tttt -65.74 118.57 9.8 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.446 -179.243 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 36.5 p90 -61.18 -25.09 66.79 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.667 -179.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.734 HD12 ' HE2' ' A' ' 78' ' ' LYS . 95.7 mt -63.08 -39.55 85.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 120.845 0.355 . . . . 0.0 110.634 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 18.3 m-85 -84.79 3.95 35.23 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.897 -179.54 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.758 ' CG1' ' HB1' ' A' ' 31' ' ' ALA . 86.3 t -126.22 136.09 61.86 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 CA-C-O 121.184 0.516 . . . . 0.0 110.914 179.801 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -111.17 142.48 43.3 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.422 179.461 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.466 HG13 ' O ' ' A' ' 84' ' ' VAL . 8.5 p -89.63 122.83 41.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.767 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 36.5 pt -128.92 158.96 41.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.719 179.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 29.3 t -90.1 124.73 35.04 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.457 179.638 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 . . . . . 0 C--O 1.219 -0.517 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.674 -179.874 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.329 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -72.9 142.82 35.69 Favored 'Trans proline' 0 C--N 1.305 -1.711 0 C-N-CA 122.738 2.292 . . . . 0.0 112.183 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -138.38 151.17 47.25 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.793 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 17.0 p -69.52 162.81 26.75 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-O 121.103 0.478 . . . . 0.0 109.997 179.608 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 169.63 -138.3 4.97 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 111.024 -0.831 . . . . 0.0 111.024 -179.579 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 39.1 mmt180 -111.81 142.73 43.81 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.763 0.316 . . . . 0.0 110.361 -179.601 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -122.41 141.08 51.97 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.516 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -116.08 132.22 56.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.316 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 84.0 t -82.39 125.99 39.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.819 -179.086 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 28.2 p80 -114.14 -13.75 12.39 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.91 179.609 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 87.9 m -126.28 130.45 50.89 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.418 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.4 t0 -64.22 122.15 15.96 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.303 -179.771 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . 0.434 ' HB3' HD11 ' A' ' 49' ' ' ILE . 15.3 t80 -117.83 128.14 54.56 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.437 179.826 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 38' ' ' THR . 5.9 t -133.51 92.44 23.85 Favored Pre-proline 0 CA--C 1.539 0.53 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.485 179.561 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.85 151.45 62.86 Favored 'Trans proline' 0 N--CA 1.495 1.6 0 C-N-CA 121.955 1.77 . . . . 0.0 112.148 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 99.9 p -70.82 155.48 93.32 Favored Pre-proline 0 CA--C 1.533 0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.628 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -62.7 -21.89 73.4 Favored 'Trans proline' 0 N--CA 1.497 1.682 0 C-N-CA 122.491 2.127 . . . . 0.0 112.253 179.674 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -64.59 -25.16 67.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.442 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -64.89 143.71 57.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.356 179.442 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 61.9 p -84.39 -29.58 26.08 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.582 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.437 ' O ' ' C ' ' A' ' 46' ' ' SER . 97.9 m-20 -100.23 -0.86 37.81 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.716 -179.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.437 ' C ' ' O ' ' A' ' 45' ' ' ASP . 16.3 t -20.81 95.86 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.675 0 O-C-N 124.033 0.833 . . . . 0.0 112.697 -178.757 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 63.5 tp -104.98 134.05 48.74 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.933 -179.427 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -97.17 129.19 44.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.558 179.392 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.434 HD11 ' HB3' ' A' ' 37' ' ' PHE . 40.2 pt -136.62 160.4 37.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.429 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -137.25 134.57 36.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.648 179.839 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 5.4 ptmm? -49.58 137.02 16.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.775 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.98 -17.76 58.71 Favored Glycine 0 CA--C 1.528 0.863 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 -179.839 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -79.15 157.57 27.88 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.831 0.348 . . . . 0.0 110.452 179.541 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 47.9 mm -114.73 129.67 70.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.298 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 85.7 mt -111.1 132.58 59.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.725 -179.494 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -78.45 113.71 16.7 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.841 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.4 mt -68.23 125.93 26.98 Favored 'Isoleucine or valine' 0 C--O 1.232 0.178 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.472 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.457 HD11 ' HB2' ' A' ' 69' ' ' MET . 80.7 mt -105.34 -50.79 8.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.338 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 77.9 m -139.31 149.88 44.75 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.709 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 62.5 mtpt -132.07 159.64 38.28 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.612 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 82.4 p -132.0 158.57 75.15 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.537 179.697 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_exo -53.11 -39.23 80.72 Favored 'Trans proline' 0 N--CA 1.497 1.722 0 C-N-CA 122.488 2.125 . . . . 0.0 112.155 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 11.5 tpt -162.23 90.31 0.74 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.491 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 179.66 -178.18 48.5 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.1 mtp -62.49 147.59 48.36 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.02 0.438 . . . . 0.0 110.569 -179.406 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 43.8 m0 -95.86 147.05 24.06 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.462 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 96.8 m -107.62 132.75 52.96 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.882 179.513 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -151.3 -177.8 25.47 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . 0.457 ' HB2' HD11 ' A' ' 58' ' ' ILE . 66.7 ttp -121.0 141.24 50.91 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 120.975 0.417 . . . . 0.0 110.631 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.436 HD22 ' ND2' ' A' ' 71' ' ' ASN . 0.5 OUTLIER -140.93 110.84 6.52 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.4 179.785 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . 0.436 ' ND2' HD22 ' A' ' 70' ' ' LEU . 50.9 m-20 54.99 56.38 6.66 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.876 -0.33 . . . . 0.0 110.197 179.447 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 87.0 m-20 56.13 36.52 27.56 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.724 0.297 . . . . 0.0 110.781 -179.668 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 18.4 tptm -138.43 113.26 9.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.11 179.337 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 98.3 t -93.48 126.89 45.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 120.811 -0.356 . . . . 0.0 110.507 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -154.77 177.62 31.96 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.653 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -106.94 155.0 20.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.057 0.456 . . . . 0.0 110.953 -179.549 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 32.1 p90 -156.29 162.75 40.09 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.02 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 7.4 ttmm -76.67 115.98 16.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.72 -179.218 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.465 ' HA ' HG12 ' A' ' 82' ' ' VAL . 51.9 p90 -58.34 -22.61 53.95 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.818 179.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.6 mt -66.29 -39.35 83.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 121.062 0.458 . . . . 0.0 110.602 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 13.3 m-30 -79.65 -0.18 32.85 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.122 -179.017 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.465 HG12 ' HA ' ' A' ' 79' ' ' PHE . 0.5 OUTLIER -130.0 158.09 42.52 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 CA-C-O 120.857 0.36 . . . . 0.0 110.263 179.749 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -121.08 141.31 50.9 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.46 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 8.3 p -92.02 126.16 44.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.816 -179.782 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 44.4 pt -128.29 154.3 38.82 Favored 'Isoleucine or valine' 0 C--O 1.236 0.375 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.764 179.691 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 36.9 t -110.5 130.73 55.49 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.608 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 6.6 tm-20 . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.684 -179.977 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -58.73 145.03 97.47 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 123.037 2.491 . . . . 0.0 111.952 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -112.55 138.67 48.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.421 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.1 m -115.02 145.46 42.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.285 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 166.88 -140.31 6.23 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.5 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -117.29 154.96 30.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.348 . . . . 0.0 110.7 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.545 ' HB1' HG22 ' A' ' 82' ' ' VAL . . . -122.96 137.2 55.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.391 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.427 ' HE ' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -99.36 118.66 36.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.347 179.879 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 69.6 t -69.41 130.05 34.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.914 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 23.9 m-70 -108.86 -22.52 12.16 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.811 179.389 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 50.7 p -125.99 158.4 35.38 Favored 'General case' 0 C--N 1.332 -0.177 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.348 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -91.27 116.55 28.92 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.823 -179.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 14.1 t80 -116.16 117.53 30.31 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.049 179.347 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 8.1 t -117.76 141.11 28.54 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.136 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -72.42 153.82 55.61 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.668 2.245 . . . . 0.0 112.456 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.5 p -72.91 166.17 45.67 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.036 -179.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -55.47 -42.14 71.02 Favored 'Trans proline' 0 N--CA 1.501 1.968 0 C-N-CA 122.906 2.404 . . . . 0.0 112.639 -179.461 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -97.37 11.43 36.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.879 -179.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 65.2 t0 -112.19 112.07 23.42 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.768 0.318 . . . . 0.0 110.517 -179.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 48.9 p -110.86 -24.16 10.58 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.484 179.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -63.36 -38.43 91.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.615 179.595 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.2 t -61.58 140.61 58.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.901 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 19.3 tp -89.39 143.71 26.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.748 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.8 pttt -97.03 137.55 35.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.452 179.093 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 2.4 pt -142.17 145.72 23.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.283 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.173 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 17.1 mttm -117.76 152.32 35.53 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.352 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -61.28 129.98 43.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.958 0.409 . . . . 0.0 110.285 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.19 -22.18 41.22 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -71.72 154.97 40.99 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.826 0.346 . . . . 0.0 110.609 179.186 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.427 HD11 ' HE ' ' A' ' 32' ' ' ARG . 76.2 mt -119.42 133.64 65.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.332 179.682 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 84.3 mt -117.66 132.04 68.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.913 -179.601 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -75.42 123.12 24.85 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 109.89 179.484 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 93.3 mt -69.11 129.34 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 O-C-N 123.881 0.738 . . . . 0.0 110.365 -179.662 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 89.9 mt -109.55 -54.53 5.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.66 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 44.1 t -163.99 147.65 9.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.189 -179.604 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -92.94 146.27 23.75 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.726 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.2 p -103.25 154.45 37.68 Favored Pre-proline 0 C--N 1.328 -0.346 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.514 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -62.11 -25.71 77.53 Favored 'Trans proline' 0 N--CA 1.497 1.704 0 C-N-CA 122.653 2.235 . . . . 0.0 112.159 179.332 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 96.4 mmm -70.17 -22.13 62.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.521 179.693 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 114.31 -26.26 9.87 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.4 mtp -64.95 147.04 54.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.983 0.421 . . . . 0.0 110.765 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 43.4 m0 -102.38 146.09 28.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.241 0.544 . . . . 0.0 111.321 -179.269 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 98.3 m -108.8 135.33 50.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.605 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -153.76 -176.93 26.7 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.9 ttp -118.46 140.29 50.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.933 0.397 . . . . 0.0 111.244 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.457 HD22 ' ND2' ' A' ' 71' ' ' ASN . 0.4 OUTLIER -143.92 113.96 7.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.511 179.659 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . 0.457 ' ND2' HD22 ' A' ' 70' ' ' LEU . 47.0 m-20 56.98 55.31 6.21 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 32.6 m120 54.53 35.91 24.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.613 0.244 . . . . 0.0 110.491 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 36.6 ttpt -139.48 114.92 9.86 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 120.624 -0.43 . . . . 0.0 110.431 179.465 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 86.9 t -93.28 128.17 44.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.442 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -156.22 179.36 32.17 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 57.2 m-80 -104.38 158.46 16.45 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.222 0.534 . . . . 0.0 110.96 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 7.2 p90 -155.97 160.23 39.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.223 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -63.94 116.27 5.68 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.109 -179.141 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -58.24 -29.0 65.4 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.514 179.753 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.478 HG23 ' CD1' ' A' ' 81' ' ' TYR . 16.3 tt -74.6 -33.96 33.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.896 179.146 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.478 ' CD1' HG23 ' A' ' 80' ' ' ILE . 13.8 m-30 -72.1 -20.79 61.59 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.519 179.596 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.545 HG22 ' HB1' ' A' ' 31' ' ' ALA . 6.1 p -114.97 160.07 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.112 179.06 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . 0.421 ' N ' HG22 ' A' ' 82' ' ' VAL . 8.3 t70 -128.92 149.39 50.81 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.688 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.3 p -92.85 135.19 28.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.594 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 23.2 pt -121.04 158.24 23.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.461 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 41.1 t -61.37 138.72 58.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.587 -179.74 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 20.0 tp10 . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.182 -0.913 . . . . 0.0 110.521 179.983 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -58.73 145.03 97.47 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 123.037 2.491 . . . . 0.0 111.952 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -112.55 138.67 48.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.421 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 75.1 m -115.02 145.46 42.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.285 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 166.88 -140.31 6.23 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.5 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 9.1 mtp180 -117.29 154.96 30.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.83 0.348 . . . . 0.0 110.7 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.545 ' HB1' HG22 ' A' ' 82' ' ' VAL . . . -122.96 137.2 55.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.391 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.427 ' HE ' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -99.36 118.66 36.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.347 179.879 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 69.6 t -69.41 130.05 34.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.914 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 23.9 m-70 -108.86 -22.52 12.16 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.811 179.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 50.7 p -125.99 158.4 35.38 Favored 'General case' 0 C--N 1.332 -0.177 0 C-N-CA 120.495 -0.482 . . . . 0.0 110.348 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -91.27 116.55 28.92 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.823 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 14.1 t80 -116.16 117.53 30.31 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.049 179.347 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 8.1 t -117.76 141.11 28.54 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.136 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -72.42 153.82 55.61 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.668 2.245 . . . . 0.0 112.456 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 4.5 p -72.91 166.17 45.67 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.036 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -55.47 -42.14 71.02 Favored 'Trans proline' 0 N--CA 1.501 1.968 0 C-N-CA 122.906 2.404 . . . . 0.0 112.639 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 53.0 p90 -97.37 11.43 36.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.879 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 65.2 t0 -112.19 112.07 23.42 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.768 0.318 . . . . 0.0 110.517 -179.714 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 48.9 p -110.86 -24.16 10.58 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.484 179.241 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -63.36 -38.43 91.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.615 179.595 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.2 t -61.58 140.61 58.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.901 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 19.3 tp -89.39 143.71 26.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.748 -179.704 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 64.8 pttt -97.03 137.55 35.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.452 179.093 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 2.4 pt -142.17 145.72 23.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.283 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.173 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 17.1 mttm -117.76 152.32 35.53 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.352 179.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -61.28 129.98 43.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.958 0.409 . . . . 0.0 110.285 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.19 -22.18 41.22 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -71.72 154.97 40.99 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.826 0.346 . . . . 0.0 110.609 179.186 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.427 HD11 ' HE ' ' A' ' 32' ' ' ARG . 76.2 mt -119.42 133.64 65.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.332 179.682 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 84.3 mt -117.66 132.04 68.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.913 -179.601 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -75.42 123.12 24.85 Favored 'General case' 0 C--O 1.234 0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 109.89 179.484 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 93.3 mt -69.11 129.34 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 O-C-N 123.881 0.738 . . . . 0.0 110.365 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 89.9 mt -109.55 -54.53 5.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.66 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 44.1 t -163.99 147.65 9.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.189 -179.604 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -92.94 146.27 23.75 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.639 -0.424 . . . . 0.0 110.726 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.2 p -103.25 154.45 37.68 Favored Pre-proline 0 C--N 1.328 -0.346 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.514 -179.668 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -62.11 -25.71 77.53 Favored 'Trans proline' 0 N--CA 1.497 1.704 0 C-N-CA 122.653 2.235 . . . . 0.0 112.159 179.332 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 96.4 mmm -70.17 -22.13 62.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.521 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 114.31 -26.26 9.87 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 99.4 mtp -64.95 147.04 54.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.983 0.421 . . . . 0.0 110.765 179.71 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 43.4 m0 -102.38 146.09 28.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.241 0.544 . . . . 0.0 111.321 -179.269 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 98.3 m -108.8 135.33 50.2 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.605 179.652 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -153.76 -176.93 26.7 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.9 ttp -118.46 140.29 50.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.933 0.397 . . . . 0.0 111.244 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.457 HD22 ' ND2' ' A' ' 71' ' ' ASN . 0.4 OUTLIER -143.92 113.96 7.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.511 179.659 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . 0.457 ' ND2' HD22 ' A' ' 70' ' ' LEU . 47.0 m-20 56.98 55.31 6.21 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 32.6 m120 54.53 35.91 24.54 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.613 0.244 . . . . 0.0 110.491 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 36.6 ttpt -139.48 114.92 9.86 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 120.624 -0.43 . . . . 0.0 110.431 179.465 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 86.9 t -93.28 128.17 44.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 C-N-CA 120.803 -0.359 . . . . 0.0 110.442 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -156.22 179.36 32.17 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 57.2 m-80 -104.38 158.46 16.45 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.222 0.534 . . . . 0.0 110.96 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 7.2 p90 -155.97 160.23 39.9 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.223 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -63.94 116.27 5.68 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.109 -179.141 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -58.24 -29.0 65.4 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.514 179.753 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.478 HG23 ' CD1' ' A' ' 81' ' ' TYR . 16.3 tt -74.6 -33.96 33.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.896 179.146 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.478 ' CD1' HG23 ' A' ' 80' ' ' ILE . 13.8 m-30 -72.1 -20.79 61.59 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.519 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.545 HG22 ' HB1' ' A' ' 31' ' ' ALA . 6.1 p -114.97 160.07 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.112 179.06 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . 0.421 ' N ' HG22 ' A' ' 82' ' ' VAL . 8.3 t70 -128.92 149.39 50.81 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.688 179.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.3 p -92.85 135.19 28.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.594 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 23.2 pt -121.04 158.24 23.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.461 179.815 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 41.1 t -61.37 138.72 58.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.587 -179.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 20.0 tp10 . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.182 -0.913 . . . . 0.0 110.521 179.983 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.208 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -59.03 146.81 92.97 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 122.992 2.461 . . . . 0.0 112.022 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -117.35 150.31 39.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.41 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 31.5 p -126.69 154.0 44.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.132 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.424 ' H ' HD12 ' A' ' 57' ' ' ILE . . . 179.0 -125.45 0.98 Allowed Glycine 0 CA--C 1.523 0.537 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.237 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 28.4 mmt85 -129.56 141.72 50.91 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.053 0.454 . . . . 0.0 110.659 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.637 ' HB1' HG21 ' A' ' 82' ' ' VAL . . . -107.59 118.68 37.37 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.315 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 68.7 ttt180 -98.45 123.81 42.8 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.977 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.477 HG21 ' HB ' ' A' ' 49' ' ' ILE . 65.9 t -79.54 125.18 38.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.135 -178.76 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 33.2 p80 -105.77 -10.04 16.93 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.202 179.327 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 14.4 t -145.38 151.21 37.9 Favored 'General case' 0 C--O 1.231 0.1 0 CA-C-O 120.841 0.353 . . . . 0.0 110.174 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -80.8 110.42 16.29 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.938 -179.403 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 11.2 t80 -120.69 130.6 54.16 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.369 179.229 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 71.3 p -124.5 152.87 69.19 Favored Pre-proline 0 CA--C 1.53 0.2 0 C-N-CA 120.74 -0.384 . . . . 0.0 110.793 -179.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -76.45 159.91 35.73 Favored 'Trans proline' 0 N--CA 1.492 1.399 0 C-N-CA 122.72 2.28 . . . . 0.0 112.232 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 57.7 m -71.57 157.6 89.53 Favored Pre-proline 0 C--N 1.331 -0.213 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.663 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_exo -53.0 -43.39 57.31 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.241 1.961 . . . . 0.0 111.959 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -84.26 -13.96 51.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.963 179.647 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -91.3 104.13 16.71 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.288 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 71.7 p -102.15 -24.84 13.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.816 0.341 . . . . 0.0 110.53 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -63.08 -38.2 90.25 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.534 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.0 t -73.55 131.15 41.41 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.255 179.742 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 2.5 tp -88.5 161.58 16.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.231 -179.757 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 23.6 pttm -97.35 145.72 25.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.401 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.546 HG22 HD11 ' A' ' 55' ' ' ILE . 27.3 pt -133.57 149.65 31.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.175 179.706 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 38.0 ttmt -130.71 150.64 51.8 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 57.3 mtmt -55.03 125.72 21.62 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.092 0.472 . . . . 0.0 110.819 -179.21 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.3 -17.36 57.02 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -71.77 142.8 49.71 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 116.923 0.362 . . . . 0.0 110.492 179.631 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 50.5 mm -114.89 128.18 72.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.106 179.76 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.546 HD11 HG22 ' A' ' 49' ' ' ILE . 85.9 mt -118.45 127.87 75.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.636 -179.596 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -78.44 135.22 37.34 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 120.705 -0.398 . . . . 0.0 110.479 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.424 HD12 ' H ' ' A' ' 29' ' ' GLY . 97.3 mt -76.91 120.9 28.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 C-N-CA 120.822 -0.351 . . . . 0.0 110.318 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.5 mt -107.75 -51.73 7.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.771 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 49.0 t -153.71 144.36 22.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.965 -179.553 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -96.5 142.58 28.41 Favored 'General case' 0 C--N 1.325 -0.46 0 C-N-CA 120.766 -0.374 . . . . 0.0 110.018 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 28.2 m -98.93 135.6 20.86 Favored Pre-proline 0 CA--C 1.54 0.563 0 C-N-CA 120.09 -0.644 . . . . 0.0 110.117 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -50.81 -32.57 37.56 Favored 'Trans proline' 0 N--CA 1.5 1.885 0 C-N-CA 122.373 2.049 . . . . 0.0 112.456 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 24.3 mmt -60.81 -38.85 86.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.273 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 140.67 -40.16 1.4 Allowed Glycine 0 CA--C 1.524 0.596 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 179.745 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 96.5 mtp -61.83 145.92 51.2 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.129 0.49 . . . . 0.0 110.767 -179.359 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 42.5 m0 -98.64 153.89 18.35 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.703 -179.372 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.4 m -111.12 134.56 52.62 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 109.592 -0.522 . . . . 0.0 109.592 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.25 -174.22 25.77 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.333 -0.707 . . . . 0.0 111.333 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.1 ttp -119.33 138.16 53.23 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.831 0.348 . . . . 0.0 110.593 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -145.47 126.25 14.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.342 -179.879 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 6.5 p-10 43.46 56.13 4.52 Favored 'General case' 0 N--CA 1.466 0.371 0 O-C-N 123.441 0.463 . . . . 0.0 111.363 -179.525 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 55.08 34.16 21.95 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.935 0.397 . . . . 0.0 110.544 179.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.7 mmtp -142.34 115.04 8.59 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.392 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 16.0 m -97.68 139.4 20.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 C-N-CA 120.546 -0.462 . . . . 0.0 110.509 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -168.54 -177.42 39.52 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.415 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 -103.36 149.15 25.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.959 0.409 . . . . 0.0 110.701 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -146.71 157.97 43.81 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.334 179.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.524 ' HG2' HG22 ' A' ' 80' ' ' ILE . 23.0 ttmt -81.67 116.89 21.61 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.779 -178.564 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.438 ' HA ' HG12 ' A' ' 82' ' ' VAL . 36.5 p90 -57.98 -24.58 58.69 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.989 -179.658 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.524 HG22 ' HG2' ' A' ' 78' ' ' LYS . 10.6 tp -58.18 -25.17 26.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.883 0.373 . . . . 0.0 110.653 -179.667 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 25.1 m-85 -100.94 14.06 33.12 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.191 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.637 HG21 ' HB1' ' A' ' 31' ' ' ALA . 0.3 OUTLIER -143.22 156.13 17.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.746 0.307 . . . . 0.0 110.311 -179.727 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -130.54 149.93 51.98 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.563 179.254 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 22.6 m -93.78 131.71 39.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.272 179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 42.0 pt -126.53 149.77 31.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.832 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 83.7 p -75.85 163.37 27.29 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.732 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.018 -0.992 . . . . 0.0 110.546 179.712 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -70.72 156.7 60.34 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 C-N-CA 122.943 2.429 . . . . 0.0 112.138 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 -125.88 150.52 47.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.502 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 28.1 p -116.45 142.4 46.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.363 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.55 -146.6 6.61 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 -179.421 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 8.2 mmm180 -121.02 142.15 50.07 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.901 -0.32 . . . . 0.0 110.543 -179.516 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -114.11 127.68 56.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.532 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 17.9 mtp180 -105.14 128.26 53.29 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.46 179.782 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.9 t -86.28 131.26 35.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.327 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 64.4 m170 -111.89 -11.66 13.87 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.047 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.452 HG21 ' HD2' ' A' ' 81' ' ' TYR . 4.2 p -124.89 174.67 7.8 Favored 'General case' 0 N--CA 1.455 -0.188 0 CA-C-O 121.173 0.511 . . . . 0.0 110.419 -179.416 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -103.48 112.0 24.7 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.627 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 8.9 t80 -119.19 118.9 32.58 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-O 121.011 0.434 . . . . 0.0 110.253 179.62 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.517 HG23 ' O ' ' A' ' 38' ' ' THR . 4.8 t -133.61 95.2 18.0 Favored Pre-proline 0 CA--C 1.543 0.696 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.519 -179.879 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -68.41 153.61 73.66 Favored 'Trans proline' 0 C--N 1.301 -1.924 0 C-N-CA 122.305 2.003 . . . . 0.0 112.313 -179.444 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 48.1 m -65.65 154.49 88.37 Favored Pre-proline 0 N--CA 1.453 -0.294 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.533 -179.564 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.15 -20.98 64.15 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.847 2.365 . . . . 0.0 112.0 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -66.94 -23.56 65.98 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.249 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -99.69 96.53 7.68 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.324 179.409 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.423 ' H ' HG22 ' A' ' 44' ' ' THR . 2.1 t -75.96 -32.8 59.69 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.614 179.617 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -66.85 -38.12 85.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.532 179.722 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 69.1 m -67.49 123.32 20.1 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.671 -179.477 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -85.08 156.31 21.12 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.586 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 60.4 mtpt -98.56 127.84 44.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.645 179.625 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 45.8 pt -138.48 148.37 24.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.509 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 28.2 mttm -127.4 163.44 24.04 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.537 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -61.37 124.61 21.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.52 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 107.42 -31.18 8.32 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.799 -0.92 . . . . 0.0 110.799 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -66.63 145.86 55.11 Favored 'General case' 0 N--CA 1.456 -0.174 0 C-N-CA 120.881 -0.328 . . . . 0.0 110.346 179.503 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 60.6 mt -116.49 132.23 66.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.51 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.449 HG12 HD12 ' A' ' 70' ' ' LEU . 2.7 mp -114.86 129.17 71.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.857 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -72.78 122.52 21.67 Favored 'General case' 0 CA--C 1.518 -0.286 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.122 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.96 127.02 28.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 120.986 0.422 . . . . 0.0 110.93 -179.484 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.5 mt -109.39 -54.64 5.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.247 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 20.4 p -162.64 172.6 15.1 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.614 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 31.1 mtpt -120.39 150.23 41.1 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.451 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 67.3 p -121.71 151.66 57.63 Favored Pre-proline 0 CA--C 1.535 0.386 0 C-N-CA 120.339 -0.545 . . . . 0.0 110.915 -179.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -69.02 -20.73 37.92 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.682 2.255 . . . . 0.0 112.242 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 3.0 mpp? -60.0 -15.51 23.0 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.484 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 97.16 22.8 16.23 Favored Glycine 0 C--N 1.336 0.564 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 96.4 mmm -127.19 144.41 51.04 Favored 'General case' 0 C--O 1.236 0.379 0 CA-C-O 121.039 0.447 . . . . 0.0 110.671 179.726 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 6.0 m0 -98.4 142.49 29.96 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.469 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 89.0 m -105.97 132.1 52.47 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 116.01 -0.541 . . . . 0.0 109.875 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -151.66 -179.87 27.69 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 60.7 ttm -115.81 142.02 47.32 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.989 0.424 . . . . 0.0 110.878 -179.792 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.449 HD12 HG12 ' A' ' 55' ' ' ILE . 0.6 OUTLIER -143.45 107.94 4.83 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.869 -179.89 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 53.77 53.92 10.64 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.29 179.491 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 54.4 t30 61.07 30.75 19.67 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.64 -179.607 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 62.8 tttm -137.63 112.81 9.19 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.05 179.344 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 27.4 m -99.09 144.12 12.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.875 0.369 . . . . 0.0 110.648 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -170.09 -173.08 37.19 Favored Glycine 0 CA--C 1.528 0.901 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 -179.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 35.4 m120 -103.4 148.29 26.08 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.985 0.421 . . . . 0.0 110.851 -179.287 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.8 p90 -153.21 160.1 42.75 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.727 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.473 ' HB3' HG12 ' A' ' 80' ' ' ILE . 96.7 mttt -79.71 122.34 26.45 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-O 121.433 0.635 . . . . 0.0 110.518 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 12.0 p90 -68.99 -24.11 64.19 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.199 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.473 HG12 ' HB3' ' A' ' 78' ' ' LYS . 28.4 pt -62.2 -19.69 22.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.833 0.349 . . . . 0.0 110.825 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.452 ' HD2' HG21 ' A' ' 35' ' ' THR . 30.6 m-85 -102.69 5.66 39.12 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.865 179.56 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -136.16 153.86 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 CA-C-O 121.109 0.481 . . . . 0.0 110.638 -179.697 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 -127.51 143.19 51.22 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.565 179.245 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.8 m -88.61 136.93 22.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.229 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 42.5 pt -120.23 157.79 22.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.803 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 83.3 p -72.95 160.77 31.59 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.656 179.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 118.015 -0.993 . . . . 0.0 110.543 179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -69.39 154.56 69.03 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 C-N-CA 122.855 2.37 . . . . 0.0 112.203 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 32.9 t80 -121.09 139.56 53.16 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.277 -179.487 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 79.9 m -107.38 135.03 49.56 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.652 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -172.98 -153.29 9.36 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 -179.529 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 39.6 mmt180 -116.45 144.03 44.83 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.886 0.374 . . . . 0.0 110.58 -179.491 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -113.04 121.86 45.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.619 -179.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.476 ' HD2' HG21 ' A' ' 85' ' ' ILE . 94.8 mtt180 -95.77 121.4 37.46 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.51 178.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.431 HG21 ' HB ' ' A' ' 49' ' ' ILE . 67.2 t -76.64 119.84 25.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.352 -179.399 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 4.3 p80 -105.85 -16.05 14.76 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.438 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.54 HG21 ' CD2' ' A' ' 81' ' ' TYR . 1.3 m -126.34 142.56 51.49 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.579 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -77.33 104.57 7.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.978 0.418 . . . . 0.0 110.333 -179.474 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 26.0 t80 -116.52 115.25 25.43 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.63 179.674 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 10.2 t -129.76 137.42 30.88 Favored Pre-proline 0 N--CA 1.452 -0.375 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.605 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -73.49 160.79 43.77 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.855 2.37 . . . . 0.0 112.242 -179.462 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 89.1 p -70.39 161.22 77.81 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.467 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -55.35 -37.71 94.42 Favored 'Trans proline' 0 N--CA 1.496 1.652 0 C-N-CA 122.736 2.291 . . . . 0.0 112.189 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -85.59 1.49 48.9 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.72 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -107.25 108.88 20.5 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-O 120.855 0.36 . . . . 0.0 110.34 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 10.1 t -111.03 -27.26 8.84 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.77 179.809 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -62.44 -38.94 91.68 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.659 -179.684 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.5 t -69.53 141.59 53.82 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.579 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 59.8 tp -83.36 143.64 30.19 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.554 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 26.0 pttm -98.64 137.75 36.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.899 0.381 . . . . 0.0 110.74 178.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.431 ' HB ' HG21 ' A' ' 33' ' ' VAL . 46.3 pt -137.7 147.5 26.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.78 179.526 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -119.38 156.14 30.65 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.032 -179.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 40.7 ttpt -61.61 120.8 11.29 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.461 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 104.84 -22.19 34.32 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 111.092 -0.803 . . . . 0.0 111.092 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -65.81 147.54 53.21 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-O 120.884 0.373 . . . . 0.0 110.906 179.257 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 47.2 mm -108.73 126.72 65.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.661 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.4 mt -109.22 128.9 64.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.78 -179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -79.29 112.51 16.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.306 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.3 mt -65.35 126.5 24.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.606 -179.487 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.6 mt -112.41 -55.29 4.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.6 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.9 t -162.86 151.69 14.71 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.74 -179.439 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.4 156.08 17.83 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.46 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 44.4 p -110.38 154.56 42.91 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.319 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -60.03 -26.84 83.53 Favored 'Trans proline' 0 C--N 1.305 -1.735 0 C-N-CA 122.807 2.338 . . . . 0.0 112.286 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 78.9 mtm -63.99 -38.15 90.02 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.501 179.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 133.82 -35.55 2.24 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 8.7 mtt -63.0 147.31 51.03 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.918 0.389 . . . . 0.0 110.624 -179.601 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 21.6 m0 -101.88 151.58 21.93 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.865 -179.534 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 91.0 m -114.08 136.37 53.0 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.866 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -154.56 -174.54 24.7 Favored Glycine 0 CA--C 1.524 0.646 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 -179.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 65.3 ttp -117.83 141.36 48.5 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 120.624 0.249 . . . . 0.0 110.638 -179.771 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.421 ' O ' ' HB3' ' A' ' 73' ' ' LYS . 1.3 mt -143.46 110.44 5.65 Favored 'General case' 0 C--O 1.219 -0.512 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.58 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . 0.4 ' ND2' ' N ' ' A' ' 71' ' ' ASN . 0.1 OUTLIER 54.27 54.16 9.9 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 178.926 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 59.79 28.57 18.06 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.369 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.421 ' HB3' ' O ' ' A' ' 70' ' ' LEU . 85.1 tttt -133.99 112.99 11.67 Favored 'General case' 0 C--O 1.225 -0.214 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.107 179.572 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 19.1 m -99.84 144.0 12.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.855 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -174.86 -173.84 41.03 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -179.536 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 78.1 m-20 -101.57 149.45 24.09 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.849 0.357 . . . . 0.0 110.646 -179.548 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -148.96 160.78 42.98 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.857 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.601 ' CG ' HG22 ' A' ' 80' ' ' ILE . 24.3 tptt -82.01 114.3 20.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.434 -179.168 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.472 ' HA ' HG12 ' A' ' 82' ' ' VAL . 49.0 p90 -62.9 -26.18 68.67 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.588 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.601 HG22 ' CG ' ' A' ' 78' ' ' LYS . 10.2 tt -58.94 -30.33 42.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.814 0.34 . . . . 0.0 110.917 -179.408 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.54 ' CD2' HG21 ' A' ' 35' ' ' THR . 25.2 m-85 -93.32 5.34 51.89 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.04 179.817 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.472 HG12 ' HA ' ' A' ' 79' ' ' PHE . 0.3 OUTLIER -131.42 156.44 42.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 CA-C-O 121.05 0.453 . . . . 0.0 110.68 -179.884 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 85.3 m-20 -123.6 140.07 53.36 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.436 179.352 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -93.84 142.83 12.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 120.949 0.404 . . . . 0.0 110.724 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.476 HG21 ' HD2' ' A' ' 32' ' ' ARG . 39.3 pt -128.6 159.02 40.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.82 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 99.1 p -106.61 160.67 15.27 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.598 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.569 179.966 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -69.57 148.09 65.52 Favored 'Trans proline' 0 C--N 1.305 -1.741 0 C-N-CA 122.768 2.312 . . . . 0.0 112.084 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 83.4 t80 -137.22 130.39 30.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.478 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 81.0 m -105.9 133.73 50.15 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.006 0.431 . . . . 0.0 110.212 179.736 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -176.08 -144.36 5.09 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 111.394 -0.682 . . . . 0.0 111.394 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -117.83 142.87 46.82 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.694 0.283 . . . . 0.0 110.468 -179.726 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -116.44 137.1 52.43 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.853 0.359 . . . . 0.0 110.454 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 16.0 ptm180 -116.77 133.87 55.48 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.404 HG22 HD12 ' A' ' 49' ' ' ILE . 89.6 t -82.3 127.98 39.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.42 -178.669 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 88.5 m-70 -109.71 -17.13 13.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.435 179.267 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.44 HG21 ' HD2' ' A' ' 81' ' ' TYR . 7.4 p -120.22 173.79 6.9 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.879 0.371 . . . . 0.0 110.143 -179.548 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -101.03 107.71 19.23 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.803 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -117.82 109.84 17.05 Favored 'General case' 0 N--CA 1.463 0.217 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.129 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 90.8 m -128.62 128.23 23.54 Favored Pre-proline 0 CA--C 1.537 0.45 0 C-N-CA 120.678 -0.409 . . . . 0.0 110.852 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -74.48 163.89 35.14 Favored 'Trans proline' 0 N--CA 1.489 1.25 0 C-N-CA 122.489 2.126 . . . . 0.0 112.165 179.612 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 69.7 m -70.57 158.61 87.41 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.565 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -54.4 -35.05 83.49 Favored 'Trans proline' 0 N--CA 1.499 1.807 0 C-N-CA 122.605 2.203 . . . . 0.0 112.128 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 35.5 p90 -90.56 4.11 52.15 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.212 179.803 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -108.58 111.57 23.47 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.551 -0.295 . . . . 0.0 110.364 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 61.4 p -112.89 -19.66 11.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.729 179.504 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -61.98 -38.74 89.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.665 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 58.2 m -80.3 144.19 33.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.682 179.79 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 47.1 tp -81.98 144.03 31.18 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.721 -179.612 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 7.1 ptpp? -98.34 118.56 35.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.622 178.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.404 HD12 HG22 ' A' ' 33' ' ' VAL . 20.1 pt -140.04 158.33 26.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.163 0.506 . . . . 0.0 110.926 -179.733 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.5 164.45 30.31 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.016 0.436 . . . . 0.0 110.679 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -60.59 129.1 39.87 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.914 -179.674 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 109.83 -20.39 26.9 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 111.361 -0.695 . . . . 0.0 111.361 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -85.18 147.41 26.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.003 0.43 . . . . 0.0 110.495 179.273 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 21.7 mm -112.49 129.33 68.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.316 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.417 HG21 ' CE2' ' A' ' 77' ' ' PHE . 75.9 mt -112.55 127.93 69.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.752 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 67.9 m-20 -78.62 124.94 28.7 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.232 -0.44 . . . . 0.0 109.877 179.591 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 93.4 mt -70.58 123.24 24.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 120.882 0.372 . . . . 0.0 110.478 -179.204 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 96.6 mt -106.34 -51.34 7.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.41 179.837 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 49.6 t -168.29 154.76 7.39 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.022 0.439 . . . . 0.0 110.975 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -90.15 136.15 33.22 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.083 179.26 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.5 t -123.45 148.02 54.34 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.87 -179.307 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -52.32 -169.67 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.454 0 C-N-CA 122.418 2.079 . . . . 0.0 112.126 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 91.6 mtp 63.64 15.85 9.24 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.376 -179.196 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 63.71 37.4 94.65 Favored Glycine 0 CA--C 1.522 0.471 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 179.466 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 75.0 mtp -126.46 150.68 48.54 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 120.411 -0.516 . . . . 0.0 111.387 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 10.7 m0 -110.82 147.9 33.53 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.625 179.625 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 85.1 m -104.99 131.26 52.74 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 179.716 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -155.94 -176.45 28.1 Favored Glycine 0 CA--C 1.522 0.487 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.487 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.4 ttp -122.46 138.31 54.59 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.757 0.313 . . . . 0.0 110.657 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -144.3 121.58 11.58 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.185 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 75.6 m-20 53.18 48.4 22.27 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 80.8 m-20 59.71 29.72 19.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.706 0.289 . . . . 0.0 110.354 -179.537 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 42.9 tptt -130.48 114.9 16.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.259 -0.428 . . . . 0.0 109.881 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 89.7 t -96.54 125.89 49.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.878 -0.329 . . . . 0.0 110.586 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -160.16 -179.71 35.12 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 -179.496 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 -98.83 149.79 22.53 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.026 0.441 . . . . 0.0 110.923 -179.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.417 ' CE2' HG21 ' A' ' 55' ' ' ILE . 48.8 p90 -152.17 159.16 43.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.692 179.731 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 1.5 mptp? -78.73 116.29 18.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.82 -179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.464 ' HA ' HG12 ' A' ' 82' ' ' VAL . 33.8 p90 -61.49 -25.11 67.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.629 179.809 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.436 HG23 ' CE1' ' A' ' 79' ' ' PHE . 40.9 pt -62.37 -20.12 23.89 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 CA-C-O 120.78 0.324 . . . . 0.0 110.8 179.634 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.44 ' HD2' HG21 ' A' ' 35' ' ' THR . 49.5 m-85 -100.18 3.61 43.87 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.805 179.002 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.464 HG12 ' HA ' ' A' ' 79' ' ' PHE . 0.3 OUTLIER -132.17 157.42 43.09 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 CA-C-O 120.86 0.362 . . . . 0.0 110.314 -179.544 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -120.06 133.16 55.6 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.714 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 3.2 m -88.05 137.61 20.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 C-N-CA 120.579 -0.448 . . . . 0.0 110.354 179.659 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 43.0 pt -129.71 158.79 42.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.756 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 67.2 m -112.57 143.96 42.86 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.507 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.556 179.875 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -58.9 145.56 96.6 Favored 'Trans proline' 0 C--N 1.304 -1.783 0 C-N-CA 122.901 2.401 . . . . 0.0 112.057 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -119.7 148.26 43.6 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.601 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 28.4 p -124.88 149.16 47.82 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.575 -179.612 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.99 -148.13 11.0 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 -179.377 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 1.7 mpt_? -113.01 141.91 46.31 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.95 0.405 . . . . 0.0 110.463 179.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -117.77 130.97 56.63 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.643 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 41.2 ttm180 -97.14 121.51 39.11 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.576 179.624 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.404 HG22 HG23 ' A' ' 82' ' ' VAL . 77.1 t -82.65 129.18 37.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.495 -179.872 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -112.88 8.63 18.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.974 179.452 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.0 p -137.12 166.87 22.69 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.74 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -108.56 104.74 14.12 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.356 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 16.1 t80 -118.72 119.19 33.69 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.628 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 82.4 p -120.74 152.28 55.66 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.609 -179.748 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -76.14 153.44 36.49 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.763 2.309 . . . . 0.0 112.406 -179.751 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 58.3 m -73.34 156.69 88.89 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.483 179.268 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_endo -54.28 -39.4 86.93 Favored 'Trans proline' 0 C--N 1.301 -1.948 0 C-N-CA 122.858 2.372 . . . . 0.0 112.059 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -93.15 4.14 54.5 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.427 179.385 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -113.71 117.98 33.05 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.31 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 t -112.22 -25.13 9.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.79 179.592 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 -62.04 -38.43 88.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.595 -179.741 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 62.0 m -62.13 142.54 57.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.727 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 56.8 tp -90.38 142.49 27.68 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.423 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -94.73 121.84 36.73 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-O 120.939 0.399 . . . . 0.0 110.414 179.066 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.423 ' CG2' HD11 ' A' ' 55' ' ' ILE . 37.8 pt -131.1 155.21 41.75 Favored 'Isoleucine or valine' 0 C--O 1.235 0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.62 -179.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 48.7 pttt -137.27 160.68 38.34 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.564 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -66.3 131.85 47.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.95 179.349 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 102.42 -18.75 50.31 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -82.87 152.01 25.77 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.823 0.344 . . . . 0.0 110.369 179.505 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 96.4 mt -116.29 133.11 63.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.62 179.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.423 HD11 ' CG2' ' A' ' 49' ' ' ILE . 82.5 mt -118.11 134.15 62.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.783 -179.294 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -80.49 122.94 27.62 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.189 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 96.3 mt -72.92 124.48 29.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.75 -179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 8.9 tt -107.0 -33.86 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.449 179.722 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 24.0 p -175.54 175.34 2.13 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.463 -179.324 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -126.35 151.8 47.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.536 179.464 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 31.0 p -105.18 153.42 39.56 Favored Pre-proline 0 N--CA 1.454 -0.261 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.611 -179.404 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -57.05 -35.93 99.1 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 C-N-CA 122.779 2.319 . . . . 0.0 112.227 179.717 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . . . . . . . . . 98.2 mtp -61.29 -37.35 82.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.646 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 131.13 -25.46 4.1 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 96.4 mtp -62.15 139.67 58.46 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.027 0.441 . . . . 0.0 110.341 -179.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 37.7 m0 -96.25 148.11 23.08 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.986 -179.371 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 58.3 m -119.48 140.49 50.38 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-N 116.022 -0.536 . . . . 0.0 109.885 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -164.81 -168.93 27.71 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 -179.769 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 66.8 ttp -116.03 135.34 54.05 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-O 120.671 0.272 . . . . 0.0 110.739 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.471 ' C ' HD23 ' A' ' 70' ' ' LEU . 3.1 tt -135.7 112.51 10.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.371 179.702 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . 0.46 ' N ' HD23 ' A' ' 70' ' ' LEU . 66.9 t30 55.41 53.9 9.26 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.855 178.794 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 96.3 m-20 59.02 28.61 17.92 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.743 179.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -139.33 113.31 8.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.086 179.395 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 19.4 m -95.31 143.67 11.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.859 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -172.34 -173.39 38.95 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.664 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -111.73 155.14 23.96 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.748 0.309 . . . . 0.0 110.451 -179.355 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 9.2 p90 -155.62 157.85 37.4 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.812 179.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.403 ' HB3' HG12 ' A' ' 80' ' ' ILE . 99.2 mttt -63.99 132.81 51.76 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.45 -179.639 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 29.6 p90 -67.08 -21.32 65.89 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.684 -179.17 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.403 HG12 ' HB3' ' A' ' 78' ' ' LYS . 12.5 pt -78.22 -27.0 14.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.334 -179.618 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.2 m-85 -84.3 1.16 46.21 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.71 179.724 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.404 HG23 HG22 ' A' ' 33' ' ' VAL . 7.1 p -139.33 157.88 28.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.31 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -132.22 147.41 52.41 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.392 179.798 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 2.1 p -83.36 131.21 34.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.597 179.744 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 61.1 mt -88.78 115.84 29.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.456 -178.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 70.8 p -79.4 165.34 23.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.488 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 78.2 mm-40 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.566 179.55 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.231 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.71 147.43 87.91 Favored 'Trans proline' 0 C--N 1.303 -1.844 0 C-N-CA 123.063 2.509 . . . . 0.0 112.069 179.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -118.57 152.7 35.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.27 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 31.7 p -116.94 140.32 49.61 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.927 0.394 . . . . 0.0 110.342 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -166.86 -162.92 19.67 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 -179.375 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 10.9 mpt_? -119.6 147.55 44.37 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.764 0.316 . . . . 0.0 110.786 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.588 ' HB1' ' CG1' ' A' ' 82' ' ' VAL . . . -134.57 154.61 51.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.807 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 17.5 ptm180 -131.0 148.95 52.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.741 -179.589 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.444 HG22 HD12 ' A' ' 49' ' ' ILE . 58.8 t -86.26 128.71 39.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.301 -179.043 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 26.4 m170 -97.87 -16.98 19.54 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.517 178.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 13.1 t -144.53 142.8 30.48 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.885 -0.326 . . . . 0.0 110.145 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -62.59 117.45 6.26 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.777 -0.369 . . . . 0.0 110.731 -179.37 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -121.69 110.63 16.18 Favored 'General case' 0 C--O 1.233 0.201 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 88.0 m -129.14 94.73 32.91 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.057 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -54.78 152.7 27.36 Favored 'Trans proline' 0 N--CA 1.494 1.521 0 C-N-CA 122.358 2.039 . . . . 0.0 112.013 -179.596 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 39.0 m -59.14 154.73 38.59 Favored Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.474 -179.425 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -57.28 -24.65 60.86 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.554 2.17 . . . . 0.0 112.186 -179.434 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -65.87 -20.63 66.3 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.331 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 50.3 m-20 -96.11 59.68 1.96 Allowed 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 120.956 0.408 . . . . 0.0 110.521 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 12.8 t -60.46 -18.65 52.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.575 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 57.9 p-10 -90.1 7.23 38.91 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.314 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 67.8 m -106.57 144.41 33.28 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-O 120.917 0.389 . . . . 0.0 110.629 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 58.5 tp -81.6 142.03 33.16 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.536 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 1.6 mptm? -98.7 126.79 44.42 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.47 179.051 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.444 HD12 HG22 ' A' ' 33' ' ' VAL . 21.6 pt -131.49 148.5 32.65 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.631 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 39.3 ttpt -122.65 152.57 40.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.844 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 38.7 ttmt -57.11 128.35 36.56 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.058 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.38 -18.67 55.03 Favored Glycine 0 CA--C 1.524 0.635 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.451 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -72.23 144.96 48.27 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.796 0.332 . . . . 0.0 110.718 179.618 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 90.9 mt -111.96 129.08 68.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.35 179.243 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.416 ' CD1' HD12 ' A' ' 70' ' ' LEU . 81.3 mt -122.62 128.5 75.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.908 -179.172 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -76.9 134.03 39.08 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.367 179.349 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 85.9 mt -71.06 103.58 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.919 0.39 . . . . 0.0 110.16 -179.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.8 tt -89.09 -34.52 6.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.327 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 17.1 t -167.45 161.27 13.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.29 -179.46 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -120.57 144.7 47.95 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . 0.459 HG22 ' H ' ' A' ' 63' ' ' MET . 27.6 m -101.67 135.69 19.72 Favored Pre-proline 0 CA--C 1.539 0.538 0 C-N-CA 120.232 -0.587 . . . . 0.0 109.98 -179.479 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -57.6 -25.7 68.7 Favored 'Trans proline' 0 N--CA 1.501 1.917 0 C-N-CA 122.359 2.039 . . . . 0.0 112.69 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' MET . . . . . 0.459 ' H ' HG22 ' A' ' 61' ' ' THR . 65.5 mtt -62.22 -38.74 90.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.959 0.409 . . . . 0.0 110.186 179.503 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 142.17 -40.12 1.32 Allowed Glycine 0 CA--C 1.524 0.634 0 N-CA-C 111.106 -0.798 . . . . 0.0 111.106 179.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' MET . . . . . . . . . . . . . 95.5 mtp -64.07 144.39 57.14 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.217 0.532 . . . . 0.0 111.108 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' TRP . . . . . . . . . . . . . 38.4 m0 -97.4 156.31 16.52 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.369 -179.579 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 80.3 m -117.19 139.31 50.92 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.056 -179.719 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -156.23 -175.78 27.6 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' MET . . . . . . . . . . . . . 16.9 tmm? -121.31 141.55 50.81 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.723 0.297 . . . . 0.0 110.507 -179.697 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.459 HD22 ' ND2' ' A' ' 71' ' ' ASN . 0.5 OUTLIER -149.31 121.62 8.41 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.992 179.921 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . 0.459 ' ND2' HD22 ' A' ' 70' ' ' LEU . 69.5 m-20 50.31 49.96 19.6 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.714 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 53.0 t30 59.82 35.07 21.93 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.764 0.316 . . . . 0.0 110.708 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 24.3 tptp -134.26 115.94 14.71 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.786 -0.449 . . . . 0.0 109.786 179.43 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 97.1 t -105.78 129.03 59.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.446 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -165.86 -172.42 33.21 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.59 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.7 m-80 -101.43 153.18 19.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.024 0.44 . . . . 0.0 111.056 -179.508 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.538 ' CD1' HG21 ' A' ' 82' ' ' VAL . 53.4 p90 -149.93 160.43 43.61 Favored 'General case' 0 C--O 1.239 0.54 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.619 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 35.6 tptt -69.62 111.77 5.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.514 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 53.4 p90 -61.53 -24.31 66.53 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.8 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 96.9 mt -63.14 -39.24 84.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 121.022 0.439 . . . . 0.0 110.437 -179.807 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 20.6 m-85 -84.71 2.22 42.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.971 -179.581 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.588 ' CG1' ' HB1' ' A' ' 31' ' ' ALA . 85.6 t -126.02 136.9 59.43 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.147 0 CA-C-O 120.987 0.422 . . . . 0.0 110.813 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -124.41 148.42 47.59 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.373 -179.878 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 16.9 m -90.37 139.6 17.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 C-N-CA 120.662 -0.415 . . . . 0.0 110.58 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 38.9 pt -120.96 149.78 23.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.796 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 83.9 p -90.84 170.49 10.05 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.674 179.808 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . . . . . . . . . 2.5 tp10 . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.049 -0.977 . . . . 0.0 110.482 179.756 . . . . . . . . 0 0 . 1 stop_ save_